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Introduction 
As always, it is a pleasure 
to present the Health 
Protection Surveillance Centre 
epidemiological report which 
provides an analysis of the most 
important infectious diseases 
affecting Ireland during 2014.  
In Ireland, the 2014/2015 
influenza season was more severe than recent seasons. 
Influenza A (H3N2) viruses predominated, with an increase 
in the predominance of influenza B viruses later in the 
season. The impact of influenza during the 2014/2015 
season predominantly affected those aged 65 years and 
older. This was seen by the large numbers of outbreaks 
in residential care facilities, high hospitalisation rates, 
an increase in deaths reported in notified influenza cases 
and excess mortality which was significantly higher than 
recent seasons. Over 1,000 confirmed influenza cases 
were reported as hospitalised during the 2014/2015 
season, a similar number to the 2009 pandemic. There 
was a significant increase in the overall hospitalisation 
rate for those aged 65 years and older compared to 
previous seasons, reaching the highest rate (81.4/100,000 
population) ever reported for this age group. As most of 
those with complications from influenza do not get tested 
for influenza infection, another way to see the impact of 
influenza is to examine the excess deaths that occur while 
influenza is circulating. The estimated number of excess 
deaths reported during the 2014/2015 season for those 
aged 65 years and older in Ireland was 726. It is likely that 
influenza contributed significantly to these excess deaths, 
although adverse winter weather conditions and other 
respiratory infections may have also contributed.
In Ireland and most Northern Hemisphere countries, the 
emergence of A(H3N2) viruses antigenically and genetically 
drifted from the 2014/2015 vaccine strain resulted in 
reduced vaccine effectiveness (VE). The Irish overall 
adjusted VE in preventing confirmed influenza infection 
in primary care was very low. Excess all-cause mortality 
among people aged 65 years and older, concomitant with 
increased influenza activity and the predominance of 
drifted A(H3N2) viruses was observed in Ireland for nine 
consecutive weeks between weeks 2 and 10 2015.
Antimicrobial resistance remains one of the priority 
challenges facing the Irish healthcare services. For the 
eighth consecutive year, the proportion of S. aureus 
bloodstream infections (BSI) attributable to meticillin 
resistant S. aureus (MRSA) further declined to 19.5%, the 
lowest reported level since Ireland joined EARS-Net in 1999. 
Unfortunately, antimicrobial resistance in other important 
BSI causative pathogens increased further and remains 
a cause for concern. Following the establishment of the 
national multi-drug resistant K. pneumoniae (MDRKP) 
outbreak control team (OCT) in 2013 to look at the emerging 
problem of MDRKP, initial recommendations were made 
to try to control the spread of MDRKP strains in healthcare 
settings. A welcome reduction in the proportion of   
K. pneumoniae BSI that were MDRKP was seen in 2014 (to 
8.1% of isolates) and this may be in part due to some of 
the control measures put in place during 2014. However, 
many of the recommendations have still not been fully 
implemented and the OCT proposed that a national task 
force should be established with greater powers to influence 
and implement changes in policy and infrastructure needed. 
This task force has been established in 2015 and is working 
to strengthen control measures in both acute and non-acute 
healthcare settings. The findings of biannual hand hygiene 
compliance audit reports from acute hospitals in 2014, 
reported continued improvement to 86% compliance, but 
this fell short of the 90% compliance target set by HSE.
As well as improvements in the proportions of MRSA BSI, 
there were small improvements in Clostridium difficile 
infections that were categorised as healthcare-associated. 
(2.3 cases per 10,000 bed days used, a decrease from 2.4 in 
2013). 
There was a small improvement in the rates of antimicrobial 
consumption in both the community and acute hospital 
settings, but further work is required to restrict the use 
of certain antibiotics for essential care and the new HSE 
task force addressing the MDRKP outbreak will issue 
recommendations on this in the near future.
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There were 33 reported cases (20 confirmed) of measles in 
2014 – the lowest number since reporting began in 1948. 
There were no confirmed rubella cases and one probable 
case which was acquired outside Ireland. This reflects 
the excellent progress made in improving immunisation 
coverage with MMR vaccine, now at 93% almost reaching 
the 95% target. Unfortunately the mumps component 
of this vaccine has not been as successful in controlling 
mumps and there were over 740 cases reported in 2014, 
with the highest number of cases reported in 15-24 year 
olds. Chickenpox (Varicella) is a childhood infection that 
is now prevented through the use of a vaccine in many 
countries (not yet routinely used in Ireland). Chickenpox 
can be associated with serious complications and 61 cases 
required hospitalisation in 2014. Seven cases of varicella 
were complicated by invasive group A streptococcal disease 
(iGAS), a life threatening bacterial infection.
In 2014, the incidence of tuberculosis continued to 
fall in Ireland with 318 cases notified (incidence rate 
of 6.9/100,000). The rate in the indigenous Irish born 
population was lower again at 4.7 per 100,000. This decline 
has prompted a review of the need for universal BCG 
vaccination and it is likely that universal BCG vaccination 
will be discontinued in the near future. 
Campylobacter infection remains the commonest cause of 
bacterial gastroenteritis in Ireland and Europe. Rotavirus 
is the commonest viral cause of gastroenteritis in children. 
Again a vaccine is available and hopefully the rotavirus 
vaccine will shortly be introduced into the vaccination 
schedule to protect Irish children. Shigella is a bacterial 
cause of gastroenteritis and affected 57 people in Ireland in 
2014.  
Hepatitis C remains the most significant infectious cause of 
liver disease in Ireland with 710 cases notified in 2014. There 
have been major advances in the treatment of hepatitis 
C in recent years and there is cautious optimism that the 
national programme of treatment established in the HSE in 
2015 will avert the serious complications such as cirrhosis 
and cancer of the liver in many of those affected. 
There was an increase in the number of people notified with 
HIV infection in 2014 – 377 cases an 11% increase from 2014. 
It is of concern that the number of new diagnoses among 
men who have sex with men has trebled (from 60 to 183) in 
the last ten years. Recent initiatives offering screening to 
attendees of some emergency departments in Dublin may 
result in earlier detection in those who may otherwise be 
unaware of their infection.
Four hundred and thirty five outbreaks of infectious 
disease were investigated by Departments of Public Health 
throughout the country. The highest numbers ill were 
reported from nursing homes, community hospitals and 
acute hospitals. 
As alluded to with measles immunisation, coverage for all 
vaccines in the childhood schedule continues to improve 
and for the fourth consecutive year exceeded the target 
of 95% for the 6in-1 vaccine given to infants. Almost 85% 
of girls in first year in the 2013/2014 academic year were 
vaccinated against HPV infection which reflects a great 
collaboration of those working in school immunisation 
teams, administrative staff and those working nationally in 
the National Immunisation Office. We still have a long way 
to go to improve influenza vaccine coverage in healthcare 
workers (HCW) – while not advocating mandatory HCW 
vaccination as they do in the US we do advocate mandatory 
assessment of coverage data in all acute and long term care 
facilities (LTCF). Not all hospitals and LTCF report their data 
and in those that do not all staff report their flu vaccination 
status. Well done to the four hospitals and 24 LTCF who 
reached the 40% target last year.  
Well done also to the CIDR team who maintained IS27001 
Information Security Accreditation in 2014. Maintenance of 
this standard is vital to ensuring the information security 
of the data we hold on infectious diseases and essential to 
reassure our partners and the public of the importance of 
the privacy and confidentiality of their data.
Once again, I would like to express my gratitude to all 
those who provide data and participate in committees and 
to staff in HPSC and elsewhere in the HSE. This report is a 
testament to all of those who are managing to do more with 
less and continue to support the prevention and control of 
infectious disease in Ireland.
Dr Darina O’Flanagan
Director
HSE Health Protection Surveillance Centre
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In 2014, 61 cases of invasive Haemophilus influenzae 
disease were notified in Ireland (1.3/100,000 total 
population). This is a 48.8% increase on the number 
reported in the previous year. The annual average 
between 2004 (when H. influenzae first because a 
notifiable disease) and 2013 was 36 (figure 1). No 
imported cases were reported in 2014.
The main change in 2014, when compared to 2013, 
is the increase in the number of non-typeable/non-
capsular strains from 32 to 38, not typed PCR only 
diagnosed cases from one to eight and of not typed 
cases from one to seven (figure 1). 
Non-typeable/non-capsular cases accounted for the 
majority of the invasive H. influenzae cases notified 
in 2014 (62.3%, n=38/61). The remaining cases were 
due to H. influenzae type f (8.2%; n=5), ‘not type 
b’ (3.3%; n=2), type b (1.6%; n=1) and isolates that 
were not typed (24.5%; n=15), of which eight (13.1%) 
were diagnosed by PCR testing only. The median 
age of cases was 44 years (range three days to 95 
years). The incidence rates were highest in infants 
<1 year (16.6/100,000) and those aged 1 to 4 years 
(3.5/100,000) (table 1).
Cases occurring in children <10 years of age (n=23) 
and in elderly adults (65 years of age and older (n=21)) 
accounted for 72.1% of all invasive H. influenzae 
notifications in 2014 (table 1). One notable trend 
since 2004 is the increase in the overall proportion of 
cases 65+ years of age from 26.3% to 34.4% in 2014 
compared to the decline in those aged between 5 and 
64 years from 47.4% to 29.5%. 
In 2014, the highest frequency of cases tend to occur 
in the 0-4 year age group, after which it falls sharply 
1.1 Haemophilus influenzae (invasive) 
Number of cases, 2014: 61
Number of cases, 2013: 41
Number of cases, 2012: 41
Crude incidence rate, 2014:1.3/100,000
Summary
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Figure 1. Number of invasive H. influenzae cases and proportion of cases attributable to type b and non-typeable strains with 
95% confidence intervals, Ireland, 2004-2014
type b type  e type f
not type b non-typeable/non-capsular not typed
% type b % non-typeable/non-capsular
before increasing again among those aged 65+ years 
(table 1), consistent with what has been observed since 
2004 (figure 2).
In 2014 the number of male cases (n=38) substantially 
exceeded that of females (n=22) (male to female ratio 
of 1.7:1.0), and for one case no gender details were 
reported. This M:F ratio was considerably higher than 
the 0.4:1.0 ratio recorded in 2013 (figure 3) which is 
atypical and is explained by the unusually large number 
in that year of non-typeable infections reported among 
females (n=23) compared to males (n=9), especially in 
the >65 year age group. Between 2004 and 2014, there 
were 132 and 109 cases of non-typeable cases among 
males and females, respectively, giving a M:F ratio of 
1.2:1.0.
Between 2005 and 2011, the fewest quarterly number 
of cases has consistently been in the third quarter, but 
since 2012 that pattern no longer applies (figure 3). 
Incidence of disease in 2014 was highest in the HSE SE 
area (2.41/100,000) with the lowest in the HSE NW area 
(0.39/100,000) (table 2). No HSE area had an incidence 
rate that was significantly different from the national 
rate (figure 4).
A breakdown by clinical diagnosis for all cases by age 
group between 2004 and 2014 is presented in Table 3. 
In 2014, 16.4% (n=10/61) of cases did not have a clinical 
diagnosis recorded. 
Seven deaths were reported among the 61 cases in 
2014; three were not caused by the infection; and the 
cause of death was not recorded for the remaining four 
cases. The age range was 36 to 95 years. Four non-
typeable, two type f and one type b infection were 
recorded with these deaths.
 
In 2014, one case of H. influenzae type b (Hib) occurred 
in a 60-64 year old with an unknown vaccination status, 
no risk factors were identified. In the previous year, two 
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Figure 2. Number of H. influenzae cases by agegroup and type*, Ireland, 2004-2014
* Typed includes b, e, f, not-b
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Table 1. Number and incidence rates of invasive H. influenzae cases by serotype and age group, Ireland, 2014
Age 
Group
Type 
b
Type 
e
Type f
Not 
type b
Non-typeable/
non-capsular
Not 
Typed, 
PCR only 
diagnosis
Not 
Typed
Total
ASIR of H. 
influenzae 
type b
ASIR of all H. 
influenzae
<1 0 0 1 1 5 4 1 12 0.00 16.57
1-4 0 0 1 0 5 2 2 10 0.00 3.52
5-9 0 0 0 0 0 1 0 1 0.00 0.31
10-14 0 0 0 0 1 0 0 1 0.00 0.33
15-19 0 0 0 0 1 0 0 1 0.00 0.35
20-24 0 0 1 0 0 0 0 1 0.00 0.34
25-34 0 0 0 1 1 0 0 2 0.00 0.26
35-44 0 0 0 0 3 0 1 4 0.00 0.58
45-54 0 0 1 0 1 0 0 2 0.00 0.35
55-64 1 0 1 0 3 1 0 6 0.22 1.30
65+ 0 0 0 0 18 0 3 21 0.00 3.92
All Ages 1 0 5 2 38 8 7 61 0.02 1.33
CIR 0.02 0.00 0.11 0.04 0.83 0.17 0.15 1.33 - -
CIR, crude incidence rate per 100,000 total population; ASIR, age specific incidence rate per 100,000 population
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Figure 3. Number of H. influenzae cases by year/quarter and gender, Ireland, 2004-2014
Table 2. Incidence rates per 100,000 population of invasive H. influenzae by HSE area, Ireland, 2004-2014
HSE Area 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
HSE E 1.07 1.00 0.87 0.80 0.53 0.74 0.56 1.11 1.11 0.62 0.99
HSE M 1.19 1.19 0.40 1.19 0.79 1.06 0.35 1.06 0.35 1.42 1.77
HSE MW 0.83 0.28 0.83 0.55 0.83 2.11 0.53 0.53 1.05 0.79 2.11
HSE NE 0.25 1.27 0.25 0.00 0.00 0.23 0.45 1.59 0.91 1.36 1.59
HSE NW 0.42 0.00 2.11 0.42 0.00 0.39 0.39 0.77 0.77 1.16 0.39
HSE SE 1.08 0.43 0.87 1.08 0.65 1.00 1.00 0.80 1.21 1.00 2.41
HSE S 1.13 0.32 1.29 0.32 0.64 1.20 1.05 0.30 0.60 0.90 1.20
HSE W 0.48 1.45 0.72 1.45 0.48 1.12 0.22 1.35 0.45 0.90 0.90
Ireland 0.90 0.80 0.90 0.73 0.52 0.94 0.61 0.96 0.89 0.89 1.33
Table 3. Number of invasive H. influenzae cases by clinical diagnosis, Ireland, 2004-2014
Clinical Diagnosis 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
% 
2014
Septicaemia 8 14 13 6 3 9 9 11 11 14 15 24.6%
Pneumonia 5 0 3 6 3 8 5 12 12 4 12 19.7%
Meningitis 3 9 3 2 2 2 1 3 2 2 7 11.5%
Bacteraemia (w/o focus) 1 0 1 1 2 0 0 3 5 6 9 14.8%
Other 1 2 1 0 0 0 0 3 4 7 7 11.5%
Epiglottitis 1 3 3 1 1 0 2 0 0 3 1 1.6%
Cellulitis 1 1 2 1 1 0 0 1 0 0 0 0.0%
Meningitis & Septicaemia 1 0 1 0 1 1 1 1 1 0 0 0.0%
Osteomyelitis 1 0 0 0 0 0 0 0 0 0 0 0.0%
Septic arthritis 0 1 0 0 1 0 0 0 0 0 0 0.0%
Not specified 16 4 11 14 8 23 10 10 6 5 10 16.4%
Total 38 34 38 31 22 43 28 44 41 41 61 100%
% Known 57.9% 88.2% 71.1% 54.8% 63.6% 46.5% 64.3% 77.3% 85.4% 87.8% 83.6% -
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Figure 4. Crude incidence rates per 100,000 population with 95% confidence intervals for 
H. influenzae notifications by HSE area, Ireland, 2014
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cases of Hib occurred, both were two years of age and 
both were unvaccinated.
Between Q3-2007 and Q4-2014, a seven and a half year 
period, only one true Hib vaccine failure was reported, 
highlighting the continuing positive impact that the Hib 
booster catch up campaign has had in Ireland. 
Since September 2008, the Hib booster dose has 
been administered at 13 months of age as part of the 
routine childhood immunisation schedule in addition 
to the three doses given during infancy (at 2, 4 and 6 
months of age). Furthermore, vaccination is routinely 
recommended for those at increased risk of Hib disease 
due to underlying medical conditions or treatments.
In September 2014, a mother and baby pair of H. 
influenzae type f cases were reported, both of whom 
had septicaemia, but recovered. Type f H. influenzae 
was isolated from a placental swab. 
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 13th August, 
2015. These figures may differ from those published 
previously due to on-going updating of notification data 
on CIDR.
There were 33 measles cases (0.7/100,000) in 2014. 
This is the lowest annual number reported since 1948 
(figures 1 and 2). 
Fifteen (45%) of the cases in 2014 were linked to an 
outbreak associated with a university/college. Of the 
15 cases, 12 were in the HSE W and three were in the 
HSE S. The cases ranged in age from 14 years to 33 
years with a median age of 19 years and a mean age of 
20 years. Eleven (73%) of the cases were unvaccinated, 
one (7%) had received one dose of MMR and three 
(20%) were reported to have received two doses. Of 
the cases reported to have received two doses of MMR 
vaccine only one had both vaccination dates reported. 
Of the 15 cases, ten were classified as confirmed and 
five were classified as probable. Measles virus from four 
of the cases were genotyped by the NVRL and all were 
genotype D8.
Two other localised measles outbreaks were notified 
during 2014. One of these was an outbreak in a 
workplace with two ill. One of the cases in this outbreak 
1.2 Measles 
Summary
Number of cases, 2014: 33
Number of confirmed cases, 2014: 20                                       
Crude incidence rate, 2014: 0.7/100,000
Crude confirmed incidence rate, 2014: 0.4/100,000
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Figure 1. Annual number of measles cases in Ireland 1948-2014, the year of introduction of the measles vaccine and the measles 
mumps rubella (MMR) vaccine and vaccination campaigns years
A measles and rubella (MR) campaign for primary school age children was conducted in 1995
*A MMR vaccination campaign started in April 2009 for students in fourth, fifth and sixth year of second level schools
*A MMR catch-up campaign was conducted during the 2012/2013 and 2013/2014 academic years for children/students attending primary 
schools, second level schools and special schools and home-schooled students who had not completed (or were not sure they had) their two 
dose MMR vaccination schedule.
MMR1-first dose of MMR
MMR2-second dose of MMR
1948-June 2000 data collated by DoHC
July 2000-2014 data collated by HPSC
occurred in 2013 and was therefore in the 2013 data 
and 2013 annual report. The cases were in the age 
groups 25-34 years and 35-44 years and the vaccination 
status of both cases was reported as unknown. Measles 
virus from both of these cases was genotyped by the 
NVRL and both were genotype D8. 
The remaining outbreak was associated with a 
private house with two ill. Both cases were laboratory 
confirmed. These cases were in the age groups 20-24 
years and 25-34 years and both were unvaccinated.
Measles cases by HSE Area are shown in table 1.  The 
largest number (45%, n=15/33) of cases in 2014 and 
the highest crude incidence rate was in the HSE W 
(table 1). The majority of the cases in the HSE W (80%, 
n=12/15) and the HSE S (75%, n=3/4) were linked to the 
university/college outbreak.
Of the 33 measles cases 24% (n=8) were classified as 
possible, 15% (n=5) were classified as probable while 
61% (n=20) were classified as confirmed, giving a crude 
confirmed incidence rate of 0.4 per 100,000 population.  
The cases ranged in age from six months to 37 years; 
with a median age of 19 years and a mean age of 16 
years.  The number of cases by age group and the age 
specific incidence rates are shown in figures 3 and 4. 
Seventy one per cent (n=15/21) of the cases aged 10-34 
years were linked to the university/college outbreak. Of 
the 33 measles cases, 67% (n=22) were male and 33% 
(n=11) were female.
Laboratory results were provided for 25 cases in 2014. 
Sixty one per cent (n=20/33) of cases were laboratory 
test positive for measles. Three cases were laboratory 
negative for measles, however, for all three of these the 
specimens were not taken at the optimal time following 
disease onset. For two cases the laboratory tests were 
inconclusive for measles.
Isolates from eight cases were genotyped by the NVRL. 
Five were genotype D8, four of these had country of 
infection recorded as Ireland, while for one the country 
of infection was recorded as unknown. Three cases were 
genotype B3; the country of infection of these cases was 
Philippines (n=2) and Japan (n=1).
Of the 33 cases, the country of infection was recorded 
as Ireland for 15 cases, Philippines for two cases, Japan 
for one case and was unknown or not reported for the 
remainder.
Measles vaccine in Ireland is available as part of the 
combined Measles-Mumps-Rubella (MMR) vaccine. 
In Ireland, vaccination with the first dose of MMR 
is routinely recommended at twelve months of age 
and the second dose at four to five years of age. A 
MMR catch up campaign started in the academic 
year 2012/2013 and continued during the academic 
year 2013/2014. During the MMR catch up campaign 
the HSE offered a dose of MMR vaccine to children/
students attending primary schools, second level 
schools and special schools and home-schooled 
students who had not completed (or were not sure they 
had) their two dose MMR vaccination schedule.
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Table 1. Number of measles cases and the crude incidence 
rate per 100,000 population (CIR) by HSE Area in 2014
HSE Area Number CIR
HSE E 9 0.6
HSE M 1 0.4
HSE MW 2 0.5
HSE NE 1 0.2
HSE NW 0 0.0
HSE SE 1 0.2
HSE S 4 0.6
HSE W 15 3.4
Total 33 0.7
Figure 2. Number of measles cases by year, 2004-2014
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Vaccination data were reported for 88% (n=29/33) of 
measles cases in 2014. Sixty one per cent (n=20/33) of 
cases were unvaccinated; of these 30% (n=6/20) were 
less than 12 months of age.
Twelve percent (n=4/33) of cases were reported to have 
one dose of MMR vaccine; the majority (75%, n=3/4) of 
these were less than three years of age. One of those 
reported to have one dose of MMR was classified as 
confirmed. All four cases had a MMR vaccination date 
reported. 
Fifteen per cent (n=5/33) of cases were reported as 
having received two doses of MMR. Only two of these 
cases had both vaccination dates reported. Three of the 
cases with two MMR doses were classified as confirmed, 
one case was classified as probable and one as possible.
Of the 33 cases, the country of birth was recorded as 
Ireland for seven cases, Romania for one, Japan for one 
and was unknown or not specified for the remainder.
Seven cases were reported as hospitalised, representing 
21% (n=7/33) of all cases. The mean and median age 
of hospitalised cases was 23 years with cases ranging in 
age from 11 months to 37 years. All seven cases were 
classified as confirmed. Length of hospitalisation was 
reported for four cases with a median duration of stay 
of six days (range three to eight days). Four hospitalised 
cases were unvaccinated and three had no MMR details 
reported.
Reported complications of measles included pneumonia 
and seizures (4%, n=1/25), dehydration (n=1) and 
abnormal liver function tests and hematemesis (vomiting 
blood) (n=1).
Of the 33 cases, the setting where the case most likely 
acquired measles was reported as third level (18%, n=6), 
home (9%, n=3), overseas (9%, n=3), work (9%, n=3), 
and was unreported for the remainder (55%, n=18).
The figures presented above are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 19th August 2015. These 
figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR. 
WHO require information on discarded measles cases 
ie measles cases investigated and who were found not 
to meet the case definition. The HSE Areas reported 
the number of discarded CIDR cases to HPSC. For 
2014, 59 cases were discarded from CIDR as following 
investigation they were not considered to be measles 
cases. Discarded cases are not available in CIDR for 
reporting and are therefore not included in the analysis 
above.
The NVRL is the WHO accredited National Measles 
Rubella laboratory for Ireland.  Laboratories that 
perform measles/rubella investigations in their own 
laboratories are requested to send all positive samples 
for measles or rubella to the NVRL for confirmatory 
testing.  In addition, a selection of negative specimens 
should also be referred. Genotyping is undertaken on a 
selection of specimens. 
Figure 4. The age specific incidence rate (per 100,000) of 
measles cases in 2014 by case classification
Figure 3. Number of measles cases in 2014 by age group and 
case classification
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Between 1999 and 2012, a marked downward trend in 
invasive meningococcal disease (IMD) incidence was 
observed: in 1999 there were 536 cases (14.8/100,000) 
and in 2012 there were 66 cases (1.4/100,000), a decline 
of almost 88%. In 2014, however, 82 cases (1.8/100,000) 
of IMD were notified, similar to that reported in the 
previous year (n=81). 
Typically, most cases in 2014 were diagnosed by blood/
CSF culture testing, blood/CSF PCR testing or by 
detection of Gram negative diplococci in skin lesions/
culture or in CSF specimens. Isolation of the organism 
from non-sterile sites (such as the eye, nose or throat) in 
clinically compatible cases is considered a possible case. 
Of the 82 cases notified in 2014, 79 (96.3%) were case 
classified as confirmed and three (3.7%) as possible. 
Confirmation of diagnosis by laboratory testing of 
cases has improved with time. In 2014, 96.3% (n=79/82) 
of cases were confirmed by laboratory testing in 
comparison to 83.0% (n=445/536) in 1999.
In 2014, 49 of the 79 confirmed cases (62.0%) were 
confirmed by PCR testing alone and another eight 
confirmed cases (10.1%) were diagnosed by culture of 
sterile specimens alone. Of the remaining 22 (27.9%) 
confirmed cases, all were diagnosed by both culture and 
PCR testing of sterile specimens. Additional laboratory 
testing was done on the 79 confirmed cases: one had 
a positive skin lesion culture and 11 had positive CSF 
microscopy test results. 
Of the three possible cases reported in 2014, only one 
had a positive laboratory test result and it was based on 
an eye swab culture in which the peri-orbital cellulitis 
infection was attributable to a non-groupable strain.
In 2014, male cases (n=44) exceeded female cases 
(n=38), resulting in a male to female ratio of 1.2:1.0, 
following a consistent pattern observed since 2005. IMD 
cases in 2014 ranged in age from three weeks to 90 
years (median age of 3 years). 
Overall incidence in Ireland was 1.8/100000 population 
in 2014. The incidence of IMD was highest in infants 
and young children. Age specific incidence rate 
(ASIR) was highest among infants <1 year of age 
(30.4/100,000; n=22), followed by children in the 1 to 4 
year (9.2/100,000; n=26), and 15 to 19 year age groups 
(2.5/100,000; n=7) (table 1, figure 1). 
Figure 2 presents the number of IMD cases by gender 
and age group between 1999 and 2014 and shows the 
decline in numbers across all of the age groups, with 
the steepest declines observed in the <1, 5-9 and 10-
24 year age groups following the introduction of the 
meningococcal C conjugate (MCC) vaccine in late 2000.
1.3  Meningococcal Disease (Neisseria 
meningitidis) (invasive)  
Summary
Number of cases, 2014: 82
Number of cases, 2013: 81
Number of cases, 2012: 66
Crude incidence rate, 2014:1.8/100,000
Table 1. Number of cases, deaths, age-group specific incidence rates per 1000,000 population (calculated using Census 2011 
denominator data) and case fatality ratios of IMD, Ireland, 2014
Age Group No. Cases ASIR No. Deaths %CFR
<1 22 30.4 1 4.5%
1-4 26 9.2 1 0.0%
5-9 6 1.9 0 0.0%
10-14 3 1.0 0 7.1%
15-19 7 2.5 1 0.0%
20-24 3 1.0 0 0.0%
25+ 15 0.5 1 0.0%
All ages 82 1.8 4 4.9%
ASIR, age specific incidence rate per 100,000 population; %CFR, case fatality ratio
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At regional level incidence was highest in the HSE 
M area (3.5/100,000) and lowest in the HSE MW 
area (0.3/100,000) (table 2). Apart from HSE MW, no 
other area had an incidence rate that was significantly 
different from the national rate (figure 3). There were no 
imported cases identified in 2014.
Apart from the years 2003, 2013 and 2014, IMD cases 
have tended to occur most frequently in the first quarter 
of each calendar year (figure 4). 
Neisseria meningitidis serogroup B was the pathogen 
most commonly associated with IMD in 2014 and 
accounted for 69 of the 82 (84.1%) notifications. Since 
2002 serogroup B has consistently accounted for more 
than 80% of annual IMD notifications (figure 5). 
One meningococcal outbreak was reported in 2014. The 
serogroup B outbreak occurred in a child care facility in 
the HSE NE in which two cases (age range one month to 
20 years) were notified.
Figure 1. Age-specific rates per 100,000 population for invasive meningococcal disease 
(IMD), Ireland, 1999-2014
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Table 2. Age specific incidence rates per 100,000 population (calculated using Census 2011 denominator data) of IMD by HSE 
area and age group, Ireland, 2014
HSE Area <1 1-4 5-9 10-14 15-19 20-24 25+ Total
HSE E 34.6 8.2 2.8 0.0 1.0 0.0 0.4 1.5
HSE M 62.2 26.2 4.5 0.0 0.0 0.0 0.6 3.5
HSE MW 0.0 4.4 0.0 0.0 0.0 0.0 0.0 0.3
HSE NE 78.0 16.0 0.0 3.1 0.0 0.0 0.7 3.2
HSE NW 25.7 6.3 0.0 0.0 6.0 6.7 0.0 1.5
HSE SE 39.2 9.7 0.0 0.0 0.0 0.0 0.6 1.6
HSE S 0.0 5.0 2.2 0.0 4.9 2.4 0.5 1.2
HSE W 0.0 3.8 3.2 6.8 10.8 3.6 1.3 2.7
Ireland 30.4 9.2 1.9 1.0 2.5 1.0 0.5 1.8
Table 3. Number of cases, deaths and case fatality ratios (%CFR) by year for meningococcal B and C disease, Ireland, 1999-2014
Meningococcal B Meningococcal C
Year No. Cases No. Deaths %CFR No. Cases No. Deaths %CFR
1999 292 12 4.1% 135 5 3.7%
2000 258 13 5.0% 139 11 7.9%
2001 245 8 3.3% 35 3 8.6%
2002 199 8 4.0% 14 0 0.0%
2003 206 11 5.3% 5 1 20.0%
2004 163 7 4.3% 5 1 20.0%
2005 169 5 3.0% 5 0 0.0%
2006 168 5 3.0% 4 0 0.0%
2007 157 6 3.8% 2 0 0.0%
2008 149 6 4.0% 4 1 25.0%
2009 119 6 5.0% 5 0 0.0%
2010 93 4 4.3% 4 0 0.0%
2011 84 2 2.4% 2 0 0.0%
2012 58 1 1.7% 0 0 0.0%
2013 68 4 5.9% 1 0 0.0%
2014 69 3 4.3% 6 1 16.7%
%CFR, case fatality ratio
There were four IMD related notified deaths in 2014 
(case fatality ratio of 4.9%) (age range 9 months to 90 
years) (table 1). This compares to an annual average of 
five deaths between 2005 and 2013. In 2014, the %CFR 
was highest amongst cases 65+ years of age (20.0%) as 
a result of one death among five cases. The next highest 
%CFR was 14.3% (n=1/7) due to a MenC death in an 
adult aged 15-19 years.
All but one of the four IMD deaths in 2014 disease 
was due to serogroup B. This is in marked contrast to 
the 13 deaths due to serogroup B out of all 25 deaths 
reported in 2000. In the same year, 11 deaths were due 
to serogroup C disease. 
IMD due to serogroup C (MenC) has remained at 
very low levels over the last decade with five cases or 
less occurring annually. However, in 2014, the highest 
number of MenC cases (n=6) since 2002 was observed, 
all aged between 18 and 72 years (table 3). Three of 
these six cases were unvaccinated and were aged 
between 19 to 77 years with no risk factors reported; 
the vaccination status of the remaining three cases was 
unknown, they ranged in age between 18 and 53 years, 
two of whom were foreign born, including one who was 
a student who died.
Since 2003, 11 true vaccine failures have been recorded, 
the most recent of which occurred in 2013. Prior to the 
introduction of the MCC vaccine, serogroup C incidence 
rate in 1999 was 3.7/100,000 population; in 2014 it was 
0.13/100,000.
The recent small increase in MenC cases may represent 
waning population herd immunity and would be 
consistent with recent studies undertaken in the United 
Kingdom which have reported waning immunity to 
serogroup C disease following infant vaccination in 
early childhood. Furthermore, protection given by 
vaccination at 12 months also wanes by the teenage 
years, but vaccination later in childhood provides higher 
levels of antibody that persist for longer.1-4 There is 
Figure 2. Number of IMD cases by gender and age group in Ireland, 1999-2014 (excludes 
one case with unknown gender details in 2009)
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Figure 3. Crude incidence rates per 100,000 population with 95% confidence intervals for 
IMD notifications by HSE area, Ireland, 2014
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Figure 4. Number of IMD cases by quarter and serogroup, Ireland, 1999-2014
evidence that shows that MCC vaccination significantly 
reduces nasopharyngeal carriage of the serogroup C 
meningococcus, providing indirect protection through 
herd immunity.5-6 The increase in MenC cases in Ireland 
in 2014 may reflect a decline in this herd immunity. 
This emerging evidence of waning immunity and 
the recent increase in MenC cases has led to the 
routine MenC vaccination programme in Ireland being 
changed. Instead of three doses of meningococcal C 
conjugate (MCC) being administered to children at 4, 
6 and 13 months of age, from July 2015 a single dose 
will be given at 4 months, 13 months and at 12-13 
years (if not previously vaccinated at >10 years of age) 
(http://www.hse.ie/eng/health/immunisation/hcpinfo/
guidelines/chapter13.pdf). The National Immunisation 
Advisory Committee (NIAC) has also recommended a 
booster dose of the MCC vaccine for those considered 
at increased risk of MenC disease, and since 2011, the 
MCC vaccine booster has been recommended for close 
contacts of cases if their last dose was more than one 
year before. In August 2014, NIAC recommended an 
adolescent booster at 12-13 years to be offered in the 
first year of secondary level school. The adolescent 
booster MenC programme commenced in January 
2015. 
IMD is still an important public health concern due to 
its associated severity, high mortality rate and serious 
adverse sequelae, despite the marked reduction in 
the overall incidence in the past decade. Effective 
vaccination is necessary for complete IMD prevention 
and control. Effective vaccines are now available against 
serogroups A, B, C, W135 and Y forms of the disease. 
In 2012, Bexsero®, a recombinant multicomponent 
vaccine (4CMenB) against serogroup B disease was 
approved by the European Medicines Agency. In 
March 2014, the United Kingdom’s Joint Committee on 
Vaccination and Immunisation (JCVI) recommended the 
vaccination of infants against serogroup B.7 In August 
2014, NIAC issued guidelines on how this vaccine 
should be administered in Ireland (http://www.hse.ie/
eng/health/immunisation/hcpinfo/guidelines/chapter13.
pdf). In September 2015, the National Immunisation 
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Figure 5. Number of IMD notifications in Ireland by serogroup and proportion of cases attributable 
to serogroup B with 95% confidence intervals, Ireland, 1999-2014
Office (NIO) included a universal MenB vaccination 
proposal in the HSE 2016 service plan. At the time of 
writing this report (September 2015), no decision has 
yet been made. 
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 13th August, 
2015. These figures may differ from those published 
previously due to on-going updating of notification 
data on CIDR.
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There was a large increase in mumps in 2014 with 742 
(16.2/100,000) mumps cases notified. This is 3.3 fold 
higher than 2013 when 223 cases were notified and 4.6 
fold higher than 2012 when 163 cases were notified 
(figure 1). Large mumps outbreaks previously occurred 
during the years 2004/2005 and 2008/2009 (figure 1). 
Nearly two-thirds (n=489) of the cases in 2014 were 
notified between September and December (figure 
2). Of the cases notified between September and 
December 40% were in the HSE S, 22% in the HSE SE 
and 17% in the HSE E (figure 2).
In 2014, the largest number of cases was notified in the 
HSE S and the highest crude incidence rate was in the 
HSE S followed by the HSE SE (table 1).
Of the 742 mumps cases notified 40% (n=299) were 
classified as confirmed, 30% (n=222) as probable and 
30% (n=221) were classified as possible.
The mean age of cases was 22 years and the median 
age of cases was 19 years with cases ranging in age 
from eight months to 81 years (age was unknown for 
three cases). The largest number of cases and the 
highest age specific incidence rates were in those 15-
19 years and 20-24 years (figures 3 and 4). Fifty five per 
cent (n=406) of cases were male and 45% (n=336) were 
female.
Mumps vaccine in Ireland is available as part of the 
combined measles mumps rubella (MMR) vaccine. 
In Ireland, vaccination with the first dose of MMR is 
1.4 Mumps 
Summary
Number of cases, 2014: 742
Number of cases, 2013: 223
Crude incidence rate, 2014: 16.2/100,000
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Figure 1. Number of mumps cases by year 
A MMR catch-up campaign was conducted during the 2012/2013 and 2013/2014 academic years for children/students attending primary 
schools, second level schools and special schools and home-schooled students who had not completed (or were not sure they had) their two 
dose MMR vaccination schedule
MMR1- first dose of MMR
MMR2- second dose of MMR
1988-June 2000 data collated by DoHC
July 2000-2014 data collated by HPSC
routinely recommended at twelve months of age and 
the second dose at four to five years of age. A MMR 
catch up campaign started during the academic year 
2012/2013 and continued during the academic year 
2013/2014. During the MMR catch up campaign 
the HSE offered a dose of MMR vaccine to children/
students attending primary schools, second level 
schools and special schools and home-schooled 
students who had not completed (or were not sure they 
had) their two dose MMR vaccination schedule.
Of the 742 mumps cases, 13% (n=97) were 
unvaccinated, 16% (n=118) had one dose of MMR, 38% 
(n=281) were reported to have received two doses 
of MMR, one per cent (n=9) were reported to have 
three doses of MMR while for 32% (n=237) of cases 
the number of doses of MMR were not reported. The 
vaccination date was reported for 52% (n=61/118) 
of cases reported to have received one dose of 
MMR. Both vaccination dates were reported for 42% 
(n=118/281) of cases vaccinated with two doses of 
MMR. Thirty-four per cent (n=96/281) of the cases 
reported to have received two doses of MMR were 
classified as confirmed; 46% (n=44/96) of these cases 
had both MMR vaccination dates reported. All three 
vaccination dates were available for 89% (n=8/9) of 
the cases given three doses of MMR. Of the nine cases 
reported to have received three MMR doses four were 
classified as confirmed cases; three of these four cases 
had all vaccination dates reported.
The country of birth was recorded as Ireland (n=162), 
United Kingdom (n=8), France (n=7), Brazil (n=4), 
Philippines (n=3), Poland (n=3), Australia (n=1), Belgium 
(n=1), Hungary (n=1), Lithuania (n=1), Malaysia (n=1), 
Russian Federation (n=1), Togo (n=1), Uganda (n=1) and 
were unknown or not specified for the remainder.
 
Thirty six cases were hospitalised, representing five 
per cent (n=36/742) of all cases and seven per cent 
(n=36/541) of cases where hospitalisation data was 
known. The number of days hospitalised was reported 
for 23 of the hospitalised cases; the median number of 
days hospitalised was two days (range one to 17 days). 
Reported complications of mumps included orchitis 
(12%, n=33/265), mastitis (1%, n=6/463), pancreatitis 
Figure 3. Number of mumps cases in 2014 by age group and 
case classification 
Figure 2. Number of mumps cases in 2014 by month and 
HSE Area
Figure 4. The age specific incidence rates (per 100,000) of 
mumps cases in 2014 (age unknown for three cases)
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Table 1. Number of mumps cases and the crude incidence 
rate per 100,000 population (CIR) by HSE Area in 2014
HSE Area Number CIR
HSE E 142 8.8
HSE M 21 7.4
HSE MW 47 12.4
HSE NE 13 2.9
HSE NW 41 15.9
HSE SE 141 28.3
HSE S 258 38.8
HSE W 79 17.7
Total 742 16.2
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(0.4%, n=2/455), meningitis (0.4%, n=2/467), deafness 
(0.2%, n=1/465), abdominal pain and neck stiffness 
(n=1), elevated amylase (n=1), arthritis and hepatitis 
(n=1), back pain (n=1), chest infection (n=1), earache 
(n=2), neck stiffness (n=1), respiratory tract infection 
(n=1), stomach ache (n=1), testicular pain (n=1), query 
tonsillitis (n=1) and possibly viral myocarditis related 
to mumps (n=1).For some cases a number of clinical 
complications were reported. 
The setting where the case most likely acquired 
mumps was reported for 53% (n=396/742) of cases. 
The identified settings were: university/college (32%, 
n=236), secondary school (7%, n=55), social setting 
(6%, n=47), family/household (4%, n=31), work (2%, 
n=13), primary school (1%, n=10), day-care/pre-school 
(0.4%, n=3) and international travel (0.1%, n=1).
The countries of infection were recorded as Ireland 
(n=328), United Kingdom (n=4), Bulgaria (n=1), Czech 
Republic (n=1), Pakistan (n=1), United Republic of 
Tanzania (n=1), United States (n=1) and was unknown/
not specified for 405 cases.
Twenty-three localised outbreaks of mumps were 
notified during 2014 with a total of 426 associated 
cases of illness. The outbreak locations included 11 
university/college outbreaks (with 322 ill), seven private 
houses (with 17 ill), two community outbreaks (with 72 
ill) and three school outbreaks (with 15 ill).
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 15th October 2015. 
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.  
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Other Forms of Bacterial Meningitis* 
Apart from Neisseria meningitidis, which is the most 
common cause of bacterial meningitis in Ireland, other 
pathogens cause this disease, including those caused 
by non-notifiable organisms. For information on invasive 
meningococcal disease (Neisseria meningitidis), see 
that chapter within this report. Information on bacterial 
meningitis caused by specified notifiable diseases 
is summarised below and further pathogen-specific 
data are available in the relevant chapter. The figures 
presented in this chapter are based on data extracted 
from the Computerised Infectious Disease Reporting 
(CIDR) system on 13th August, 2015. These figures may 
differ from those published previously due to on-going 
updating of notification data on CIDR. 
Bacterial meningitis caused by diseases not otherwise 
specified (NOS):
In total, 23 cases of meningitis under this disease 
category were notified in 2014, none of whom died. 
Thirteen of the 23 (56.5%) cases were case classified 
as confirmed, eight as probable (34.8%) and two as 
possible (8.7%) (table 1). The causative pathogens were 
identified in 47.8% (n=11/23) of cases (table 2).
Prior to 1st January 2012, all cases of Group B 
streptococcus, also known as S. agalactiae, were 
notifiable under the ‘Bacterial Meningitis (NOS)’ disease 
category. In 2012, this changed when Streptococcus 
agalactiae in children < 90 days of age was notifiable 
in its own right, including those which were meningitis-
related. This has meant that the overall number of 
bacterial meningitis (NOS) cases has, as a result, 
declined between 2012 and 2014 compared to previous 
years. In other words, without this change there would 
have been 21 extra cases reported under the Bacterial 
meningitis (NOS) category between 2012 and 2014. 
Furthermore, there is evidence of an additional 32 
possible meningitis-related cases of this disease in this 
same age group during this same three year period 
where S. agalactiae was either isolated from or detected 
in CSF specimens from patients that were not clinically 
categorised as having ‘meningitis’ and had in fact no 
clinical diagnosis reported on CIDR. These 32 cases 
have been excluded from Table 3, which is a summary 
breakdown of all bacterial meningitis cases by their 
causative pathogen (both specified and not specified 
types except for meningococcal disease) between 2009 
and 2014.
Among the bacterial meningitis (NOS) cases notified in 
2014 were six caused by Escherichia coli (age range two 
to eight weeks; none of which had serotype details), 
one each caused by Enterococcus species (30-34 years), 
Klebsiella pneumoniae (age unknown), Micrococcus 
luteus (2 months old); Streptococcus agalactiae (7 
months old), and Streptococcus suis (50-54 years old). 
There were 12 other cases whose causative organism 
was not identified. 
Bacterial meningitis caused by specified notifiable 
diseases:
Haemophilus influenzae
Seven cases of meningitis due to H. influenzae were 
notified in 2014, five of which were attributable to non-
typeable/non-capsulated strains and the remaining two 
were PCR diagnosed positive, not typed. The age range 
was one month to 64 years. No deaths were reported 
among these cases. See Table 3 and the chapter on 
invasive H. influenzae disease for further details.
Listeria species
One case of listeriosis meningitis was notified in 2014. 
The case was 23 months of age, serotype 4b infection 
was diagnosed and the case had no underlying medical 
condition reported. See Table 3 and the chapter on 
listeriosis disease for further details.
Streptococcus pneumoniae
In 2014, 39 cases of pneumococcal meningitis were 
notified, compared to 33 in the previous year. The 
median age was 55 years (range one month to 87 years). 
Five (12.8%) pneumococcal meningitis related deaths 
were reported in 2014, with a median age of 56 years 
(range 9 to 83 years). The cause of death was reported 
for two cases: one was caused by this infection, the 
other was not; the cause of death was not reported on 
the remaining three cases. 
Of the 39 cases in 2014, 24 were eligible for vaccination 
(13 cases were aged >65 years and 11 others had risk 
factors reported). Data on vaccination status were 
available for 34 of the 39 cases (87.2%). Eleven (28.2%) 
were vaccinated with either the PCV13 or PPV23 
1.5  Other Forms of Bacterial Meningitis*    
(*excluding meningococcal disease)
Summary
Number of cases, 2014: 23
Number of cases, 2013: 21
Number of cases, 2012: 29
Crude incidence rate, 2014:0.5/100,000
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Table 1. Number and percentage of bacterial meningitis (NOS) cases reported by case classification, Ireland, 2009-2014
Case Classification 2009 2010 2011 2012 2013 2014 2009-2014
Confirmed 17 21 18 12 6 13 87
Probable 8 7 4 5 5 8 37
Possible 15 14 13 12 10 2 66
Total 40 42 35 29 21 23 190
% Confirmed 42.5% 50.0% 51.4% 41.4% 28.6% 56.5% 45.8%
Note: Streptococcus agalactiae < 90 days of age excluded from 2012, 2013 and 2014 figures
Table 2. Number and percentage of bacterial meningitis (NOS) cases reported with and without an identified 
causative organism, Ireland, 2009-2014
Causative Organism 2009 2010 2011 2012 2013 2014 2009-2014
Known 15 21 20 11 6 11 84
Unknown/Not specified 25 21 15 18 15 12 106
Total 40 42 35 29 21 23 190
% Known 37.5% 50.0% 57.1% 37.9% 28.6% 47.8% 44.2%
Note: Streptococcus agalactiae < 90 days of age excluded from 2012, 2013 and 2014 figures
Table 3. Annual notifications of bacterial meningitis (specified and NOS) except meningococcal disease, Ireland, 2009-2014
Notified under Causative organism 2009 2010 2011 2012 2013 2014 2009-2014
Haemophilus influenzae disease 
(invasive)
Haemophilus influenzae 3 2 4 3 2 7 21
Leptospirosis Leptospira spp. 1 0 1 1 0 0 3
Listerosis Listeria spp. 1 3 2 2 2 1 11
Salmonellosis Salmonella enteritidis 1 0 0 0 0 0 1
Streptococcus pneumoniae infection 
(invasive)
Streptococcus pneumoniae 22 16 23 37 33 39 170
Streptococcus Group A infection 
(invasive) (iGAS)
Streptococcus pyogenes 0 2 0 1 3 0 6
Streptococcus Group B infection 
(invasive) (Group B Strep) < 90 days 
of age
Streptococcus agalactiae† NA NA NA 11 5 5 21
Tuberculosis* Mycobacterium spp.* 8 9 2 3 3 1 26
Total Bacterial Meningitis, specified 36 32 32 58 48 53 259
Bacterial Meningitis, not otherwise 
specified
Enterococcus faecalis 1 0 0 0 0 0 1
Enterococcus faecium 0 0 0 1 0 0 1
Enterococcus species 0 0 0 0 0 1 1
Escherichia coli 3 2 1 7 4 6 23
Group C Streptococcus 0 0 0 1 0 0 1
Klebsiella oxytoca 0 0 1 0 0 0 1
Klebsiella pneumoniae 0 0 0 0 0 1 1
Micrococcus luteus 0 0 0 0 0 1 1
Mycoplasma pneumoniae 0 1 0 0 0 0 1
Staphylococcus aureus 2 6 2 1 0 0 11
Staphylococcus aureus & 
Staphylococcus capitis
0 0 0 1 0 0 1
Staphylococcus capitis 0 1 0 0 0 0 1
Streptococcus agalactiae** 7 11 16 0 1 1 36
Streptococcus bovis biotype II/2 2 0 0 0 0 0 2
Streptococcus salivarius 0 0 0 0 1 0 1
Streptococcus suis 0 0 0 0 0 1 1
Unknown 1 1 1 2 2 1 8
Not specified 24 20 14 16 13 11 98
Total Bacterial Meningitis, not 
otherwise specified
40 42 35 29 21 23 190
Total Bacterial Meningitis, specified 
and not otherwise specified
76 74 67 87 69 76 449
*Tuberculosis meningitis figure for 2014 is provisional       
†Streptococcus agalactiae < 90 days of age in 2012 to 2014-these figures do not include 32 meningitis-related cases where the causative 
organism was isolated from or detected in CSF specimens from patients that were not clinically categorised as having ‘meningitis’ 
**Streptococcus agalactiae for all ages only in 2009 to 2011 and for cases > 90 days of age only in 2012 to 2014   
NA not applicable 
vaccines, one (2.6%) was incompletely vaccinated 
with PCV13; the remaining 27 (69.2%) cases with 
pneumococcal meningitis were either unvaccinated 
(n=12; 30.8%) or had an unknown vaccination status 
(n=15; 38.5%). 
Fourteen cases (35.9%) had serotypes that were 
covered by either the PCV13 or PPV23 vaccines. Of the 
eleven cases (28.2%) that were vaccinated, six (15.4%) 
had serotypes that were covered by either the PCV13 
or PCV23 vaccines, including two cases (aged 1-4 years) 
which were vaccinated with two and four doses of the 
PCV13 vaccine, respectively. Of the 24 cases eligible for 
vaccination, including 13 that were aged >65 years, 20 
were reported to have additional risk factors. Additional 
details are presented in Table 4. See also a separate 
chapter on invasive pneumococcal disease for further 
details.
Mycobacterium species
In 2014, one tuberculosis meningitis case was notified 
(provisional at the time of writing) aged 6-10 years, with 
no risk factors reported. See the chapter on tuberculosis 
for further details.
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Table 4. Details of the 39 pneumococcal meningitis cases reported, Ireland, 2014
Age Group 
(years)
Died
Vaccination 
Status
No. of PCV13 
/ Prevenar 13 
Doses
No. of PPV23 
/ Pneumovax 
23 Doses
Serotype 
of 
Infection
Serotype Covered by 
Vaccine Type
Risk Factors
<1
 I 1 NA NA NA
 U 0 NA NA N
1-4
 Y 2 NA 19A PCV13, PPV23 N
 Y 4 NA 15B PPV23 Y
5-9
Y U 0 NA 19F PCV13, PPV23 Y
 N 0 0 NA N
10-14  U 0 NA 35B Not covered Y
15-19  U 0 NA NA N
25-29  U 0 NA 15A Not covered NA
30-34  U 0 NA 23A Not covered Y
35-39
 U 0 NA 35B Not covered Y
 U 0 NA NA N
40-44
Y Y 0 1 37 Not covered Y
 U 0 NA 11A PPV23 NA
 U 0 NA 29 Not covered Y
45-49
 N 0 0 NA N
 N 0 0 22F PPV23 N
 N 0 0 NA Y
50-54  U 0 NA 3 PCV13, PPV23 NA
55-59
Y* U 0 NA 10A PPV23 U
 N 0 0 15A Not covered Y
 N 0 0 NA NA
 Y 0 1 NA NA
60-64
 N 0 0 6C Not covered Y
Y N 0 0 15C Not covered Y
 Y 0 1 NA U
65+
 U 0 NA NA Y
 U 0 NA 15A Not covered NA
 U 0 NA 9N PPV23 NA
 N 0 0 NA Y
 N 0 0 NA Y
 N 0 0 20 PPV23 Y
 N 0 0 33F PPV23 NA
Y Y 0 1 8 PPV23 Y
 Y 0 1 24F Not covered Y
 Y 0 1 12F PPV23 Y
 Y 0 1 NA N
 Y 0 1 3 PCV13, PPV23 Y
 Y 0 2 19A PCV13, PPV23 Y
NA=not applicable or not available; Vaccinated: Y=Yes, N=No, U=Unknown, I=Incompletely vaccinated; * IPD was cause of death
Following an increase in pertussis in 2012 with 458 
notifications (10.0/100,000), pertussis declined in 2013 
with 173 cases (3.8/100,000) notified and declined 
further in 2014 with 73 cases (1.6/100,000) notified 
(figures 1 and 2). 
Of the 73 cases in 2014, 86% (n=63) were classified 
as confirmed, four per cent (n=3) were classified as 
probable and 10% (n=7) were classified as possible.
The largest number of cases was notified in the HSE E 
while the highest crude incidence rate was in the HSE W 
followed by the HSE MW (table 1).
Fifty-eight per cent of cases (n=42) were female, 41% 
(n=30) were male (female to male ratio 1.4:1.0) while 
gender was not reported for one case.
The largest number of cases (51%, n=37/73) and the 
highest age-specific incidence rate (51/100,000) were in 
children aged less than one year with 47% (n=34/73) of 
all cases aged less than six months of age (figures 3  
and 4). 
Maternal antibodies from women immunised before 
pregnancy wane quickly and the concentration of 
1.6 Pertussis
Summary
Number of cases, 2014: 73
Number of cases, 2013: 173
Crude incidence rate, 2014: 1.6/100,000
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Figure 1. Number of notified pertussis cases in Ireland by year, 1948-2014
1948-June 2000 data collated by DoHC
July 2000-2014 data collated by HPSC
Figure 2. Number of notified pertussis cases in Ireland by year, 2000-2014
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pertussis antibodies is unlikely to be high enough to 
provide passive protection to their infants prior to 
primary vaccination. Since August 2012, the National 
Immunisation Advisory Committee (NIAC) has 
recommended that pregnant women should be offered 
tetanus and low dose diphtheria and acellular pertussis 
(Tdap) vaccine during 27 -36 weeks gestation in each 
pregnancy, to protect themselves and their infant. Tdap 
can be given at any time in pregnancy before 27 or after 
36 weeks gestation although it may be less effective 
in providing passive protection to the infant. Data on 
maternal antenatal vaccination status was provided 
for 54% (n=20/37) of children aged less than one year 
and none of the mothers of these infant pertussis cases 
reported vaccination during the antenatal period. 
Gestational age at birth was reported for seven cases 
and ranged from 28 to 41 weeks with a median of 40 
weeks and an average of 38 weeks. All seven cases 
were aged ≤6 months at the time of notification. Data 
on maternal antenatal vaccination status was provided 
for four of these cases and none of the mothers of these 
infant pertussis cases reported vaccination during the 
antenatal period. 
In Ireland, it is recommended that children be 
vaccinated with an acellular pertussis containing 
vaccine at two, four and six months of age and a 
booster dose at four to five years of age. In 2008, 
NIAC recommended a booster with low dose acellular 
pertussis vaccine for children aged 11-14 years. The 
adolescent pertussis booster was introduced into the 
school programme, in 19 LHOs, in 2011 and to all 
schools in 2012. In August 2012, an additional pertussis 
booster was recommended for health care workers 
Table 1. Number of pertussis cases notified and the crude 
incidence rate per 100,000 population (CIR) by HSE Area in 
2014
HSE Area Number CIR
HSE E 25 1.5
HSE M 1 0.4
HSE MW 9 2.4
HSE NE 5 1.1
HSE NW 5 1.9
HSE SE 8 1.6
HSE S 9 1.4
HSE W 11 2.5
Total 73 1.6
Figure 3. Number of notified pertussis cases in 2014 by age 
group and case classification.
‘Mo’ in graph indicates months i.e. 0-5 months and 6-11 
months, the remaining age groups are in years
Figure 4. The age specific incidence rate (per 100,000 
population) of notified pertussis cases in 2014 by case 
classification
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and pregnant women; please see the HSE National 
Immunisation Office website at http://www.hse.ie/eng/
health/immunisation/ for additional information on 
pertussis vaccination recommendations.
In 2014, the number of doses of pertussis vaccine 
the cases received was reported for 71% (n=52/73) 
of cases. Forty four per cent of cases (n=32/73) were 
unvaccinated; these cases ranged in age from one 
month to 54 years, with 72% (n=23/32) of these cases 
aged less than six months. Forty-one per cent of the 
unvaccinated cases (n=13/32) were less than two 
months of age and were therefore not eligible for 
pertussis vaccine in the Irish schedule.
Twelve per cent (n=9/73) of cases were reported to 
have one dose of pertussis vaccine, all were less than 
five months of age. Ten per cent (n=7/73) had three 
doses of pertussis vaccine, these cases ranged in age 
from one to 12 years. Five per cent (n=4/73) had four 
doses of pertussis vaccine (one had no vaccination 
details available), these cases ranged in age from 
eight to 13 years with one case classified as confirmed. 
Vaccination status was unknown or not reported for the 
remainder of cases.
Country of birth was reported as Ireland for 24 cases, 
Brazil for one, Spain for one, United States for one and 
was unknown/not specified for the remainder. 
Some reported symptoms included cough (98%, 
n=57/58), paroxysmal cough (87%, n=48/55), inspiratory 
whoop (59%, n=30/51), apnoea (34%, n=18/53), 
post-tussive vomiting (34%, n=17/50), cyanosis (29%, 
n=14/48), choking episodes in infant (46%, n=11/24) 
and tachypnoea (n=1). Reported complications included 
pneumonia (4%, n=2/50), conjunctival haemorrhages 
(2%, n=1/48), seizures (2%, n=1/50) and respiratory 
tract infection (n=1).
Thirty-six cases were hospitalised, representing 49% 
(n=36/73) of all cases and 58% (n=36/62) of cases 
where hospitalisation data was known. Eighty-nine per 
cent (n=32/36) of those hospitalised were aged less 
than one year and 36% (n=13/36) were less than two 
months of age. 
Of the 73 cases, the likely setting of exposure to 
pertussis included home (21%, n=15), crèche/childcare 
(4%, n=3), healthcare associated (1%, n=1), other family 
setting (1%, n=1), work (1%, n=1) and was unreported 
or not specified for the remainder (71%, n=52).
The likely source of exposure included sibling (14%, 
n=10), mother (4%, n=3), father (1%, n=1), other 
relative (1%, n=1) and was unknown/not specified for 
the remainder (80%, n=58).
Antibiotic was known to be given for 89% (n=49/55) of 
cases where this data was provided and for 67% of all 
cases (n=49/73). A second antibiotic was known to be 
given for 40% (n=10/25) of cases where this data was 
provided and 14% (n=10/73) of all cases.
Three localised pertussis outbreaks were notified during 
2014, with ten associated cases of illness. One was an 
outbreak in a private house with four ill and one was a 
community outbreak with three ill. The third outbreak 
was travel related with three ill; two of these cases were 
diagnosed in Ireland while the third case was diagnosed 
abroad and never travelled to Ireland.
The figures presented in this summary are based on 
data extracted from the CIDR system on 20th October 
2015. These figures may differ slightly from those 
published previously due to ongoing updating of 
notification data on CIDR.
In 2014, three cases (0.07/100,000) of rubella were 
notified in Ireland while there were no cases in 2013. 
The three cases were in the age groups 1-2 years, 5-9 
years and 15-19 years.
Of the three cases, one was classified as probable with 
country of infection Poland and two were classified as 
possible cases.
The probable case tested weakly positive for rubella 
IgM in the laboratory. The case was unvaccinated, their 
clinical details fitted the case definition and the case 
reported contact with friends in Poland diagnosed with 
rubella. 
Both possible cases met the possible rubella case 
classification; however, the clinicians felt they were 
unlikely to have rubella. Unfortunately in both cases 
efforts to obtain samples failed. One of these cases had 
country of infection recorded as Ireland while country 
of infection was not recorded for the second case. 
One case had received one dose of MMR and one was 
unvaccinated. 
The diagnosis of rubella based solely on clinical signs 
and symptoms is often unreliable because there are 
many other causes of fever and rash illness which may 
resemble rubella infection. Therefore, timely diagnostic 
samples should always be obtained from patients in 
order to accurately diagnose rubella. Since 2012 the 
laboratory criteria for case confirmation of rubella 
requires the identification of rubella virus specific 
antibody response (IgG) in serum or saliva or detection 
of rubella virus nucleic acid in a clinical specimen or 
isolation of rubella virus from a clinical specimen.  
Isolation of rubella virus is not routinely performed in 
Ireland but can be done following consultation with 
the National Virus Reference Laboratory (NVRL). The 
NVRL is the WHO accredited National Measles Rubella 
laboratory for Ireland. Laboratory results always need to 
be interpreted according to the vaccination status and 
history of recent vaccination.  Since 2012 the laboratory 
criteria for a probable case require the identification 
of rubella virus specific antibody response (IgM); again 
laboratory results need to be interpreted according 
to the vaccination status. When rubella in pregnancy 
is suspected, further confirmation of a positive rubella 
IgM result is required (e.g. a rubella specific IgG avidity 
test showing a low avidity).  In certain situations, such as 
confirmed rubella outbreaks detection of rubella virus 
IgM can be considered confirmatory in non-pregnant 
cases.
Accurate and detailed information on all notified rubella 
cases is needed to monitor progress as part of the WHO 
European Measles and Rubella Elimination Strategy. 
HPSC is currently working with the HSE Areas and the 
NVRL to improve rubella surveillance data.  
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 26th November 
2015. These figures may differ slightly from those 
published previously due to ongoing updating of data 
on CIDR.
WHO require information on discarded rubella cases 
i.e. rubella cases investigated and who were found not 
to meet the case definition. The HSE Areas reported 
the number of discarded CIDR cases to HPSC. For 
2014, nine cases were discarded from CIDR as following 
investigation they were not considered to be rubella 
cases. Discarded cases are not available in CIDR for 
reporting and are therefore not included in the analysis 
above.
The NVRL is the WHO accredited National Measles 
Rubella laboratory for Ireland.  Laboratories that 
perform measles/rubella investigations in their own 
laboratories are requested to send all positive samples 
for measles or rubella to the NVRL for confirmatory 
testing. In addition, a selection of negative specimens 
should also be referred. Genotyping is undertaken on a 
selection of specimens. 
1.7 Rubella
Summary
Number of cases, 2014: 3
Number of confirmed cases, 2014: 0
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Streptococcus pneumoniae (invasive)
Background
Invasive Streptococcus pneumoniae infection is a 
notifiable disease in Ireland; clinicians and laboratories 
are legally obliged to notify this infection.  For the 
purposes of this report the term invasive pneumococcal 
disease (IPD) will be used to describe these infections.  
IPD includes meningitis and bloodstream infection (BSI) 
with and without pneumonia. 
A number of different initiatives are in place in Ireland 
for the surveillance of IPD.  Data on IPD notifications 
are collated in the Computerised Infectious Disease 
Reporting (CIDR) system.  Enhanced surveillance of 
IPD notifications is undertaken by Departments of 
Public Health, particularly of children and adolescents 
<15 years, and these data are also collated in CIDR.  
A separate surveillance strand (EARS-Net project) 
involving the microbiology laboratories and the HPSC 
is used to monitor in detail the antimicrobial resistance 
profiles of invasive S. pneumoniae isolates from 
blood and/or CSF.  EARS-Net laboratories can also 
collect additional information, including risk factors, 
admission and outcome for each S. pneumoniae isolate 
reported and these data are collated by HPSC through 
the Enhanced Surveillance of Bloodstream Infection 
(ESBSI) system. In order to improve data quality regular 
processes for cross-checking CIDR data with other data 
sources was established in 2014; to identify missing 
IPD notifications and/or missing information  CIDR data 
were linked to both the typing and ESBI databases and 
additional information on either of these systems but 
missing or incomplete in CIDR was collated.
Since April 2007, the National Pneumococcal Typing 
Laboratory has provided a typing service to Irish 
laboratories for all invasive S. pneumoniae isolates.  This 
is a collaborative project involving the Royal College of 
Surgeons in Ireland/Beaumont Hospital, the Children’s 
University Hospital, Temple Street and the HPSC. In 
addition, since August 2012 HPSC is participating in a 
European Centre for Disease Prevention and Control 
(ECDC) project called SpID-net. The project aims to 
strengthen or set up long term active population based 
IPD surveillance in order to estimate the impact of the 
pneumococcal conjugate vaccines in children less than 
five years of age in Europe.
In September 2008, the 7-valent pneumococcal 
conjugate vaccine (PCV7) was introduced into the Irish 
infant immunisation schedule at 2, 6 and 12 months 
of age.  A catch-up campaign was also implemented 
at that time, targeting children <2 years of age.  In 
December 2010, PCV13 replaced PCV7 in the infant 
schedule. Uptake of three doses of PCV by 24 months 
of age for 2014 was 92%.
Notification data for IPD was extracted from CIDR on 
29th May 2015. These figures may differ slightly from 
those previously published due to ongoing updating of 
notification data on CIDR.  For the 2012, 2013 and 2014 
notifications, the 2012 HPSC case definition for IPD was 
used.  In brief, isolation or detection of S. pneumoniae 
from a normally sterile site was classified as confirmed; 
detection of S. pneumoniae antigen from urine was 
classified as possible case. Since 2012 the previously 
used probable case definition is no longer applicable 
and any case in which S. pneumonia  antigen is detected 
from urine (previously defined as a probable case) is 
1.8 Streptococcus pneumoniae (invasive)
Summary
Number of confirmed cases in 2014:350
Number of confirmed cases in 2013: 345
Number of deaths in 2014: 37
Number of deaths in 2013: 24
Crude incidence rate of confirmed cases in 2014:7.6/100,000
Figure 1.  Number of confirmed invasive pneumococcal dis-
ease (IPD) notifications by typing status and the incidence 
rate (IR) of confirmed IPD with 95% confidence intervals, 
2008-2014
Data source: CIDR
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now classified as possible, and antigen detection from a 
sterile site is now categorized as confirmed. 
Results
All IPD notifications
In 2014, 681 cases of IPD (14.8/100,000) were notified 
in Ireland, an increase compared with 2013 (637 cases; 
13.9/100000). This increase is related to an increase 
in the number of possible cases notified in 2014 in 
comparison to 2013 (293 in 2013 and 331 possible cases 
in 2014).
In 2014, 51% (n=350) of notifications were classified as 
confirmed and 49% (n=331) as possible. The majority 
of possible cases (89%) were notified by HSE-SE, HSE 
E and HSE MW (n=119/331; n=82/331 and n=94/331, 
respectively).  These figures do not necessarily indicate 
a higher burden of IPD in these areas relative to other 
areas, but more likely reflects an increase in the use of 
urinary antigen tests being used and therefore more 
reports of positive urinary antigen cases from these 
areas. 
Confirmed IPD notifications
Focusing specifically on the confirmed IPD notifications, 
350 cases were notified in 2014 (7.6/100,000; 95% CI 
6.8 - 8.4/100,000), unchanged compared with 2013 
(7.5/100,000; 95% CI 6.8 - 8.3/100,000; 350 cases) 
(Figure 1). In 2014, the incidence of confirmed IPD 
declined by 13% compared with 2008 (9.5/100,000; 95% 
CI 8.6 – 10.5/100,000; 404 cases; p<0.05) (Figure 1).
In 2014, 81% of the confirmed IPD notifications had 
an isolate submitted for serotyping, similar to the 
proportion of cases in 2013 (80%) and  in  2008 and 
2009 when 79% of notifications had an isolate typed, 
however less than in 2012 when 86% of all isolates were 
typed (Figure 1).  In 2014 however, 46% of notifications 
(17/37) relating to children <5 years of age did not have 
an isolate submitted for serotyping.  For six of the 17 
the cases were confirmed by PCR only and no isolate 
was available. For the remaining eleven isolates from a 
sterile site, no sample was available for typing.
Incidence rates by HSE area ranged from 6.3 per 
100,000 in HSE-S to 9.2 per 100,000 in HSE-M, with the 
highest incidence in the HSE MW, HSE NE and HSE-SE 
(Figure 2).  However, the incidence rates in each of the 
eight HSE areas were not statistically different from the 
national one.
A clinical diagnosis was reported for 168 of the 350 
confirmed cases (48%), which included BSI with 
pneumonia (n=107), meningitis (n=40), and other BSI for 
the remainder (n=21).
More cases occurred in males (n=183,52%) than in 
females.  Cases ranged in age from 1 month to 96 
years, with an average age of 55.5 years (median age 
63 years).  Those aged 65 years and older accounted 
for half of the cases (48%, n=168). The age specific 
incidence rate (ASIR) was highest in those 85 years of 
age and older (61.6/100,000; n=36), followed by those 
in the 75-84 years age group (36.6/100,000; n=63) and 
the 65-74 year age group (22.6/100,000; n=69) (Figure 
3).  In children < 2 years of age the ASIR was 13.1 
cases per 100,000 population (n=19).  A statistically 
significant decline (63%) in IPD incidence was seen in 
this age group when compared with 2008 (42/100,000; 
n=52; p<0.0001), highlighting the positive impact of the 
introduction of PCV7 in September 2008 to the infant 
schedule followed by PCV13 in December 2010 
(Figure 3). 
The medical risk factor field was completed for 113 
(32%) confirmed cases; 37 cases (11%) did not have 
an identified risk factor; for the remaining 200 cases 
this information was either unknown or not specified.  
Based on the 113 cases for whom this information 
was reported, 91 (80%) of them had an underlying 
medical risk factor, with some patients having multiple 
risk factors.  The main risk factors reported included 
immunosuppressive condition or therapies (n=30), 
chronic lung disease (n=31), chronic heart disease 
(n=37), chronic liver disease (n=5) and renal diseases 
(n=11). It should also be noted that being aged 65 years 
and older was also a recognised IPD risk factor; 168 
cases in 2014 were in this age group.  Apart from their 
age, 66 cases in this age group also had a reported 
medical risk factor.
IPD death notifications
Outcome was reported in 39% (n=264) of the IPD 
notifications in 2014 versus 30% in 2013. Therefore, 
Figure 2. Crude incidence rate of confirmed invasive pneumo-
coccal disease notifications by HSE area, 2014
Data source: CIDR
Figure 3.  Age specific incidence rate of confirmed invasive 
pneumococcal disease notifications by age group, 2008-2014
Data source: CIDR
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these figures may not accurately estimate the burden of 
IPD in terms of mortality. Based on the data available in 
2014, 41 deaths in individuals with IPD were reported; 
for six case-patients the cause of death was reported as 
directly due to IPD, not due to IPD in four case- patients 
and for the remaining 31, the cause of death was not 
specified or was unknown.  Thirty-five deaths occurred 
in adults, ranging in age from 36-94 years and two 
deaths occurred in a two and nine year old child. Thirty 
four deaths were in confirmed cases. 
The apparent increase in IPD death notifications in 
2014, 2013 and 2012 (24 cases in 2013 and 37 cases 
in 2012 versus 11 cases in 2011) is most likely related 
to the additional information that was available by 
linking CIDR data to the Enhanced Surveillance of Blood 
Stream Infections (ESBI) database. Using BSI data it was 
possible to identify missing information on outcome in 
CIDR and then the CIDR database was updated by HSE 
areas. 
Impact of pneumococcal conjugate vaccines (PCV)
Data from the National Pneumococcal Typing 
Laboratory were used to assess the impact of 
introducing PCV on the distribution of S. pneumoniae 
serotypes associated with IPD and on the burden of 
IPD in Ireland.  In 2014, of the 350 confirmed IPD 
notifications reported in CIDR, 284 had isolates sent for 
typing (81%).  Six percent of IPD infections were due 
to serotypes covered by PCV7 (4, 6B, 9V, 14, 18C, 19F 
and 23F), 28% were associated with the six additional 
serotypes included in PCV13 (1, 3, 5, 6A, 7F and 19A) 
and the remaining 66% of infections were due to non-
vaccine types (NVTs).  
Since introducing PCV7 to the Irish childhood 
immunisation schedule towards the end of 2008, there 
has been a 19% reduction in the overall burden of 
IPD disease.  Reductions in the incidence of IPD due 
to PCV7 serotypes have been seen in all age groups 
(Figure 4a).  Overall, the incidence of IPD due to PCV7 
serotypes has significantly declined in 2014 compared 
with 2008 (89% decline, p<0.0000001).  The greatest 
impact has been seen in children <5 years of age where 
the incidence due to PCV7 serotypes has declined by 
100% (p<0.0000001) (Figure 4a).  In 2014 the incidence 
of disease due to the additional six serotypes covered 
by the PCV13 declined by 78% in children <2 years 
of age compared with 2008 (Figure 4b).  The decline 
was also observed in the other age groups with these 
additional six serotypes compared with 2008; however, 
this decline was not significant (Figure 4b).  An increase 
in incidence due to the non-vaccine types (NVTs) was 
also seen in 2014 compared with 2008. In those aged 
65 years and greater, an increase in incidence was 
observed in 2014 compared with 2013. There has been 
little change in the incidence of NVTs among other age 
groups (Figure 4c).  
The predominant serotypes in circulation in 2014, 
were 7F and 15A (7F included in PCV13), followed by 
serotypes 22F (NVT), 3 (included in PCV13), 8 (NVT) 
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Figure 4.  Age specific incidence rate by age group of con-
firmed invasive pneumococcal disease cases due to (a) PCV7 
serotypes, (b) the additional six serotypes covered by PCV13 
and (c) non-vaccine types , 2008-2014. Data source: National 
Pneumococcal Typing Laboratory
Figure 4a Figure 4b
Figure 4c
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and 19A (included in PCV13).  In children <5 years of 
age, the predominant serotypes were 15B (NVT), 19A 
(included in PCV13), 22F(NVT),  10A, 11A, 15A and 15C  
(all NVTs); all these serotypes accounted for a two thirds 
of the isolates serotyped in this age group (Figure 5).
For ongoing updates, see “Slides – Impact of PCV in 
Ireland” at http://www.hpsc.ie/A-Z/VaccinePreventable/
PneumococcalDisease/PostersPresentations/
PCV vaccine failures
Based on data obtained through the IPD enhanced 
surveillance system, two PCV vaccine failures were 
reported in 2014, both due to serotype 19A (PCV 13). 
Since 2008, a total of nine  vaccine failures have been 
reported in addition to the two reported in 2014, two in 
2010 (19F and 14), two in 2012 (19F and 19A) and three 
in 2013 (19A). 
Penicillin non-susceptible S. pneumoniae (PNSP)
In 2014, the proportion of penicillin non-susceptible 
invasive S. pneumoniae (PNSP) was 17.1%, (2.4% and 
14.5% with high and intermediate level resistance, 
respectively) while 13.8% of isolates were resistant to 
erythromycin (Data source: HPSC/EARS-Net Ireland).  
This compares to 20.8% and 17.9% in 2013 respectively. 
In the UK, the PNSP proportion in 2013 was 4.9% (0.5% 
and 4.4%, with high and intermediate level resistance, 
respectively). 
In 2013, Ireland had one of the highest proportions of 
PNSP in Europe, ranking 5th out of 29 countries overall.  
Although, 34 different serotypes were identified in 2014, 
only 11 serotypes were associated with penicillin non-
susceptibility. The predominant PNSP serotypes in 2014 
were 7F, 15A and 22F whereas in 2008 serotypes 9V and 
14 were the leading ones. For details on the antimicro-
bial resistance patterns of S. pneumoniae, please see the 
link on EARS-Net Report, Quarters 1-4 2014: http://www.
hpsc.ie/A-Z/MicrobiologyAntimicrobialResistance/Euro 
peanAntimicrobialResistanceSurveillanceSystemEARSS/
EARSSSurveillanceReports/2014Reports/File,14686,en.
pdf 
Discussion
Although there was no significant changes in the 
incidence of confirmed cases of IPD in Ireland in 2014 
compared with 2013, since its introduction in 2008, 
PCV7 has had a significant impact in reducing the 
overall burden of the disease in the total population.  
There has been a decline in IPD in all age groups due to 
serotypes covered by PCV7, indicating the indirect/herd 
immunity effect the vaccine confers on the population.  
The greatest impact has been in children <5 years of 
age where disease incidence due to PCV7 serotypes has 
fallen by over 100%.  The impact due to additional six 
serotypes covered by PCV13 vaccine was observed in 
children <2 years of age, amongst whom the reduction 
in the incidence of disease was 78%.
However, despite reductions in the IPD burden during 
childhood, the incidence of disease due to non-PCV7 
serotypes has increased in other age groups.  There has 
been a shift in the prevalent serotypes associated with 
invasive disease.  Serotypes 7F, 15A, and 22F were the 
predominant serotypes identified in 2014.  
To accurately assess the impact of PCV on immunisation 
programmes and to monitor for vaccine failures in 
Ireland, it is crucial that samples from sterile sites are 
obtained for culture and sensitivity. Isolates obtained 
by culture are required for serotyping and antibiotic 
susceptibility. Furthermore it is crucial that laboratories 
continue to send all invasive S. pneumoniae isolates for 
typing to the National Pneumococcal Typing Laboratory. 
Although 81% of confirmed notifications had an isolate 
submitted for serotyping in 2014, 19% (n=66) did 
not, including 17 cases in children <5 years of age.  In 
six of these 17 cases, an isolate was not available for 
Figure 5. Serotype distribution of invasive Streptococcus pneumoniae isolates by age group 
(years) in Ireland, 2014
* Denotes serotypes included in PCV7
*^ Denotes additional six serotypes included in PCV13 (PCV13-7)
Data source: National Pneumococcal Typing Laboratory
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typing and confirmation was by PCR only.  Serotype 
information is unavailable for 46% of confirmed 
notifications in this age group and the absence of this 
data is of concern.
Continued good quality IPD surveillance including the 
monitoring of invasive S. pneumoniae serotypes is 
crucial in identifying any epidemiological changes in 
the disease, in assessing the impact of PCV13 on public 
health and in guiding further vaccination strategies, as 
newer expanded valency vaccines become available 
and changes to recommendations of PCV are made 
e.g. age related.  For example, due to the incomplete 
data we do not know the impact of IPD on mortality 
and this is a key metric in assessing the true impact 
of this disease and the effectiveness of interventions, 
including new vaccines.
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Tetanus
One case of non-fatal tetanus was notified in 2014. The 
case was in the age group 15-19 years and was clas-
sified as probable based on clinical presentation. The 
case was incompletely vaccinated and had received 
one dose of a tetanus vaccine as an infant and another 
dose at two years of age. The case reported having a 
discharging wound on a toe one week prior to onset of 
tetanus symptoms developing. The cause of the wound 
was not reported.
Summary of case data since 1981:
Fifteen cases of tetanus were reported since tetanus 
became notifiable in November 1981. The number of 
tetanus cases notified by age group is shown in figure 1. 
Two deaths were reported, both cases were aged >60 
years.
Of the 15 tetanus cases, eight (53%) were male, five 
(33%) were female while gender was unreported for two 
(13%).
The following wound injuries (n=10) were reported 
among the 15 notified cases: wound injuries from a road 
traffic accident (n=1), wound from a fall outdoors (n=1), 
wound associated with a dog bite (n=1), wound from 
a kitchen knife (n=1), gardening associated leg wound 
(n=1), leg scratches in an avid gardener (n=1), hand 
wound associated with a clean piece of wood (n=1), a 
farming associated hand wound (n=1), a foot wound 
from a thorn (n=1) and hand injuries from a can and a 
rusty nail (n=1). In the case reported in 2014 the details 
of the wound injury on the toe were not reported.
Vaccination data were reported for six of the 15 cases. 
Two cases were unvaccinated. One case, in the age 
group 15-19 years, was reported to have received three 
doses of tetanus vaccine as a child and a booster at 
four years and again at five-six years of age. One case 
was reported to have received a single tetanus vaccine 
around 40 years prior to infection. One case was re-
ported as having received one dose of a tetanus vaccine 
20 years earlier but it was not known if the case had re-
ceived any previous doses (i.e. primary tetanus vaccines 
as an infant). One case (in 2014) was reported as having 
received one dose of a tetanus vaccine as an infant and 
a dose when they were 2 years of age.
Vaccine efficacy after a complete series of vaccines (five 
doses) is almost 100%. However, immunity wanes and 
1.9 Tetanus
Summary
Number of cases, 2014: 1
Number of cases, 2013: 1
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Figure 1.  Tetanus cases notified (n=15) from November 1981 to 2014 by age group
after 10 years may be insufficient to provide protection. 
The childhood immunisation schedule in Ireland recom-
mends children receive a dose of tetanus toxoid con-
taining vaccine at two, four and six months of age and 
booster doses at four-five years of age and 11-14 years 
of age. For vaccinated persons who have received five 
doses of tetanus toxoid, booster doses may be consid-
ered every 10 years. This is based on concern regarding 
the decline of antibody levels with age and potential 
failure of single booster doses to produce protective 
levels in older individuals. For more complete and de-
tailed information on recommended tetanus immunisa-
tions please see the HSE National Immunisation Office 
website at http://www.hse.ie/eng/health/immunisation/. 
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 12th August 
2015. These figures may differ from those published 
previously due to ongoing updating of notification data 
on CIDR.
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HPSC has worked in collaboration with the National 
Virus Reference Laboratory (NVRL), the Irish College 
of General Practitioners (ICGP) and the Departments 
of Public Health on the influenza sentinel surveillance 
project since 2000. During the 2014/2015 influenza 
season, 61 general practices (located in all HSE-Areas) 
were recruited to report electronically, on a weekly 
basis, the number of patients who consulted with 
influenza-like illness (ILI). Sentinel GPs were requested 
to send a combined nose and throat swab to the NVRL 
on one ILI patient per week. The NVRL also tested 
respiratory non-sentinel specimens, referred mainly from 
hospitals. 
Other surveillance systems set up to monitor ILI/
influenza activity include: 
•   Surveillance of all calls to GP out-of-hours (OOHs) 
centres, monitored for self-reported influenza. These 
data were provided by HSE-NE.  
•   Surveillance of all confirmed influenza notifications, 
including hospitalisation status reported to the 
Computerised Infectious Disease Reporting System 
(CIDR) in Ireland. 
•   Enhanced surveillance of hospitalised influenza cases 
aged 0-14 years.   
•   Intensive Care Society of Ireland (ICSI) enhanced 
surveillance of all critical care patients with confirmed 
influenza 
•   Surveillance of all reported influenza-associated 
deaths. 
•   All-cause mortality monitoring associated with the 
European mortality monitoring group (EuroMOMO)
•   A network of sentinel hospitals reporting admissions 
data.
•   Outbreak surveillance – acute respiratory infections 
and influenza
•   Influenza vaccine effectiveness study (I-MOVE)
This report summarises influenza and other seasonal 
respiratory virus activity in Ireland during the 2014/2015 
influenza season. The 2014/2015 season commenced on 
29/09/2014 (week 40 2014) and ended on 17/05/2015 
(week 20 2015). The data presented in this summary 
were based on all data reported to HPSC by 3rd 
December 2015. 
Sentinel GP clinical data
Influenza activity reported from the sentinel GP 
network in Ireland was at moderate levels during the 
2014/2015-influenza season, with ILI consultation rates 
peaking at 70.4 per 100,000 population during week 7 
2015 (early February) (figure 1). ILI rates first increased 
above baseline levels (18.2 per 100,000) during week 2 
2015 and remained there for 11 consecutive weeks, a 
longer period than for the previous season (2013/2014). 
The highest age specific ILI rates were reported in the 
5-14 year age group (peaking at 82.7/100,000), followed 
by those aged 15-64 years (74.9/100,000), those aged 
65 years and older (64.1/100,000) and the 0-4 year age 
group (43.4/100,000). It is notable that the age specific 
rates in those aged 65 years and older were the highest 
reported in this age group since the 2010/2011 season 
and were only higher during the 2003/2004, 2008/2009 
and 2010/2011 seasons. 
Virological data from NVRL – influenza 
Sentinel GP data: The NVRL tested 782 sentinel 
specimens for influenza virus during the 2014/2015 
season. Three hundred and seventy-eight (48.3%) 
sentinel specimens were positive for influenza: 266 
influenza A (227 A(H3), 35 A(H1)pdm09 and 4 A not 
subtyped) and 112 influenza B. Sixty percent of all 
confirmed influenza sentinel cases were positive for 
influenza A(H3). One hundred and twenty (16%; n=752 
with known vaccination status) ILI cases tested for 
influenza were vaccinated with the 2014/2015 influenza 
vaccine; 47% (56/120) were positive for influenza. Fifty-
nine percent of those aged 65 years and older were 
2.1  Influenza and Other Seasonal Respiratory 
Viruses
Summary
2014/2015 influenza season summary:
Peak influenza-like illness rate: 70.4/100,000 population
Confirmed influenza cases hospitalised: 1,009
Confirmed influenza cases admitted to ICU: 69
Notified influenza cases that died: 66
Estimated excess deaths in those aged 65 years and older: 726
Number of acute respiratory infection/influenza outbreaks: 117 
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vaccinated, 42% (17/41) of these cases were positive 
for influenza. One third of those aged less than 65 years 
with an underlying risk factor were vaccinated; 44% of 
these cases were positive for influenza. Only four cases 
were known to have commenced antiviral treatment. 
Non-sentinel data: The NVRL tested 9,830 non-sentinel 
respiratory specimens during the 2014/2015 season, 
1,578 (16.1%) of which were positive for influenza: 1,200 
influenza A [1,003 A(H3), 129 A(H1)pdm09 and 68 A 
(not subtyped)] and 378 influenza B. Sixty-four percent 
of all confirmed influenza non-sentinel cases were 
positive for influenza A(H3). 
Influenza A(H3) was the predominant influenza virus 
circulating during the 2014/2015 season, followed by an 
increase in the predominance of influenza B later in the 
season. Influenza A accounted for 75% of all influenza 
positive specimens and influenza B for 25%. Of the 
1,394 influenza A sentinel and non-sentinel specimens 
that were subtyped, influenza A(H3) accounted for 
88% and influenza A(H1)pdm09 for 12%. In total 1,230 
positive influenza A(H3) cases were detected by the 
NVRL during the 2014/2015 season, this is the highest 
number of A(H3) viruses ever detected in any season by 
the NVRL. 
Influenza virus characterisation: 
For the 2014/2015 influenza season, genetic 
characterisation of influenza viruses circulating in 
Ireland was carried out by the NVRL on 91 positive 
samples: 49 A(H3), 22 A(H1)pdm09 and 20 B. Of the 
49 A(H3N2) viruses attributed to a genetic group, the 
majority (79.6%) fell into genetic subgroups that were 
shown to be antigenically dissimilar to the A(H3N2) 
2014/2015 vaccine virus. Over 75% (37/49) of A(H3) 
viruses tested were in genetic subgroup 3C.2a, 
represented by A/Hong Kong/5738/2014; and two 
viruses were in genetic subgroup 3C.3a, represented by 
A/Switzerland/9715293/2013. Of the remaining A(H3) 
viruses, 18.4% (9/49) fell into the genetic group 3C.3, 
represented by A/Samara/73/2013, which was shown 
to be antigenically similar to the A(H3N2) 2014/2015 
vaccine virus. One additional A(H3) virus could not be 
attributed to a genetic group. Of the 18 B/Yamagata-
lineage viruses characterised genetically, all fell in 
clade 3, and were represented by B/Phuket/3073/2013 
which is related to, but antigenically and genetically 
distinguishable, from the B/Massachusetts/2/2012 
2014/2015 vaccine virus. Two B/Victoria-lineage viruses 
were also genetically tested during the 2014/2015 
season and belonged to the B/Brisbane/60/2008 clade 
(clade 1A), similar to the influenza B/Victoria-lineage 
component (B/Brisbane/60/2008) of the 2014/2015 
quadrivalent vaccine. Of the 22 influenza A(H1)pdm09 
viruses genetically characterised during the 2014/2015 
season, all were similar to the 2014/2015 A(H1)pdm09 
vaccine strain. The majority of influenza A(H3) and 
influenza B viruses and all influenza A(H1)pdm09 viruses 
genetically characterised during the 2014/2015 season 
in Ireland, belonged to genetic groups antigenically 
similar to the vaccine virus strains selected for the 
2015/2016 Northern Hemisphere influenza vaccines. 
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Figure 1: ILI sentinel GP consultation rates per 100,000 population, baseline ILI threshold rate, and 
number of positive influenza A and B specimens tested by the NVRL, by influenza week and season. 
Source: Clinical ILI data from ICGP and virological data from the NVRL.
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Virological data from NVRL - Other seasonal respiratory 
viruses 
During the 2014/2015 season, of 9,830 non-sentinel 
specimens tested by the NVRL, 896 (9.1%) positive 
detections of respiratory syncytial virus (RSV) were 
reported, peaking (at 34.1% positivity) during week 49 
2014, a slightly earlier season than usual. A total of 204 
(2.1%) positive detections of human metapneumovirus 
(hMPV) were reported, peaking during late January. 
Seventy-six (0.8%) positive detections of adenovirus 
were reported, 3 (0.03%) parainfluenza virus type 1 
(PIV-1), 77 (0.8%) PIV-3 and 4 (0.04%) PIV-4 during the 
2014/2015 season. There were no positive detections 
of PIV- 2 from non-sentinel sources reported during the 
2014/2015 season. 
Of the 782 sentinel GP specimens tested during the 
2014/2015 season, 28 (3.6%) were positive for RSV 
and 24 (3.1%) were positive for hMPV. There were 
no positive detections of adenovirus or parainfluenza 
viruses from sentinel GP sources during the 2014/2015 
season. 
Positive detections of RSV and hMPV from sentinel 
and non-sentinel sources were at higher levels than 
previously reported by the NVRL. 
Outbreaks, GP OOHs & sentinel hospital data
Ninety influenza general outbreaks were reported 
during the 2014/2015 influenza season (table 1), 
which is the highest number of influenza outbreaks 
reported with the exception of the 2009 pandemic. 
The majority of these outbreaks were associated with 
influenza A(H3), in community hospitals/residential 
care facilities mainly affecting the elderly. Seventeen 
outbreaks were reported from acute hospitals, which is 
the highest number of confirmed influenza outbreaks 
in acute hospital settings ever reported. Over 74% of 
these outbreaks were associated with influenza A(H3). 
Seventy-four outbreaks were associated with influenza A 
(65 A(H3), 5 A(H1)pdm09, 2 associated with both A(H3) 
and A(H1)pdm09 and 2 A - not subtyped) and 14 with 
influenza B. No influenza type/subtype was reported 
for two outbreaks. In total 27 deaths were recorded 
associated with these 90 outbreaks. It is probable that 
the actual number of deaths linked with these outbreaks 
exceeds this number. Vaccination status was reported 
for patients from 24 healthcare facilities/residential 
care facilities, with over 92% (953/1,039) of patients 
vaccinated prior to these outbreaks. Vaccination status 
was reported for staff from only 13 healthcare facilities/
residential care facilities, with only 22% (153/691) of 
staff reported as vaccinated prior to these outbreaks. 
Use of antiviral chemoprophylaxis was reported from 47 
outbreaks in healthcare settings (of 53 outbreaks with 
reported data on antiviral use).      
A further 27 acute respiratory infection (ARI) general 
outbreaks were reported during the 2014/2015 
influenza season, four were associated with RSV, 
four with hMPV and 19 associated with unidentified 
pathogens. 
The percentage of influenza-related calls to GP out-of-
hours services in Ireland, peaked during week 7 2015 
at 4.6% (coinciding with the peak in sentinel GP ILI 
consultation rates). During the peak of activity, each 
service received on average, one call per hour relating 
to influenza.
  
Hospital respiratory admissions reported from a 
network of sentinel hospitals during the 2014/2015 
season, peaked twice and reached the highest peak 
level reported since 2010. The first and largest peak 
in respiratory admissions reported (n=464) occurred 
during week 51 2014, coinciding with high RSV activity. 
The second peak in respiratory admissions (n=382) 
occurred during week 8 2015; coinciding with elevated 
influenza activity. Total emergency admissions reported 
from sentinel hospitals were also elevated during the 
periods of peak RSV and influenza activity, peaking at 
2,945 during week 51 2015 and again during week 8 
2015 at 2,999.  
Influenza and RSV notifications
A total of 530 influenza notifications were reported 
on CIDR during the 2014/2015 influenza season; the 
highest number of influenza notifications reported with 
the exception of the 2009 pandemic. Of the 2,530 
notified cases, 2,484 were confirmed, 13 were probable 
and 33 were possible. Of the 2,484 confirmed influenza 
cases, 1,260 (50.7%) were influenza A(H3), 200 (8.1%) 
were influenza A(H1)pdm09, 376 (15.1%) were influenza 
A (not subtyped) and 648 (26.1%) were influenza B. A 
total of 1,890 RSV notifications were reported to HPSC 
during the 2014/2015 season; the highest number of 
notifications reported since RSV was made notifiable in 
2012. 
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Table 1: Number of influenza outbreaks by HSE-Area for the 2014/2015 influenza season (n=90). It is known that the number of 
hospitalised cases associated with these outbreaks was under-reported.
HSE-Area No. of outbreaks Total number ill Total number hospitalised Total number dead Total number lab confirmed
HSE-E 25 544 74 10 259
HSE-M 5 58 2 1 24
HSE-MW 7 78 24 3 39
HSE-NE 7 96 2 4 31
HSE-NW 15 189 11 3 52
HSE-SE 10 126 9 4 34
HSE-S 17 283 22 1 45
HSE-W 4 46 14 1 25
Total 90 1420 158 27 509
Confirmed influenza cases hospitalised 
One thousand and nine cases (22/100,000 population) 
with confirmed influenza were reported as hospitalised 
during the 2014/2015 influenza season; over 40% of 
all confirmed influenza notified cases. The highest age 
specific rate in hospitalised cases for the 2014/2015 
season was in those aged 65 years and older 
(81.4/100,000 population) the highest ever reported in 
this age group, followed by those aged less than one 
year (74.6/100,000). The age specific rates in those less 
than one year of age were only higher during the 2009 
pandemic. Of the 1,009 hospitalised cases, 780 (77.3%) 
were confirmed influenza A cases and 229 (22.7%) were 
influenza B cases. Of the 578 subtyped influenza A 
cases: 490 (84.8%) were influenza A(H3) and 88 (15.2%) 
were influenza A(H1)pdm09. Further data on confirmed 
influenza hospitalised cases are detailed in tables 1-4. 
Enhanced surveillance hospital data on 0-14 year age 
group 
A total of 351 confirmed influenza cases aged between 
0 and 14 years were notified on CIDR for the 2014/2015 
influenza season, 213 (60.7%) of these cases were 
hospitalised. One hundred and sixty-two cases (76.1%) 
were positive for influenza A [89 A(H3), 40 A(H1)pdm09 
and 33 A (not subtyped)] and 51 (23.9%) were positive 
for influenza B. The median age of cases were 3 years. 
Over 63% of cases were aged between 0 and 4 years, 
with one quarter of cases aged less than one year. 
The most frequently reported symptoms included: 
fever (73.6%), cough (65.3%), fatigue (35.2%) and 
gastroenteric manifestations (29.6%). Complications 
were reported for 45 (21.1%) cases; of these cases more 
than one complication was reported for 29.2% of cases. 
The most frequently reported complications included 
secondary bacterial pneumonia, primary influenza viral 
pneumonia and other respiratory complications. The 
median length of stay in hospital was 2 days (ranging 
from 1 - 25 days). Approximately, 33% of hospitalised 
cases in this age group were reported as having an 
underlying medical condition, with chronic respiratory 
disease (including asthma), chronic neurological 
disease, immunosuppression, conditions that can 
compromise respiratory function and other medical 
conditions being the most frequently reported. Four 
cases were reported as being premature. Of the 52 
cases with reported underlying medical conditions and 
known vaccination status, 90% were not vaccinated. 
Approximately, 27% of cases (44/162) commenced 
antiviral treatment and 73% (118/162) did not. Nine 
cases were reported as being admitted to critical care 
units (for further details, see below). 
Confirmed influenza cases admitted to ICU  
Of the 1,009 hospitalised confirmed influenza cases, 
69 (6.8%) were admitted to critical care (60 adults and 
9 paediatric cases). Of the 69 critical care cases, 33 
(47.8%) were infected with influenza A(H3), 11 (15.9%) 
with influenza A(H1)pdm09, 11 (15.9%) influenza A 
(not subtyped) and 14 (20.3%) with influenza B. Age 
specific rates for patients admitted to critical care units 
were highest in those aged 65 years and over (6.2 per 
100,000 population) followed by those aged less than 
one year (4.1 per 100,000 population) (table 2). The 
median age in years for paediatric cases was 2, and 67 
for adult cases. Fifty-three (53/60, 88.3%) adults and six 
(6/9, 66.7%) paediatric cases had pre-existing medical 
conditions. The most frequently reported underlying 
medical conditions for adults were chronic respiratory 
disease (36/60, 60%), followed by chronic heart disease 
(30/60, 50%), and immunosuppression (11/60, 18.3%). 
One adult case was pregnant. Twenty-four (40.0%) 
adult cases were reported as current/former smokers 
and four (6.7%) adult cases were reported to have 
alcohol related disease. The most frequently reported 
underlying medical conditions for paediatric cases 
were respiratory disease (3/9; 33.3%) and neurological/
neuromuscular conditions (2/9, 22.2%). Fifty-two (52/60, 
86.7%) adults were ventilated during their stay in critical 
care units. Ventilation status was only reported for 
one of nine paediatric cases; this case was ventilated. 
The median length of stay in critical care for adult 
cases was 9 days (ranging from 1 - 44 days) and for 
paediatric cases was 3 days (ranging from 1 - 26 days). 
Of the 34 cases with underlying medical conditions 
and known vaccination status, 55% were vaccinated. 
Vaccination status was only known for four paediatric 
cases with underlying medical conditions, none of these 
cases were vaccinated. Twenty-three (23/69, 33.3%) 
confirmed influenza cases reported from critical care 
units died. 
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Table 2: Age specific rate for confirmed influenza cases hospitalised and admitted to critical care during the 2014/2015 influenza 
season. Age specific rates are based on the 2011 CSO census
Hospitalised Admitted to ICU
Age (years) Number Age specific rate per 100,000 pop. Number Age specific rate per 100,000 pop.
<1 54 74.6 3 4.1
1-4 80 28.2 4 1.4
5-14 79 12.7 1 0.2
15-24 44 7.6 1 0.2
25-34 82 10.9 2 0.3
35-44 78 10.3 9 1.3
45-54 52 9.0 6 1.0
55-64 104 22.4 10 2.2
≥65 436 81.4 33 6.2
Total 1009 22.0 69 1.5
Mortality data 
During the 2014/2015 influenza season, of the 2,530 
influenza cases notified, 66 (2.6%) cases were reported 
as having died. The case classification of influenza 
was confirmed for 62 of these cases, probable for one 
and possible for three cases. Influenza was reported 
as a cause of death (either on the death certificate or 
by the physician) for 48 cases. Of the 62 cases with 
known virology, 36 were associated with influenza 
A(H3), 10 with influenza A(H1)pdm09, eight influenza 
A (not subtyped) and eight with influenza B. The 
median age of cases who died during the 2014/2015 
influenza season was 77 years, ranging from 1-95 years. 
Cumulative excess all-cause mortality was reported in 
those aged 65 years and older, for nine consecutive 
weeks between weeks 2 and 10 2015. The estimated 
number of excess deaths during the 2014/2015 season 
for those aged 65 years and older was 726.
Summary tables of confirmed influenza hospitalised and 
critical care cases and influenza-associated deaths for all 
ages are detailed in tables 3, 4 and 5.
Overview of the 2014/2015 season 
In Ireland, the 2014/2015 influenza season was more 
severe than recent seasons. Influenza A (H3) viruses 
predominated, with an increase in the predominance 
of influenza B viruses later in the season. The impact of 
influenza during the 2014/2015 season predominantly 
affected those aged 65 years and older, with high 
numbers of outbreaks in residential care facilities, high 
hospitalisation rates, an increase in deaths reported 
in notified influenza cases and excess mortality 
significantly higher than recent seasons. Over 1,000 
confirmed influenza hospitalised cases were reported 
during the 2014/2015 season, a similar number to the 
2009 pandemic. There was a significant increase in the 
overall hospitalisation rate for those aged 65 years 
and older compared to previous seasons, reaching the 
highest rate (81.4/100,000 population) ever reported 
for this age group (hospitalisation data available from 
2009). 
In Ireland and most Northern Hemisphere countries, 
the emergence of A(H3N2) viruses antigenically and 
genetically drifted from the 2014/2015 Northern 
Hemisphere vaccine strain, resulted in reduced vaccine 
effectiveness (VE).1, 2, 3 The Irish overall adjusted VE in 
preventing influenza confirmed infection in primary 
care was very low, likely reflecting this mismatch 
between circulating A(H3) viruses and the 2014/2015 
vaccine strain. Despite some antigenic drift among B/
Yamagata viruses, the B/Yamagata and A(H1N1)pdm09 
components in the 2014/2015 vaccine were thought 
likely to protect against circulating viruses.1,4 Excess all-
cause mortality among people aged 65 years and older, 
concomitant with increased influenza activity and the 
predominance of drifted A(H3N2) viruses was observed 
in Ireland and across Europe. It is likely that influenza 
contributed significantly to these excess deaths, 
although adverse winter weather conditions and other 
respiratory infections may also have contributed.4,5,6  
Sentinel GP ILI consultation rates in Ireland were 
above baseline levels for 11 consecutive weeks during 
the 2014/2015 season, a longer period than for the 
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Table 3: Summary table of confirmed influenza cases hospitalised for all ages by influenza season: 2009-2015. Rates are based 
on the 2011 CSO census. 
Hospitalised  
Pandemic period 2010/11 2011/12 2012/13 2013/14 2014/15
Total cases 1059 968 147 469 693 1009
Crude rate /100,000 23.1 21.1 3.2 10.2 15.1 22.0
Median age (years) 17 29 27 32 51 59
Females 50% 55% 56% 57% 57% 53%
Case fatality rate 2% 4% 4% 5% 5% 5%
Table 4: Summary table of confirmed influenza cases admitted to critical care units for all ages by influenza season: 2009-2015. 
Rates are based on the 2011 CSO census. 
Admitted to ICU
Pandemic period 2010/11 2011/12 2012/13 2013/14 2014/15
Total cases 100 121 15 39 83 69
Crude rate /100,000  2.2 2.6 0.3 0.8 1.8 1.5
Median age (years) 34 49 60 39 50 63
Females 50% 53% 80% 49% 41% 41%
Cases with risk factor 82% 74% 93% 90% 85% 86%
% Vaccinated NA 17% - - 32% 47%
Hospital:ICU ratio 9% 13% 10% 8% 12% 7%
ICU Median LOS - Adult 12 14 5 9 9 9
ICU Median LOS - Paediatric 8 7 3 5 8 3
Case fatality rate 18% 29% 33% 28% 33% 33%
previous season. The NVRL reported the highest 
number of influenza A(H3) viruses ever detected since 
surveillance began in 2000. Positive detections of RSV 
and hMPV were also at higher levels than previously 
reported. 
The number of acute respiratory infection/influenza 
outbreaks reported during the 2014/2015 season was 
at the highest level reported in Ireland since the 2009 
pandemic. The majority of these outbreaks were caused 
by influenza A(H3) and mainly affected the elderly in 
residential care facilities. Reported influenza vaccination 
status of patients/clients in these outbreaks was high, 
whilst vaccination status of staff was low, highlighting 
the need to improve influenza vaccine uptake amongst 
healthcare workers in order to reduce influenza-
related morbidity and mortality. Further information 
on seasonal influenza vaccine uptake in hospitals and 
long term care facilities is available in the Immunisation 
uptake chapter of the HPSC Annual Epidemiological 
Report, 2014. 
For the 2015/2016 influenza season in the Northern 
Hemisphere, WHO have recommended trivalent 
influenza vaccines contain the following strains: an 
A/California/7/2009 (H1N1)pdm09-like virus; an A/
Switzerland/9715293/2013 (H3N2)-like virus; and a B/
Phuket/3073/2013-like virus.7 This represents a change 
in the influenza A(H3) and influenza B(Yamagata 
lineage) components compared with the composition 
of the 2014/2015 influenza vaccine. The vast majority 
of influenza viruses genetically tested during the 
2014/2015 season in Ireland, belonged to genetic 
groups antigenically similar to the influenza virus strains 
selected for the 2015/2016 Northern Hemisphere 
influenza vaccines.
In Ireland, for the 2015/2016 season, existing 
surveillance systems are being further strengthened. 
HPSC are currently evaluating the critical care influenza 
surveillance system, with a view to improving the 
efficiency of the system and overall reporting of cases 
for future seasons. HPSC are also focusing on improving 
influenza vaccine uptake and antiviral data on severe 
influenza cases, outbreaks, health care workers and 
those in risk groups for influenza. HPSC, ICGP and the 
NVRL are continuing to work on the European influenza 
vaccine effectiveness study (I-MOVE). Data from all 
of these surveillance projects will assist in guiding the 
management and control of influenza and of any future 
epidemics or pandemics. www.hpsc.ie
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Table 5: Summary table of notified influenza cases that died from all causes and were reported on Ireland’s Computerised 
Infectious Disease Reporting System (CIDR) by influenza season: 2009-2015. Rates are based on the 2011 CSO census. 
Influenza notifications - Deaths from all causes
Pandemic period 2010/11 2011/12 2012/13 2013/14 2014/15
Total deaths 32 43 12 38 58 66
Crude rate /100,000 0.7 0.9 0.3 0.8 1.3 1.4
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In 2014, there were eight cases of Legionnaires’ disease 
notified in Ireland, a rate of 1.7 per million population, a 
decrease from the rate of 3.1 per million seen in 2013. 
No deaths associated with Legionnaires’ disease were 
reported.
Six cases were reported from HSE East, one from HSE 
North West and one from HSE West.
Males and females were equally affected by 
Legionnaires’ disease with half of all cases occurring 
in males and half in females. Although the number of 
cases reported was low, this was the first year since the 
reporting of cases to the national infectious disease 
surveillance system, CIDR that the majority of cases did 
not occur in males. The median age was 59.5 years with 
a range from 37 to 85 years.
All eight cases were classified as confirmed. The 
organism involved in seven of these cases which 
was detected by urinary antigen test was Legionella 
pneumophila serogroup 1. The diagnosis in one of the 
seven cases also included the use of the laboratory 
method nucleic acid amplification (PCR). The organism 
cultured from the remaining confirmed case was a 
previously unrecognised Legionella pneumophila non 
serogroup 1 or 2-15, with a novel sequence type ST1796. 
Monoclonal subtyping information was not available for 
any of the cases.
Four cases were travel-associated. Countries of travel 
included Democratic Republic of Congo (1), Italy (1), 
Portugal (1) and Spain (1). No cases were linked to travel 
related clusters. The remaining four cases were assumed 
to be community acquired.
An autumnal seasonality was evident in the cases in 
2014 where half of all cases reported were notified in 
September, as described in Figure 1.
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Figure 1. Number of Legionnaires’ disease cases by month of 
notification in Ireland, 2014
Figures for the year 2014 presented in this report were 
extracted from the computerised infectious disease 
reporting (CIDR) system on the 11th August, 2015.
2.2 Legionellosis
Summary
Number of cases in 2014: 8
Crude incidence rate: 1.7 per million
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Table 1. Number of Legionnaires’ disease cases per million population in Ireland, 2007-2014 
Age group (years) 2007 2008 2009 2010 2011 2012 2013 2014
<30 1 0 0 1 0 0 0 0
30-39 3 0 0 0 0 1 1 1
40-49 4 2 0 2 0 1 3 1
50-59 2 3 2 1 1 1 4 2
60-69 3 4 3 3 4 6 1 3
70+ 2 2 2 4 2 6 5 1
Total 15 11 7 11 7 15 14 8
CIR 3.5 2.6 1.5 2.4 1.5 3.3 3.1 1.7
For details of denominator data used, please see Explanatory Notes section at the end of the HPSC annual report
Notifications
In 2014, 164 cases of invasive group A streptococcal 
(iGAS) disease were notified, which   corresponds with 
a rate of 3.57 iGAS cases per 100,000 population [95% 
confidence interval (CI): 3.05 – 4.17 per 100,000]. The 
2014 iGAS rate was slightly lower than in 2013 (3.57 
versus 3.66 [95% CI: 3.13 – 4.26 per 100,000]). However, 
the increase is not considered to be statistically 
significant as the confidence intervals overlap. 
Case classification
The majority (n = 160; 98%) were classified as confirmed 
cases: patients with group A streptococcus (GAS; 
Streptococcus pyogenes) isolated from a sterile site. 
However, one of these cases did not meet the case 
definition for a confirmed case as the case presented 
with an abscess and GAS was isolated from a non-sterile 
site (throat swab) only. Three cases were classified as 
probable iGAS cases: patients with streptococcal toxic 
shock syndrome (STSS) or necrotising fasciitis and GAS 
isolated from a non-sterile site (e.g. throat, sputum, 
vagina). However, two of these cases did not meet the 
case definition for a probable case as neither presented 
with STSS or necrotising fasciitis and GAS was isolated 
from non-sterile sites only. One case was classified as 
a possible case, i.e. the case presented with STSS and 
there was serological evidence of recent GAS infection 
(high antibody titres to streptolysin O were detected).
Patient demographics
Of the 164 cases, 94 (57%) were male. The mean age of 
patients with iGAS was 44 years (range = 4 months – 99 
years) and iGAS was more common in young children 
and older adults (Figure 1). 
Geographic spread and seasonal variation
Table 1 displays the numbers and crude incidence rates 
(CIRs) of iGAS disease by HSE area from 2010 to 2014. 
While HSE East accounted for the highest number 
of reported cases in 2014 (n=65), HSE West had the 
highest CIR (4.94 per 100,000 population). In two of the 
HSE areas, HSE South and HSE West, both numbers 
of cases and CIRs increased, while in the other six HSE 
areas decreases were reported.
The peak months in 2014 were March (23 cases), April 
and July (21 cases each) and May (20 cases).  As in 
2.3  Invasive Group A Streptococcal 
 Disease
Summary
Total number of cases, 2014 = 164
Crude incidence rate, 2014 = 3.57 per 100,000 
population
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Figure 1.  Age and sex specific rates of iGAS disease in 2014
previous years, the peak period occurred during the 
first half of the year (Figure 2). Upon annual review of 
cumulative monthly data, an increase in notifications 
was first noted from April 2012 (Figure 3). The increase 
was sustained throughout 2013 and into 2014 with the 
numbers starting to level off in the latter months of 
2014. Data presented here are based on the date the 
case was notified to public health, not on the date the 
case was first detected.
Isolate details
Of 160 confirmed cases, GAS was isolated from a sterile 
site in 151 cases and a non-sterile site (throat) for one 
case (see earlier comment on this case classification), 
with a source site not reported for eight cases. GAS 
was isolated primarily from blood cultures (n=100; 
66%), abscesses (n=21), deep tissue (n=12), joints (n=6), 
pleural fluid (n=3), bone (n=1) and peritoneal fluid (n=1). 
For four cases, GAS was isolated from another sterile 
site in addition to blood: abscess (n=2), bone (n=1) and 
joint (n=1). 
Of the three probable iGAS cases notified, GAS was 
isolated from non-sterile sites, i.e. vaginal, perineal and 
thigh wound swabs. In two of these cases, the case 
definition for probable iGAS was not met as they did 
not have a clinical presentation that included STSS or 
necrotising fasciitis (see earlier comment under “case 
classification”). In the possible iGAS case, there was no 
isolate but high antibody titres to streptolysin O were 
detected in conjunction with a clinical presentation that 
included STSS. 
 
Typing data, based on sequencing of the emm genes 
that encode the M protein (the major virulence factor), 
were available on 130 isolates submitted from 29 
laboratories: emm-types 3 (n=47; 36%), 1 (n=21; 16%), 
28 (n=12; 9%), 89 (n=8; 6%), 4 and 81 (n=7; 5% each) 
and 12 (n=6; 5%) comprised 86% of all the isolates 
typed. Twelve other emm-types (each represented 
by four isolates or less) were also detected. Of the 
15 patients with STSS for whom emm-typing was 
undertaken, eight GAS isolates belonged to emm3 
(53%) and three to emm1 (20%). 
Enhanced surveillance data
 Enhanced data were provided for 150 (91%) of the 
168 iGAS cases, which is slightly lower than in 2013 
(156 of 168 cases; 93%). The source laboratory could 
be ascertained for all cases. As in previous years, there 
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Figure 2.  Monthly distribution of iGAS cases, 2010-2014
HSE Area 2010 2011 2012 2013 2014
 n   CIR    n   CIR    n   CIR    n   CIR    n   CIR    
HSE E 22 1.36 29 1.79 51 3.15 67 4.14 65 4.01
HSE M 2 0.71 5 1.77 7 2.48 7 2.48 4 1.42
HSE MW 6 1.58 6 1.58 8 2.11 16 4.22 13 3.43
HSE NE 7 1.59 1 0.23 11 2.50 14 3.18 12 2.72
HSE NW 8 3.10 2 0.77 5 1.94 6 2.32 3 1.16
HSE SE 5 1.00 7 1.41 16 3.22 21 4.22 18 3.62
HSE S 12 1.81 12 1.81 14 2.11 18 2.71 27 4.06
HSE W 6 1.35 5 1.12 10 2.25 19 4.27 22 4.94
IRELAND 68 1.48 67 1.46 122 2.66 168 3.66 164 3.57
Table 1. Numbers (n) and Crude Incidence Rates (CIRs) per 100,000 population of iGAS disease by HSE Area (2010-2014)
CIRs calculated using the 2011 census
was wide variation in completeness of enhanced data 
reporting. Table 2 summarises characteristics of iGAS 
cases in Ireland from 2010 to 2014.
Clinical details
Clinical presentation data were provided for 132 cases 
(80%). As in previous years, bacteraemia (n=100 cases, 
including cases where bacteraemia was not specifically 
stated but GAS was isolated from blood) and cellulitis 
(n=58) were the commonest presentations, followed 
by STSS (n=21; seven of which were implied based on 
the information provided on the clinical presentation), 
pneumonia (n=14), septic arthritis (n=11), necrotising 
fasciitis (n=7), myositis (n=6), puerperal sepsis (n=4), 
erysipelas (n=2) and peritonitis (n=1). Note that an iGAS 
case could have more than one clinical manifestation of 
infection.
Risk factors
Risk factor data were provided for 126 iGAS cases 
(77%). Risk factors included: age ≥65 years (n=56), 
presence of skin or wound lesions (n=50), diabetes 
mellitus (n=11), malignancy (n=10), varicella infection 
(n=7), steroid use (n=6), alcoholism (n=5), injecting 
drug use (IDU) (n=5), recent childbirth (n=4), and non-
steroidal anti-inflammatory drug (NSAID) use (n=2). 
Note that an iGAS case could have more than one risk 
factor. No risk factors were identified for 37 cases. 
Clinical management/Severity
Surgical intervention was required for 41 patients (aged 
14 months – 86 years). This included one patient with 
STSS, three patients with necrotising fasciitis and three 
patients with both STSS and necrotising fasciitis.
Among patients requiring surgical intervention, risk 
factor data were provided for 39 cases. Risk factors 
included: skin and wound lesions (n=16), age ≥65 
years (n=5), varicella infection (n=2), alcoholism (n=1), 
malignancy (n=1), IDU (n=1) and NSAID use (n=1). Note 
that an iGAS case requiring surgery could have more 
than one risk factor. No risk factors were identified for 
17 patients.
Thirty-six patients (aged 14 months – 99 years) required 
intensive care unit (ICU) admission. This included 12 
patients with STSS, four patients with necrotising 
fasciitis and three patients with both STSS and 
necrotising fasciitis.
Among patients admitted to an ICU, risk factor data 
were provided for 32. Risk factors included: age ≥65 
years (n=15), skin and wound lesions (n=13), diabetes 
mellitus (n=4), malignancy (n=3), alcoholism (n=2), IDU 
(n=1) and varicella infection (n=1). Note that an iGAS 
case requiring ICU admission could have more than 
one risk factor. No risk factors were identified for eight 
patients. Length of ICU stay was provided for 18 cases. 
The median length of ICU stay was three days (range = 
1 – 7). 
Other epidemiological information
Three cases were reported as hospital-acquired. 
There were no iGAS outbreaks reported.
Outcome
Outcome at seven-days following GAS isolation was 
reported for 102 cases: 
•  92 were still alive 
•  10 patients had died, where GAS was the main or 
contributory cause of death
The seven-day case fatality rate (CFR) for iGAS disease 
was 10%.
Of 21 STSS cases, outcome at seven-days was reported 
for 17. Of those, there were six deaths due to GAS (CFR 
= 35%).  
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Figure 3.  Cumulative monthly numbers of iGAS cases, 2010-2014
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Year
2010 2011 2012 2013 2014
Notifications
Total iGAS cases notified 68 67 122 168 164
iGAS incidence rate per 100,000 population 1.48 1.46 2.66 3.66 3.57
Cases for which Enhanced data provided** (%) 61 (90%) 60 (90%) 106 (87%) 156 (93%) 150 (91%)
Patient Demographics
Male (%) 36 (53%) 28 (42%) 59 (48%) 95 (57%) 94 (57%)
M:F ratio 1.13:1 0.72:1 0.94:1 1.30:1 1.34:1
Mean age 49 43 44 41 44
Median age 49 39 42 40 44
Age range 0-97 0-97 0-92 0-93 0-99
Paediatric cases (aged <18 years) (%) 10 (15%) 15 (22%) 28 (23%) 45 (27%) 47 (29%)
Older cases (aged 65+ years) (%) 22 (32%) 22 (33%) 42 (34%) 50 (30%) 56 (34%)
Clinical Presentation†
Data on Clinical Presentation (%) 60 (88%) 58 (87%) 103 (84%) 142 (85%) 132 (80%)
Streptococcal Toxic Shock-like Syndrome (STSS) without NF (%) 7 (12%) 4 (7%) 22 (21%) 28 (20%) 18 (14%)
Necrotising fasciitis (NF) without STSS (%) 2 (3%) 1 (2%) 2 (2%) 6 (4%) 4 (3%)
STSS and NF (%) 2 (3%) 2 (3%) 4 (4%) 4 (3%) 3 (2%)
Bacteraemia with focal presentations (%) 27 (45%) 30 (52%) 42 (41%) 45 (32%) 45 (34%)
Bacteraemia with no focal presentations (%) 21 (35%) 15 (26%) 21 (20%) 36 (25%) 35 (27%)
Other focal presentations with no bacteraemia (%) 1 (2%) 6 (10%) 11 (11%) 23 (16%) 28 (21%)
Bacteraemia (%) 55 (92%) 52 (90%) 80 (78%) 107 (75%) 100 (76%)
Other focal presentations:
Cellulitis (%) 22 (37%) 24 (41%) 41 (40%) 45 (32%) 58 (44%)
STSS (%) 9 (15%) 6 (10%) 26 (25%) 32 (23%) 21 (16%)
Pneumonia (%) 10 (17%) 8 (14%) 17 (17%) 24 (17%) 14 (11%)
Septic arthritis (%) 2 (3%) 2 (3%) 7 (7%) 10 (7%) 11 (8%)
Necrotising fasciitis (%) 4 (7%) 3 (5%) 6 (6%) 10 (7%) 7 (5%)
Myositis (%) 2 (3%) 0 (0%) 4 (4%) 3 (2%) 6 (5%)
Puerperal sepsis (%) 4 (7%) 5 (9%) 6 (6%) 6 (4%) 4 (3%)
Erysipelas (%) 0 (0%) 0 (0%) 3 (3%) 3 (2%) 2 (2%)
Peritonitis (%) 1 (2%) 3 (5%) 1 (1%) 4 (3%) 1 (1%)
Meningitis (%) 2 (3%) 1 (2%) 3 (3%) 3 (2%) 0 (0%)
Risk Factors†
Data on Risk Factors (%) 49 (72%) 49 (73%) 96 (79%) 138 (82%) 126 (77%)
Age 65+ years (%) 22 (32%) 22 (33%) 42 (34%) 50 (30%) 56 (34%)
Skin lesions/wounds (%) 16 (33%) 20 (41%) 34 (35%) 56 (41%) 50 (40%)
Diabetes (%) 8 (16%) 7 (14%) 5 (5%) 16 (12%) 11 (9%)
Malignancy (%) 6 (12%) 6 (12%) 10 (10%) 23 (17%) 10 (8%)
Varicella (%) 2 (4%) 2 (4%) 9 (9%) 5 (4%) 7 (6%)
Steroid use (%) 2 (4%) 1 (2%) 8 (8%) 11 (8%) 6 (5%)
Alcoholism (%) 3 (6%) 1 (2%) 5 (5%) 6 (4%) 5 (4%)
Injecting drug user (%) 6 (12%) 3 (6%) 6 (6%) 5 (4%) 5 (4%)
Childbirth (%) 4 (8%) 5 (10%) 6 (6%) 6 (4%) 4 (3%)
Non-steroid anti-inflammatory drug use (%) 6 (12%) 1 (2%) 2 (2%) 4 (3%) 2 (2%)
No identified risk factor (%) 7 (14%) 8 (16%) 14 (15%) 37 (27%) 37 (29%)
Outcome at 7 days
Data on outcome at 7 days (%) 43 (63%) 43 (64%) 65 (53%) 108 (64%) 102 (62%)
RIP/GAS main cause or contributory (%) 4 (9%) 5 (12%) 8 (12%) 16 (15%) 10 (10%)
STSS cases: Data on outcome at 7 days (%) 8 (89%) 5 (83%) 17 (65%) 26 (81%) 17 (81%)
STSS cases: RIP/GAS main cause or contributory (%) 2 (25%) 1 (20%) 6 (35%) 10 (38%) 6 (35%)
Severity
Data on Admission to ITU (%) 57 (84%) 57 (85%) 99 (81%) 153 (91%) 144 (88%)
Admitted to ITU (%) 14 (25%) 11 (19%) 40 (40%) 44 (29%) 36 (25%)
Data on Surgical Intervention (%) 49 (72%) 45 (67%) 86 (70%) 136 (81%) 127 (77%)
Surgical Intervention Required (%) 12 (24%) 8 (18%) 26 (30%) 39 (29%) 41 (32%)
Typing
iGAS isolates that were typed (%) 109 (89%) 140 (83%) 130 (79%)
Emm-1 (%) 53 (49%) 41 (29%) 21 (16%)
Emm-3 (%) 4 (4%) 33 (24%) 47 (36%)
Other emm-types (%) 52 (47%) 66 (47%) 62 (48%)
STSS cases: iGAS isolates that were typed (%) 25 (96%) 28 (88%) 15 (71%)
Emm-1 (%) 17 (68%) 9 (32%) 3 (20%)
Emm-3 (%) 2 (8%) 9 (32%) 8 (53%)
Other emm-types (%) 6 (24%) 10 (36%) 4 (27%)
** Degree of completion of enhanced surveillance forms varies from case to case: information may not be available on all variables/ catego-
ries, thus calculations of percentages take into account only those cases for which data are provided
†Note: A patient may have more than one clinical presentation or risk factor
 Table 2. Characteristics of iGAS cases in Ireland, 2010-2014
Of 41 cases requiring surgical intervention, outcome at 
seven-days was reported for 32. Of those, there were 
no deaths due to GAS. 
Of 36 cases admitted to ICU, outcome at seven-days 
was reported for 26. Of those, there were six deaths 
due to GAS (CFR = 23%). 
Antimicrobial susceptibility
Antimicrobial susceptibility data were reported on 
94 GAS isolates (88 from blood and six from other 
specimens) by 25 laboratories via the European 
Antimicrobial Resistance Surveillance Network 
(EARS-Net). All isolates tested were susceptible to 
penicillin (n=84) and vancomycin (n=71).  Resistance to 
erythromycin was reported in four (5%) of 85 isolates, 
to clindamycin in one (2%) of 42 isolates and to 
tetracycline in four (12%) of 33 isolates.
CONCLUSION
In 2014, 164 cases of iGAS infection were notified in 
Ireland, the second highest annual number reported 
to date after 2013 (n=168). The CIR decreased from 
3.66 in 2013 to 3.57 per 100,000 in 2014, but this was 
not statistically significant. There were signs that the 
numbers of iGAS infections was levelling off towards 
the end of 2014.
Invasive GAS is a potentially life-threatening disease. 
In 2014, the CFR was 10% for all iGAS infections and 
even higher for patients admitted to ICU (23%) or 
presenting with STSS (35%). Since 2012, more patients 
have presented with STSS than in previous years: with 
26 cases in 2012, 32 cases in 2013, and 21 cases in 2014 
compared with 6-9 cases in each of the previous four 
years.
Typing of emm genes was undertaken on a national 
basis for the first time in 2012, with the establishment 
of a GAS typing service by the Epidemiology and 
Molecular Biology Unit (EMBU) at the Children’s 
University Hospital, Temple St. In 2014, one emm type, 
emm3, predominated comprising 36% of all isolates 
typed. This is in contrast with the situation in 2012 when 
another emm type, emm1, was predominant comprising 
49% of all isolates typed; while in 2013 both emm1 
and emm3 were the dominant emm types. Certain 
emm types, including emm1 and emm3, are associated 
with STSS, and STSS in turn is strongly associated 
with increased mortality. The changes observed in the 
predominant emm types in circulation and in the clinical 
presentations over the last couple of years highlight the 
dynamic nature of iGAS infection. 
Ongoing surveillance is essential, specifically 
completion of the enhanced data questionnaire, to 
gain a greater understanding of iGAS, to enable early 
detection of clusters/outbreaks, to ensure prompt 
implementation of infection prevention and control 
precautions and appropriate management of contacts. 
Epidemiological typing as provided by the EMBU is 
another vital element to increase insight into GAS 
infection in Ireland, as certain emm types are associated 
with greater morbidity and mortality.
Antimicrobial susceptibility data confirm that iGAS 
remains susceptible to penicillin and that penicillin 
should continue to be the treatment of choice for iGAS. 
HPSC thanks participating microbiology laboratories 
and public health departments for their ongoing 
contribution to the iGAS enhanced surveillance scheme. 
All microbiology laboratories are encouraged:
•  to return enhanced iGAS surveillance forms for every 
patient with iGAS 
•  to submit all iGAS isolates to the Epidemiology and 
Molecular Biology Unit (EMBU), Children’s University 
Hospital, Temple St for emm-typing 
•  to submit antimicrobial susceptibility data on all iGAS 
cases along with EARS-Net quarterly returns
The enhanced surveillance form can be downloaded 
from the HPSC web site at:
http://www.hpsc.ie/hpsc/A-Z/Other/
GroupAStreptococcalDiseaseGAS/SurveillanceForms/
Further information on iGAS disease in Ireland, 
including factsheets for patients and contacts, national 
guidelines is available at: http://www.hpsc.ie/A-Z/
Other/GroupAStreptococcalDiseaseGAS/
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Diseases Reporting (CIDR) System on 1st October 
2015. 
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Background
Invasive group B streptococcal (iGBS; Streptococcus 
agalactiae) infections in infants <90 days old or 
stillborn infants have been notifiable in Ireland via the 
Computerised Infectious Diseases Reporting (CIDR) 
system since January 2012.
In neonates two syndromes exist:
•  Early-onset disease (EOD; age at onset/diagnosis <7 
days old)
•  Late-onset disease (LOD; age at onset/diagnosis 7-89 
days old)
Both include sepsis, pneumonia and meningitis. Stillbirth 
associated with isolation/detection of Streptococcus 
agalactiae from the placenta or amniotic fluid is also 
notifiable.
Notifications
In 2014, there were 68 iGBS cases, of which 46 and 22 
cases represented EOD and LOD, respectively (Figure 
1 and Table 1). The EOD and LOD rates were 0.68 
and 0.33 per 1,000 live births, respectively (67,462 
live births, CSO 2014 data obtained from http://
www.cso.ie/en/releasesandpublications/ep/p-vsys/
vitalstatisticsyearlysummary2014/) 
Five cases presented with meningitis and five cases 
were associated with stillbirth.
The figures presented in this summary are based on 
data extracted from CIDR on 19th October 2014. 
2.4  Invasive Group B Streptococcal 
Infections
Summary
Number of cases, 2014: 68 
• 46 cases of early-onset disease (EOD)
•22 cases of  late-onset disease (LOD)
EOD rate per 1,000 live births, 2014: 0.68
LOD rate per 1,000 live births, 2014: 0.33
-56-HPSC Annual Epidemiological Report 2014 2. Respiratory and Direct Contact Diseases
0
5
10
15
20
25
30
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51+ 
Nu
m
be
r o
f c
as
es
 
Age at disease onset/diagnosis (days) 
Early-onset disease Late-onset disease
Figure 1. Distribution of cases of invasive Group B streptococcal infection by age (in 
days) at time of onset/diagnosis in 2014: early-onset disease (<7 days) and late-onset 
disease (7-89 days)
Table 1. Annual breakdown, including rates, of iGBS cases by disease syndrome, 
2012-2014 
Year
Disease syndrome 2012 2013 2014
n (%) Rate* n (%) Rate* n (%) Rate*
EOD 57 (75%) 0.79 41 (62%) 0.59 46 (68%) 0.68
LOD 19 (25%) 0.26 25 (38%) 0.36 22 (32%) 0.33
Total 76 1.05 66 0.96 68 1.01
* Incidence rate per 1,000 live births
Live births in the Republic of Ireland (source: www.cso.ie): 2012, 72,225; 2013, 68,930; 2014, 
67,462
In 2014, 318 cases of tuberculosis (TB) were notified in 
Ireland, corresponding to a crude incidence rate (CIR) 
of 6.9 per 100,000 population, a decrease compared 
to 2013 (8.1/100,000 population)*. A summary of the 
epidemiology of TB in Ireland during 2013 and 2014 
is shown in table 1 while the number of notifications 
and CIR from 1991 to 2014† with three-year moving 
averages is illustrated in figure 1. Outcome data will 
not be available for cases diagnosed during 2014 until 
February 2016.
Regional distribution:
The highest crude incidence rate in both 2013 and 2014 
was reported by HSE-S (9.9) while the lowest rate was 
reported by HSE-M (5.7) in 2013 and HSE-W (3.8) in 
2014. 
The highest age-specific rate (ASIR) in 2014 was 
observed in those aged 65 years and older (13.1) while 
the highest ASIR in 2013 occurred among those aged 
25-34 years (11.7). For both years, rates among males 
were higher than females for all age groups except in 
the 15-24 year age group in 2013 and the 35-44year 
age group in 2014. The highest rate among males in 
2014 occurred in those aged 65 years and older (16.9) 
while the highest rate in 2013 (15.1) occurred in males 
aged 55-64 years. The highest rate in females in 2014 
occurred in those aged 65 years and older (9.9) and 
those aged 25-34 years (9.8) while in 2013 it occurred 
in the 15-24 year age group (10.1). The male to female 
ratio (1.7:1) reported in 2013 was consistent with the 
ratio reported in previous years, while it was slightly 
lower during 2014 (1.2:1). 
Geographic origin
During 2014, 43.1% (137 cases) of TB cases were born 
outside Ireland, a slight decrease from the proportion 
reported in 2013 (44.9%). The crude rate in the foreign-
born population decreased from 21.8 per 100,000 in 
2013 to 17.9 per 100,000 in 2014. The crude rate in the 
indigenous population was 4.7 per 100,000 in 2014, 
which decreased slightly compared to 5.4 per 100,000 
reported in 2013. There was a notable difference in 
age between indigenous and foreign born cases, with a 
2.5  Tuberculosis, 2014 and      
outcome data for 2013 
Summary
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  *All crude incidence rates (CIR) are calculated per 100,000 population unless otherwise stated.
  †Data for 2014 are provisional data which may change significantly following validation
  ‡Country of birth was missing for 4 cases in 2014 and for 3 cases in 2013.
Table 1: Summary of the epidemiology of TB in Ireland, 2013 and 2014
Parameter
2013 2014
Number of 
cases
CIR % of total
Number of 
cases
CIR % of total
Total number of cases 372 8.1 n/a 318 6.9 n/a
Cases in indigenous population 202 5.4 54.3 177 4.7 55.7
Cases in foreign-born persons‡ 167 21.8 44.9 137 17.9 43.1
Culture positive cases 281 6.1 75.5 231 5.0 72.6
Pulmonary cases 249 5.4 66.9 196 4.3 61.6
Smear positive pulmonary cases 127 2.8 34.1 91 2.0 28.6
Multi-drug resistant cases 4 0.09 1.1 2 0.04 0.6
Mono-resistant to isoniazid 19 0.4 5.1 8 0.2 2.5
Deaths attributable to TB 6 0.1 1.6 n/a n/a n/a
Outcomes reported in cases§ 294 6.4 79.0 n/a n/a n/a
TB meningitis cases 3 0.07 0.8 2 0.04 0.6
2013: 372 (8.1/100,000 population)
2014: 318 (6.9/100,000 population)
median age of 58 years in 2014 and 47 years in 2013 in 
Irish-born cases, compared to 34 years in 2014 and 35 
years in 2013 in foreign-born cases. 
Site of infection 
During 2014, pulmonary TB was reported in 196 (61.8%) 
cases and 121 (38.2%) had exclusively extrapulmonary 
disease while in 2013, 249 cases (66.9) were pulmonary 
and 123 (33.1) were exclusively extrapulmonary. Of the 
extrapulmonary cases reported, there were three cases 
of TB meningitis in 2013 (0.07/100,000 population) and 
two in 2014 (0.04/100,000 population).
Microbiology
Of the 318 cases reported in 2014, 72.6% (231 cases) 
were culture confirmed. Of the 196 cases with a 
pulmonary component reported, 159 (81.1%) were 
reported as culture confirmed and 91 (46.4%) were 
reported as smear positive. Of the 372 cases reported 
in 2013, 75.5% (281 cases) were culture confirmed. Of 
the 249 cases with a pulmonary component reported, 
207 (83.1%) were reported as culture confirmed and 127 
(51.0%) were reported as smear positive. 
Drug sensitivity 
Information on antibiotic sensitivity testing was available 
for 230 (99.6%) of 231 culture confirmed cases in 2014 
and 272 (96.8%) of the 281 culture confirmed cases 
in 2013. In 2014, there were 17 (7.4%) documented 
resistant cases, two (0.6% of total cases) of which 
were MDR-TB cases. In 2013 there were 32 (11.8%) 
documented resistant cases, three (0.8% of total cases) 
of which were MDR-TB of which one was an XDR-TB 
case (0.3% of total cases). This is the second XDR-TB 
case reported since enhanced surveillance began in 
2000. The previous XDR-TB case was reported in 2005.
 
Outcomes for 2013 cases
In 2013, information on treatment outcome was 
provided for 79.0% (294) of cases, similar to 78.3% in 
2012. Treatment outcome was reported as completed 
for 229 (61.6%) cases, 10 were still on treatment (2.7%), 
18 (4.8%) cases died, 16 (4.3%) were lost to follow 
up, 14 cases transferred out (3.8%), seven (1.9%) had 
treatment interrupted. Six (1.6% of total cases) of the 18 
deaths were reported as attributable to TB. 
Outbreaks 
The introduction of the amendment to the Infectious 
Disease Regulations 1981 on January 1st 2004, made 
outbreaks, unusual clusters or changing patterns of 
illness statutorily notifiable by medical practitioners and 
clinical directors of laboratories to the medical officer of 
health. Standard reporting procedures for surveillance 
of TB outbreaks were formally agreed in 2007. 
During 2014, five outbreaks of TB were reported to 
HSPC, a decrease compared to 2013. Twenty cases of 
active TB and 10 cases of latent TB infection (LTBI) were 
reported. Three outbreaks were reported by HSE-S and 
one each was reported by HSE-E and NE. Two general 
outbreaks were reported, one occurred in a community 
setting and one occurred in a public house. There were 
also three family outbreaks, two were in private houses 
and one occurred across an extended family. 
During 2013, 12 outbreaks of TB were reported to 
HSPC, with 46 reported cases of active TB, 174 with 
latent TB infection (LTBI) and 17 hospitalisations. Three 
outbreaks each were reported by HSE-E, -S and –W, two 
outbreaks by HSE-MW and one by HSE-SE. There were 
seven general outbreaks, four in a community setting 
and one each in a university/college, a workplace and 
a residential institution. There were also five family 
outbreaks, three of which occurred across extended 
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Figure 1: Notified cases of TB in Ireland with CIR per 100,000 population, 1991 to 2014 and 3-year 
moving averages, 1992-2014
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families and two were in private houses. The number of 
outbreaks reported during 2013 increased compared 
to 2012, while the number of cases of LTBI reported as 
associated with the outbreaks increased sharply. 
Figure 2 shows a summary of reported TB outbreaks 
from 2004 to 2014 by year of outbreak, number of 
active TB cases and number of persons with LTBI. Please 
note that numbers of LTBI for outbreaks reported during 
2013 and 2014 are provisional and may increase as 
outbreak investigations continue.
Further details on the epidemiology of TB cases 
reported in 2013 and 2014 will be available in the HPSC 
Report on the Epidemiology of TB in Ireland, 2013-2014 
(www.hpsc.ie).
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Figure 2: TB outbreak summary by year, 2004-2014
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Chickenpox-hospitalised cases
The Health Act, 1947 entitles the Minister for Health 
to declare by regulation diseases that are infectious, 
covered by legislation and that require notification to 
a Medical Officer of Health. The infectious diseases 
notifiable in Ireland are regulated in the 1981 Infectious 
Diseases Regulations. The amendment S.I. No. 452 of 
2011 to these regulations specified for the first time 
the disease chickenpox, hospitalised cases only, as 
notifiable. Chickenpox is caused by varicella-zoster 
virus. The case definition is available at www.hpsc.ie.
In 2014, 61 (1.3/100,000) hospitalised chickenpox cases 
were notified in Ireland compared to 53 (1.2/100,000) 
in 2013. The largest number of cases was in the HSE E 
(table 1). Of the 61 cases, 42 (69%) were classified as 
confirmed and 19 (31%) as possible. The largest number 
of cases and the highest age specific incidence rate was 
in the age group <1 year (figures 1 and 2). Of the 61 
cases, 34 (56%) were male and 27 (44%) were female 
giving a male:female ratio of 1.3:1.
Chickenpox/varicella outbreaks
The amendment S.I. No. 707 of 2003 to the infectious 
disease regulations specified that unusual clusters 
or changing patterns of illness that may be of 
public health concern must be reported. Therefore, 
outbreaks of chickenpox must be notified regardless 
of hospitalisation status. Two outbreaks of chickenpox/
suspected chickenpox were notified in 2014. One 
outbreak occurred in a childcare facility with 25 ill, the 
other occurred in a school, with 24 ill.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 11th August 2015. 
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.
2.6 Chickenpox-hospitalised cases
Summary
Number of cases, 2014: 61
Crude incidence rate, 2014: 1.3/100,000
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Figure 1. Number of notified hospitalised chickenpox cases in 
2014 by age group and case classification
Figure 2. The age specific incidence rate (per 100,000 
population) of notified hospitalised chickenpox cases in 2014 
by case classification
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Table 1. Number of notified hospitalised chickenpox cases and 
the crude incidence rate per 100,000 population (CIR) by HSE 
Area in 2014
HSE Area Number CIR
HSE E 33 2.0
HSE M 1 0.4
HSE MW 3 0.8
HSE NE 4 0.9
HSE NW 5 1.9
HSE SE 6 1.2
HSE S 8 1.2
HSE W 1 0.2
Total 61 1.3
AnnuAl 
EpidEmiologicAl 
REpoRt 
20
1 4
03
infEctious intEstinAl disEAsEs
Campylobacteriosis became a notifiable disease 
in Ireland in 2004 under the Infectious Diseases 
regulations. Prior to this, data on laboratory-confirmed 
cases of Campylobacter infection in humans were 
collected nationally as part of the EU Zoonoses 
Regulations (while some cases were included in the 
former category of “Food Poisoning (bacterial other 
than Salmonella)”). It is an acute zoonotic bacterial 
disease characterised by diarrhoea, abdominal pain, 
malaise, fever, nausea and vomiting. Symptoms 
generally last for only a few days. Campylobacteriosis 
is the commonest bacterial cause of gastroenteritis in 
Ireland and Europe. 1
During 2014, levels of campylobacteriosis remained 
elevated for the fourth consecutive with 2,615 
notifications reported to HPSC, an increase of 25.6% 
compared to 2013. This corresponded to a crude 
incidence rate of 57.0/100,000 population, which is 
comparable with the 2013 European crude incidence 
rate of 64.8 per 100,000 population.7 
Historically, variation in campylobacteriosis crude 
incidence rates (CIRs) has been reported between HSE 
areas. During 2014, the highest CIRs occurred in HSE-
SE (78.6/100,000 population) and HSE-M (76.1/100,000 
population). Both HSE areas also had the highest 
increases in CIR during 2014 compared to the mean CIR 
during 2004-2013 (HSE-M 52.1% and HSE-SE 47.7%). 
The lowest CIR was reported by HSE-NE (43.8/100,000 
population). 
Campylobacteriosis occurs in all age groups with the 
highest rate of notification reported in the 0-4 year age 
group. This preponderance in younger children is a 
well described characteristic of the disease and is also 
observed at European level. A comparison of the mean 
age-specific incidence rate between 2004-2013 and the 
age-specific rate in 2014 showed an increase of >45% 
in those aged 65 years and older (46.6%). This is the 
third consecutive year that the CIR has increased in this 
age group. Figure 1 compares the campylobacteriosis 
age specific rates (ASIR) for 2014 with the mean 
campylobacteriosis ASIR for 2004 to 2013. 
3.1 Campylobacter 
Summary
Number of cases: 2,615
Crude incidence rate: 57.0/100,000
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Figure 1: Campylobacteriosis ASIR 2014 compared to 2004-2013 mean ASIR (CIDR)
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Campylobacteriosis has a well documented seasonal 
distribution with a peak in summer. In Ireland, 
notifications typically peak during May to July. While 
this typical warm-season peak was observed during May 
to July 2014, levels of campylobacteriosis notifications 
were also elevated during January 2014 with an increase 
of 38.3% reported compared to the mean number of 
notifications during January in 2004-2013. Figure 2 
compares the monthly number of campylobacteriosis 
notifications for 2014 to the mean monthly number of 
campylobacteriosis notifications between 2004 and 
2013. 
All bar two of the cases notified in Ireland during 
2014 were laboratory confirmed. However, as there 
is currently no national reference facility for routine 
typing of Campylobacter isolates, information on 
Campylobacter species is strikingly incomplete. In 2014, 
29.9% (n=781) of isolates were speciated. Of the 781 
speciated isolates, 93.2% of isolates were C. jejuni, 
6.5% were C. coli, while C. fetus and C. sputorum each 
accounted for 0.1%. The remaining 70.1% (n=1,834) 
of Campylobacter isolates identified were not further 
speciated. 
During 2014, there were 10 outbreaks of 
campylobacteriosis reported to HPSC with 68 
associated cases of illness. Six outbreaks were family 
outbreaks occurring in private houses. Four reported 
mode of transmission as person to person, while mode 
of transmission was unknown for the remaining two 
outbreaks. Four general outbreaks were also reported, 
two in nursing homes and two in community settings. 
Mode of transmission was foodborne for one and 
unknown for the remaining three outbreaks. During 
2013, 16 European countries reported 414 food-borne 
outbreaks of campylobacteriosis which accounted for 
8.0% of the total food-borne outbreaks reported to 
EFSA.1
References:
1.  European Food Safety Authority (EFSA), European Centre for 
Disease Prevention and Control (ECDC). The Community summary 
report on trends and sources of zoonoses, zoonotic agents and 
food-borne outbreaks in the European Union in 2013. The EFSA 
Journal (2015); 11(4):3129 Available at:     
http://www.efsa.europa.eu/en/efsajournal/doc/3547.pdf  
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Figure 2: Campylobacteriosis notifications by month during 2014 compared to mean monthly notifications 2004-2013 
(CIDR)
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Table 1: Campylobacteriosis outbreaks summary, 2014   (CIDR)
Outbreak location Mode of transmission Number outbreaks Number ill Number hospitalised Number dead
Nursing home Foodborne 1 9 0 0
Nursing home Unknown 1 9 0 0
Other Unknown 2 37 4 0
Private house Unknown 2 5 0 0
Private house Person to person 4 8 0 0
Total 10 68 4 0
Cryptosporidium is a protozoal parasite that causes a 
diarrhoeal illness in humans known as cryptosporidiosis. 
It is transmitted by the faeco-oral route, with both 
animals and humans serving as potential reservoirs. 
Human cryptosporidiosis became a notifiable disease 
in Ireland in 2004, and the case definition in use is 
published on the HPSC website. 
In 2013, 394 cases of cryptosporidiosis were notified in 
Ireland, a crude incidence rate (CIR) of 8.6 per 100,000 
population (95% CI 7.7-9.4). Of the notified cases 34.8% 
were hospitalised. There were no reported deaths.
Compared with 2013 (11.2/100,000), in 2014 the 
incidence decreased by 23% (p<0.001), which is the 
second lowest annual crude incidence rate since the 
disease became notifiable in 2004 (Figure 1). In 2012 
(the most recent year for which data are available), the 
ECDC reported an overall incidence rate of 3.85 per 
100,000 population in the European Union. Among the 
countries reporting on cryptosporidiosis at the time, 
Ireland reported the second highest rate after the 
United Kingdom (9.97/100,000), while Sweden had the 
third highest rate (2.61/100,000).1
Consistent with previous years, the highest incidence 
rate was in children under 5 years of age, with 58 cases 
per 100,000 population in this age group (Figure 2). 
While there is likely to be a bias towards testing of 
diarrhoeal stool specimens from children (as opposed 
to adults) for Cryptosporidium, it is also likely that this 
distribution reflects to some extent a true difference 
in risk between adults and children. In 2014, the 
distribution of cases by gender in children under 5 years 
of age was almost equal (M: F ratio 1.03:1), compared 
with 2013 when the majority of cases in this age group 
were male (M: F ratio 1.54:1).
Compared with 2013, in 2014, the crude incidence rate 
declined in six of the eight HSE areas, remaining stable 
in the HSE-M and increasing in the HSE-S (Figure 3). As 
in previous years, there was a strong urban-rural divide, 
with the HSE-E having a much lower reported incidence 
rate (1.4 per 100,000) than all other HSE areas. The 
HSE-NW, HSE-S and HSE-M reported the highest 
crude incidence rates (15.5, 15.5 and 15.2 per 100,000, 
respectively). 
As in previous years, the highest number of cases was 
notified in spring and peaked in April (Figure 4).
Risk factors
Reviewing case-based enhanced surveillance data, 
exposure to farm animals or their faeces either by virtue 
of residence on a farm or by visiting a farm during the 
potential incubation period was common among cases; 
3.2 Cryptosporidiosis
Summary
Number of cases, 2014: 394
Number of cases, 2013: 514
Crude incidence rate, 2014: 8.6/100,000
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Figure 1. Annual number and crude incidence rate 
cryptosporidiosis, Ireland 2004-2014
Figure 2.  Age-specific incidence rate (ASIR) cryptosporidiosis, 
Ireland 2014
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61% of cases reported either or both of these exposures 
(Table 1). This is consistent with the low incidence of 
cryptosporidiosis among residents in the largely urban 
HSE-E population and the higher incidence recorded 
in more rural parts of the country. The proportion of 
cases reporting exposure to pets were similar to last 
year, whereas exposure to swimming pools increased, 
although not significantly from 22.6% last year to 28.3% 
in 2014 (p=0.074) (Table 1).
Unlike salmonellosis, foreign travel plays only a minor 
role in cryptosporidiosis in Ireland with 96.7% of 
infections acquired indigenously (Table 1). However, 
similar to the United Kingdom a slightly higher 
proportion of cases from late summer/early autumn 
were reported as being acquired abroad (Figure 5).
Table 2 shows the distribution of notified cases by home 
water supply type. It appears that persons who are not 
served by public water supplies have an increased risk 
of cryptosporidiosis as they are over-represented among 
the cases relative to the distribution of households 
by water supply type nationally; this was particularly 
noticeable for private well users (25% and 10%, 
respectively). However, it should be borne in mind that 
persons whose household drinking water is not from a 
public supply are more likely to be rural dwellers and 
therefore may also have a higher likelihood of exposure 
to farm animals and rural environments which is also 
likely to increase their risk. 
Outbreaks
In 2014, in total 18 outbreaks were reported, including 
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Figure 3.  Regional crude incidence rates (CIR) 
cryptosporidiosis, Ireland 2011-2014
Figure 4.  Seasonal distribution of cryptosporidiosis cases, 
Ireland 2014 compared to the mean for 2011-2013
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*Comparing the proportion of cases and households served by public water supplies versus all other supply types: X2=52.1, P<0.001
Table 2.  Number of cases (and percentage of cases where information available) by home water supply type compared to the 
number and percentage of households in Ireland by water supply type, Ireland 2014
Home water supply of notified cases Number of cases % of known
No. households served by these water 
supply types in the general population 
2011 (Census 2011)
% of known P value*
Group water scheme (private) 13 3.6% 45,774 2.9%
<0.001
Group water scheme (public) 31 8.6% 144,428 9.0%
Other 1 0.3% 2,080 0.1%
Private well 92 25.4% 161,532 10.1%
Public water supply 225 62.2% 1,247,185 77.9%
Unknown/not specified 32 48,409
Total 394 1,649,408 100%
Table 1.  Number of cases (and percentage of cases where information available) where selected risk factors were reported for 
cryptosporidiosis cases (n=394), Ireland 2014
Risk factor Yes (% of known) No Unknown / Not Specified
Travel 12 (3.7%) 310 72
Lives/cared for on farm 145(40.6%) 212 37
Visited farm 85 (27.2%) 228 81
Lives/works on or visited farma 205 (61.0%) 131 58
Swimming pool visit 95 (28.3%) 241 58
Other water based activities 20 (7.2%) 258 116
Pets 207 (62.9%) 122 65
aComposite of the 2 previous variables
four general and 14 family outbreaks (Figure 6). This is 
a decrease from 2013 when 28 outbreaks were notified. 
However, overall since 2011 there has been an increase 
in the number of outbreaks notified which is most likely 
due to increased recognition of small family outbreaks 
following the introduction of enhanced surveillance for 
cryptosporidiosis cases late in 2010.
Among the four general outbreaks, three were 
associated with crèches/childcare settings and one 
with a swimming pool (Table 3 and Figure 7). The 
four general outbreaks were small in size and none of 
the cases were hospitalised. In 2014, there were no 
outbreaks reported associated with drinking water. 
In 2014, all 14 family outbreaks occurred in private 
Figure 5.  Seasonal distribution of cryptosporidiosis cases by 
country of infection, Ireland 2014
Figure 6.  Number of cryptosporidiosis outbreaks notified by type, 
Ireland 2004-2014
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Table 3.  Number of outbreaks and number ill by transmission route and location, Ireland 2014
Outbreak 
location
Person-to-person Waterborne Animal contact UNK/Not specified Total
No. 
outbreaks No. ill
No. 
outbreaks No. ill
No. 
outbreaks No. ill
No. 
outbreaks No. ill
No. 
outbreaks No. ill
Private house 5 12 0 0 6 12 3 9 14 33
Swimming pool 0 0 1 5 0 0 0 0 1 5
Childcare setting 1 3 0 0 1 2 1 4 3 9
Total 6 15 1 5 7 14 4 13 18 47
Figure 7. Number of general cryptosporidiosis outbreaks by 
transmission route and year, Ireland 2004-2014
Note: In this figure, reported transmission routes were grouped for 
simplicity. Any outbreak where food contributed was reported as 
foodborne, any outbreak where water contributed was reported as 
waterborne, any outbreak where animal contact contributed was 
reported as animal contact. Person-to-person outbreaks include only 
those outbreaks reported as being due only to person-to-person 
transmission. The waterborne outbreak in 2014 was reported as a 
recreational waterborne outbreak rather than a drinking waterborne 
outbreak.
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Figure 8. Number of cryptosporidiosis outbreaks by transmission 
route, Ireland 2004-2014
Note: In this figure, reported transmission routes were grouped 
for simplicity. Any outbreak where food contributed was 
reported as foodborne, any outbreak where water contributed 
was reported as waterborne, any outbreak where animal contact 
contributed was reported as animal contact. Person-to-person 
outbreaks include only those outbreaks reported as being due 
only to person-to-person transmission.
homes, with 33 cases ill and seven hospitalised. The 
most common mode of transmission reported was 
animal contact consisting of six family outbreaks 
resulted in 12 persons ill and two hospitalised. Contact 
with sick animals was suspected for two of these 
outbreaks. The second most common transmission 
route reported in family outbreaks was person-person 
spread (five outbreaks, 12 persons ill and three 
hospitalised). The transmission route was unknown for 
the remaining three family outbreaks; nine persons ill 
including three hospitalised cases (Table 3 and Figure 
8).
Summary
In 2014, the incidence of cryptosporidiosis in Ireland 
declined such that it was one of the lowest rates 
reported since the disease became notifiable in 2004. 
However, the incidence of cryptosporidiosis in Ireland 
remains high relative to most other EU countries. The 
seasonal, age and regional distribution in incidence 
reported in 2014 was also typical of previous years; 
consistently there was a higher incidence in springtime, 
in young children and in non HSE-E areas. 
Person-to-person spread appears to be an important 
mode of transmission within family outbreaks, while 
both enhanced surveillance data and outbreak 
surveillance data are consistent with animal contact 
being an important risk factor for cryptosporidiosis in 
Ireland. Unlike in the United Kingdom, travel-associated 
disease is reported infrequently, and is likely to be a 
minor contributor to transmission, as is transmission 
associated with food.
From the enhanced information on CIDR, exposure to 
water from non-public supplies appears to present a 
higher risk of cryptosporidiosis; persons who are not 
served by public water supplies were over-represented 
among the sporadic cases relative to the distribution of 
households by water supply type nationally. However, in 
2014, there were no waterborne outbreaks associated 
with drinking water supplies, which is in contrast with 
2013 when three such outbreaks occurred.
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Verotoxigenic E. coli
Introduction
The reported verotoxigenic Escherichia coli (VTEC) 
incidence rate in Ireland is generally high relative to 
other European countries. In 2012 (the latest year for 
which data are published), the overall VTEC incidence 
rate in the European Union was 1.59 per 100,000, which 
was 5.9% higher than in 2012.1 The highest country-
specific rates were observed in Ireland, the Netherlands 
and Sweden (12.3, 7.1 and 5.8 per 100,000 population, 
respectively). For many years, Ireland has reported the 
highest VTEC incidence rate of any Member State in the 
EU, except in 2011 when Germany reported the highest 
rate due to a large VTEC O104 outbreak linked with 
fenugreek seeds.2-3 
The dominant transmission routes reported for VTEC 
infection in Ireland have been person-to-person spread, 
especially in childcare facilities and among families with 
young children, and waterborne transmission associated 
with exposure to water from untreated or poorly treated 
private water sources. 4-7 Other important transmission 
routes identified internationally include food (often 
minced beef products or fresh produce such as lettuce 
and spinach), and contact with infected animals or 
contaminated environments.3, 8-9
Materials and Methods
Infection with verotoxigenic E. coli became a notifiable 
disease in 2012; prior to that VTEC were notifiable since 
2004 under the category Enterohaemorrhagic E. coli 
(EHEC). Enhanced epidemiological information was 
supplied as in previous years by HSE personnel, and 
the VTEC National Reference Laboratory at the Public 
Health Laboratory, Cherry Orchard Hospital Dublin 
(VTEC-NRL at PHL) provided VTEC confirmation and 
typing data. Data from all sources are maintained in 
the Computerised Infectious Disease Reporting (CIDR) 
system. Outbreaks of VTEC are notifiable since 2004 
and data are provided to CIDR by the eight regional 
public health departments. The data used in this report 
were extracted from CIDR on 31st August 2015.
Data from the Central Statistics Office (CSO) 2011 
census were used to provide denominators for the 
calculation of national, regional and age-specific 
incidence rates in 2014.
Results
Incidence
In 2014, there were 707 notifications of VTEC, equating 
to a crude incidence rate (CIR) of 15.4 per 100,000 (95% 
CI 14.3-16.5). This compares to an overall incidence 
rate of 13.1 per 100,000 in 2013, an increase of 0.9% 
and an overall incidence rate of 12.1 per 100,000 in 
2012, an increase of 28%. Of the 707 VTEC notifications 
in 2014, 569 (80%) were classified as confirmed cases 
(CIR 12.4 95% CI 11.4-13.4), 136 as probable and 2 as 
possible cases. The criteria under which notified cases 
were reported in 2014 under the VTEC case definition 
3.3 Verotoxigenic E. coli 
Summary
Number of VTEC cases, 2014: 707
Crude incidence rate, 2014: 15.4/100,000
Number of VTEC-associated HUS, 2014: 27
Number of VTEC cases, 2013: 701
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Table 1. Number of VTEC notifications by criteria for notification, Ireland, 2014
Notification criteria Confirmed Probable Possible Total
Culture confirmationa 467 123 - 590
Laboratory confirmation by PCRb 102 12 - 114
Serodiagnosis (valid for HUS only) - - - 0
Reported solely on the basis of epidemiological link - 1 - 1
Clinical HUS not meeting lab or epi criteria - - 2 2
Total 569 136 2 707
a Symptomatic culture confirmed cases are classified as confirmed cases, while asymptomatic culture confirmed cases are classified as probable 
cases
b Symptomatic PCR-confirmed cases are classified as confirmed cases, while asymptomatic PCR-confirmed cases are classified as probable 
cases
is outlined in Table 1. As the classification of VTEC 
cases changed significantly upon the amendment of 
the Irish VTEC case definition in 2012, it is not valid to 
directly compare the number of notifications by case 
classification with the period before 2012. 
Of the 704 cases with laboratory evidence of infection, 
233 cases were reported as being infected with E. 
coli O26 (5.1 per 100,000; 95% CI 4.4-5.7), 177 with 
E. coli O157 (3.9 per 100,000; 95% CI 3.3-4.4), 290 
with other VTEC strains, and 4 cases had mixed VTEC 
infections, being infected with more than one VTEC 
strain. The one probable case reported on the basis of 
an epidemiological link to a confirmed case, was linked 
to an E. coli O157 outbreak. Figure 1 illustrates the 
distribution of VTEC cases in Ireland by serogroup since 
1999. Compared to 2013, the serogroup distribution in 
2014 represents a 20.4% decrease in O157 infections, a 
7.8% increase in O26 infections, and a 12.4% increase in 
other non-O157/O26 infections.
Severity of illness
Five hundred and sixty-eight (80.3%) of the 707 
notified cases were symptomatic, 220 (38.7%) of 
which developed bloody diarrhoea (42.3% when only 
symptomatic cases where the bloody diarrhoea variable 
completed are included). Twenty-seven individuals 
(3.8%) developed HUS, a decrease of 12.9% on 2013 
(n=31). There was one death in a confirmed VTEC case; 
three other persons diagnosed with VTEC infection in 
2014 also died, but their deaths were not reported as 
due to VTEC. Where reported (n=688), 237 (34.4%) of 
notified cases were hospitalised (40.0% of symptomatic 
cases). 
Of the 27 HUS cases, 13 were infected with E. coli 
O157, eight with E. coli O26 and one each with E. coli 
O103, O111, O145 and ungroupable (Table 2). The 
remaining two HUS cases were reported as possible 
VTEC notifications. HUS cases ranged in age from 9 
months to 68 years and 77.8% (n=21) of the cases were 
in children under 10 years of age. Seventeen of the HUS 
cases were sporadic cases, eight were part of family 
outbreaks (including two cases in one household), and 
two were part of a general outbreak (i.e. two cases in a 
childcare setting).
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Figure 1. Annual number of confirmed and probable VTEC 
cases by serogroup, Ireland 1999-2014
Note: For simplicity in this figure, cases with mixed VTEC O157/other 
serogroup infections are included in the data for O157, as are probable 
cases linked to known E. coli O157 outbreaks. Non-O157 data includes 
cases with mixed non-O157 infections and probable cases linked to 
known O26 outbreaks
Figure 2. Seasonal distribution of the number of VTEC 
notifications in Ireland, 2014 and the mean of 2011-2013
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Table 2. Number of VTEC notifications by serogroup and verotoxin and HUS status, Ireland, 2014
Serogroupa HUS non-HUS Total
O157 VT2b 13 135 148
O157 VT1+VT2 0 31 31
O26 VT1 0 100 100
O26 VT2 1 8 9
O26 VT1+VT2 7 120 127
Other VT1
Other VT2
Other VT1+VT2
1
1
2
121
93
72
122
94
74
No organism 2 0 5
Total 27 680 707
a For simplicity mixed infections were recorded as O157 if at least one strain was O157, as O26 if at least one strain was O26 but not O157, and 
as Other if only non-O157 non-O26 strains were detected. 
bIncludes one probable case epi-linked to an O157 VT2 outbreak
Seasonal distribution
Figure 2 shows the seasonal distribution of notifications 
in 2014 relative to the mean monthly number of cases 
in the years 2011-2013. Despite the increase in the 
number of notifications, the typical summer seasonal 
peak was maintained, the peak month was July followed 
by September/October and April/May. An increase in 
December was also noted in 2014.
 
Similar to previous years, during 2014 there was 
variation in the seasonal distribution by serogroup, 
with VTEC O157 showing the typical peak in numbers 
in late summer / early autumn; in contrast, VTEC O26 
notifications peaked in July with a smaller peak in May 
(Figure 3). Other non-O157 serogroups were also more 
common in early summer in 2014. Unlike previous years, 
in 2014 an upsurge in VTEC O157 and O26 notifications 
was also observed in December.
Regional distribution
In 2014, the highest VTEC incidence rates overall were 
reported in the HSE-W followed by the HSE-MW, 
HSE-M and HSE-SE, where the rates were significantly 
higher than the national crude incidence rate (Table 
3). The incidence of VTEC overall in HSE-E and HSE-
NW were significantly lower than the national crude 
incidence rate (Table 3).
The incidence of E. coli O157 was significantly higher 
in HSE-W and significantly lower in HSE E when 
compared with the national crude incidence rate. With 
the exception of the HSE NW, in seven of the eight HSE 
areas, the incidence of non-O157 infections was at least 
twice that of E. coli O157 infections (Table 3). 
The highest incidence of HUS amongst VTEC cases was 
in HSE-NE, despite being ranked sixth in the overall 
VTEC incidence rates (Table 3).
Age-sex distribution
As in previous years, the highest reported age-specific 
incidence rate was in the 0-4 years age group (92 per 
100,000). Incidence rates were higher among females in 
the majority of the age groups; however, the incidence 
rate was higher in males compared with females in the 
0-4 years age group (Figure 5).
Laboratory typing
In 2014, the serogroup and verotoxin profiles of VTEC 
isolates/samples referred to the VTEC-NRL at PHL, 
Cherry Orchard Hospital are displayed in Table 4. The 
most common serogroup reported was VTEC O26 
(n=233), followed by VTEC O157 (n=178). Among 
the other serogroups listed by the World Health 
Organisation as having the highest association with 
HUS internationally, there were 18 VTEC O103 cases, 10 
VTEC O111, and 31 VTEC O145. Compared with 2013, 
there was an 82% increase in the number of VTEC O145 
notified in 2014 (17 and 31 cases, respectively). 
The number of serogroup 0146 quadrupled in 2014, 
compared with 2013 (20 and 5 cases, respectively).
As usual among VTEC O157 in Ireland, isolates 
containing the genes for verotoxin 2 (vt2) were more 
common (82.6%) than strains containing genes for 
both vt1 and vt2. Among the VTEC O26 strains those 
containing the genes for both vt1 and vt2 accounted 
for the majority of these strains (54%), followed by vt1 
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Figure 3: Seasonal distribution of VTEC notifications by 
serogroup, Ireland 2014
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Table 3. Number and crude incidence rates of by serogroup and HSE area, and number and crude incidence rate of VTEC-
associated HUS by HSE area, Ireland, 2014
HSE-area a Number [CIR; 95% CI] VTEC 
O157 b
Number [CIR; 95% CI] non-
O157 VTEC c
Number [CIR; 95% CI] all 
VTEC d
Number [CIR; 95% CI)] VTEC-
associated HUS
E 27 [1.7; 1.0-2.3] 69 [4.3; 3.3-5.3] 96 [5.9; 4.7-7.1] 6 [0.4; 0.07-0.7]
M 15 [5.3; 2.6-8.0] 51 [18.1; 13.1-23.0] 66 [23.4; 17.7-29.0] 3 [1.1 ; 0.0-2.3]
MW 21 [5.5; 3.2-7.9] 85 [22.4; 17.6-27.2] 107 [28.2; 22.9-33.6] 5 [1.3; 0.2-2.5]
NE 15 [3.4; 1.7-5.1] 40 [9.1; 6.3-11.9] 55 [12.5; 9.2-15.8] 6 [1.4; 0.3-2.5]
NW 13 [5.0; 2.3-7.8] 4 [1.6; 0.03-3.1] 17 [6.6; 3.5-9.7] 1 [0.4; 0.0-1.2]
S 28 [4.2; 2.7-5.8] 92 [13.8; 11.0-16.7] 120 [18.1; 14.8-21.3] 2 [0.3; 0.0-0.7]
SE 16 [3.2; 1.6-4.8] 100 [20.1; 16.2-24.0] 116 [23.3; 19.1-27.6] 0 [0.0; 0.0-0.0]
W 44 [9.9; 7.0-12.8] 85 [19.1; 15.0-23.1] 130 [29.2; 24.2-34.2] 4 [0.9; 0.02-1.8]
IE 179 [3.9; 3.3-4.5] 526 [11.5; 10.5-12.4] 707 [15.4; 14.3-16.5] 27 [0.6; 0.4-0.8]
a Rates per 100,000 calculated using CSO census 2011 for denominator data
b  For simplicity, cases with mixed VTEC O157/other serogroup infections are included in the data for O157, as are probable cases linked to known 
E. coli O157 outbreaks. 
c Non-O157 data includes cases with mixed non-O157 infections and probable cases linked to known O26 outbreaks. 
d  Possible cases (i.e. those with no associated organism are also included in this column), and therefore the total in this column will not always be 
the sum of the previous two columns.
only (42.1%) and those containing vt2 making up the 
remaining 9.1% of VTEC O26. In contrast, the majority 
(80.6%) of O145 strains were vt2-postive. Furthermore, 
vt1-containing strains made up the majority of O103 
strains (88.8%), while VTEC O111 comprised mainly of 
and vt1+vt2-containing (90%) strains (Table 4).
Risk factors
Under the enhanced surveillance system for VTEC, 
risk factor information is routinely collected on VTEC 
notifications (Table 5).
Exposure to farm animals or their faeces and exposure 
to private well water were relatively common among 
cases; 34.2% and 32.0% reported these exposures 
respectively. However, both were less commonly 
reported than in 2013 and in 2012. According to CSO 
data, in the general population, around 10.1% of 
households are served by private wells, indicating that, 
on a national basis, exposure to private wells appears to 
be more common among VTEC cases than among the 
general population.
Unlike salmonellosis, foreign travel plays only a minor 
role in VTEC infection in Ireland, with the overwhelming 
majority of infections acquired indigenously. 
Where the information was available, just under a 
quarter of VTEC cases in 2014 reported attendance  at 
a childcare facility (CCF). When these analyses were 
restricted to notified VTEC under five years of age, 
47.8% reported attendance at a childcare facility. This 
is higher than the proportion of children in the general 
population who use non-parental childcare (42%) as 
reported by the Central Statistics Office. 10
Outbreak and environmental investigations
The outbreak surveillance system plays a key role in our 
understanding of VTEC transmission in Ireland. Eighty-
three VTEC outbreaks were notified in 2014, which 
included 275 of the 707 VTEC notifications. Twenty-two 
outbreaks were due to VTEC O157, 38 to VTEC O26, 12 
were mixed VTEC strain outbreaks, and 11 were caused 
by other VTEC strains. 
The majority of outbreaks (88%) were family outbreaks, 
with ten general outbreaks notified. The 73 family 
outbreaks resulted in 134 persons becoming ill, an 
average of 1.9 (range 1-4) persons ill per outbreak, 
while the ten general outbreaks resulted in 68 persons 
becoming ill, an average of 6.8 (range 2-23) persons ill 
per outbreak. 
Sixty-nine outbreaks occurred in private homes, eight 
involved childcare facilities, one was a community 
outbreak, three involved extended families and the 
locations for two outbreaks was not specified. 
The suspected modes of transmission are listed in  
Table 6.
Person-to-person spread is consistently the most 
common mode of VTEC transmission reported in Ireland, 
particularly between young children, and was suspected 
to have played a role in 45 (54%) VTEC outbreaks in 
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Figure 4: Crude incidence rate VTEC O157, O26 and other 
serogroups by HSE area, Ireland, 2014
Table 4. Serotype and verotoxin (vt) profiles for strains 
associated with laboratory confirmed VTEC cases, as 
determined at the VTEC-NRL at PHL, Cherry Orchard 
Hospital, 2014
Serogroup vt1 vt1+vt2 vt2 Total
O26 98 126 9 233
O157 31 147 178
O145 1 5 25 31
O146 9 6 5 20
O103 16 2 18
O111 1 9 10
O5 5 2 7
O182 6 6
O76 4 1 5
O84 5 5
O128ab 3 1 4
O55 2 2 4
O91 1 2 1 4
O108 3 3
O118 3 3
O177 2 1 3
O113 1 1 2
O163 2 2
O165 2 2
O75 1 1 2
O78 2 2
O8 2 2
O105ac 1 1
O107 1 1
O112ab 1 1
O123 1 1
O128ac 1 1
O128ad 1 1
O138 1 1
O181 1 1
O98 1 1
OE11362-78 1 1
Ungroupable 56 41 48 145
Mixed 2 1 3
Total 220 232 250 704
2014 in which 140 persons were reported ill (Table 6 
and Figure 5). Forty of these outbreaks were reported 
as being solely due to person-to-person transmission, 
including six of the outbreaks which occurred in CCFs. 
Animal/environmental contact and waterborne 
transmission were joint second as the most common 
reported routes of transmission. Animal/environmental 
contact was reported to have contributed to nine 
outbreaks (10.8%) with 16 persons ill. All were family 
outbreaks in private houses. This is similar to the 
number of VTEC outbreaks due to this transmission 
route, notified in 2013 (Figure 6). 
Waterborne transmission was reported to have 
contributed to nine outbreaks (10.8%) with 19 persons 
ill. This is similar to the number of waterborne VTEC 
outbreaks reported in 2013 but less than half the 
number reported in 2012 (Figure 6). Two were general 
outbreaks and seven were family outbreaks; with private 
wells suspected in eight of the nine outbreaks. 
One outbreak (family outbreak, 3 persons ill) was 
reported as being suspected to be foodborne, however 
the suspected food item was not reported.
For 29% (n=24) of VTEC outbreaks in 2014, the 
transmission route was reported as unknown or not 
specified (Table 6 and Figure 6).
Summary
The number of VTEC notifications remained stable in 
2014 relative to 2013, following a statistically significant 
increase in 2013 compared with 2012. Since 2011, 
there has been a continuous increase in non-O157 
notifications and this trend continued in 2014, reflecting 
the more widespread use of diagnostic methods in the 
primary hospital laboratories that detect both O157 and 
non-O157 VTEC. 
Interesting the incidence of VTEC O157 continued to 
decrease in 2014.
Guidance for Laboratory Diagnosis of Human 
Verotoxigenic E. coli Infection developed by The 
Laboratory Sub-Group of the VTEC Sub-Committee 
of the HPSC Scientific Advisory Committee was issued 
in September 2014. It is anticipated that this will 
further contribute to a co-ordinated approach to VTEC 
diagnosis in Ireland.11
Within the European Union, Ireland continues to 
have the highest incidence rate for VTEC, reporting 
over seven times the European average in 2013.1 It is 
anticipated when the data are available across Europe 
for 2014, that Ireland will have one of the highest 
reported incidence rates in Europe again
Foodborne transmission was the first recognised 
transmission route for VTEC infection historically, with 
minced beef, unpasteurised dairy products, and fresh 
produce consumed raw all having been implicated 
in outbreaks across the world. Foodborne outbreaks 
typically comprise a small percentage of the total 
number of VTEC outbreaks in Ireland and 2014 was 
not an exception with foodborne outbreaks comprising 
1.2% of the VTEC outbreaks notified.
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Figure 5. Age-sex distribution VTEC notifications, Ireland, 2014
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Table 5. Number of cases of VTEC (and percentage where information available) for selected risk factors, Ireland, 2014 (n=707)
Risk factor Yes 
(% of known)
No Unknown or not reported
Food suspected 30 (6.1) 465 212
Exposure to farm animals or their faeces 211 (34.2) 406 90
Exposure to private well watera 202 (32.0) 430 75
Travel-associatedb 21 (3.3) 625 61
Attendance at a CCFc 137 (23.1) 455 115
Attendance at a CCFc (among <5 yrs) 128 (47.8) 140 59
aComposite variable recoded from two different water supply exposure enhanced variables in CIDR
bInferred from CIDR core variable Country of Infection
c CCF=childcare facility
Similar to 2013, animal/environmental contact was 
reported as the second most common route of 
transmission for VTEC outbreaks in 2014. This has long 
been recognised as a risk factor for VTEC infection,8-9 
and cases due to this transmission route are not 
unexpected in Ireland given the large cattle population, 
the high proportion of rural dwellers, and the large 
number of farming families. Fortunately, none of these 
animal contact outbreaks were associated with public 
venues such as open farms, and so the numbers of 
people affected were small. Advice is available on 
the HPSC website on how to minimise the risk of 
gastrointestinal infections following exposure to farm 
animals and environments, and for the safe recreational 
use of farmland.12
In 2014, contaminated drinking water contributed to 
a similar number of outbreaks as 2013. As in previous 
years, the majority of the drinking water associated 
outbreaks reported were linked with private water 
supplies. Exposure to water from contaminated 
untreated or poorly treated private water supplies has 
historically been recognised as a strong risk factor for 
VTEC infection in Ireland.6,7 This has been particularly 
pronounced following periods of heavy rainfall. The 
HSE and EPA have both developed resources for 
owners of private wells, providing advice on private well 
maintenance.13-14
Transmission by person-to-person spread, however, 
remained the most common transmission route 
reported in VTEC outbreaks and was involved in 54% of 
outbreaks. As usual, person-to-person spread was most 
frequently associated with private house and childcare 
facility outbreaks. Handwashing and exclusion of cases 
in risk groups from high risk settings remains a key 
prevention measures for VTEC.15
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Figure 6. Number of VTEC outbreaks by suspected 
transmission route and year, Ireland 2005-2014
Note: In this figure, reported transmission routes were grouped for 
simplicity. Any outbreak where food contributed was reported as 
foodborne, any outbreak where water contributed was reported as 
waterborne, any other outbreak where animal contact contributed 
was reported as animal contact. Person-to-person outbreaks include 
only those outbreaks reported as being due only to person-to-person 
transmission.
Table 6. VTEC outbreaks by suspected mode of transmission, Ireland, 2014 
Transmission Route Number of  outbreaks Number ill
Number of associated CIDR 
Events
Person-to-person 40 124 166
Foodborne 1 3 5
Person-to-person and foodborne 0 0 0
Waterborne 7 12 15
Person-to-person and animal contact 3 9 8
Person-to-person and waterborne 2 7 8
Animal contact 3 2 6
Environmental / fomite 3 5 8
Foodborne and animal contact 0 0 0
Unknown 22 37 55
Not specified 2 3 4
Total 83 202 275
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Hepatitis A virus causes an acute, usually self-limiting 
disease of the liver. It is primarily transmitted from person 
to person via the faecal-oral route and is associated with 
poor hygiene and sanitation. Common source outbreaks 
due to contaminated food or water also occur.
The incidence of hepatitis A in Ireland has been low 
in recent years and remained low in 2014, with 21 
cases notified (figure 1). This corresponds to a crude 
notification rate of 0.45/100,000 population. This rate is 
lower than the previous two years with rates of 0.63 and 
1.1/100,000 population for 2012 and 2013 respectively. 
Case classification was reported for all cases and all were 
laboratory confirmed. The number of notifications in each 
HSE area is shown in figure 2.
Fifty two percent of cases were female (n=11) and 48% 
were male (n=10). The highest notifications rates were 
3.4 Hepatitis A
Summary
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Figure 1: Number of hepatitis A notifications, 1988-2014
Figure 2: Number of hepatitis A notifications by HSE area, 2014
in children and young adults, with 52% of cases aged 
between 0 and 24 years (figure 3).
Six cases were reported as infected in Ireland and eight 
cases were linked to travel outside of Ireland. Country of 
infection was not known for seven cases.
Two hepatitis A outbreaks were reported in 2014. 
One outbreak involved three adults in two separate 
households. All cases reported the same genotype 
however no source of infection was identified. A second 
outbreak involved an adult and two children in the same 
household for which there was no source of infection 
identified. 
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) System on 10th August 2015. These 
figures may differ from those published previously due to 
ongoing updating of notification data on CIDR.
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Figure 3: Hepatitis A age and sex-specific notification rates/100,000 population, 2014
Rotavirus is the commonest global cause of paediatric 
gastrointestinal infection and causes sporadic, seasonal 
and occasionally severe gastroenteritis of infants and 
young children, characterised by vomiting, fever and 
watery diarrhoea. Transmission is usually person-to-
person, mainly via the faecal-oral route. Children 
less than two years of age are most susceptible to 
infection, although cases are often seen in elderly and 
immunocompromised adults, particularly in institutional 
settings. By the age of six years old, virtually all 
children will have had at least one episode of rotavirus 
infection. Symptoms usually last for only a few days but 
in severe cases hospitalisation may be required due to 
dehydration. 
Prior to 2004, rotavirus cases were notified under 
the “Gastroenteritis in children under two years” 
disease category. From 2004 to 2010, rotavirus was 
notifiable in all age groups under the “Acute Infectious 
Gastroenteritis” (AIG) disease category, until it 
became notifiable as a disease in its own right under 
the Infectious Diseases (Amendment) Regulations 
2011 (S.I. No. 452 of 2011). Since March 2013, 
rotavirus notifications from HSE-East are based on 
laboratory testing results rather than patient episodes. 
Notifications from HSE-E may also refer to area of 
laboratory testing rather than area of patient residence.
During 2014, there were 2,061 cases of rotavirus 
notified in Ireland, corresponding to a national crude 
incidence rate (CIR) of 44.9 per 100,000 population 
and representing a decrease of 11.9% compared to the 
mean CIR during 2004-2013. 
Significant geographical variation was observed in 
regional rotavirus CIR. The highest regional CIRs 
were observed in HSE-W (73.9/100,000 population) 
and in HSE-M (73.7/100,000 population). The lowest 
regional CIR was observed in HSE-E (25.4 per 100,000 
population) and HSE-MW (30.3 per 100,000 population). 
3.5 Rotavirus
Summary
Number of cases: 2,061
Crude incidence rate: 44.9/100,000 population
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Figure 1: Rotavirus 2014 CIR compared to 2004-2013 mean CIR by HSE area (CIDR)
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Figure 1 illustrates the rotavirus CIR by HSE area for 
2014 compared to the mean CIR during 2004-2013. 
Rotavirus infection has a well documented seasonal 
pattern in Ireland with the number of cases typically 
peaking during March to May. During 2014, rotavirus 
notifications peaked during April (n=421) and May 
(n=368). Figure 2 illustrates the seasonal variation 
in rotavirus cases by month of notification for 2014 
compared to the mean monthly number of notifications 
reported during 2004 to 2013. 
During 2014, 1,103 cases (53.5%) were male and 957 
(46.4%) were female. Sex was not reported for the 
remaining case. This represented a ratio of females: 
males of 1.0:1.2, which was similar to the ratio observed 
in previous years.
Four outbreaks of rotavirus were notified during 2014 
with 36 cases of associated illness, two of whom 
were hospitalised. Three general outbreaks occurred 
across two child-care facilities and one hospital. The 
remaining outbreak was a family outbreak that occurred 
in a private home. All outbreaks reported mode of 
transmission as person to person spread. 
Figure 2: Number of rotavirus notifications by month, 2014 compared to mean monthly number of 
notifications 2004-2013 (CIDR)
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Salmonellosis typically presents clinically as an acute 
enterocolitis, with sudden onset of abdominal pain, 
diarrhoea, nausea, headache and occasionally vomiting. 
Fever is almost always present. Dehydration, especially 
amongst vulnerable populations such as infants, the 
immunocompromised and the elderly, may be severe. 
Invasive infection occurs in a proportion of cases. S. 
Typhi and S. Paratyphi can cause enteric fever, a severe 
systemic life threatening condition, but these are not 
common in Ireland and are almost invariably travel-
associated.
The common reservoirs for non-typhoidal Salmonella 
are the intestinal tract of domestic and wild animals 
(including birds), which may result in a variety of 
foodstuffs, of both animal and plant origin, becoming 
contaminated with faecal organisms either directly 
or indirectly. The organism may also be transmitted 
through direct contact with infected animals or humans 
or faecally contaminated environments. Infected food 
handlers may also act as a source of contamination for 
foodstuffs. Of particular concern is the number of cases 
of infection associated with direct contact with reptiles 
kept as companion animals. 
During 2014, 260 cases of salmonellosis were notified, 
corresponding to a crude incidence rate (CIR) of 5.7 
per 100,000 population (figure 1). The annual CIR has 
remained consistently low over the last five years (2010-
2014 mean: 6.8 per 100,000) compared to the previous 
five year (2005-2009: 9.3 per 100,000). The highest CIR 
in 2014 occurred in HSE-M (8.1) and the lowest in HSE-S 
(4.8). 
The number of male cases was slightly higher than for 
females in 2014 (male: female ratio=1.3:1.0) which is 
consistent with previous years. Overall, the highest age-
specific incidence rate was in children under 5 years of 
age (18.2) which is likely to be influenced by clinicians 
more readily seeking clinical samples in that age group. 
Specifically, the incidence rates were higher in males 
than females in all age groups less than 45 years old. 
Incidence rates were higher in females for those aged 
45-54 years while the rates were comparable for both 
sexes in those aged over 55 years. 
3.6 Salmonella 
Summary
Number of confirmed cases: 260
Crude incidence rate: 5.7/100,000
Figure 1: Salmonellosis notifications and CIR by year of notification
[Data source: CIDR]
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Figure 3: Salmonellosis notifications by month of notification and travel history, 2014 [Data source: CIDR]
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National Salmonella, Shigella and Listeria Reference 
Laboratory (NSSLRL) data:
The National Salmonella, Shigella and Listeria 
Reference Laboratory (NSSLRL) based in Galway has 
been providing reference services nationally since 2000. 
In 2014, the NSSLRL analysed 258 human non-typhoidal 
Salmonella isolates referred for further typing. Figure 
2 shows the trend in referral of isolates to NSSLRL by 
organism over time. 
The NSSLRL conducted phage typing analysis on all 
107 S. Typhimurium and all 44 S. Enteritidis isolates. 
Phage type DT193 (n=26) comprised over 24.3% of all 
S. Typhimurium strains. Other currently important S. 
Typhimurium phage types included Untypable (16.8%) 
and DT104 (8.4%). Phage types PT8 (20.5%), PT14b 
(15.9%), and PT1 (13.6%) were the most common types 
observed among S. Enteritidis isolates. 
Of the 258 isolates analysed for antimicrobial 
resistance, 139 (53.9%) were fully susceptible to all 
antimicrobials tested. The remaining 119 isolates 
exhibited some degree of antimicrobial resistance, 
43 of which exhibited resistance to five or more 
antimicrobials among 27 antibiograms. The majority 
of isolates exhibiting this level of resistance were S. 
Typhimurium (67.4% of multi-drug resistant isolates). 
Overall, the commonest resistance pattern seen was 
resistance to ampicillin, streptomycin, sulphadiazine 
and tetracycline (ASSuT, n=26, 10.1% of isolates). The 
ASSuT pattern was almost exclusively identified in 
S. Typhimurium isolates (96.2% of resistant isolates). 
Resistance to nalidixic acid and ciprofloxacin (NaCp, 
n=18, 7.0% of isolates) was the second most common 
AMR profile among all isolates. The NaCp pattern was 
mostly seen in S. Enteritidis isolates (68.4% of resistant 
S. Enteritidis strains). 
The NSSLRL’s Annual Report 2014 provides a more 
detailed analysis of clinical Salmonella typing results 
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and a comparison with isolates from non-human 
sources.1 
Foreign travel as a risk factor for salmonellosis in 
Ireland
Country of infection was reported for over 81% of 
notifications in 2014. Where country of infection was 
reported, 37.0% of cases were travel associated. The 
number of travel associated cases peaked during the 
period May to August while indigenous cases peaked 
during August and September (Figure 3). Among 
travel associated cases, the most common countries of 
infection reported were: Spain (n=18), Thailand (n=8) 
and Poland (n=5). The popularity of a country as a 
travel destination is likely to be an important factor in 
determining the number of cases associated with each 
country. 
When serotyping data were analysed by travel history, 
over half of all indigenous cases were infected with 
S. Typhimurium (or monophasic S. Typhimurium), with 
‘Other’ serotypes making up a further 34.8% of cases. 
In contrast, S. Enteritidis features more prominently 
among travel-associated cases (29.5%) with just 10.6% of 
indigenous cases due to S. Enteritidis (table 1).
Outbreaks
During 2014, eight outbreaks of salmonellosis were 
reported, comprising 20 cases of illness, three of whom 
were hospitalised. Five family outbreaks occurred in 
private houses and one family outbreak was travel 
related. Two general outbreaks occurred in community 
settings. Two outbreaks were reported as being 
foodborne, four were reported as due to person to 
person spread while mode of transmission for the 
remaining two outbreaks was reported as unknown. 
In consequence of the increasing recognition in recent 
years of fresh produce as a cause of gastrointestinal 
disease outbreaks, the National Salmonella Outbreak 
Trawling Questionnaire was recently expanded and 
updated. The form is available at 
http://www.hpsc.ie/A-Z/Gastroenteric/Salmonellosis/
SurveillanceInvestigativeForms/ 
Typhoid/Paratyphoid:
In 2014 there were seven cases of typhoid notified and 
five cases of paratyphoid (3 Paratyphi A and 2 Paratyphi 
B). Of the seven S. Typhi cases, two had travelled to 
India and one each to Bangladesh, Qatar and Tanzania. 
The remaining two typhoid cases did not report country 
of infection. Among the paratyphoid cases, one each 
reported travel to Bolivia, Cambodia and Peru. The 
remaining two paratyphoid cases did not report country 
of infection. 
References: 
1.  National Salmonella Reference Laboratory of Ireland, Annual Report 
for 2014. Available at:      
http://www.nuigalway.ie/research/salmonella_lab/reports.html 
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Table 1: Salmonellosis notifications by serotype and travel history, 2014 [Data source: CIDR]
Salmonella serotype Indigenous Travel associated Travel history unknown
Number % Number % Number %
S. Typhimurium 77 54.6 19 24.4 14 34.1
S. Enteritidis 15 10.6 23 29.5 6 14.6
Other serotypes 49 34.8 36 46.2 21 51.2
All serotypes (n) 141 100.0 78 100.0 41 100.0
Listeriosis 
During 2014, 15 cases of listeriosis were notified, an 
increase compared to eight cases reported in 2013. This 
equates to a crude incidence rate of 0.3 per 100,000 
population which remains below the EU average of 0.4 
per 100,000 in 2013. 
Two neonatal cases were reported in 2014, which 
compared to three neonatal cases reporting in 2013 
(Figure 1). Eight adult/juvenile cases were reported in 
2014, which was similar to the numbers reported in 
the previous 10 years. Five of the eight adult/juvenile 
cases were male. Three adult/juvenile cases developed 
bloodstream infection, while a fourth developed 
meningitis. One case with a predisposing condition 
died, but the case of death was not known. Outcome 
was reported as recovered for five adult/juvenile cases 
and as unknown or not specified for the remaining two 
adult cases. Five of the eight adult/juvenile cases were 
more than 65 years of age, with a sixth being in the 55-
64 years age group. 
Since 2007, the National Salmonella, Shigella and 
Listeria Reference Laboratory in Galway has offered a 
national service for typing of Listeria strains. In 2014, 
isolates from 10 of the 15 notified cases were referred. 
The serotypes for these 10 cases are listed in table 1 
below. 
Listeria in Ireland remains a hazard for the elderly, 
persons with underlying illness, and other vulnerable 
groups such as pregnant women and neonates.
3.7  Less common gastroenteric 
 infections
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Figure 1: Number listeriosis notifications by case type, Ireland 2004-2014
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Table 1: Listeriosis notifications by case type and serotype, Ireland 2014*
Type Serotype 1/2a Serotype 1/2b Serotype 4b Not referred for serotyping Total
Adult or juvenile 2 0 2 0 4
Pregnancy-related 2 0 0 0 2
Neonatal 2 0 2 0 4
Total 6 0 4 0 10
* typing data provided by the National Salmonella, Shigella and Listeria Reference Laboratory (NSSLRL)
Giardiasis
In 2014, there were 71 cases of giardiasis notified, 
corresponding to a crude incidence rate (CIR) of 1.5 
per 100,000 population. Cases ranged in age from 7 
months-79 years (median age=27 years) with 16 cases 
reported in children under 15 years of age. The male to 
female ratio was 1.3:1.0. Hospitalisation rates were low 
with six cases admitted, corresponding to 9.8% of cases 
where patient type was reported. 
The number of cases for which travel status was 
reported has improved markedly over the last six 
years from 11% of cases in 2006 to 69.0% of cases this 
year (Figure 2). Forty-eight cases (67.6% of all cases; 
98.0% of those with known travel status) were reported 
as being associated with foreign travel. The most 
commonly reported countries of infection included India 
(n=16), Spain (n=4), Australia (n=3) and Indonesia (n=2) 
while there was one case each reported associated 
with travel to 12 other countries. Sixteen cases were 
reported as being acquired in Ireland, and for the 
remaining 22 cases, country of infection was unknown or 
not specified. 
Three family outbreaks of giardiasis were notified in 
2014. Two outbreaks occurred in private houses and one 
was travel associated.  
According to CDC, Giardia infects nearly 2% of adults 
and 6% to 8% of children in developed countries 
worldwide so it is likely that there is a high degree 
of underreporting of the illness in Ireland. Giardiasis 
in Ireland is mainly identified among adults, unlike 
countries such as the United States, Australia and the 
United Kingdom where children are mainly reported. 
Yersiniosis 
In 2014, there were five cases of yersiniosis (one female 
and four males), three of whom were aged 65 years 
and older. Four were reported as being infected with 
Y. enterocolitica and one was Y. pseudotuberculosis. 
The reported incidence of yersiniosis in Ireland is low 
relative to the EU as a whole, and to Northern Europe in 
particular. 
Foodborne intoxications 
Notifications of foodborne intoxications in Ireland are 
uncommon. 
There was one case of infant botulism notified in 2014. 
The causative organism was identified as C. botulinum.
In 2014, there were no cases or outbreaks of 
staphylococcal food poisoning, Clostridium perfringens 
(type A) food-borne disease or Bacillus cereus food-
borne infection/intoxication notified. 
Figure 2: Number of giardiasis notifications by country of infection, 2004-2014
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Summary
Number of notifications: 57
Crude incidence rate: 1.2/100,000
Fifty-seven cases of shigellosis were notified in Ireland 
in 2014, corresponding to a crude incidence rate (CIR) 
of 1.2 per 100,000. This represents an increase of 16% 
compared to 2013. Of 43 cases where hospitalisation 
status was recorded, 11 (26%) were reported as 
hospital in-patients. Of the 57 cases, 54 were laboratory 
confirmed. 
During 2014, there was an excess of male cases 
compared to females, with a male to female ratio of 2.3: 
1.0. This trend has been observed since 2009 with the 
exception of 2013 where more females were notified 
(figure 1). During 2014, cases ranged in age from 10 
months to 72 years (median age=30 years). The male to 
female ratio was highest in the age groups 25-34 years 
(3.5:1.0), 35-44 years (6.0:1.0) and 45-54 years (2.0:1.0). 
Males in the 35-54 years age group were mostly travel 
associated whereas males in the 25-34 year age group 
were mostly indigenous or travel history unknown  
(table 1). 
3.8 Shigellosis
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Figure 1: Annual number of notifications shigellosis by sex and year (Data source: CIDR)
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Table 1: Number of notifications shigellosis by travel association, age group and sex, 2014 (Data source: CIDR)
2014
Indigenous Travel associated Travel history unk Total notifications
F M F M F M Sex unk F M Sex unk Total M: F ratio
0-4 yrs 0 0 2 2 1 2 0 3 4 0 7 1.3
5-14 yrs 0 0 0 2 3 1 0 3 3 0 6 1.0
15-24 yrs 0 0 2 2 0 1 0 2 3 0 5 1.5
25-34 yrs 0 5 4 0 0 9 1 4 14 1 19 3.5
35-44 yrs 0 1 1 4 0 1 0 1 6 0 7 6.0
45-54 yrs 1 1 1 4 1 1 0 3 6 0 9 2.0
55-64 yrs 1 0 0 0 0 1 0 1 1 0 2 1.0
65+ yrs 0 1 0 1 0 0 0 0 2 0 2 0.0
Total 2 8 10 15 5 16 1 17 39 1 57 2.3
M:F ratio 4.0: 1.0 1.5: 1.0 3.2: 1.0 2.3: 1.0
Information on travel history is very valuable when 
reviewing surveillance data for possible indigenous 
clusters. Data on country of infection was available for 
58% of shigellosis notifications this year, a decrease 
compared to 88% in 2013. Twenty-five cases were 
reported as being associated with foreign travel in 
2014. The countries of infection reported were India 
(n=6), Egypt (5), two each associated with Kenya and 
Morocco, and one case each associated each with 
travel to Afghanistan, Croatia, Haiti, Lebanon, Somalia, 
Spain, Nigeria, Pakistan, Poland and UK. Ten cases were 
reported as being acquired in Ireland, while no country 
of infection information was available for 22 cases. 
S. sonnei was the most common species reported 
(n=32), followed by S. flexneri (n=19). Species was 
not reported for the remaining three confirmed cases. 
When analysed by travel association, S. flexneri was 
equally common among indigenous cases (22.2%) as 
travel associated cases (20.8%) but more common in 
cases without travel history reported (50.0%). S. sonnei 
was slightly more common among indigenous cases 
(77.8%) than travel associated cases (62.5%).
There were four shigellosis outbreaks notified in 2014, 
resulting in 11 cases of illness. All four outbreaks 
were family outbreaks, of S. sonnei. Three outbreaks 
occurred in private houses while one was in an 
extended family associated with travel to Egypt.The 
mode of transmission was reported as person-to-person 
for two while the transmission was unknown for the 
remaining two. 
More detailed typing of Shigella isolates can provide 
useful information on the relatedness of strains 
which can be used by public health personnel to 
outrule/provide evidence for links between cases 
during investigations of case clusters. The National 
Salmonella, Shigella and Listeria Reference Laboratory 
(NSSLRL) provide laboratory services for speciation, 
serotyping, antimicrobial resistance profiling, and 
where appropriate, Pulsed Field Gel Electrophoresis 
(PFGE) of Shigella isolates. The species/serotype and 
antimicrobial resistance patterns of these cases are 
reported in Table 2. 
During 2014 the NSSLRL reported an increase in 
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Table 3: Notified shigellosis outbreaks 2014 (Data source: CIDR)
HSE-area Outbreak type Location Transmission mode Number ill Serotype
HSE-W Family Private house Person-to-person 4 S. sonnei
HSE-W Family Private house Person-to-person 2 S. sonnei
HSE-NE Family Travel-related in extended family Unknown 3 S. sonnei
HSE-E Family l Private house Unknown 2 S. sonnei
Table 2: Species/serotypes and AMR profiles of Shigella isolates referred to NSSLRL in 2014 
Serotype Number by serotype AMR profile Number by serotype and AMR profile
Shigella flexneri 1b
4
ACST 1
Shigella flexneri 1b ACSTTm 1
Shigella flexneri 1b ASSuTTmNaCtx 1
Shigella flexneri 1b STTm 1
Shigella flexneri 2a
4
ACSSuTTm 2
Shigella flexneri 2a ACSSuTTmAzt 1
Shigella flexneri 2a ACSSuTTmNaCp 1
Shigella flexneri 2b 1 SuTTm 1
Shigella flexneri 3a
2
ACSTAzt 1
Shigella flexneri 3a none 1
Shigella flexneri 4
2
A Azt 1
Shigella flexneri 4a ACSSuTTm 1
Shigella flexneri X variant
4
ASSuTTmAzt 2
Shigella flexneri X variant ASuTTmAzt 1
Shigella flexneri X variant T 1
Shigella sonnei
27
ASSuTTm 1
Shigella sonnei ASuTm 1
Shigella sonnei SSuTm 1
Shigella sonnei SSuTTm 15
Shigella sonnei SSuTTmNa 3
Shigella sonnei SSuTTmNaCp 5
Shigella sonnei TmNaCp 1
Total 44 Total 44
specimen referral from regional laboratories. This 
is likely a result of the increased sensitivity of direct 
molecular detection methods which were recently 
introduced for faecal pathogen screening by regional 
laboratories. 1 An increase in ciprofloxacin resistance 
among S. sonnei isolates has been identified by 
NSSLRL since 2010; this appears to have a significant 
association with exposure in India.1 Further details of 
Shigella strain characterisation performed at NSSLRL 
can be found in the NSSLRL Annual Report.1 
References
1. National Salmonella Reference Laboratory of Ireland, Annual 
Report for 2014. Available at:     
http://www.nuigalway.ie/research/salmonella_lab/reports.html 
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VEctoRboRnE And Zoonotic disEAsEs
In 2014, 80 malaria cases were notified in Ireland, an 
increase of 13% compared to 71 cases in 2013 (Figure 
1). The incidence rate now stands at 1.74 per 100,000 
population. Among European Union (EU) member 
states reporting malaria data to the European Centre 
for Disease Control, Ireland had the third highest 
incidence rate for imported malaria in 2012 (the latest 
year for which comparative data are available); only 
the United Kingdom and Belgium had higher reported 
incidence rates.
In common with the rest of the EU, males predominated 
(male: female ratio 2.2:1), with the highest numbers 
of cases among males aged between 35 and 54. The 
number of paediatric cases reported was 10, a slight 
decrease compared to 12 cases reported during 2013 
(Figure 1).
Four of the paediatric cases reported “visiting family in 
country of origin” as their reason for travel, two were 
new entrants to Ireland and one was an Irish citizen 
living abroad. There was no information on reason for 
travel for the remaining three paediatric cases. Of the 
four paediatric cases that travelled to visit family, three 
visited sub-Saharan Africa and one visited South Asia. 
Duration of the visit was reported for two of these cases 
and ranged between 20 days to 4 months duration. 
Two of the paediatric cases reported taking malaria 
prophylaxis but were not fully compliant, four paediatric 
cases reported not taking any prophylaxis for their 
travel, while the remaining four paediatric cases did not 
have information on prophylaxis reported. 
Among all age groups, the category of traveller most 
affected in Ireland continued to be African immigrants 
and their families who were exposed while returning to 
‘visit family in country of origin’. This almost certainly 
reflects the greater frequency with which this group 
travels to malarious areas, but also reflects Ireland’s 
importance as a destination for those emigrating from 
English speaking West Africa. Where the reason for 
travel was reported in 2014, 62% cited ‘visiting family in 
country of origin’, 91.7% of whom travelled to Africa.
The second most commonly cited reasons for travel this 
year were “Business/professional travel” (n=8, 13.8%) 
and “New entrant to Ireland” (n=6, 10.3%). 
Nigeria remained the country most frequently visited, 
accounting for 49% of total cases and 60% of cases 
4.1 Malaria 
Summary
Number of cases malaria, 2014: 71
Crude incidence rate malaria 2014: 1.55/100,000
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Figure 1: Annual number of malaria notifications by age, Ireland 2004-2014
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where country of infection was reported. The remaining 
cases were exposed in other countries within Africa and 
South Asia. The majority of cases who reported travel 
to Nigeria were “visiting family in country of origin” 
(25/34) with known reason for travel.
Plasmodium falciparum accounted for 74% of infections 
in 2014, reflecting the dominance of exposure in Africa 
as the source of the majority of notifications. Six cases 
of P vivax, and one case each of P. ovale and P. malariae 
were also reported which remains stable in comparison 
to previous years. The remaining 12 cases did not have 
Plasmodium species specified.
HPSC resources for health professional include a poster 
which can be downloaded from the HPSC website for 
display in GP surgeries, maternity hospitals, paediatric 
hospitals and A&E departments, advising immigrant 
families travelling to Africa to consult their doctor 
about malaria before travelling. A leaflet for intending 
travellers, available in English and French, highlights the 
value of antimalarial prophylaxis and protection against 
mosquito bites. The poster and leaflet are available 
here.
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Figure 2: Annual number of notifications malaria by reason for travel, Ireland 2006-2014
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Twenty-three cases of leptospirosis were notified in 
Ireland in 2014, an increase compared to 13 cases 
notified in 2013 (Figure 1). This equates to a crude 
incidence rate (CIR) of 0.15 per 100,000 population. 
The latest year for which data is available across the 
European Union is 2012. Among the 27 countries 
that reported leptospirosis incidence in 2012, Ireland 
reported the fifth highest incidence rate after Estonia, 
Malta, Lithuania and Romania. The incidence in the EU 
as a whole was 0.1 per 100,000. 
The age range of cases was 16-74 (mean age =42 years, 
median age=43 years). Cases in the younger age groups 
were mainly associated with recreational exposure 
and history of foreign travel while older cases were 
mainly indigenous and associated with occupational 
exposure. Figure 1 illustrates the annual trend by 
travel history. The leptospirosis notification dataset is 
typically dominated by adult males, and this year was no 
exception with male cases accounting for 87% of cases 
(Table 1).
Thirteen cases (56.5%) were believed to have acquired 
their illness occupationally, seven of whom were either 
farmers or reported contact with farm environments 
while the remaining six occupationally acquired cases 
reported contact with rats or other animals. Five 
(21.7%) cases were reported as being associated with 
recreational activities, four of whom reported river 
water exposure Thailand. One case reported both 
recreational and occupational exposures and one case 
had accidental exposure to farm animals. No risk factors 
were reported for the remaining three cases but one 
case reported recent travel history to multiple countries 
in SE Asia. Figure 2 shows the trend in notifications by 
exposure group and year. 
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4.2 Leptospirosis           
Summary
Figure 1: Annual number of leptospirosis notifications by year 
and travel history (Data source: CIDR)
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Figure 2: Annual number of leptospirosis notifications by 
exposure group by year (Data source: CIDR)
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Table 1: Leptospirosis notifications by age and sex, 2014
Age group 
(years)
Male Female Total
0-4 0 0 0
5-14 yrs 0 0 0
15-24 yrs 2 3 5
25-44 yrs 1 6 7
45-64 yrs 0 8 8
65+ yrs 0 3 3
Total 3 20 23
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Among the 20 cases for which hospital admission status 
was reported, 15 (75%) required hospitalization. There 
were no deaths reported. 
While a number of regional hospital laboratories offer 
a diagnostic service for leptospirosis, around two thirds 
of cases are diagnosed by the National Virus Reference 
Laboratory each year. Positive specimens are generally 
referred to the United Kingdom’s Leptospirosis 
Reference Unit (LRU) for confirmation and for typing 
where possible. In 2014, species information was 
available on CIDR for only three cases (13%)–one was 
Leptospira ballum and two were L. interrogans hardjo. 
Activities that continue to be associated with 
leptospirosis risk in Ireland include recreational activities 
such as water sports, and farming. In recent years, travel 
to Asia and other tropical destinations has emerged as a 
risk factor for leptospirosis. 
Toxoplasmosis
During 2014, 20 cases of toxoplasmosis were notified, 
a slight decrease compared to an annual mean of 
35 notifications in the previous five years. Among 
cases where patient type was reported, 18.8% were 
hospitalised. No congenital cases were reported. 
Cases ranged in age from 16 to 75 years (median: 32 
years). As in previous years, more cases were reported 
among females then males, (F:M ratio 2.6:1.0). This was 
particularly evident among females in the 25-34 year 
age group, which is most likely a reflection of enhanced 
testing during pregnancy (Table 1). 
Brucellosis
During 2014, there were three case of brucellosis 
notified, with cases ranging in age from 2 to 55 years. 
This remains stable compared to an annual mean of two 
notifications in the previous five years. Two cases were 
reported as Brucella species; and one was reported 
as B. melitensis. Country of infection was reported as 
Turkey for one case while the remaining two cases did 
not report country of infection. 
Despite the reporting of two female cases this year, the 
age and sex distribution for brucellosis in recent years 
in Ireland has tended towards adult males, suggesting 
that occupational exposure is likely to be a major 
transmission route for this disease. 
Echinococcosis, Trichinosis and 
Q Fever
No cases of echinococcosis, trichinosis and Q fever were 
notified in Ireland in 2014. 
4.3  Other Notifiable Non-IID Zoonotic 
Diseases
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Table 1: Toxoplasmosis notifications by age and sex, Ireland 2014
Age group Female Male Unknown Total %
15-19 yrs 0 1 1 2 10.0
20-24 yrs 1 1 0 2 10.0
25-34 yrs 7 2 1 10 50.0
35-44 yrs 2 1 0 3 15.0
45-54 yrs 1 0 0 1 5.0
55-64 yrs 1 0 0 1 5.0
65+ yrs 1 0 0 1 5.0
Total 13 5 2 20 100.0
% 65.0 25.0 10.0 100.0
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Four vectorborne diseases were added to the notifiable 
disease list in Ireland from the beginning of 2012. This 
chapter summarises the information gathered on these 
notifications in the second year of formal surveillance. 
The case definitions for these diseases are outlined on 
the HPSC website at
http://www.hpsc.ie/NotifiableDiseases/CaseDefinitions/.
Lyme neuroborreliosis
Lyme neuroborreliosis is an infection caused by a spiral-
shaped bacterium called Borrelia burgdorferi that is 
transmitted to humans by bites from ticks, generally 
hard-bodied ticks (Ixodidae). 
During 2014, 18 cases of Lyme neuroborreliosis were 
notified in Ireland, 10 female and eight male. Six 
patients were admitted to hospital, two were reported 
as hospital out-patients and nine were GP patients. The 
hospitalisation status of the remaining case was not 
specified. One case was reported as being acquired 
abroad, seven acquired the infection in Ireland and the 
remaining 10 cases did not report country of infection.
Cases were reported from five of the eight HSE areas, 
with 72.2% of the cases reported by HSE-S and -MW. 
Table 1 displays the regional distribution of cases by age 
group in years. 
Dengue Fever
During 2014, 21 confirmed cases of dengue fever were 
notified. Three cases were reported as being admitted 
to hospital, 10 were GP patients, one was a hospital 
outpatient and one was an emergency department 
patient. Patient type was not reported for the remaining 
six cases. Table 2 displays the regional distribution of 
cases by age group in years.
Dengue is found commonly throughout the tropics and 
subtropics and is endemic in about 100 countries. Of 
the 21 cases reported in 2014, country of infection was 
reported for 11 cases (47.6%). Three cases reported 
country of infection as Thailand, two as Malaysia 
and one case each as Columbia, Costa Rica, India, 
Philippines, Tunisia and Viet Nam. The remaining 10 
cases did not have a country of infection specified but 
two of these cases reported recent travel in Asia. These 
destinations most likely reflect the frequency of travel by 
Irish residents to dengue endemic countries. 
West Nile fever 
No cases of West Nile fever was notified in Ireland in 
2014. 
Chikungunya fever: 
One case of chikungunya was notified in Ireland in 2014. 
Country of infection was not reported but the case had 
a recent travel history to South America.
4.4 Other Vectorborne Diseases
Table 1: Lyme neuroborreliosis notifications by age group (years) and HSE-area, 2014
Age group (years) HSE-E HSE-M HSE-MW HSE-NE HSE-NW HSE-SE HSE-S HSE-W Total
15-19 yrs 1 1 2
20-24 yrs 1 1
25-34 yrs 2 1 3
35-44 yrs 1 1
45-54 yrs 3 1 4
55-64 yrs 1 1 2 4
65+ yrs 1 2 3
Total 1 0 5 0 0 2 8 2 18
Table 2: Dengue fever notifications by age group (years) and HSE-area, 2014
Age group (years) HSE-E HSE-M HSE-MW HSE-NE HSE-NW HSE-SE HSE-S HSE-W Total
15-19 yrs 1 1
20-24 yrs 2 2
25-34 yrs 5 1 1 7
35-44 yrs 3 1 1 2 7
45-54 yrs 1 1
55-64 yrs 1 1 2
65+ yrs 1 1
Total 12 1 0 0 0 4 1 3 21
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Hepatitis B is a vaccine preventable disease caused 
by the hepatitis B virus. It is transmitted through 
percutaneous or mucocutaneous contact with the blood 
or body fluids of an infected person. After acute HBV 
infection, the risk of developing chronic hepatitis B 
declines with increasing age.1 Approximately 90% of 
infants infected at birth will develop chronic infection, 
compared to 20% - 50% of children infected between 
the ages of one and five years. Only 1%-10% of those 
infected as older children or adults will develop chronic 
hepatitis B. An estimated 15%-25% of those who go on 
to develop chronic infection with die prematurely, of 
either cirrhosis of the liver or hepatocellular carcinoma.
The prevalence of hepatitis B in the general population 
in Ireland is low (less than 1%). Most cases fall into 
defined risk groups such as people with multiple sexual 
partners, household or sexual contacts of known cases, 
injecting drug users and people who were born in 
countries of intermediate (2-7%) or high ( >8%) hepatitis 
B endemicity.
The number of hepatitis B cases reported in Ireland 
increased by 5% in 2014, with 445 cases (9.7/100,000 
population) notified compared to 425 in 2013. 
However, there has been a general downward trend in 
the number of notifications since peak levels in 2008 
(n=901). Annual hepatitis B notifications since 1997 are 
shown in figure 1. 
Notification rates were highest in HSE E (15.6/100,000 
population, n=253) and HSE M (11/100,000 population, 
n=31). Geographic trends for the past four years are 
shown in figure 2.
All cases were laboratory confirmed and 97% (n=431) 
contained information on acute/chronic status. Where 
status was known, 7% of cases were acute (n=29, 
0.6/100,000 population) and 93% were chronic (n=402, 
8.8/100,000 population). Both acute and chronic cases 
of hepatitis B are notifiable in Ireland.
Acute cases (recent infections)
The number of acute cases of hepatitis B notified in 
Ireland is relatively low and decreased by 3% in 2014 
5.1 Hepatitis B
Summary
Number of cases, 2014: 445
Crude notification rate, 2014: 9.7/100,000 population
Number of cases, 2013: 425
HPSC Annual Report 2008  
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Figure 1. Number of hepatitis B notifications by acute/chronic status, 1997-2014
(n=29) compared to 2013 (n=30) (figure 3). The majority 
of acute cases of hepatitis B in Ireland are sexually 
acquired.
Of the 29 acute cases notified in 2014, 69% (n=20) 
were male and 31% (n=9) were female. The highest 
notification rates were in young to middle aged adults, 
with 90% (n=26) of acute cases aged between 20 and 
54 years (figure 4). Males were older overall, with a 
median age of 38.5 years compared to 28 years for 
females. The median age at notification decreased in 
2014 compared to previous years (figure 3).
Information on risk factor was available for 97% (n=28) 
of acute cases. Of these, 61% (n=17) were likely to have 
been sexually acquired (12 heterosexual and five men 
who have sex with men), one case was a household 
contact of an infected person in Ireland and another 
case was attributed to dental procedures. No risk factor 
was identified for six cases despite public health follow 
up. Three further cases had no risk factor information 
but were known to have been born in hepatitis B 
endemic countries.
Country of birth was specified for 83% (n=24) of acute 
cases notified in 2014. Fifty four percent (n=13) were 
born in Ireland and 17% (n=5) were born in Western 
Europe. A further two cases were born in Asia, two 
cases were born in Sub-Saharan Africa and there 
was one case born in each of Latin America and the 
Caribbean. Reasons for testing were available for 97% 
(n=28) of acute cases. Of these, 61% of cases reported 
being tested because they were symptomatic.
Chronic cases (long-term infections)  
There was a 3% increase in chronic hepatitis B 
notifications in 2014 (n=402) compared to 2013 (n=389) 
(figure 5). However, notifications have decreased 
significantly since peak levels in 2008. The large increase 
in hepatitis B notifications between 1997 and 2008 
(figure 1) was mostly due to increased numbers of 
people immigrating to Ireland from hepatitis B endemic 
countries. Following a drop in immigration numbers 
from 2009 to 2011, immigration has increased again 
each year from 2012 (52,700 immigrants) to 2014 
(60,600), which could explain the slight increase in 
chronic hepatitis B in 2014.2
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Figure 3. Number of acute cases of hepatitis B notified, by sex and median age, 2004-2014
Figure 2. Hepatitis B notification rates/100,000 population, by HSE area, 2011-2014
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Of the 402 chronic cases notified in 2014, 59% (n=237) 
were male, 38.5% (n=155) were female and sex was 
not reported for 2.5% (n=10). Seventy nine percent 
(n=316) of chronic cases were aged between 20 and 44 
years when notified (figure 6). Males were slightly older 
overall, with a median age at notification of 36 years 
compared to 28 years for females (figure 5). 
Although risk factor was reported for a minority of 
chronic cases, some information on country of birth or 
asylum seeker status was available for 60% (n=242). Of 
these, 86% (n=208) were either born in a hepatitis B 
endemic country (hepatitis B surface antigen prevalence 
>2%) or were asylum seekers. Most of these cases are 
likely to have been infected outside Ireland, but the 
actual mode of acquisition of infection is unknown 
for the majority. Where country of birth was available 
(59%, n=236), the most common birth countries were 
in Central or Eastern Europe (37%, n=87), Asia (30%, 
n=70), Sub-Saharan Africa (21%, n=49) and Western 
Europe (10%, n=24). Of those born in Western Europe, 
18 were born in Ireland. 
Risk factors for transmission were provided for 15% 
(n=60) of the chronic cases notified in 2014. Where 
data were available, the most common risk factors 
were sexual exposure (28%, n=17), vertical transmission 
(20%, n=12), being a household contact of a case (10%, 
n=6), injecting drug use (7%, n=4) and attending an 
intellectual disability setting (7%, n=4). Three of the 
cases with an intellectual disability were born in Ireland, 
but infection may have been acquired in the past and 
only diagnosed in 2014 as part of routine testing. 
The reason for testing was known for 66% (n=265) 
of chronic cases. The main reasons were: antenatal 
screening (21%, n=56), re-testing of known cases (not 
previously notified) (15%, n=41), routine health screening 
(13%, n=34), asylum seeker screening (11%, n=29) and 
STI screening (9%, n=24). 
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Figure 5. Number of chronic cases of hepatitis B notified, by sex and median age, 2004 to 2014
Figure 4. Age and sex-specific notification rates/100,000 population for acute cases of hepatitis B, 2014
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Co-infections
Co-infection with HIV or hepatitis C can lead to more 
severe liver disease and an increased risk of liver cancer 
in people with hepatitis B infection. Eleven of the cases 
of hepatitis B notified in 2014 were co-infected with  
HIV. One additional case was infected with HIV and 
hepatitis C.
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) System on 13th August 2015. These 
figures may differ from those published previously due 
to ongoing updating of notification data on CIDR.
1.   Heyman DL. Control of Communicable Diseases Manual. 19th 
Edition. Washington: American Public Health Association, 2008.
2.   Central Statistics Office (2014) Immigrants (thousand) by country of 
origin. Accessed 21st August 2015. Available from:   
http://www.cso.ie/multiquicktables/quickTables.aspx?id=pea18_1 
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Figure 6. Age and sex-specific notification rates/100,000 population for chronic cases of hepatitis B, 2014
0
5
10
15
20
25
30
0-4 5-9 10-14 15-19 20-24 25-34 35-44 45-54 55-64 65+ Uk Age 
N
ot
ifi
ca
tio
n 
ra
te
 p
er
 1
00
,0
00
 
Age group (years) 
Male Female
Hepatitis C is a major cause of liver disease worldwide. 
The hepatitis C virus (HCV) is primarily transmitted 
through sharing contaminated equipment when injecting 
drugs or through receipt of unscreened blood or blood 
products (this is no longer a risk in Ireland). Sexual, 
occupational and vertical transmission can also occur but 
are less common. 
Infection is initially asymptomatic in most cases, but 
approximately 75% of those infected fail to clear 
the virus and develop chronic infection. Between 5 
and 20% of chronically infected individuals develop 
cirrhosis of the liver after 20 years of infection. Of 
those with cirrhosis, 1.5% to 2.5% will go on to develop 
hepatocellular carcinoma (liver cancer) each year.1 There 
have been major advances in the treatment of hepatitis 
C in recent years with the arrival of all-oral interferon-
free regimens. Sustained virological response (SVR) rates 
of 90% to 100% have been reported.2 SVR is regarded 
as a virological cure and is associated with improved 
morbidity and mortality.2
The overall prevalence of chronic hepatitis C in Ireland 
is comparable to other Northern European countries, 
and is estimated to be between 0.5% and 1.2%. Most 
cases fall into defined risk groups such as people who 
inject drugs, people who received unscreened blood or 
blood products in the past and people who were born in 
hepatitis C endemic countries.3
Hepatitis C notifications decreased by 7% in 2014 
(n=710, 15.4/100,000 population) compared to 2013 
(n=761, 16.5/100,000 population) (figure 1). This was 
a continuation of a general downward trend since 
peak levels in 2007 (n=1539). There was a strong 
predominance of males: 70% (n=497) of cases were 
male, 29.7% (n=211) were female and sex was not 
reported for two cases. The highest notification rates 
were in young to middle aged adults. Eighty four 
percent (n=593) of cases were aged between 25 and 
54 years (figure 2). The median age at notification has 
continued to rise. The median age for females was 
younger (36 years) than that for males (39 years). 
The geographical distribution of cases was skewed, with 
the HSE-East reporting 69% of the cases notified in 2014 
(n=493, 30.4/100,000 population) (figure 3).
Data on most likely risk factor were available for 49% of 
cases (n=348) in 2014. The most common risk factors 
reported were injecting drug use (80%, n=278), sexual 
exposure (5%, n=18), receipt of blood or blood products 
(4.5%, n=16) and vertical transmission (2%, n=7) (figure 
4). Of those infected through vertical transmission, six 
were born in Ireland and one was born in a hepatitis 
C endemic country. Of those who were infected 
5.2 Hepatitis C
Summary
Number of cases, 2014:  710
Crude notification rate, 2014: 15.4/100,000 population
Number of cases in 2013: 761
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Figure 1. Number of notifications of hepatitis C and median age at notification, by sex, 2004-2014
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through contaminated blood or blood products, three 
were infected in Ireland, eight were infected in other 
countries and country of infection was unknown for the 
remaining five cases. The Irish infections occurred many 
years in the past, but were notified for the first time 
in 2014. Figure 4 shows recent risk factor trends for 
hepatitis C in Ireland.
Data on country of birth were available for 33% of cases 
(n=232) in 2014. Where information was available, 
47.5% of cases were born in Ireland and 52.5% were 
born outside of Ireland. For the non-Irish nationals, the 
most common regions of birth were Central and Eastern 
Europe (65%, n=79), Western Europe (excluding Ireland) 
(12%, n=15) and Asia (11%, n=14). Sub-Saharan Africa 
(n=5), North Africa (n=3), Latin America (n=3), North 
America (n=2) and Oceania (n=1) were also reported as 
countries of birth of hepatitis C cases.
Hepatitis C genotype data were collected 
retrospectively from NVRL and the Molecular Diagnostic 
& Research Laboratory in University College Cork and 
were available for 24.5% of notifications in 2014. Of 
these, 59% (n=103) were genotype 1, 37% (n=64) were 
genotype 3, 2.3% (n=4) were genotype 2 and 1.7% 
(n=3) were genotype 4. Subtype was available for 91% 
(n=94) of genotype 1 cases. Of these, 70 cases were 
reported as genotype 1a and 24 cases as genotype 1b.
Co-infections with HIV or hepatitis B can lead to more 
severe liver disease and an increased risk of liver cancer 
in those with hepatitis C infection. Eighteen of the 
hepatitis C cases notified in 2014 were known to be co-
infected with HIV and six with hepatitis B. Two of these 
were infected with hepatitis B, hepatitis C and HIV. 
Hepatitis C notifications have been decreasing in recent 
years. Some of this decline may be explained by the 
introduction of new case definitions, explicitly excluding 
the notification of resolved cases, in 2012. Data 
completeness has also improved in recent years and 
this has facilitated better deduplication of notifications. 
However, overall indications are that the incidence of 
hepatitis C in Ireland is decreasing. Where risk factor 
information was available, 80% of cases were drug 
users who were likely to have been infected through 
unsafe injecting practices. Anecdotally, the proportion 
of drug users who are injecting is decreasing and the 
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Figure 3. Notification rates/100,000 population for hepatitis C by HSE area, 2011-2014
Figure 2. Age and sex-specific notification rates/100,000 population for hepatitis C, 2014
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incidence of hepatitis C appears to be decreasing in this 
population. 
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 14th August 2015. 
These figures differ from those published previously and 
those reported in the appendices of this report due to 
ongoing updating of notification data on CIDR.
1.  Global Burden of Hepatitis C Working Group. Global burden of 
disease (GBD) for hepatitis C.J Clin Pharmacol. 2004 Jan;44(1):20-9.
2. Conjeevaram H. Continued progress against hepatitis C infection. 
JAMA 2015;313(17):1716-17.
3.  Thornton L, Murphy N, Jones L, Connell J, Dooley S, Gavin S et al. 
Determination of the burden of hepatitis C virus infection in Ireland. 
Epidemiol Infect. 2011 Sep 19:1-8
Figure 4. Most likely risk factor for hepatitis C, 2010-2014
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Summary
Number of notifications: 377
Crude notification rate: 8.2 per 100,000 population
In 2014, 377 people were newly diagnosed with HIV in 
Ireland, an increase of 11% compared to 2013. Between 
2010 and 2013, the annual rate of new HIV diagnoses 
had been relatively stable in Ireland, ranging from 7.0 
to 7.5 per 100,000 population. Cumulatively, to the end 
of 2014, 7,353 people have been newly diagnosed with 
HIV in Ireland but this number does not represent the 
number of people living with HIV (PLHIV) in Ireland, as it 
does not take factors such as death and migration into 
account.
A summary of new HIV diagnoses in 2014 is given in 
table 1. Notifications of HIV include all people who 
test HIV positive for the first time in Ireland and include 
a number of people who have previously tested HIV 
positive abroad. Among the new diagnoses in 2014, 
17% were reported to have previously tested HIV 
positive abroad, compared to 16% in 2013, 17% in 2012 
and 14% in 2011. 
Probable route of transmission 
Probable route of transmission was known for 89% of 
new diagnoses in 2014. Figure 1 shows the trends in 
new HIV diagnoses from 2003 to 2014. As in recent 
years, the highest number of new diagnoses was among 
men who have sex with men (MSM) (183; 49%). In the 
10 years since 2005, the number of new diagnoses 
among MSM has increased threefold (from 60 to 183) 
and the median age at diagnosis has dropped from 37 
to 31 years. 
Heterosexual contact was the second most commonly 
reported mode of transmission in 2014, (125; 
33%). Since 2010, the number of diagnoses among 
heterosexuals has remained stable, ranging from 125 to 
133 diagnoses per year. The majority of heterosexuals 
(62%) diagnosed in 2014 were born in countries with 
generalised HIV epidemics!. The proportion diagnosed 
late in male heterosexuals (71%) was higher than in 
previous years (60% in 2013 and 68% in 2012) while in 
female heterosexuals, the proportion diagnosed late 
(56%) was less than in previous years (59% in 2013 and 
58% in 2012). 
There were 27 (7%) new diagnoses among people 
who inject drugs (PWID) in 2014, the highest number 
reported in this risk group since 2009. Of the new 
diagnoses, 85% were Irish-born, 89% were resident in 
Dublin and 89% were co-infected with hepatitis C. Forty 
one percent of PWID newly diagnosed in 2014 were 
recently infected, with documented previous negative 
HIV tests in either 2013 or 2014.
5.3 HIV
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Figure 1: New HIV diagnoses by probable route of transmission, 2003 to 2014
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[1] A generalised HIV epidemic is where greater than 1% of the 
general population is HIV positive
Two mother to child transmission (MTCT) cases were 
notified in 2014. Both of the children were born in 
sub-Saharan Africa.  No MTCT cases were identified in 
children born in Ireland in 2014. 
Late diagnosis
Forty nine percent of new diagnoses in 2014 were late 
presenters (with CD4 <350 cells/µl or an AIDS defining 
illness at diagnosis) and 28% had advanced HIV infection 
(with CD4 <200 cells/µl. or an AIDS defining illness at 
diagnosis). Late presentation was less common among 
MSM (38%) and PWID (44%) than among heterosexuals 
(56% in females and 71% in males). Thirty eight (10%) 
people were diagnosed with an AIDS defining illness at 
the time of their HIV diagnosis.
Discussion
There was an 11% increase in the number of new 
HIV diagnoses in 2014, which can be accounted for 
by an increasing number of HIV notifications among 
MSM and PWID. Sex between men is the commonest 
mode of transmission in Ireland since 2010 and is 
also the predominant mode of transmission in EU/
EEA countries (43% in 2013).2 In light of the continued 
increase in new HIV diagnoses among MSM, effective 
interventions such as promoting condom use, and peer 
led outreach interventions that provide information and 
support to the MSM community, need to be sustained 
and strengthened. The increase in recently acquired 
infections among PWID in Dublin since January 2014 is 
currently under investigation.1
Overall, the number of individuals that were diagnosed 
at a late stage of infection remains high: 49% compared 
with 50% in 2013 and 49% in 2012. The proportion 
diagnosed late varied by risk group and was highest 
among heterosexuals followed by PWID and lowest 
in MSM. More emphasis on the benefits of early 
testing, and ready access to HIV testing are needed 
to reduce the proportion presenting late, which will 
benefit both the individual and will also reduce the 
likelihood of transmission to others. Recent initiatives 
offering HIV screening to attendees of some emergency 
departments at large hospitals in Dublin may result 
in earlier detection of infections in people that may 
otherwise be unaware of their infection.  
The detailed 2014 annual report and slide set 
are available at http://www.hpsc.ie/A-Z/HIVSTIs/
HIVandAIDS/SurveillanceReports/   
Note: Data for this chapter were extracted from CIDR in May 2014.
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Table 1: Summary of HIV diagnoses in Ireland, 2014 
Number of HIV diagnoses 377
Rate of diagnoses (per 100,000 population) 8.2
Age Median age of adult cases 33 years
Age range of adult cases 18 to 77 years
Young people (15-24 years) 44 (11.7%)
Aged 50 and older 32 (8.5%)
Gender Males 277 (73%)
Females  100 (27%)
Male to female ratio 2.8
Route of Transmission Men who have sex with men (MSM) 183 (49%)
Heterosexual 125 (33%)
PWID (People who inject drugs) 27 (7%)
Mother to Child transmission (MTCT) 2 (0.5%)
Unknown 40 (11%)
Geographic origin Born in Ireland 137 (36.3%)
Born Abroad 203 (53.8%)
Unknown 37 (9.8%)
Stage of Infection Late 159 (48.6%)
Advanced HIV infection 90 (27.5%)
Concurrent AIDS diagnosis 38 (10.1%)
Co-infections Acute STI 39 (10.3%)
TB 16 (4.2%)
Hepatitis B 18 (4.8%)
Hepatitis C 31 (8.2%)
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Seventeen (of 19) maternity hospitals and units provided 
antenatal HIV screening data for 2014. Table 1 describes 
the data collected from maternity hospitals between 
2008 and 2014. Antenatal screening data were available 
for 63,538 women from 17 maternity hospitals in 2014. 
Data for 2014 were not available for two hospitals 
(Letterkenny General Hospital and Waterford Regional 
Hospital). In addition, 9 of the 17 hospitals (52.9%) were 
able to provide data on public patients only. There were 
67,462 births in 2014 and while these figures are not 
directly comparable, there was a shortfall in returns for 
approximately 6% of antenatal women. This is a lower 
figure than 2013 (16%) and 2012 (10%). 
Ninety three women tested HIV positive at their 
antenatal screen, giving a HIV prevalence rate of 
0.15%, slightly higher than the rate in 2013 (0.14%).
The prevalence of HIV infection among pregnant 
women varied among HSE areas, ranging from 0.05% 
in HSE West to 0.23% in HSE Dublin Northeast. Of 
the 93 HIV cases, 11 were newly diagnosed at their 
antenatal screen. The prevalence of newly diagnosed 
HIV infection was 0.02% in 2014, the same as 2013, and 
slightly lower than the prevalence reported in 2012, 
2011 and 2010 (0.03%). 
Some hospitals can only provide estimates or proxy 
measures for the number of women booked and/or the 
number offered HIV testing. Booking data was retrieved 
from a variety of sources including maternity IT systems 
(6 hospitals), maternity unit manual data collection (6 
hospitals), patient administrations systems (4 hospitals), 
and laboratory IT systems (3 hospitals).
Background information on the system, a copy of 
the data collection form and the full 2014 report can 
be found at http://www.hpsc.ie/hpsc/A-Z/HIVSTIs/
HIVandAIDS/AntenatalHIVTesting/ 
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(Footnotes)
1   Uptake of HIV antenatal test is calculated as the number of women 
tested divided by the number of women booked, multiplied by 100
2   Prevalence of HIV infection is calculated as the number of women 
testing positive divided by the number of women tested, multiplied 
by 100
5.4  Voluntary antenatal HIV testing in 
Ireland: 2014 
Key Points
National reported uptake rate: 99.9%*
Number HIV positive cases 93
Prevalence: 0.15%
Number new HIV positive cases: 11
Prevalence of new HIV positive cases:  0.02%
* Returns not available for approximately 6% of antenatal women 
in 2014
Table 1: Results of the antenatal screening programme, 2008 to 2014
Parameter 2008 2009 2010 2011 2012 2013 2014
Number of hospitals participating 18/20 19/20 19/20 20/20 18/20 16/19 17/19
Number of live births per year (CSO) 75,173 75,554 75,174 74,650 72,225 68,930 67,462
Number of women booked 66,558 68,378 70,024 68,111 64,803 57,638 63,538
Number offered test 66,558 68,026 69,615 67,849 64,803 57,638 63,538
Number tested 66,210 67,694 69,292 67,135 64,781 57,618 63,532
Uptake of HIV antenatal test1 (%) 99.5 99.0 99.0 98.6 99.9 99.9 99.9
Number HIV positive 123 140 118 109 105 83 93
Prevalence2 (%) 0.19 0.21 0.17 0.16 0.16 0.14 0.15
Number newly diagnosed HIV positive 34 32 21 17 22 14 11
Prevalence of new diagnoses (%) 0.05 0.05 0.03 0.03 0.03 0.02 0.02
Summary
During 2014, a total of 12,626 cases of sexually 
transmitted infections (STIs) were reported. The most 
frequently reported STIs were Chlamydia trachomatis 
infection (n=6,695), ano-genital warts (n=2,147), 
gonorrhoea (n=1,320) and non-specific urethritis 
(n=897; table 1). The burden of STIs is greatest among 
those aged less than 25 years and among men who 
have sex with men (MSM).
Chlamydia trachomatis infection
Chlamydia trachomatis infection was the most 
frequently reported STI with 6,695 notifications in 
2014. The crude incidence rate (CIR) increased to 145.9 
per 100,000 population having remained steady in 
recent years with rates between 139.6/100,000 and 
136.4/100,000 between 2011 and 2013 (figure 1).Half 
(n=3,426) of chlamydia cases were among those aged 
25 years or younger. There were 10 cases of Chlamydia 
trachomatis infection in young children (<6 months); half 
of these were reported as conjunctivitis. Data on mode 
of transmission are not collected for chlamydia cases.
Gonorrhoea
In 2014, a total of 1,320 cases of gonorrhoea were 
reported in Ireland, giving a notification rate of 28.8 per 
100,000 population. The overall trend has increased by 
200% between 2009 and 2014. The trend among men 
has been consistently upwards since 2009 while the 
notification rate amongst women decreased slightly in 
2014 (9.7/100,000 in 2014 vs. 11.4/100,000 in 2013). 
The vast majority of cases were among men (n=1,097, 
83%) and 43% (n=566) of gonorrhoea cases notified in 
2014 were among those aged less than 25 years old. 
Where mode of transmission was available, mode of 
transmission was reported as men who have sex with 
men (MSM) for 73% of cases (n=344) and heterosexual 
for 27% (78 male and 49 female).
Ano-genital warts
During 2014, 2,147 cases of ano-genital warts were 
reported in Ireland giving a CIR of 46.8 per 100,000 
population, an increase from 2013 (42.2/100,000) (figure 
1). There were more notifications among men (55%) 
than women (35%); gender was not provided for 10% 
of cases. The highest age-specific incidence rate was 
5.5  Sexually Transmitted Infections  
 (STIs), 2014
Summary
Total number of STIs in 2014: 12,626
Crude notification rate, 2014: 275.2/100,000
Most frequently reported STI in 2014: Chlamydia 
trachomatis infection (n=6,695)
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Table 1: Number, crude incidence rate (CIR) per 100,000 & median age 
of STIs, 2014
STI Number CIR Median Age (range)
Chlamydia 6,695 145.9 27 years (14 -89 years)*
Ano-genital warts (AGW) 2,147 46.8 NA
Gonorrhoea 1,320 28.8 27 years (14-66 years)*
Herpes simplex (genital) 1,235 26.9 27 years (14-71 years)
Non-specific urethritis (NSU) 897 19.5 NA
Syphilis (early infectious) 205 4.5 32 years (19-70 years)
Trichomoniasis 92 2.0 33 years (18-75 years)
LGV 35 0.8 35 years (20 -55 years)
Total 12,626 275.2 -
*Excludes those <14 years; NA: case-based data were not collected
among those aged 20-24 years (193/100,000). The 
numbers reported here are likely to be an underestimate 
of the true incidence as data were not reported from 
every STI clinic. Further details on the completeness of 
reporting are available in the report Ano-genital Warts 
in Ireland, 2014, available on the HPSC website, 
www.hpsc.ie.
Herpes simplex (genital)
There were 1,235 cases of herpes simplex (genital) 
notified in Ireland during 2014 corresponding to a CIR 
of 26.9 per 100,000 population, a small increase from 
2013 (24.8/100,000) (see figure 1). Most cases were 
reported as Herpes simplex virus (HSV) type 1 (42%) 
and 31% as HSV type 2; subtype was not reported for 
27% of cases. Three-quarters of cases (n=924) were in 
women and 39% (n=476) were aged less than 25 years.
Trichomoniasis
During 2014 there were 92 cases of trichomoniasis 
notified in Ireland corresponding to a CIR of 2.0 per 
100,000 population, a slight increase from 1.6/100,000 
in 2013. The majority of cases were among women 
(n=90, 98%) and 28% (n=26) of cases were aged less 
than 25 years. The highest gender- and age-specific rate 
was among women aged 20-24 years (12.6/100,000).
Lymphoganuloma venereum (LGV)
There were 35 cases of LGV reported in 2014 giving 
a crude incidence rate of 0.8 per 100,000 population 
(compared with five cases in 2013 and four in 2012). 
This is the highest number of LGV cases ever notified 
in a single year and follows an outbreak among MSM 
in the Greater Dublin area. All cases were reported in 
HSE East (n=34) or HSE North East (n=1) in men who 
have sex with men (MSM) and most were HIV positive. 
A multidisciplinary outbreak control team (OCT) was 
convened in October, 2014, to actively investigate cases 
and instigate control measures1 and the outbreak was 
declared over in July, 2015.
Non-specific urethritis
At total of 897 cases of non-specific urethritis were 
reported in 2014 compared with 1,272 in 2012. 
More detailed annual reports on STIs are available on 
the HPSC website at http://www.hpsc.ie/A-Z/HIVSTIs/
SexuallyTransmittedInfections/Publications/STIReports/
STIAnnualReports/. Weekly reports on STIs and HIV are 
available on the HPSC website at http://www.hpsc.ie/
A-Z/HIVSTIs/SexuallyTransmittedInfections/Publications/
STIReports/STIWeeklyReports/.
Data on syphilis, HIV and hepatitis B are presented 
elsewhere in this report.
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Figure 1: Trend in CIR per 100,000 population of selected STIs, 1995-2014
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As of 1st January, 2014, all laboratories are asked 
to notify new cases of syphilis, with one of: positive 
serology (T. pallidum EIA and TPPA) AND either 
RPR OR T. pallidum EIA IgM positive; demonstration 
of treponemes in lesions, exudates or tissues from 
clinically appropriate sites by dark ground microscopy; 
or demonstration of treponemes in lesions, exudates 
or tissues from clinically appropriate sites by PCR. Re-
infections, as defined by the laboratory’s own criteria, 
are also notifiable. 
During 2014, 279 cases of syphilis were notified which 
met the criteria for laboratory diagnosis of early syphilis. 
Of these, 205 (73%), where enhanced information was 
provided by clinicians, were reported as early infectious 
syphilis. Stage of infection was reported as unknown or 
enhanced surveillance forms were not received for the 
remaining 74 cases. No congenital syphilis cases were 
notified in 2014.
This analysis focuses on cases fitting the laboratory 
criteria and clinical criteria (n=205) and so the number 
of early cases in this report is likely to be an under-
estimate of the true number of early infectious syphilis 
cases.
The crude incidence rate for early infectious syphilis in 
2014 was of 4.5 per 100,000 population, an increase 
of 13% compared to 2013 (4.0 per 100,000). Figure 1 
shows the trend in crude incidence rate (CIR) for early 
syphilis cases from 2000 to 2014.
Of the 205 early infectious syphilis cases notified in 
2014:
•  126 (61%) were primary, 39 (19%) secondary and 40 
(20%) early latent; two cases classified as secondary 
syphilis were reported as neurosyphilis. 
•  Rates varied throughout the country, with the age-
standardised incidence rate (9.0 per 100,000) in HSE 
East (Dublin, Kildare and Wicklow) twice the national 
rate (4.5 per 100,000) (figure 2).
•  The majority of cases occurred in males (n=192; 
94%), with a male to female ratio of 15:1. 
5.6 Syphilis, 2014
Summary
Number of early infectious syphilis cases: 205
Crude incidence rate of early infectious syphilis: 
4.5/100,000 population
Number of congenital syphilis cases: 0
-107-HPSC Annual Epidemiological Report 2014 5 Blood-borne and Sexually Transmitted Infections
Figure 1: Crude incidence rate of early infectious syphilis (per 100,000 population), 
2000-2014
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•  The crude incidence rates in men and women were 
8.4 and 0.6 per 100,000 population respectively 
(figure 1).
•  The majority of cases (84%) were reported in people 
over 25 years of age.
•  Almost three quarters of cases (73%) were identified 
in STI clinics, with 18% being diagnosed in general 
practice. 
•  More than two thirds (69%) of all cases occurred in 
men who have sex with men (MSM) (table 1), with 
rates highest in the 25 to 29 year age group.  In 
MSM, a significant proportion (29%) was co-infected 
with HIV at the time of syphilis diagnosis, a small 
reduction compared to 2013 when 33% were co-
infected. 
•  Seventeen percent of cases were among 
heterosexuals. Eleven percent of heterosexuals were 
co-infected with HIV. 
•  Three of the 13 female cases were pregnant at time 
of diagnosis. 
•  A quarter of early cases were also diagnosed with 
an STI other than HIV during 2014. Since full patient 
identifiers were not provided for all cases, the true 
figure for STI co-infections is likely to be much higher.
Discussion
For the first time in 2014 only cases of early infectious 
syphilis were notifiable with the aim of improving 
completeness of information and data quality. An 
improvement was seen in that a higher proportion of 
enhanced forms were received (73% vs. 60% in 2013); 
this is very welcome. However, the true number of 
early infectious syphilis cases may be higher than that 
reported here, as only cases with both laboratory and 
clinical data indicating infectious syphilis, were included 
in the analysis. 
In 2014, the crude incidence rate of early syphilis 
increased to 4.5 per 100,000, the highest rate since 
the syphilis outbreak among MSM in Dublin in 
2001 (6.1/100,000). The increase in early syphilis in 
2014 was concentrated among men (94% of cases). 
The rate among men increased to 8.4 per 100,000 
compared to 4.5/100,000 and 7.7/100,000 in 2012 
and 2013, respectively. The rate among women 
increased slightly in 2014 with a rate of 0.6 per 100,000 
compared to 0.5/100,000 and 0.4/100,000 in 2012 and 
2013, respectively. As in previous years, these data 
demonstrate that MSM are disproportionately affected 
by early infectious syphilis (80% of cases where mode of 
transmission was known). This mirrors the pattern seen 
in England1 and Scotland2.  
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Figure 2: Age-standardised incidence rate of early infectious syphilis by HSE area, 
2012-2014
Table 1: Summary of early infectious syphilis cases, 2012, 2013 and 2014
2012 2013 2014
n % n % n %
Total number of early cases 115 184 205
Male 101 87.8 175 95.1 192 93.6
Men who have sex with men (MSM) 81 70.4 118 64.1 141 68.8
Heterosexuals 24 20.9 22 12.0 35 17.1
Unknown mode of transmission 10 8.7 44 23.9 29 14.1
Median age (years) 34 33 32
Age range (years) 19-68 19-73 19-70
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The proportion of early syphilis cases co-infected with 
HIV in 2014 dropped back to 24% in 2014, the same 
proportion as 2012, having increased to 29% in 2013. 
The proportion of HIV co-infection continues to be 
higher among MSM (29%) compared to heterosexuals 
(11%). Those co-infected with HIV in 2014 were younger 
than in previous years; the median age of HIV positive 
cases was 38 years in 2012, 36 years in 2013 and 34 
years in 2014. The proportion of cases co-infected with 
HIV remains a concern as co-infection increases the risk 
of acquiring and transmitting HIV3. 
A more detailed analysis of syphilis in Ireland in 2014 is 
available in the report Syphilis in Ireland, 2014, which is 
available on the HPSC website www.hpsc.ie.
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Encephalitis due to viruses not otherwise specified 
(NOS) are notifiable under the disease category ‘viral 
encephalitis’. Details of viral encephalitis cases caused 
by other notifiable diseases, if any, are presented in 
other chapters in this report. 
In 2014, 68 cases of viral encephalitis (NOS) were 
notified in Ireland (1.5/100,000 population) compared 
to six (0.1/100,000) in the previous year (figure 1). One 
contributing factor for the sharp increase in numbers 
can be attributable to the late notification of 15 cases 
from 2013 (based on their specimen dates) reported 
during weeks 4 to 7 in 2014. Another reason can be 
attributable to the 33 reported cases of varicella zoster 
virus in 2014 compared to none in the previous year; 
improved notification and investigation (with laboratory 
confirmation) may be the reason for this.
The number of viral encephalitis (NOS) cases among 
males (n=35) and females (n=33) was similar. The 
median age of cases was 48 years (range two weeks 
to 91 years); 26 (42%) cases occurred in those aged 65 
or more years. Most infant VE was caused by HSV and 
most VE in elderly (> 65 years) was associated with VZV 
and HSV (14 and 12 cases respectively) (figure 1, table 
1).
Of the 68 cases, all were laboratory tested positive and 
case classified as confirmed. All but one had a causative 
pathogen identified: varicella virus & varicella zoster 
virus (n=33; 48.5%), herpes simplex virus (n=30; 44.1%), 
human herpes virus type 6 (HHV 6) (n=2; 2.9%), and 
one each of parechovirus, enterovirus and not specified 
(n=1; 1.8%) (figure 2). 
Caution is advised regarding the detection of HHV 6 
DNA in cerebral spinal fluid (CSF) specimens, especially 
in those cases aged less than 3 months as HHV 6 
DNA can be chromosomally integrated as it may not 
be clinically relevant. Both cases of HHV 6-related 
6.1 Viral Encephalitis
Summary
Number of cases, 2014: 68 
Number of cases, 2013: 6
Number of cases, 2012: 18
Crude incidence rate, 2014:1.5/100,000
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Table 1. Number, age-specific incidence rates and proportion of viral encephalitis (NOS) cases by age group, Ireland, 2014*
* includes the late notification of 15 cases in 2013 reported in early 2014
 Causative pathogen    
Age Group
herpes 
simplex 
virus
varicella virus 
& varicella 
zoster virus
human herpes 
virus type 6
enterovirus parechovirus
not 
specified
Total ASIR
% 
Proportion
<1 4 0 0 0 1 0 5 6.91 7.4
1-4 4 1 1 0 0 0 6 2.11 8.8
5-14 1 1 0 0 0 0 2 0.32 2.9
15-24 1 6 0 0 0 1 8 1.38 11.8
25-44 4 7 0 1 0 0 12 1.17 17.6
45-64 4 4 1 0 0 0 9 0.86 13.2
65+ 12 14 0 0 0 0 26 4.86 38.2
All ages 30 33 2 1 1 1 68 1.48 100
% total 
cases
44.1 48.5 2.9 1.5 1.5 1.5 100   
ASIR, age specific incidence rate per 100,000 population of total cases
encephalitis in 2014 occurred in patients greater than 
three months of age.
There were no reported deaths associated with viral 
encephalitis (NOS) in 2014. There was one imported 
case (caused by herpes simplex virus type 1); it is not 
clear if the patient was a visitor to Ireland or if the 
patient was an Irish resident returning from abroad.
The figures presented in this report are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 13th August, 2015. These 
figures may differ from those published previously due 
to on-going updating of notification data in CIDR.
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Figure 1. Number of viral encephalitis (NOS) cases by age group and year, Ireland, 
1992-2014*
* includes the late notification of 15 cases in 2013 reported in early 2014
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Figure 2. Number of viral encephalitis (NOS) cases by causative pathogen and year, Ireland, 
1992-2014*
* includes the late notification of 15 cases in 2013 reported in early 2014
Meningitis due to viruses not otherwise specified 
(NOS) are notifiable under the disease category ‘viral 
meningitis’. Details of viral meningitis caused by other 
specified notifiable diseases (such as mumps and 
influenza viruses, if any) are presented in other chapters 
in this report. 
The sharp, steady increase in annual notifications, 
which started back in 2007 continued in 2014 when 
435 were reported. The latter number is considerably 
higher than the 300 cases notified back in 1990, the 
highest previous ever recorded in a single year (figure 
1). It should be noted that the total number of cases 
reported in 2014 includes the late notification of seven 
cases from 2013 (based on their specimen dates) 
reported during weeks 5 and 6 of 2014.
Since 1997, eight deaths have been reported with cases 
of viral meningitis (NOS), one of which was attributable 
to the infection itself. There were one reported in 2014, 
but the infection did not cause death.
Of the 435 cases notified in 2014, 428 were classified 
as confirmed (98.4%) and seven as probable (1.6%). 
There were slightly more cases among males (n=223) 
than in females (n=205), giving a male to female ratio 
of 1.09:1.0. Seven cases were reported with unknown 
gender details in 2014.
The national crude incidence rate in 2014 was 9.5 (95% 
CI 8.6–10.4) cases per 100,000 population, a 54.8% 
increase compared with the previous year when 281 
cases were notified (6.1/100,000). The highest age 
specific incidence rate (ASIR) in 2014 was in infants <1 
year of age (256.9/100,000; n=186), followed by the 
15-19 year age group (13.8/100,000; n=39). The lowest 
ASIR was in the 55-64 year age group (ASIR 0.2/100,000 
(n=1)) (table 1). 
In 2014 the highest frequency of cases was in children 
aged 1 to 2 months (n=121) and in those aged between 
15 to 39 years (n=184) with an overall median age of 11 
years (range 6 days to 86 years) (figure 2). Sixty-eight 
percent of cases (n=296) occurred in those under 25 
years of age (figure 3, table 1). 
By HSE region, the highest rate was in HSE E at 
13.5/100,000 (95%CI 11.7–15.2) and lowest in HSE 
MW at 4.2/100,000 (95%CI 2.2-6.3), with both rates 
significantly different from the national rate (figure 4).
6.2 Viral Meningitis
Summary
Number of cases, 2014: 435 
Number of cases, 2013: 281
Number of cases, 2012: 235
Crude incidence rate, 2014:9.5/100,000
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Figure 1. Number of viral meningitis (NOS) cases by organism type and year, Ireland, 1988-2014*
* includes the late notification of seven cases in 2013 reported in early 2014
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In 2014, enteroviruses were the most common 
pathogen associated with viral meningitis, accounting 
for 71.7% (n=312/435) of all notifications (figure 3, table 
1) and account for the marked increase in notifications 
in 2014 when compared to previous years. As a cause of 
viral meningitis, enteroviruses have accounted for 60% 
or more of all cases each year since 2006. Enteroviruses 
are not routinely specified on CIDR, so it is not possible 
to attribute which type of enterovirus, of which there 
are many, accounts for the majority of reported viral 
meningitis cases in recent years. It is hoped that an 
enterovirus typing service, currently in development 
in the NVRL, will in future years be able to routinely 
ascertain which type is circulating in the population.
In 2014, human herpes virus (type 6) (HHV 6) was the 
causative pathogen for 8.0% (n=35) notifications, 
parechovirus for 7.4% (n=32), varicella virus/varicella 
zoster virus for 4.4% (n=19) and herpes simplex virus 
(HSV) accounting for 3.2% (n=14) of all cases (figure 
3, table 1). There were 5.3% (n=23) cases with no viral 
pathogen specified. Caution is recommended regarding 
the detection of HHV 6 DNA in cerebral spinal fluid 
(CSF) specimens, especially in those cases aged less 
than 3 months (n=17/35; 48.6%) as HHV 6 DNA can be 
chromosomally integrated. When this occurs the HHV 
6 DNA can be inherited through the germ line and 
therefore when it is detected, it may not be clinically 
relevant.
Enterovirus was also the most common pathogen in 
infants under one year of age with viral meningitis 
(NOS) in 2014 in 111 out of total of 186 cases in 
that age group (59.7%). Between 2007 and 2014 
enteroviruses accounted for 71.7% (n=1164/1623) of 
all viral meningitis (NOS) cases, with typical summer 
peaks observed each year (figure 5). The large number 
of enterovirus-related viral meningitis cases observed in 
recent years is likely due in part to improved notification 
and investigation with laboratory confirmation.
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Figure 2. Number of viral meningitis (NOS) cases by age group and gender, 
Ireland, 2014*
* includes the late notification of seven cases in 2013 reported in early 2014
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Table 1. Number, age-specific incidence rates and proportion of viral meningitis (NOS) notifications by age group and causative 
pathogen, Ireland, 2014*
* includes the late notification of seven cases in 2013 reported in early 2014
Causative pathogen
Age Group
entero-
virus
human 
herpes 
virus
herpes 
simplex virus
varicella virus & 
varicella zoster 
virus
echo-
virus
not 
specified
Total ASIR
% 
Proportion
<1 111 29 2 1 32 11 186 256.9 42.8
1-4 9 5 2 0 0 1 17 6.0 3.9
5-9 11 0 0 0 0 0 11 3.4 2.5
10-14 12 0 0 1 0 0 13 4.3 3.0
15-19 33 0 1 3 0 2 39 13.8 9.0
20-24 23 0 0 3 0 4 30 10.1 6.9
25-34 79 1 2 4 0 3 89 11.8 20.5
35-44 32 0 2 4 0 1 39 5.6 9.0
45-54 2 0 2 1 0 0 5 0.9 1.1
55-64 0 0 1 0 0 0 1 0.2 0.2
65+ 0 0 2 2 0 1 5 0.9 1.1
All Ages 312 35 14 19 32 23 435 9.5 100
% Total 71.7 8.0 3.2 4.4 7.4 5.3 100.0
ASIR, age specific incidence rate per 100,000 population of total cases
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The figures presented in this report are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 13th August, 2015. These 
figures may differ from those published previously due 
to on-going updating of notification data in CIDR.
Figure 5. Monthly number of viral meningitis, NOS and enterovirus-related meningitis notifications, 2007-
2014* 
* includes the late notification of seven cases in 2013 reported in early 2014
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Figure 4. Crude incidence rates per 100,000 population with 95% confidence 
intervals for viral meningitis (NOS) cases by HSE area, Ireland, 2014*
* includes the late notification of seven cases in 2013 reported in early 2014
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Figure 3. Number of viral meningitis (NOS) cases by age group (<25, >25 years 
of age) and year, Ireland, 2000-2014*
* includes the late notification of seven cases in 2013 reported in early 2014
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Two cases of Creutzfeldt-Jakob disease (CJD) were 
notified in 2014 compared to 2013 when five cases were 
notified. Both cases in 2014 were sporadic CJD cases. 
One of the cases was in the age group 55-64 years and 
one was in the age group ≥65 years. Both cases were 
female.
In total, 70 cases of CJD were notified since CJD was 
first specified as a notifiable disease in December 1996 
(figure 1). Figure 2 shows the 70 CJD notifications by 
age group. The majority (80%, n=56) of the cases were 
aged greater than 54 years. Of the 70 cases, 35 were 
male and 35 were female. Sixty-six cases were sporadic 
CJD, two were familial CJD and two were iatrogenic.
Variant CJD (vCJD) is specified as a separate notifiable 
disease. No cases have been notified since 2006. In to-
tal, four cases of vCJD were notified since vCJD became 
notifiable in December 1996. A summary of these four 
cases was provided in the 2006 HPSC annual report. 
Data presented in this summary are based on notifi-
cations from HSE Areas and from the Irish National 
Creutzfeldt-Jakob Disease Surveillance Unit. Annual 
figures published here are based on the year the no-
tification was entered on the Computerised Infectious 
Disease Reporting (CIDR) system and consequently may 
differ from annual figures published by the Irish National 
Creutzfeldt-Jakob Disease Surveillance Unit.
6.3 Creutzfeldt-Jakob disease  
Summary
Number of cases, 2014: 2
Number of cases, 2013: 5
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Figure 1. Number of CJD notifications by year from December 
1996 to 2014
Figure 2. Number of CJD notifications (n=70) from December 
1996 to 2014 by age group
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infEctious disEAsE outbREAks
Outbreaks
During 2014, 435 outbreaks of infectious diseases 
were reported with 4,529 associated cases of illness, 
including 422 (9.3%) cases hospitalised and 40 deaths.* 
Regional variation in outbreaks was observed between 
HSE areas with the highest rates observed in HSE-NW 
(17.8/100,000 population) while the lowest rate was 
observed in HSE-NE at 5.2 per 100,000 population. 
Table 1 details the regional distribution of all outbreaks 
by HSE area and outbreak disease.
The number of outbreaks peaked between January and 
March. The January peak observed was mainly due to 
high numbers of norovirus and AIG outbreaks while 
the March peak was mostly due to influenza and acute 
respiratory infection outbreaks. Figure 1 illustrates 
the number of IID and non-IID outbreaks by month of 
notification during 2014.
Similar to previous years, airborne/ person-to-person 
spread was reported as the mode of transmission for 
the majority of outbreaks (75.6%, n=329). Table 2 details 
all outbreaks by infectious disease and probable mode 
of transmission. 
The most frequently reported outbreak locations were 
private houses (n=115, 26.4%), nursing homes (n=90, 
20.7%) and community hospital/ long-stay units (n=57, 
13.1%). The highest numbers ill were reported from 
outbreaks in nursing homes (n=1,452), community 
hospital/long-stay units (n=662) and hospitals (n=604). 
General outbreaks accounted for 71.0% (n= 309) of 
all outbreaks notified during 2014. The remaining 
outbreaks (29.0%, n= 126) were reported as family/
household outbreaks. 
7. Outbreaks
Summary
Number of outbreaks: 435
Number of IID outbreaks: 294
Number of non-IID outbreaks:141
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Figure 1: Number of IID and non-IID outbreaks by month of notification, 2014
Outbreak data extracted from CIDR on 24/07/2015.
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Table 1 Number of IID and non-IID outbreaks by disease and HSE area, 2014 
IID/ Non-IID Outbreak Disease HSE-E HSE-M
HSE-
MW
HSE-
NE
HSE-
NW
HSE-SE HSE-S HSE-W Total
IID
Acute infectious gastroenteritis 23 2 1 2 14 12 12 10 76
Campylobacter infection 2 1 1 2 4 10
C. difficile infection 6 1 2 1 10
Cryptosporidiosis 1 4 3 2 6 2 18
Giardiasis 1 2 3
Hepatitis A (acute) 1 1
Noroviral infection 17 14 7 3 10 13 7 4 75
Rotavirus infection 1 2 1 4
Salmonellosis 2 2 1 1 2 8
Shigellosis 1 1 2 4
Typhoid 1 1
Verotoxigenic E. coli infection 4 19 8 5 4 11 18 14 83
Viral meningitis 1 1
IID Total 58 41 19 11 33 40 50 42 294
Non-IID
Acute respiratory infection 3 1 1 2 1 5 4 17
Dengue fever 1 1
E. coli (ESBL) 1 1
Enterococci (Carbapenam resistant) 1 1
H. influenzae disease (invasive) 1 1
Hand foot and mouth (suspected) 1 1
Hepatitis B 1 1
Human metapneumovirus 1 1 2
Impetigo (suspected) 1 1
Influenza 24 2 4 7 8 7 9 4 65
K. pneumoniae (MDR) 1 1
Lymphogranuloma venereum 1 1
Measles 2 1 3
Meningococcal disease 1 1
Mumps 6 3 3 3 3 5 23
Pertussis 1 2 3
Pseudomonas 1 1 2
Respiratory syncytial virus infection 3 1 4
Scabies (suspected) 1 1 2
S. aureus (drug resistant 2 2
Tuberculosis 1 1 3 5
Varicella-zoster/ suspected varicella 
zoster
1 1 2
Viral illness 1 1
Non-IID Total 48 4 10 12 13 13 24 17 141
Total 106 45 29 23 46 53 74 59 435
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Table 2: Number of IID and non-IID outbreaks by disease and probable route of transmission, 2014
IID/ Non-IID Outbreak disease Airborne/ 
P-P
Animal 
contact
Food-
borne
Water-
borne
Other Unk Total
IID
Acute infectious gastroenteritis 61 6 1 8 76
Campylobacter infection 4 1 5 10
C. difficile infection 7 3 10
Cryptosporidiosis 6 7 1 4 18
Giardiasis 2 1 3
Hepatitis A (acute) 1 1
Noroviral infection 69 1 5 75
Rotavirus infection 4 4
Salmonellosis 4 2 2 8
Shigellosis 2 2 4
Typhoid 1 1
Verotoxigenic E. coli infection 40 6 1 9 3 24 83
Viral meningitis 1 1
IID total 199 14 10 13 3 55 294
Non-IID
Acute respiratory infection 16 1 17
Dengue fever 1 1
E. coli (ESBL) 1 1
Enterococci (Carbapenam resistant) 1 1
H. influenzae disease (invasive) 1 1
Hand foot and mouth (suspected) 1 1
Hepatitis B 1 1
Human metapneumovirus 2 2
Impetigo (suspected) 1 1
Influenza 65 65
K.pneumoniae (MDR) 1 1
Lymphogranuloma venereum 1 1
Measles 3 3
Meningococcal disease 1 1
Mumps 20 3 23
Pertussis 3 3
Pseudomonas 1 1 2
Respiratory syncytial virus infection 4 4
S. aureus (drug resistant) 2 2
Scabies (suspected) 2 2
Tuberculosis 5 5
Varicella-zoster/ suspected varicella 
zoster
2 2
Viral illness 1 1
Non-IID total 130    4 7 141
Total 329 14 10 13 7 62 435
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Infectious intestinal disease (IID) outbreaks:
During 2014, 294 IID outbreaks were reported, 
accounting for 67.6% of all outbreaks. This was 
a decrease of 21.0% compared to the number of 
reported during 2013 (n=520) and lower than the mean 
proportion of IID outbreaks in the previous 3 years 
(74.7%). After VTEC (n=83 outbreaks with 200 ill), the 
next most commonly reported IID outbreaks were 
AIG (n=76 outbreaks with 792 ill) and norovirus (n=75 
outbreaks with 1,230 ill). 
Non-infectious intestinal disease (Non-IID) outbreaks:
During 2014, 141 non-IID outbreaks were reported, 
accounting for 32.4% of all outbreaks. This remains 
stable compared to the number reported during 2014 
(n=148) but was higher than the mean proportion of 
IID outbreaks in the previous three years (25.3%). After 
influenza (n=65 outbreaks with 1,209 ill), the next most 
commonly reported non-IID outbreaks were mumps 
(n=23 outbreaks with 395 ill) and acute respiratory 
infection (n=17 outbreaks with 147 ill). 
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immunisAtion uptAkE
Introduction
In 2014, the HSE Areas provided HPSC with quarterly 
immunisation uptake data for their Area and for 
each of the Local Health Offices (LHOs) in their Area. 
HPSC collated these data and quarterly reports were 
produced which are available on the HPSC website. 
The annual immunisation uptake rates presented 
here represent the collation of the 2014 quarterly 
data. The proportion of children who completed 
the recommended primary childhood immunisation 
schedule by 12 months (born between 01/01/2013 and 
31/12/2013) and 24 months (born between 01/01/2012 
and 31/12/2012) of age in 2014 are reported.
Children who were 12 and 24 months of age in 2014 
were recommended one dose of vaccine against 
tuberculosis (BCG vaccine) at birth or by one month of 
age; three doses of vaccines against diphtheria (D3), 
tetanus (T3), pertussis (P3), Haemophilus influenzae type 
b (Hib3), polio (Polio3) and Hepatitis B (HepB3) with one 
dose of each recommended at two, four and six months 
of age; three doses of pneumococcal conjugate vaccine 
(PCV3) recommended at two, six and 12 months of age 
and three doses of meningococcal group C (MenC3) 
vaccine recommended at four, six and 13 months of 
age (table 1). Also at 12 months of age a dose of MMR 
(MMR1) was recommended and at 13 months a dose of 
Hib (Hibb) was recommended (table 1). A new primary 
childhood immunisation schedule was introduced in 
2015 for babies born on or after July 1st 2015.  Further 
vaccinations are recommended for older children and 
8.1  Immunisation uptake at 12 and 24 
months of age
Summary
Among children at 12 months of age in 2014 uptake 
of:
D3, T3, P3, Hib3, Polio3, HepB3, MenC2 and PCV2 was 
92%
Among children at 24 months of age in 2014 uptake 
of:
D3, T3, P3, Hib3, Polio3 and HepB3 reached or 
exceeded the target of 95%
D3, T3, P3, Hib3 and Polio3 was 96%
HepB3 was 95%
MMR1 was 93%
PCV3 and Hibb was 92%
MenC3 was 88%
Table 1. Primary childhood immunisation schedule for children born between 01/07/2008 and 30/06/2015 
Age Vaccines
Birth BCG
2 months DTaP/Hib/IPV/HepB (6 in 1) + PCV
4 months DTaP/Hib/IPV/HepB (6 in 1) + MenC
6 months DTaP/Hib/IPV/HepB (6 in 1) + PCV + MenC
12 months MMR + PCV
13 months MenC + Hib
Please note the primary immunisation schedule changed in 2015 for children born on or after 01/07/2015. Please see the HSE-National 
Immunisation Office website at http://www.hse.ie/eng/health/immunisation/ for current and detailed information on the Irish primary 
childhood immunisation schedule and also recommended vaccinations for older children and adults
BCG  Bacille Calmette Guerin vaccine 
DTaP  Diphtheria, Tetanus and acellular Pertussis vaccine
HepB  Hepatitis B vaccine
Hib Haemophilus influenzae type b vaccine
IPV  Inactivated Polio Virus vaccine
MenC   Meningococcal group C vaccine
MMR  Measles, Mumps and Rubella vaccine
PCV  Pneumococcal Conjugate Vaccine
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adults. Please see the HSE-National Immunisation Office 
website at http://www.hse.ie/eng/health/immunisation/ 
for current and detailed information on the Irish 
primary childhood immunisation schedule and also 
recommended vaccinations for older children and adults
In children at 12 months of age in 2014 (born between 
01/01/2013 and 31/12/2013) uptake of BCG, D3, T3, 
P3, Hib3, Polio3, HepB3 and two doses of PCV (PCV2) 
and MenC (MenC2) were measured. In children at 24 
months of age in 2014 (born between 01/01/2012 
and 31/12/2012) uptake of D3, T3, P3, Hib3, Polio3, 
HepB3, MenC3, PCV3, MMR1, Hibb, one dose of vaccine 
against meningococcal group C (MenCb) on or after 
twelve months of age and one dose of vaccine against 
pneumococcal conjugate vaccine (PCVb) on or after 
twelve months of age were measured.
The immunisation uptake rates are reported here by 
HSE Area and LHO. The uptake rates presented here 
were rounded to zero decimal place. While there are 
32 LHOs the immunisation uptake rates for the LHOs of 
North Lee and South Lee are reported as a combined 
figure.
Caveats to data
BCG uptake data at 12 months of age has been 
incomplete since reporting to HPSC began in Quarter 
3 2003. This has occurred due to differences in 
implementation of a neonatal BCG programme across 
the HSE Areas as well as difficulties in providing 
these data to the HPSC where the programme was 
implemented. Prior to the establishment of the HSE 
each former health board determined their own BCG 
vaccination policy and some health boards (Western 
and parts of the Southern Health Board) stopped 
routine neonatal BCG vaccination but provided 
BCG vaccination for adolescents or high risk groups. 
The neonatal programme has now been routinely 
implemented for all neonates in most, but not all, HSE 
Areas. Additionally more complete data on neonatal 
BCG vaccination is now available. However, in the HSE 
NE, where a neonatal programme is implemented, data 
is not currently available for reporting. In the HSE W the 
neonatal programme is not routinely or comprehensively 
implemented in all LHOs. Therefore, data provided 
for the HSE W reflects BCG vaccination data for just a 
small proportion of all babies born in this Area. Galway 
and Roscommon BCG LHO data became available for 
reporting for the first time in Quarter 4 2014. Mayo 
LHO BCG data was not available for reporting purposes 
prior to 2015. The numbers vaccinated with BCG in 
Mayo were not included in the HSE W BCG figures 
prior to 2015. National data for 2014 are presented in 
this report and compared to 2013 data. The available 
national BCG cohort data may be around 89% of the 
national birth cohort in 2014 and 90% in 2013 (these 
figures are estimates only). 
As uptake of MenC3 was low since Q3 2010 and as 
those over 12 months of age need only one dose of 
MenC and those aged 12-23 months need only one 
dose of PCV, data on MenCb (one dose of MenC on 
or after first birthday and before second birthday) and 
PCVb (one dose of PCV on or after first birthday and 
before second birthday) were requested in 2012 for the 
first time. Six HSE Areas (HSE E, M, MW, NW, SE and S) 
were able to provide data representing approximately 
81% of the national birth cohort in 2014 and 80% in 
2013 (these figures are estimates only).
Immunisation uptake rates at 12 months
Ninety-two per cent of children, at 12 months of age in 
2014, received D3, T3, P3, Hib3, Polio3, HepB3, MenC2 and 
PCV2 (table 2). Compared with 2013, the uptake rates 
for these vaccines increased by one per cent. 
The available 2014 BCG cohort data may be around 
89% (estimate only) of the national birth cohort; based 
on these data BCG uptake was 87% (table 2). In 2013, 
BCG cohort data may be around 90% (estimate only) 
of the national birth cohort; based on these data BCG 
uptake in 2013 was 86%. 
Among the HSE Areas, uptake rates for D3, T3, P3, Hib3 
and Polio3 ranged from 90% to 96%, HepB3 ranged from 
91% to 96% and MenC2 and PCV2 ranged from 88% to 
96% (table 2). The target uptake of ≥95% was reached 
in the HSE Midland Area for all vaccines (table 2). The 
target uptake of ≥95% was reached in four HSE Areas 
for BCG (table 2).
Among the LHOs, uptake rates for D3, T3, P3, Hib3, Polio3 
and HepB3 ranged from 88% to 97% and MenC2 and 
PCV2 ranged from 84% to 97% (table 2). The target 
uptake of ≥95% was reached in Laois/Offaly, Longford/
Westmeath and Roscommon for D3, T3, P3, Hib3, Polio3, 
HepB3, MenC2 and PCV2 and in Cavan/Monaghan for 
MenC2 and PCV2 with the highest uptake (97%) of these 
vaccines in Roscommon (table 2). The target uptake of 
≥95% was reached for BCG in 12 LHOs reporting data 
(table 2).
Immunisation uptake rates at 24 months
National annual immunisation uptake rates, in children 
at 24 months of age in 2014, were 96% for D3, T3, 
P3, Hib3 and Polio3, 95% for HepB3, 93% for MMR1, 
92% for Hibb and PCV3 and 88% for MenC3 (table 3). 
This is the fourth year national annual uptake rates 
reached the target of ≥95% for D3, T3, P3, Hib3, Polio3 
and HepB3. Compared with 2013, the uptake rates for 
Hibb increased by two percent, Hib3, MenC3 and PCV3 
increased by one percent while D3, T3, P3, Polio3, HepB3 
and MMR1were unchanged (figure 1). 
Six of the eight HSE Areas were able to provide uptake 
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Table 2. Immunisation uptake (%) at 12 months of age in 2014 (i.e. cohort born 01/01/2013-31/12/2013) by LHO and HSE Area
HSE Area
Local Health Office/
HSE Area
Number in 
cohort for 
BCG *
Number in 
cohort for D3, T3 
& P3 †
Immunisation Uptake (%)
BCG D3 Hib3 HepB3 MenC2 PCV2
HSE E
Dublin South 1710 1710 89 92 92 92 91 92
Dublin South East 1701 1701 88 93 93 93 92 92
Dublin South City 1813 1813 93 93 93 93 93 93
Dublin South West 2462 2462 97 93 93 93 93 93
Dublin West 2767 2767 91 92 92 92 92 92
Dublin North West 3773 3773 93 90 90 90 90 90
Dublin North Central 1953 1953 91 89 89 89 89 89
Dublin North 4181 4181 94 89 89 89 89 89
Kildare/West Wicklow 3812 3812 96 92 92 92 92 92
Wicklow 1775 1775 93 92 92 92 92 92
HSE E Total 25947 25947 93 91 91 91 91 91
HSE M
Laois/Offaly 2471 2471 96 95 95 95 95 95
Longford/Westmeath 1916 1916 95 96 96 96 96 96
HSE M Total 4387 4387 95 96 96 96 96 96
HSE MW
Clare 1535 1552 96 93 92 92 92 92
Limerick 1730 1850 97 92 92 92 92 92
Tipperary NR/East Limerick 1815 1838 97 93 93 93 93 93
HSE MW Total 5080 5240 96 92 92 92 92 93
HSE NE
Cavan/Monaghan na 2015 na 93 93 93 95 95
Louth na 1939 na 90 90 90 91 91
Meath na 3378 na 92 92 92 93 93
HSE NE Total na 7332 na 92 92 92 93 93
HSE NW
Donegal 2092 2092 95 94 94 93 93 94
Sligo/Leitrim 1368 1368 96 94 94 94 93 94
HSE NW Total 3460 3460 95 94 94 93 93 94
HSE SE
Carlow/Kilkenny 1945 1945 96 91 91 91 91 91
South Tipperary 1335 1335 97 94 94 94 94 94
Waterford 1897 1897 94 92 92 92 92 92
Wexford 2056 2056 96 94 94 94 94 94
HSE SE Total 7233 7233 96 93 93 93 92 93
HSE S
North Cork 1451 1438 94 91 91 92 89 89
North South Lee 5840 5778 94 91 91 91 89 88
West Cork 740 735 91 88 88 88 84 84
Kerry 1827 1807 92 91 91 91 87 86
HSE S Total 9858 9758 93 90 90 91 88 88
HSE W
Galway na 3703 na 94 94 94 94 94
Mayo na 1670 na 93 93 93 93 93
Roscommon na 908 na 97 97 97 97 97
HSE W Total 5863* 6281 16* 94 94 94 94 94
Ireland 61828 69638 87 92 92 92 92 92
na=not available
* Galway and Roscommon BCG LHO data became available for reporting for the first time in Quarter 4 2014 and were 12% and 62%, respectively. Prior to this BCG 
data was available for the HSE W but was unavailable for the individual LHOs in the HSE W. Mayo LHO BCG data was not available for reporting purposes prior to 
2015. The numbers vaccinated with BCG in Mayo were not included in the HSE W BCG figures prior to 2015.
†As the denominator/number in cohort varied slightly according to vaccine the D3, T3 and P3 cohorts are shown here. 
Since T3, P3 and Polio3 uptake identical to D3 uptake only D3 uptake figures are presented 
Please note while North Lee and South Lee are two separate Local Health Offices their combined immunisation uptake data are reported here 
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Table 3. Immunisation uptake (%) at 24 months of age in 2014 (i.e. cohort born 01/01/2012-31/12/2012) by LHO and HSE Area
HSE 
Area
Local Health Office/HSE 
Area
Number in 
cohort for D3, 
T3 & P3 *
Immunisation Uptake (%)
D3 Hib3 Hibb HepB3 MenC3 MenCb PCV3 PCVb MMR1
HSE E
Dublin South 1782 95 95 91 95 89 91 91 92 92
Dublin South East 1633 95 95 92 95 90 92 92 94 94
Dublin South City 1740 95 95 89 95 86 89 90 92 92
Dublin South West 2631 96 96 93 96 89 93 92 95 94
Dublin West 2926 96 96 90 96 86 89 90 93 93
Dublin North West 3924 93 93 87 93 84 87 89 90 90
Dublin North Central 1853 93 93 88 93 85 88 88 90 90
Dublin North 4380 94 94 90 94 88 90 91 93 93
Kildare/West Wicklow 3949 96 96 92 96 89 91 92 94 93
Wicklow 1985 95 95 86 95 84 86 90 91 91
HSE E Total 26803 95 95 90 95 87 90 91 93 92
 HSE M
Laois/Offaly 2552 98 98 98 98 92 95 94 96 96
Longford/Westmeath 2063 98 98 98 98 93 95 95 97 97
HSE M Total 4615 98 98 98 98 93 95 95 97 97
HSE MW
Clare 1743 96 96 93 96 90 93 92 94 93
Limerick 1931 94 94 88 94 85 88 90 92 90
Tipperary NR/East 
Limerick
1855 95 95 89 95 86 89 91 93 92
HSE MW Total 5529 95 95 90 95 87 90 91 93 92
HSE NE
Cavan/Monaghan 2025 97 97 91 97 88 na 92 na 93
Louth 1996 93 93 87 93 84 na 89 na 91
Meath 3377 95 95 90 95 87 na 91 na 92
HSE NE Total 7398 95 95 89 95 87 na 91 na 92
HSE NW
Donegal 2190 96 96 93 95 88 93 91 94 94
Sligo/Leitrim 1426 97 96 92 96 86 92 90 95 95
HSE NW Total 3616 97 96 93 96 87 92 91 95 94
HSE SE
Carlow/Kilkenny 1989 96 96 94 96 88 93 93 94 95
South Tipperary 1297 97 97 97 96 89 95 94 95 95
Waterford 1911 96 96 93 96 88 92 93 94 94
Wexford 2185 96 96 95 96 89 93 93 95 94
HSE SE Total 7382 96 96 95 96 89 93 93 95 94
HSE S
North Cork 1555 95 94 90 95 88 89 92 91 93
North South Lee 5795 96 95 90 96 87 89 91 93 93
West Cork 779 93 93 88 93 85 85 89 90 91
Kerry 1974 97 97 92 97 90 91 93 94 94
HSE S Total 10103 96 95 91 96 87 89 91 92 93
HSE W
Galway 3805 97 97 96 97 92 na 95 na 95
Mayo 1708 97 97 94 97 91 na 96 na 93
Roscommon 889 98 98 97 98 96 na 98 na 97
HSE W Total 6402 97 97 96 97 92 na 96 na 95
Ireland 71848 96 96 92 95 88 91 92 93 93
* As the denominator/number in cohort varied slightly according to vaccine the D3, T3 and P3 cohorts are shown here
Since T3, P3 and Polio3 uptake identical to D3 uptake only D3 uptake figures are presented
Please note while North Lee and South Lee are two separate Local Health Offices their combined immunisation uptake data are reported here
data on MenCb (one dose of MenC on or after first 
birthday and before second birthday) and PCVb (one 
dose of PCV on or after first birthday and before second 
birthday) in 2014. The available data may be around 
81% (estimate only) of the national birth cohort. Where 
data were available, national uptake was 91% for MenCb 
and 93% for PCVb at 24 months of age (table 3).
Among the HSE Areas uptake rates for D3, T3, P3, Hib3, 
Polio3 and HepB3 ranged from 95% to 98%, MMR1 
ranged from 92% to 97%, PCV3 ranged from 91% to 
96%, Hibb ranged from 89 to 98% and MenC3 ranged 
from 87% to 93% (table 3). Among the six Areas in a 
position to provide data PCVb uptake ranged from 92% 
to 97% and MenCb uptake ranged from 89% to 95% 
(table 3). 
The target uptake of ≥95% was reached in all eight HSE 
Areas during 2014 for D3, T3, P3, Hib3, Polio3 and HepB3, 
in three HSE Areas for Hibb and PCVb, in two for PCV3 
and MMR1, in one for MenCb and in none for MenC3 
(table 3). 
D3, Hibb, MenC3 and MMR1 uptake rates are mapped 
by LHO in figure 2. Among the LHOs the uptake rates 
ranged from 93% to 98% for D3, T3, P3, Hib3, Polio3 and 
HepB3, 90% to 97% for MMR1 and PCVb, 88% to 98% for 
PCV3, 86% to 98% for Hibb, 85% to 95% for MenCb and 
84% to 96% for MenC3 (table 3). 
The target uptake of  ≥95% was reached in 25 LHOs 
for D3, T3, P3, Polio3 and HepB3, in 24 LHOs for Hib3, in 
seven LHOs for MMR1, in six LHOs for Hibb and PCVb, in 
four LHOs for PCV3, in three LHOs for MenCb and in one 
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Figure 1. National annual immunisation uptake rates (based on available data) at 24 months, 1999-2014
Since T3 and Polio3 uptake identical to D3 uptake only D3 uptake figures presented.
P3 uptake could not be calculated accurately during 1999-2001 as DTaP/DT uptake was reported as a combined value for the HSE 
NE during 1999, Quarters 3 and 4 2000 and Quarter 1 2001 and the HSE NW in 2000 and 2001. The 2002 MenC3  figure is based on 
uptake rates for Quarter 3 and Quarter 4 2002 only. The 2005 MMR1 uptake figure is incomplete as the HSE E was unable to provide 
MMR data for Quarter 4 2005, due to technical problems.  The 2006 MMR1 figure includes the Quarter-1 2006 HSE E figure, which is 
an estimate only due to technical problems.  The 2007 national Hibb figure is incomplete, as the HSE W data for Quarter 1 2007 and 
the HSE NW data for Quarter 3 2007 were not available.  The 2007 national Hibb figure also includes the HSE SE data which are an 
underestimate due to data extraction methods.  The 2008 Hibb figure is incomplete as the HSE SE data for Q2 2008 and the HSE MW 
data for Quarter 3 2008 were not available.  The 2008 national MenC3 figure is incomplete as the HSE E and HSE MW MenC3 data for 
Quarter 3 2008 were not available. The 2009 data are incomplete as the following were unavailable: the Quarter 1 2009 HSE E D3, T3, 
P3 and Polio3 data for those born on the 31/03/2007; the Quarter 2 2009 HSE E Dublin North Hibb uptake data and; the Quarter 4 2009 
HSE MW data, HSE E Dublin North Hibb data and HSE SE Hibb data for those given a Hib dose as part of the five in one or six in one 
vaccine after 12 months of age.  The 2010 data are incomplete as the following were unavailable: the Quarter 1 2010 HSE M and HSE S 
data and the HSE E Dublin North Hibb data; the Quarter 2 2010 HSE M data and; the Quarter 4 2010 HSE NE data. As a new childhood 
immunisation schedule was introduced in 2008, for those born on or after July 1st 2008, the 2010 HepB3 and PCV3 data at 24 months 
are for those born between July 1st and December 31st 2008 (i.e. Quarters 3 and 4 2010 data) only.  The MenCb and PCVb data were 
available for only six of the eight HSE Areas.
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Figure 2. D3, Hibb, MenC3 and MMR1 immunisation uptake rates (%) in those 24 months of age in 2014 by Local 
Health Office (LHO)
LHOs in Dublin are highlighted separately for ease of viewing
North Lee and South Lee are separate LHOs, however, their combined (labelled NSL on the map) immunisation uptake rate is reported here
Please see table 4 to translate LHO abbreviations
D3 Hibb
MenC3 MMR1 
LHO for MenC3 (table 3). Roscommon was the only LHO 
to reach the target of ≥95% for D3, T3, P3, Hib3, Polio3, 
HepB3, Hibb, MenC3, PCV3 and MMR1 for children at 24 
months (table 3).
Conclusion
National immunisation uptake rates, in children at 12 
months of age in 2014, were 92% for D3, T3, P3, Hib3, 
Polio3, HepB3, MenC2 and PCV2.  Based on available 
data uptake of BCG was 87%. The HSE Midland Area 
was the only Area to reach the target uptake rate of 
≥95% for all vaccines among children at 12 months of 
age. Among the LHOs, Roscommon had the highest 
uptake (97%) of D3, T3, P3, Hib3, Polio3, HepB3, MenC2 
and PCV2 at 12 months of age.
In 2014, national uptake rates at 24 months for MenC3 
(88%), Hibb (92%), PCV3 (92%) and MMR1 (93%) were 
lower than the target uptake of ≥95%. In 2014, national 
uptake rates at 24 months of age for D3, T3, P3, Hib3, 
Polio3 and HepB3 reached the target rate of ≥95%. This 
is the fourth year national annual uptake rates reached 
the target of ≥95% for these vaccines. All eight HSE 
Areas reached the target uptake of ≥95% for D3, T3, 
P3, Hib3, Polio3 and HepB3 at 24 months during 2014. 
The target uptake of ≥95% was reached in three HSE 
Areas for Hibb and PCVb, in two HSE Areas for PCV3 and 
MMR1 and in one for MenCb. Roscommon was the only 
LHO to reach the target of ≥95% for D3, T3, P3, Hib3, 
Polio3, HepB3, MenC3, PCV3, Hibb and MMR1 uptake at 
24 months of age.
 
-129-HPSC Annual Epidemiological Report 2014 8. Immunisation Uptake
Table 4. Local Health Office (LHO) abbreviations used in this 
chapter
Local Health Office 
Abbreviations 
Local Health Office
CE Clare
CN/MN Cavan/Monaghan
CW/KK Carlow/Kilkenny
DL Donegal
DN Dublin North
DNC Dublin North Central
DNW Dublin North West
DS Dublin South
DSC Dublin South City
DSE Dublin South East
DSW Dublin South West
DW Dublin West
G Galway
KE/WW Kildare/West Wicklow 
KY Kerry
L Limerick
LD/WD Longford/Westmeath
LH Louth
LS/OY Laois/Offaly
MH Meath
MO Mayo
NC North Cork
NSL* North South Lee*
RN Roscommon
SO/LM Sligo/Leitrim
TN/EL Tipperary North /East Limerick
TS South Tipperary
WC West Cork
WD Waterford
WX Wexford
WW Wicklow 
*Please note while North Lee and South Lee are two separate LHOs 
their combined immunisation uptake data are reported 
Quarterly Reports
The immunisation reports for Quarters 1 to 4 2014 are 
available on the HPSC website in Topics A-Z under the 
heading vaccination. 
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Background
Following a recommendation from the National 
Immunisation Advisory Committee, that human 
papillomavirus (HPV) vaccine should be given to 12 
year old girls, a routine HSE school HPV vaccination 
programme began in May 2010 for girls in the first 
year of second level school and age equivalent in non-
second level schools (see below for cohort details). 
The aim of the programme is to protect girls from their 
future risk of developing cervical cancer. 
A catch-up campaign for girls in sixth year of second 
level schools and their age equivalents in non-second 
level schools (see below for cohort details) was added in 
the academic year 2011/2012. This catch-up campaign 
continued during the academic years 2012/2013 and 
2013/2014.
Quadrivalent HPV vaccine, which protects against HPV 
types 6, 11, 16 and 18 associated with 70% of cervical 
cancer, is used in the school vaccination programme. 
A schedule of three vaccine doses given over a six 
month period was recommended in the academic year 
2013/2014. The HPV vaccine does not protect against 
all cervical cancers, so regular cervical screening is still 
needed.  
The vaccinations are provided by vaccination teams 
from the Local Health Offices (LHOs) who go into 
schools in their areas to vaccinate or provide vaccination 
clinics free of charge for girls in the target cohorts. 
Please see the HSE-National Immunisation Office (NIO) 
website at http://www.hse.ie/eng/health/immunisation/ 
for detailed and current information on the HPV school 
vaccination programme.  
The target for uptake of three doses of vaccine for the 
routine HPV vaccination programme in 2013/2014 was 
≥80%.
HPV vaccinations provided through the schools 
immunisation programme are entered into the School 
Immunisation System (SIS). Here we report on the 
uptake of HPV vaccine, provided through the school 
immunisation programme and recorded on SIS, in the 
academic year 2013/2014 in Ireland. 
The data presented here are the result of collaboration 
between NIO, school immunisation teams, immunisation 
coordinators, immunisation system administrators, 
immunisation administrative staff and HPSC.
Cohorts for vaccination in the academic year 
2013/2014
The routine and catch-up cohorts for the 2013/2014 
HPV vaccination programme as agreed with the 
Department of Education and Skills was as follows: 
Routine HPV Vaccination programme 
●  All girls in first year of second level schools 
●  and their equivalents i.e. those who were born 
between 01/09/2001 and 31/08/2002
 o  attending special schools or
 o   registered with the National Educational Welfare 
Board to be home schooled.
Catch up HPV Vaccination Programme 
●  All girls in sixth year of second level schools 
●  and their equivalents i.e. those who were born 
between 01/09/1995 and 31/08/1996 and
 o  attending special schools or
 o  registered with the National Educational 
Welfare Board to be home schooled or
 o  attending Youthreach and Community Training 
8.2 HPV vaccine uptake 2013/2014
Summary
In the academic year 2013/2014, 84.9% of girls in 
first year and 44.6% of girls in sixth year in second 
level schools were recorded as having received 
at least stage 3 HPV vaccine (considered to have 
completed a three dose HPV vaccine course).
In addition, 201 girls in the first year and sixth 
year age equivalent cohorts in non-second level 
schools (ie special schools, Youthreach, Community 
Training Centres, home schooled or out of school) 
and 138 girls outside the cohorts recommended for 
vaccination were recorded as having received at least 
stage 3 HPV vaccine.
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Centres funded by the Department of Education 
and Skills.
●  A large proportion of sixth year girls in the academic 
year 2013/2014 were previously targeted for 
vaccination at the start of the HSE school programme 
in the academic years 2009/2010 and 2010/2011 ie 
girls who were in sixth year but did not do transition 
year were previously targeted for vaccination. 
Previously vaccinated girls were not vaccinated as part 
of the 2013/2014 school programme. 
Terminology used in this report
At least stage 1 - means a girl had a stage 1 HPV 
vaccine recorded on SIS, this girl may or may not have 
had a stage 2 or a stage 3 HPV vaccine recorded on SIS.
At least stage 2 - means a girl had a stage 2 HPV 
vaccine recorded on SIS, she may or may not have had 
stage 1 or a stage 3 HPV vaccine recorded on SIS.
At least stage 3 - means a girl had a stage 3 HPV 
vaccine recorded on SIS, she may or may not have had a 
stage 1 or a stage 2 HPV vaccine recorded on SIS.
Girls with at least stage 3 are considered to have 
completed a course of vaccination.
Home schooled - refers to girls registered with the 
National Educational Welfare Board to be educated at 
home. These girls were recorded on SIS and reported 
here as home schooled.
Out of school - refers to vaccinated girls who were 
neither enrolled in a second level school, special 
school, Youthreach or Community Training Centre nor 
registered with the National Educational Welfare Board 
as home schooled.
Local Health Office (LHO) - refers to the LHO the 
school is located in (it does not refer to the LHO the girl 
is resident in).
Outside cohort - refers to those who were vaccinated 
but who were not in first year or sixth year of second 
level schools or their equivalents in non-second level 
schools ie they were outside the cohorts recommended 
for vaccination.
The denominator for girls in second level schools was 
defined as the number of girls on the school roll on 30th 
September 2013 for first year in the routine programme 
and for sixth year in the catch-up programme. The 
denominator for age equivalent to first years in second 
level schools in the routine programme was defined 
as girls born between 01/09/2001 and 31/08/2002 on 
the school roll of special schools or registered with the 
National Educational Welfare Board on 30th September 
2013. The denominator for age equivalent to sixth years 
in second level schools in the catch-up programme 
was defined as girls born between 01/09/1995 and 
31/08/1996 on the school roll of special schools or 
registered with the National Educational Welfare Board 
or attending Community Training Centres or Youthreach 
on 30th September 2013. All the denominator data was 
entered on SIS by the relevant System Administrator.
Results
Academic Year 2013/2014
The figures presented in this summary are based on 
data recorded on SIS on the 30th June 2015. These 
figures are subject to change due to ongoing updating 
of data on SIS.
First year girls in second level schools
In Ireland, 84.9% of girls in first year in second level 
schools were recorded as having received at least HPV 
stage 3 (considered to have completed a three dose 
course) (Table 1). This is an increase of 0.7% compared 
to the academic year 2012/2013 when 84.2% of girls 
in first year in second level schools were recorded as 
having received at least HPV stage 3.1Among the 32 
LHOs, in the academic year 2013/2014, uptake of at 
least HPV stage 3 ranged from 71.3% to 89.7%; with 29 
reaching the target of ≥80% uptake.  
Sixth year girls in second level schools
In Ireland, 44.6% of girls in sixth year in second level 
schools were recorded as having at least HPV stage 3 
(Table 2). A large proportion of sixth year girls in the 
academic year 2013/2014 were previously targeted for 
vaccination at the start of the HSE school programme in 
the academic years 2009/2010 and 2010/2011 ie girls in 
sixth year who did not do transition year were previously 
targeted for vaccination. These vaccinated girls would 
be included in the denominator data but not in the 
numbers vaccinated as they were not vaccinated as part 
of the 2013/2014 school programme. In the academic 
year 2012/2013, 67.4% of girls in sixth year in second 
level schools were recorded as having received at least 
HPV stage 3.1
First and Sixth year second level equivalent cohorts in 
non-second level schools/Outside cohort/Out of school
An additional 339 girls were recorded as having 
received at least HPV stage 3 (Table 3); of these 201 
were recorded in the first year routine and sixth year 
catch up age equivalent cohorts in special schools, 
Youthreach, Community Training Centres, home 
schooled or out of school and 138 were recorded 
as being outside the cohorts recommended for 
vaccination. 
The target cohort of girls in special schools, Community 
Training Centres, Youthreach, and home schooled 
were identified by birth cohort either equivalent to first 
years (born between 01/09/2001 and 31/08/2002) or 
equivalent to sixth years (born between 01/09/1995 and 
31/08/1996). For operational reasons HSE vaccinating 
staff did not adhere strictly to these birth cohorts. Some 
of the vaccinations in these school settings were actually 
‘outside cohort’. The identification of denominator data 
for the target birth cohorts in these settings was difficult 
and staff focused on vaccinations rather than defining 
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Table 1. HPV vaccine uptake in the academic year 2013/2014 among first year girls (routine HPV programme) in second level 
schools
HSE 
Region
Local Health Office/
HSE Region
2013/2014
First year (routine HPV vaccination programme)**
Denominator
Numbers vaccinated with: % Vaccinated with:
At least 
Stage 1
At least 
Stage 2
At least 
Stage 3
At least 
Stage 1
At least 
Stage 2
At least 
Stage 3
Dublin 
Mid 
Leinster
Dublin South 969 842 834 821 86.9% 86.1% 84.7%
Dublin South East 596 505 501 490 84.7% 84.1% 82.2%
Dublin South City 806 703 702 681 87.2% 87.1% 84.5%
Dublin South West 800 715 705 671 89.4% 88.1% 83.9%
Dublin West 1041 931 926 898 89.4% 89.0% 86.3%
Kildare/West Wicklow 1639 1507 1489 1438 91.9% 90.8% 87.7%
Wicklow 749 643 639 623 85.8% 85.3% 83.2%
Laois/Offaly 1103 936 931 909 84.9% 84.4% 82.4%
Longford/Westmeath 1024 928 921 907 90.6% 89.9% 88.6%
Total Dublin Mid Leinster 8727 7710 7648 7438 88.3% 87.6% 85.2%
Dublin 
North 
East
Dublin North 1576 1475 1432 1368 93.6% 90.9% 86.8%
Dublin North Central 652 537 517 465 82.4% 79.3% 71.3%
Dublin North West 1260 1262 1215 951 100.2% 96.4% 75.5%
Cavan/Monaghan 863 758 752 734 87.8% 87.1% 85.1%
Louth 999 880 869 837 88.1% 87.0% 83.8%
Meath 1259 1156 1146 1128 91.8% 91.0% 89.6%
Total Dublin North East 6609 6068 5931 5483 91.8% 89.7% 83.0%
South
North Cork 606 536 530 503 88.4% 87.5% 83.0%
North Lee - Cork 1181 1058 1048 1012 89.6% 88.7% 85.7%
South Lee - Cork 1192 1086 1078 1037 91.1% 90.4% 87.0%
West Cork 377 291 291 288 77.2% 77.2% 76.4%
Kerry 918 775 768 756 84.4% 83.7% 82.4%
Carlow/Kilkenny 970 891 882 850 91.9% 90.9% 87.6%
South Tipperary 517 478 468 441 92.5% 90.5% 85.3%
Waterford 822 744 738 730 90.5% 89.8% 88.8%
Wexford 1045 919 908 868 87.9% 86.9% 83.1%
Total South 7628 6778 6711 6485 88.9% 88.0% 85.0%
West
Donegal 1103 983 977 968 89.1% 88.6% 87.8%
Sligo/Leitrim 604 549 544 542 90.9% 90.1% 89.7%
Galway 1619 1445 1442 1406 89.3% 89.1% 86.8%
Mayo 913 774 767 737 84.8% 84.0% 80.7%
Roscommon 338 299 299 297 88.5% 88.5% 87.9%
Clare 772 680 680 677 88.1% 88.1% 87.7%
Limerick 1021 894 875 847 87.6% 85.7% 83.0%
Tipperary NR/
East Limerick
955 860 847 829 90.1% 88.7% 86.8%
Total West 7325 6484 6431 6303 88.5% 87.8% 86.0%
Ireland 30289 27040 26721 25709 89.3% 88.2% 84.9%
The figures presented in this table are based on data recorded on the School Immunisation System (SIS) on the 30th June 2015. These figures 
are subject to change due to ongoing updating of data on SIS.
Local Health Office refers to the Local Health Office of the school.
‘At least stage 1’ means a girl had a stage 1 HPV vaccine recorded on SIS, this girl may or may not have had a stage 2 or a stage 3 HPV vaccine 
recorded on SIS. Similarly, ‘at least stage 2’ means a girl had a stage 2 HPV vaccine recorded on SIS, she may or may not have had a stage 1 or 
a stage 3 HPV vaccine recorded on SIS. Similarly, ‘at least stage 3’ means a girl had a stage 3 recorded on SIS, she may or may not have had a 
stage 1 or a stage 2 HPV vaccine recorded.
**Please see the background section of this report for details of the cohorts recommended HPV vaccine during the academic year 2013/2014.
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Table 2. HPV vaccine uptake in the academic year 2013/2014 among sixth year (catch up campaign) girls in second 
level schools
HSE 
Region
Local Health Office/
HSE Region
2013/2014
Sixth year (catch up campaign)**
Denominator
Numbers vaccinated with: % Vaccinated with:
At least 
Stage 1
At least 
Stage 2
At least 
Stage 3
At least 
Stage 1
At least 
Stage 2
At least 
Stage 3
Dublin Mid 
Leinster
Dublin South 894 560 550 537 62.6% 61.5% 60.1%
Dublin South East 634 363 361 353 57.3% 56.9% 55.7%
Dublin South City 751 451 439 408 60.1% 58.5% 54.3%
Dublin South West 718 279 264 231 38.9% 36.8% 32.2%
Dublin West 828 455 434 398 55.0% 52.4% 48.1%
Kildare/West Wicklow 1257 525 515 465 41.8% 41.0% 37.0%
Wicklow 592 361 354 330 61.0% 59.8% 55.7%
Laois/Offaly 840 322 317 303 38.3% 37.7% 36.1%
Longford/Westmeath 900 346 340 326 38.4% 37.8% 36.2%
Total Dublin Mid Leinster 7414 3662 3574 3351 49.4% 48.2% 45.2%
Dublin 
North East
Dublin North 1198 409 383 344 34.1% 32.0% 28.7%
Dublin North Central 516 299 264 244 57.9% 51.2% 47.3%
Dublin North West 1024 325 306 295 31.7% 29.9% 28.8%
Cavan/Monaghan 891 477 476 463 53.5% 53.4% 52.0%
Louth 831 191 184 172 23.0% 22.1% 20.7%
Meath 968 286 282 271 29.5% 29.1% 28.0%
Total Dublin North East 5428 1987 1895 1789 36.6% 34.9% 33.0%
South
North Cork 565 258 255 244 45.7% 45.1% 43.2%
North Lee - Cork 1147 703 697 677 61.3% 60.8% 59.0%
South Lee - Cork 1025 752 747 716 73.4% 72.9% 69.9%
West Cork 297 133 133 131 44.8% 44.8% 44.1%
Kerry 840 248 248 248 29.5% 29.5% 29.5%
Carlow/Kilkenny 911 486 474 455 53.3% 52.0% 49.9%
South Tipperary 542 266 257 249 49.1% 47.4% 45.9%
Waterford 768 448 444 432 58.3% 57.8% 56.3%
Wexford 939 320 312 293 34.1% 33.2% 31.2%
Total South 7034 3614 3567 3445 51.4% 50.7% 49.0%
West
Donegal 1025 456 454 447 44.5% 44.3% 43.6%
Sligo/Leitrim 579 287 284 284 49.6% 49.1% 49.1%
Galway 596 524 517 498 87.9% 86.7% 83.6%
Mayo 831 473 471 456 56.9% 56.7% 54.9%
Roscommon 316 140 138 136 44.3% 43.7% 43.0%
Clare 569 147 148 144 25.8% 26.0% 25.3%
Limerick 843 494 484 442 58.6% 57.4% 52.4%
Tipperary NR/
East Limerick
886 425 419 402 48.0% 47.3% 45.4%
Total West 5645 2946 2915 2809 52.2% 51.6% 49.8%
Ireland 25521 12209 11951 11394 47.8% 46.8% 44.6%
The figures presented in this table are based on data recorded on the School Immunisation System (SIS) on the 30th June 2015. These figures 
are subject to change due to ongoing updating of data on SIS.
Local Health Office refers to the Local Health Office of the school.
‘At least stage 1’ means a girl had a stage 1 HPV vaccine recorded on SIS, this girl may or may not have had a stage 2 or a stage 3 HPV vaccine 
recorded on SIS. Similarly, ‘at least stage 2’ means a girl had a stage 2 HPV vaccine recorded on SIS, she may or may not have had a stage 1 or 
a stage 3 HPV vaccine recorded on SIS. Similarly, ‘at least stage 3’ means a girl had a stage 3 recorded on SIS, she may or may not have had a 
stage 1 or a stage 2 HPV vaccine recorded.
**Please see the background section of this report for details of the cohorts recommended HPV vaccine during the academic year 2013/2014.
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Table 3. HPV vaccinations in the academic year 2013/2014 among those in non-second level schools and those outside the 
recommended cohorts in second level schools
HSE 
Region
Local Health Office/
HSE Region
Recommended cohorts** for vaccination and those outside cohort in special 
schools, Youthreach, Community Training Centres, home schooled and out of 
school and those outside cohort in second level schools with:
At least Stage 1 At least Stage 2 At least Stage 3
Dublin Mid 
Leinster
Dublin South 23 22 19
Dublin South East 13 13 12
Dublin South City 1 1 1
Dublin South West 12 11 8
Dublin West 24 19 19
Kildare/West Wicklow 20 14 8
Wicklow 19 19 17
Laois/Offaly 7 6 5
Longford/Westmeath 19 19 18
Total Dublin Mid Leinster 138 124 107
Dublin 
North East
Dublin North 3 3 3
Dublin North Central 4 1 0
Dublin North West 3 1 1
Cavan/Monaghan 17 16 14
Louth 10 10 9
Meath 19 17 14
Total Dublin North East 56 48 41
South
North Cork 7 6 5
North Lee - Cork 19 18 17
South Lee - Cork 23 24 22
West Cork 2 1 1
Kerry 2 2 2
Carlow/Kilkenny 16 14 11
South Tipperary 8 7 6
Waterford 36 32 32
Wexford 14 13 11
Total South 127 117 107
West
Donegal 16 16 13
Sligo/Leitrim 5 5 5
Galway 13 11 9
Mayo 9 9 3
Roscommon 3 3 3
Clare 14 11 9
Limerick 34 30 27
Tipperary NR/East Limerick 17 14 13
Total West 111 99 82
Home schooled 2 1 1
Total of LHOs and home schooled 434 389 338
Out of school 1 1 1
Total of LHOs and home schooled and out of School 435 390 339
The figures presented in this table are based on data recorded on the School Immunisation System (SIS) on the 30th June 2015. These figures 
are subject to change due to ongoing updating of data on SIS.
Local Health Office refers to the Local Health Office of the school.
‘At least stage 1’ means a girl had a stage 1 HPV vaccine recorded on SIS, this girl may or may not have had a stage 2 or a stage 3 HPV vaccine 
recorded on SIS. Similarly, ‘at least stage 2’ means a girl had a stage 2 HPV vaccine recorded on SIS, she may or may not have had a stage 1 or 
a stage 3 HPV vaccine recorded on SIS. Similarly, ‘at least stage 3’ means a girl had a stage 3 recorded on SIS, she may or may not have had a 
stage 1 or a stage 2 HPV vaccine recorded.
**Please see the background section of this report for details of the cohorts recommended HPV vaccine during the academic year 2013/2014.
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cohort numbers accurately. Therefore, this report 
gives the number of girls vaccinated in these settings 
reflecting activity in these settings rather than HPV 
vaccine uptake.
Total doses administered
A total of 116,198 administered vaccine doses were 
recorded in the academic year 2013/2014. This 
compares to 132,925 and 139,646 administered 
vaccine doses recorded in 2012/2013 and 2011/2012, 
respectively.
Academic Years 2009/2010 and 2010/2011
Uptake for 2009/2010 and 2010/2011 cohorts of first 
year girls vaccinated from May 2010 was measured by 
manual reports and national uptake for the combined 
cohort was estimated at 81.9%.2
Discussion
The uptake of HPV vaccine in Ireland is very 
encouraging and reflects the huge effort and support 
put in by all staff and schools involved in the school 
vaccination programme. Uptake of HPV vaccine 
compares very favourably with estimates in other 
countries that have introduced HPV vaccination and 
monitored uptake.3,4,5,6
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Summary
 Uptake in Hospitals during 2014-2015 Season
•   79.7% (47/59) of known hospitals (including six 
private ones) participated in the 2014-2015 survey
•   Nationally, influenza vaccine uptake among all 
categories of hospital HCWs was 23.4% (based on 
45 complete returns)
•   Uptake varied by HSE region (range 13.3%-30.6%)
•   Highest uptake was reported in Dublin Mid-
Leinster
•   At national level, uptake varied by HSE staff 
category (17.1-36.4%), the highest uptake was 
reported among ‘medical and dental’ professionals 
and lowest among ‘nursing’ staff
Uptake in LTCFs during 2014-2015 Season
•   41.7% (101/242 known LTCFs) participated in the 
2014-2015 survey 
•   Nationally, influenza vaccine uptake among LTCF 
HCWs was 25.7% (based on 91 complete returns)
•   Uptake varied by HSE region (range 17.0%-36.1%)
•   Highest uptake was reported in Dublin North-East
•   At national level, uptake varied by HSE staff 
category (range 22.8%-41.5%); the highest uptake 
was in the ‘medical and dental’ category and 
lowest among ‘general support’ staff
Seasonal influenza vaccination is recommended to 
reduce influenza infection in individuals aged six months 
and older who are at increased risk of influenza related 
complications (including all elderly), those likely to 
transmit influenza to individuals at high risk for influenza 
complications (including health care workers (HCWs), 
household contacts of at-risk persons and out of home 
carers to at-risk persons), pregnant women at any stage 
in pregnancy and those who have close regular contact 
with pigs, poultry or water fowl. The HSE procures and 
provides free influenza vaccine to all those for whom 
vaccination is recommended. For HCWs, influenza 
vaccination is typically provided by occupational health 
services, either within the facilities, or contracted by the 
facility to provide these services. 
Influenza vaccination uptake among HCWs is of 
particular interest as influenza transmission between 
patients and HCWs can occur in the health care setting. 
Influenza can cause severe disease in both patients 
and staff and infection can spread rapidly in health 
care settings. Achieving a high uptake of influenza 
vaccination among HCWs is therefore recognised 
as an important infection control intervention and 
occupational health issue. Since October 2013 the HSE 
Leadership team has recommended a national influenza 
vaccination target of 40% among HCWs.
Since the 2011-2012 influenza season, HPSC has 
collected data on seasonal influenza vaccination 
coverage among hospitals and long term care facilities 
(LTCFs). Each year since then a protocol has been 
provided to all facilities outlining the rationale and 
methodology for data collection. For the 2014-2015 
season, a similar protocol as used for previous years 
was distributed to all facilities and posted on the HPSC 
website. Separate online survey forms for hospitals 
and LTCFs were designed to capture aggregate data 
on eligible and vaccinated staff and were based on six 
categories of HSE staff: management & administration; 
8.3  Seasonal Influenza Vaccine Uptake 
in Hospitals & Long Term Care 
Facilities (LTCFs)
Table 1. Vaccine uptake (with 95% CIs) among HCWs in 21 hospitals by season (2011-2012, 2012-2013, 2013-2014 and 2014-
2015)*
Season No. Eligible Staff No. Vaccinated Staff % Uptake % Uptake 95% CIs
2011-2012 30939 5618 18.2 17.7-18.6
2012-2013 30393 6085 20.0 19.6-20.5
2013-2014 30619 7842 25.6 25.1-26.1
2014-2015 32185 8784 27.3 26.8-27.8
*Results based on complete returns consisting of eligible and vaccinated staff numbers by HSE grade in 21 hospitals that reported back in each 
survey over the past four seasons
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medical & dental; nursing; health & social care 
professionals; other patient & client care; and general 
support staff. 
For hospitals, occupational health departments were 
asked to provide data on the number and category 
of HCWs vaccinated by the service (numerator). The 
human resource (HR) departments were requested 
to provide data on the numbers of staff employed 
(denominator). For LTCFs, uptake details were sought 
from nominated coordinators (or other named contacts) 
on the number of staff, residents and respite care 
patients present and vaccinated during the influenza 
season. 
For the 2014-2015 season, a link to an online form was 
emailed to each nominated coordinator (or contact 
person) in 59 known public hospitals (including six 
private ones) and separately to 242 HSE funded LTCFs 
on 4th December 2014. Each coordinator was asked 
to complete the online form using aggregate uptake 
data since the beginning of October 2014. A second 
and final survey seeking aggregate data for the entire 
season was sent on 27th April 2015. Reminders were 
sent to non-responders in January (for mid-season data) 
and May (for end of year data). 
For the 2014-2015 influenza season, vaccination uptake 
among HCWs in hospitals and LTCFs was calculated 
based on data provided. Trend analysis for seasonal 
influenza vaccine uptake was limited to those hospitals 
and LTCFs that had reported in each of the previous 
three seasons (2011-2012, 2012-2013 and 2013-2014). 
Uptake trend analysis- consistently reporting facilities
Since 2011-2012, 21 hospitals and 21 LTCFs have been 
able to provide annual data. Between 2013-2014 and 
2014-2015, both groups have increased their uptake by 
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Figure 1. Hospital staff uptake by HSE region by season based 
on 21 reporting hospitals only
Figure 2. Hospital staff uptake by HSE grade category by 
season based on 21 reporting hospitals only
Figure 3. LTCF staff uptake by HSE region by season based on 
21 reporting LTCFs only
Figure 4. LTCF staff uptake by HSE grade category by season 
based on 21 reporting LTCFs only
Table 2. Vaccine uptake (with 95% CIs) among HCWs in 21 LTCFs by season (2011-2012, 2012-2013, 2013-2014 and 2014-
2015)**
Season No. Eligible Staff No. Vaccinated Staff % Uptake % Uptake 95% CIs
2011-2012 1397 352 25.2 22.9-27.5
2012-2013 1405 305 21.7 19.6-23.9
2013-2014 1533 425 27.7 25.5-30.0
2014-2015 1456 500 34.3 31.9-36.8
**Results based on complete returns consisting of eligible and vaccinated staff numbers by HSE grade in 21 LTCFs that reported back in each 
survey over the past four seasons
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1.7% and 6.6% respectively (tables 1, 2). Additionally, 
since 2011-2012, an upward trend in uptake was 
observed among the 21 consistently reporting hospitals 
from 18.2% to 27.3%, a difference of +9.1%. And 
since 2012-2013, the uptake among the consistently 
reporting 21 LTCF increased from 21.7% to 34.3%, a 
difference of +12.6%.
Figures 1 to 4 below give details of vaccine uptake 
among HCWs based in hospitals and LTCFs that 
consistently reported over the past four seasons by 
category of staff and HSE region. 
Uptake reporting for 2014-2015 – all facilities, by 
HSE region and professional category 
In 2014-2015, the overall uptake among 45 hospitals 
(excluding two hospitals in the North-Eastern region 
that reported a combined overall staff uptake figure) 
was 23.4% with the highest uptake reported in Dublin 
Mid-Leinster region (30.6%) and the lowest (13.3%) in 
the Southern region. At national level, hospital staff 
was highest among ‘medical and dental’ professionals 
(36.4%) and lowest among ‘nursing’ staff (17.1%).
The overall uptake among 101 LTCFs in 2014-2015 was 
25.7% with the highest uptake reported in Dublin North 
East region (36.1%) with the lowest in the Southern 
region (17.0%). Uptake at national level was highest in 
the ‘medical and dental’ category (41.5%) and lowest 
among ‘general support’ staff (22.8%).
Although there has been marked improvement in 
uptake, at national and regional level, the 40% target 
has not been met. However, four hospitals achieved 
this target during the 2014-2015 season (range 41.1% 
to 47.5%) and 24 LTCFs also achieved this target 
(range 40.0% to 96.9%) . The incomplete participation 
of hospitals is of concern, assuming that most should 
have information systems to enable them to report. 
Reasons for non-participation need to be explored and 
obstacles to reporting addressed. The low participation 
of LTCFs is also of concern as these units care for 
extremely vulnerable populations and outbreaks among 
these settings spread rapidly and have been related to 
high influenza morbidity and mortality in some years. 
Whether non-participation of many LTCFs reflects a lack 
of information systems to collect and report on vaccine 
uptake or other non-specified reasons is not known to 
HSPC, but further work is needed to identify reasons for 
non-participation and efforts made to support LTCFs in 
collating and reporting this data. 
The national uptake among hospital staff (23.4%) was 
somewhat less than the overall uptake reported among 
LTCFs (25.7%) in 2014-2015. This lack of substantial 
difference occurs against different organisational 
structures for vaccination in these services. Unlike 
many LTCFs, most hospitals have formal occupational 
health services available to hospital staff; however 
this has not translated into overall better coverage 
in hospital staff. With some notable exceptions the 
lack of progress in this area in all regions may reflect 
either a lack of awareness, lack of resources or lack of 
acceptance of vaccination. 1 Reasons for low vaccination 
in each hospital or LTCF should be identified locally if 
improvements are to be made. 
The World Health Organization has stated that annual 
vaccination is especially important for people at 
higher risk of serious influenza complications, and for 
people who live with or care for high risk individuals.2 
In Ireland, more action is required to reach a national 
HSE target of 40% vaccination uptake among HCWs if 
unnecessary disease and mortality is to be prevented. 
Other countries have already achieved uptake rates well 
above our target. For example, during the 2014-2015 
season in England, where vaccination uptake among 
those HCWs with direct patient contact is monitored 
(compared to Ireland where uptake among all HCWs 
is monitored), the reported uptake was 54.9%, similar 
to the previous season (54.8 %).3 In the United States, 
the Centre for Disease Control analysed data from an 
internet panel survey of HCWs conducted from October 
29-November 12, 20144. Early season 2014-2015 
influenza vaccination coverage among HCWs in the 
US was 64.3%, similar to the 62.9% coverage reported 
by early season 2013-20144. Furthermore, vaccination 
coverage among HCWs was found to be highest in 
hospitals (78.7%) and lowest in LTCFs (54.4%).4 In the 
HSE at local level further work is being done across the 
various clinical and management groups to improve 
uptake among HCWs. 
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Vaccine uptake (DTaP-IPV* and MMR†) in Junior 
Infants during the 2013/2014 academic year
Background
Uptake of the DTaP-IPV* and MMR† vaccines in 4-5 
year old schoolchildren was monitored across all 
Local Health Offices (LHOs) during the academic year 
2013/2014. The uptake data were compared to those 
reported for the previous 2012/2013 season, where 
possible.
HSE-school team versus GP-vaccine administered LHOs
In 29 out the 31 LHOs across the country, the junior 
infant vaccination programme is delivered by HSE 
school teams who administer the vaccine to the 
children at school. In the remaining two LHOs, Donegal 
and Sligo/Leitrim, these vaccines are administered 
to children exclusively by GPs rather than by school 
teams. During 2013/2014 however, a combination 
of a School team/GP programme also existed in 13 
HSE-administered LHOs with a percentage of children 
been given vaccines by a GP (tables 1 and 2). During 
2014-2015 most of these areas moved towards a 
predominantly school based administration programme 
for junior infants. 
Target populations
For the 2013/2014 academic year, the target population 
in HSE-vaccine administered LHOs was all children 
in Junior Infants on the school register on the 30th 
September 2013. For GP-vaccine administered LHOs, 
the target population was all children born between the 
1st September 2007 and 31st August 2008. 
The different ways in which the target populations 
have been defined in the HSE- and GP-vaccinated 
administered LHOs has meant that a national uptake for 
either vaccine could not be calculated.
Furthermore, between the 2012/2013 and 2013/2014 
seasons, the following six LHOs changed from being 
GP-administered areas to HSE-administered areas: 
Louth, Cavan/Monaghan, Meath and Dublin North 
Central, Galway and Mayo. This means that comparing 
uptake between seasons in the Dublin North East 
and Western regions is not possible as the criteria for 
defining the birth cohorts in both these regions have 
changed.
Uptake of DTaP-IPV vaccine
Between 2012/2013 and 2013/2014, the uptake of the 
DTaP-IPV vaccine in HSE-vaccine administered LHOs, 
but excluding Louth, Cavan/Monaghan, Meath, Galway, 
Mayo and Dublin North Central, increased from 90.4% 
to 91.9%. In 2013/2014, the average uptake among 
these LHOs was 90.3% with a range from 78.2% in 
Dublin West to 98.8% in Kildare/West Wicklow.
During the same period of time, DTaP-IPV vaccine 
uptake in exclusively GP-vaccine administered LHOs 
(Donegal; Sligo/Leitrim) rose from 90.6% to 92.2%.
Uptake of MMR vaccine
The uptake of the MMR vaccine between 2012/2013 
and 2013/2014 in HSE-vaccine administered LHOs 
(excluding Louth, Cavan/Monaghan, Meath, Galway, 
Mayo and Dublin North Central), rose from 90.5% to 
8.4  Uptake of other childhood and 
adolescent vaccines 
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Table 1. Proportion of DTaP-IPV vaccine uptake in HSE-
administered LHOs attributable to GPs
LHO % DTaP-IPV Vaccine Uptake
Dublin West 2.7%
Louth 64.0%
Meath 47.0%
Cavan/Monaghan 58.0%
Carlow/Kilkenny 3.5%
Tipperary South 3.3%
Wexford % not specified
North Cork 56.0%
Cork North Lee 24.0%
Cork South Lee 10.50%
West Cork 10.80%
Kerry 34.60%
Roscommon <1%
Table 2. Proportion of MMR vaccine uptake in HSE-administered LHOs 
attributable to GPs
LHO % MMR Vaccine Uptake
Dublin West 2.9%
Louth 64.0%
Meath 47.0%
Cavan/Monaghan 58.0%
Carlow/Kilkenny 3.5%
Tipperary South 3.2%
Wexford % not specified
North Cork 56.0%
Cork North Lee 24.0%
Cork South Lee 10.80%
West Cork 10.80%
Kerry 34.60%
Roscommon <1%
0-79
80-84
85-89
90-94
95-100
No Data
      
     
Figure 1. LHO Maps of DTaP-IPV & MMR percentage vaccine 
uptake at Junior Infants level during the 2013/2014 academic 
year 
HSE-DTaP-IPV Vaccine Administered LHOs HSE-MMR Vaccine Administered LHO
GP-DTaP-IPV Vaccine Administered LHOs GP-MMR Vaccine Administered LHOs          
91.6%. In 2013/2014, the average uptake among these 
LHOs was 90.4% with a range from 72% in Galway to 
99.7% in Carlow/Kilkenny.
MMR vaccine uptake in exclusively GP-vaccine 
administered LHOs also increased from 90.3% to 92.7% 
during the same time period.
MMR catch-up vaccination
Eighteen HSE-vaccine administered LHOs identified 
a number of children as needing a catch-up MMR 
dose one month later after been given their first dose. 
The total number of children identified was 127, of 
which 100 (78.7%) received a catch-up vaccine dose, 
ranging from no children in Dublin South, Dublin South 
East, Dublin West, Dublin North East and Louth to 29 
children in Wicklow.
Details of the overall uptake of the two vaccines in the 
HSE- and GP-vaccinated LHOs during 2013/2014 are 
presented in Table 1 and in the maps in Figure 1.
* DTaP-IPV = Diphtheria, Tetanus, acellular Pertussis 
and Polio vaccine
†MMR = Measles, Mumps and Rubella vaccine 
Tdap vaccine uptake during the 2013/2014 academic 
year
The National Immunisation Advisory Committee 
recommends vaccination with tetanus and low-dose 
diphtheria and acellular pertussis (Tdap) vaccine 
at 11-14 years of age. Tdap vaccine uptake in the 
academic year 2013/2014, provided through the 
school immunisation programme for those in first year 
of second level schools and their equivalents in non-
second level schools (i.e. special school, home schooled 
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Table 4. Tdap uptake data in the academic year 2013/2014 (data extracted 20/04/2015)
HSE Region Local Health Office/HSE Region
2013/2014
First year in second level and equivalent in special 
schools, home schooled and out of school Outside cohort
Denominator
Numbers 
vaccinated 
with Tdap:
% Vaccinated 
with Tdap: Denominator
Numbers 
vaccinated 
with Tdap:
Dublin Mid Leinster
Dublin South 2010 1642 81.7% N/A 12
Dublin South East 1157 883 76.3% N/A 3
Dublin South City 1466 1180 80.5% N/A 6
Dublin South West 1762 1362 77.3% N/A 10
Dublin West 2110 1574 74.6% N/A 9
Kildare/West Wicklow 3589 2991 83.3% N/A 8
Wicklow 1420 1212 85.4% N/A 3
Laois/Offaly 2197 1850 84.2% N/A 20
Longford/Westmeath 2090 1937 92.7% N/A 4
Total Dublin Mid 
Leinster 17801 14631 82.2% N/A 75
Dublin North East
Dublin North 3048 2462 80.8% N/A 8
Dublin North Central 1518 1063 70.0% N/A 2
Dublin North West 2476 2299 92.9% N/A 0
Cavan/Monaghan 1756 1319 75.1% N/A 0
Louth 2050 1631 79.6% N/A 0
Meath 2571 2206 85.8% N/A 498
Total Dublin North East 13419 10980 81.8% N/A 508
South
North Cork 1181 955 80.9% N/A 2
North Lee - Cork 2466 2089 84.7% N/A 5
South Lee - Cork 2444 2092 85.6% N/A 2
West Cork 741 643 86.8% N/A 0
Kerry 1856 1587 85.5% N/A 0
Carlow/Kilkenny 1997 1845 92.4% N/A 16
South Tipperary 1147 1032 90.0% N/A 3
Waterford 1720 1625 94.5% N/A 5
Wexford 1976 1767 89.4% N/A 83
Total South 15528 13635 87.8% N/A 116
West
Donegal 2264 2057 90.9% N/A 5
Sligo/Leitrim 1251 1142 91.3% N/A 1
Galway 3089 2537 82.1% N/A 43
Mayo 1759 1453 82.6% N/A 0
Roscommon - - - N/A -
Clare 1418 1209 85.3% N/A 17
Limerick 2185 1511 69.2% N/A 3
Tipperary NR/
East Limerick 1867 1578 84.5% N/A 16
Total West 13833 11487 80.5% N/A 85
Homeschooled 0 3 0 N/A 0
Total of LHOs and home schooled 60581 50736 83.7% N/A 784
Out of School N\A 0 N\A N/A 2
Total of LHOs and home schooled and out of 
school N\A 50736 N\A N/A 786
Outside cohort refers to those who were vaccinated but who were outside the routine cohort for vaccination
Local health office (LHO) refers to the LHO of the school. Therefore, in reports the LHOs of homeschooled and out of school children do not 
appear
N/A-Not applicable
Roscommon Tdap data were excluded as this LHO reported incomplete data entry at the time of data extraction and that a larger number 
were vaccinated than were recorded on the database; therefore their numbers are excluded here from the total denominator and calculation of 
percentage uptake figures.
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and out of school), and recorded on the School 
Immunisation System (SIS) are presented in table 4. The 
vaccinations are provided by vaccination teams from 
the Local Health Offices (LHOs) who go into schools in 
their areas to vaccinate. Data on vaccination is inputted 
into the SIS database at a local level. Please see the 
HSE National Immunisation Office (NIO) website at 
http://www.hse.ie/eng/health/immunisation for detailed 
and current information on the school vaccination 
programme.
The data presented here are the result of collaboration 
between NIO, School Immunisation Teams, 
Immunisation Coordinators, Immunisation System 
Administrators, Immunisation administrative staff and 
HPSC.
The figures presented in this summary are based on 
data recorded on the SIS database on the 20th April 
2015. These figures are subject to change due to on-
going updating of data on the database.
MMR vaccine catch-up campaign
In Ireland the first dose of MMR vaccine is 
recommended for children at 12 months of age. A 
second dose of MMR is recommended at four to five 
years of age. There was a MMR catch-up campaign 
during the 2012/2013 and 2013/2014 academic years. 
During the MMR catch up campaign the HSE offered 
a dose of MMR vaccine to children/students attending 
primary schools, second level schools and special 
schools and home-schooled students who had not 
completed (or were not sure they had) their two dose 
MMR vaccination schedule. In Ireland this campaign 
was in response to measles and mumps outbreaks 
among those who had not received their recommended 
two MMR vaccine doses. It is also part of the World 
Health Organization campaign to eliminate measles 
and congenital rubella. Please see the NIO website 
at http://www.hse.ie/eng/health/immunisation/ 
for detailed and current information on the school 
vaccination programme.
MMR catch-up data entry was not complete at the 
time of writing this report and therefore MMR catch-up 
uptake data are not reported on here.
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Notifiable C. difficile infection 
In May 2008, new cases of CDI in persons two years or 
older became notifiable in Ireland under the disease 
category “acute infectious gastroenteritis” (AIG). Since 
January 2012, CDI has become a notifiable infection in 
its own category, with both new and recurrent CDI cases 
now notifiable. 
In 2014, 1,802 cases of CDI were notified to Public 
Health Departments via the Computerised Infectious 
Diseases Reporting (CIDR) system. Of those, 1,613 
(89.5%) were classified as new, 155 (8.5%) as recurrent, 
with 34 (2%) of unknown case type. All cases were 
laboratory-confirmed.
The national crude incidence rate (CIR) of new CDI 
cases in 2014 was 35.1 per 100,000 population, a 
decrease of 3.3% from 37.5 per 100,000 population 
in 2013. Taking both new and recurrent cases into 
account, the overall CIR for 2014 was 38.5 per 100,000 
population, which is lower than the reported rate in 
2013 (41.3).
Since surveillance began in 2008, there has been a 
decrease in the incidence of CDI in Ireland (Figure 1). 
Since 2012, the CDI incidence rate has remained stable. 
There was a slight increase in the number of recurrent 
cases notified in 2014 (n=155) compared to 2013 
(n=146). Identification of seasonal patterns from CIDR 
notification data is hindered by delayed and batched 
laboratory notifications.
Figure 2 displays the gender and age breakdown of 
patients with CDI. The majority were female (61%). The 
9.1 Clostridium difficile Infection
Key Points
•   In 2014, 1,802 cases of Clostridium difficile 
infection (CDI) were notified. Of those, 1,613 
(89.5%) were classified as new cases, 155 
(8.5%) as recurrent, with 34 (2%) of unknown 
case type. This represents a national crude 
incidence rate of 38.5 cases per 100,000 
population, which represents a small decrease 
compared to the rate reported in 2013 (41.3)
•   Of the 1,802 CDI cases, 1,202 (67%) were 
reported from patients aged 65 years or older
•   The voluntary enhanced CDI surveillance 
scheme received information on 1,780 CDI 
cases from 53 hospitals, covering 94% of all 
cases notified to Public Health Departments. 
Of those, 1,131 were healthcare-associated, 
representing a national CDI incidence rate of 
2.9 cases per 10,000 bed days used for 2014, 
an increase from 2.4 in 2013 
•   Data collected on patient location at symptom 
onset highlights that CDI is not confined to 
acute healthcare facilities. It is commonly 
encountered in long term care facilities (7% of 
all CDI) and in the community (34% of all CDI) 
•   Of 290 C. difficile isolates with available 
ribotyping data (16% of all cases) reported 
from 20 hospitals, the most frequent ribotypes 
reported in 2014 were: 078 and 014 (both 
n=31; 11%), 015 (n=27, 9%) and 005 (n=18, 
6%).
Figure 1. Numbers of CDI notifications by month and case type 
(2008 – 2014)
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mean age was 67 years (range: 2 – 100 years), with 
1,202 cases (67%) reported in patients aged 65 years 
and older.  
* Rates calculated using 2011 census data  
Regarding patient location at the time of CDI diagnosis, 
most were classified as ‘hospitalised’ (72%), with 
13% from general practice, 6% from the emergency 
department, 4% from outpatients or day patients and 
4% from either ‘other’, or ‘unknown’ patient location. 
This is similar to that reported in 2013. However, this 
data does not provide information on the origin or 
onset of CDI, as that information is collected as part of 
the enhanced CDI surveillance scheme. 
In 2014, 22 deaths were reported in patients with CDI, 
which is lower than that reported in 2013. One death 
was attributed to CDI, 12 were not attributed to CDI 
and for the remaining 9 deaths, the contribution of CDI 
to death was unknown. 
Notifiable C. difficile infection: Outbreaks
In 2014, 10 CDI outbreaks, nine of which were 
healthcare-associated and involving 43 patients, were 
notified to Public Health Departments as displayed in 
Table 1. Four were linked to hospitals, three to nursing 
homes, two to residential institutions, and one specified 
as “other”.
Enhanced surveillance of C. difficile infection
Although notifiable CDI data provides important 
preliminary information on the burden of CDI in Ireland, 
it represents an underestimate of the true burden of 
CDI, as it does not capture information on the origin, 
onset or severity of CDI. National collation of C. difficile 
enhanced surveillance information commenced on a 
voluntary basis on 1st August 2009. Information on case 
type, origin, onset and infection severity is collected 
using the European Society for Clinical Microbiology 
and Infectious Diseases Study Group on C. difficile 
(ESCMID-ESGCD) interim case definitions. To the end 
of 2014, 53 acute hospitals participated in the voluntary 
enhanced surveillance CDI scheme, comprising 45 
(94%) public hospitals [27 general (100%), nine tertiary 
(100%) and nine specialist hospitals (75%)] and eight 
private hospitals (67%). 
In 2014, 1,780 CDI cases were reported to the 
enhanced surveillance scheme (94% of all the CDI cases 
notified via CIDR). Of those, 1,522 (86%) were classified 
as new, 149 (8%) as recurrent and 109 (6%) of unknown 
CDI case type. 
Of the reported cases, 48% (n=860) originated within 
the reporting healthcare facility. The overall national 
CDI incidence rate of new and recurrent cases 
combined, acquired within the reporting healthcare 
facility was 2.2 cases per 10,000 bed days used (BDU), 
a decrease from 2.4 in 2013. The incidence rate of new 
CDI was 2.1 cases per 10,000 BDU, a decrease from 2.2 
in 2013. The incidence of recurrent cases remained at 
0.2 cases, unchanged from 2013. The CDI rate is based 
on the number of new and recurrent CDI cases that 
originated in the participating healthcare facility (both 
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Table 1. CDI outbreaks reported in Ireland in 2014 by public 
health region (Source: CIDR)
Public Health Region Outbreak location Total number ill
East Hospital 4
East Hospital 6
East Hospital 7
East Other 3
East Nursing Home 3
East Nursing Home 11
South Residential 2
South Nursing Home 2
Midwest Residential 2
West Hospital 3
Table 2. Origin and onset of CDI, 2012 – 2014 
  Year
  2012 2013 2014
  % % %
ONSET: Location of where patient 
symptoms occurred    
Healthcare-onset  64 60 59
Breakdown of healthcare-onset cases:    
 Within reporting hospital 77 76 75
 Other hospital 4 2 4
 Nursing home/LTCF 16 18 18
 Unknown 3 4 3
Community-onset  30 29 34
Unknown  6 11 7
ORIGIN: Location of where infection was 
acquired    
Healthcare-associated  68 64 64
Breakdown of healthcare-associated cases:    
 Within reporting hospital 76 76 76
 Other hospital 6 5 5
 Nursing home/LTCF 15 17 16
 Unknown 3 2 3
Community-associated 17 18 21
Indeterminate  5 5 6
Unknown  10 14 9
Figure 2: Age and gender distribution of CDI in Ireland, 2014 
(Source: CIDR)
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public and private hospitals). The rate is calculated 
using acute public hospital activity data from the HSE 
Business Intelligence Unit, Corporate Planning and 
Corporate Performance (CPCP), with private hospital 
activity data provided directly by participating hospitals. 
Since enhanced surveillance began in 2009, the national 
CDI rate has declined from 3.1 cases per 10,000 BDU 
(2009) to 2.8 (2010), with an increase to 3.0 (2011). 
Since 2011, the rate steadily decreased from 2.7 (2012) 
to 2.3 (2014) (Figure 3). 
Caution should be taken when interpreting national CDI 
trends, particularly prior to 2012 due to: 
(i)   Changes in the numbers of participating hospitals, 
as displayed in Figure 3. Throughout 2012, the total 
number of hospitals participating in enhanced CDI 
surveillance stabilised. Since 2012, there has been a 
complete participation in CDI enhanced surveillance 
by all tertiary and general hospitals
(ii)  Changes in C. difficile laboratory testing protocols. 
Throughout 2013 and 2014, there were fewer 
changes in laboratory testing protocols. Please 
also refer to the section on laboratory testing of C. 
difficile in Ireland.  
There was a wide range in the incidence of CDI among 
participating hospitals in 2013 (range, 0 – 6.5 cases 
per 10,000 BDU; median = 1.8 cases). In 2013, tertiary 
hospitals (n = 9) had a median CDI rate of 2.3 cases per 
10,000 BDUs (range: 2.1 – 4.5), which was higher when 
compared to that of general hospitals (n = 27), with 
a median rate of 1.8 (range: 0 – 6.5). Since 2011, the 
median CDI rate in both tertiary (3.0 to 2.3 cases per 
10,000 BDU) and general hospitals (2.4 to 1.8 cases per 
10,000 BDU) declined.
The differences in CDI median incidence rates 
may reflect inter-hospital variation with regard to 
patient case mix, C. difficile ribotypes, laboratory 
testing protocols, antimicrobial prescribing policies, 
antimicrobial stewardship interventions and surveillance 
resources. No obvious seasonal trend for CDI is 
distinguishable from enhanced surveillance data in 
2014.
The percentage coverage of acute hospital activity was 
calculated using bed days used data from participating 
hospitals as a percentage of total acute hospital bed 
days used activity in Ireland
Severe CDI
A severe case of CDI is defined as (i) a patient requiring 
admission to an intensive care unit (ICU) for treatment 
of CDI or its complications, (ii) a patient requiring 
colectomy or (iii) death within 30 days after diagnosis, if 
CDI is either the primary or contributory cause of death. 
The enhanced CDI surveillance scheme does not collect 
information on patient outcome. Therefore, surgery and 
ICU admission for CDI are the two markers of severity 
captured via enhanced surveillance. In 2014, 26 (1.4%) 
severe CDI cases were reported, similar to 2013 (1.7%).
Eight patients required both surgery and ICU admission, 
six required surgery only and 12 required ICU admission 
without surgery. 
Onset & Origin of CDI
Onset: Patient location when symptoms of CDI 
commenced
Fifty nine percent (n=1,049) of patients had CDI 
symptom onset in a healthcare facility (healthcare-
onset), 34% (n=608) had symptom onset in the 
community and for 7% (n=123), location at CDI onset 
was unknown (Table 2). 
Of the 1,049 patients with healthcare onset CDI, 75% 
(n=783) had onset in the reporting hospital, 4% (n=42) 
in another hospital, 18% (n=192) in a long term care 
facility (LTCF) and for the remaining 4% (n=46) onset 
location was unknown. 
Between 2012 and 2014, there was a decrease in the 
proportion of patients with CDI symptom onset in a 
healthcare facility (64 to 59%), with the exception of 
LTCFs, where a slight increase was noted (16 to 18%). 
Community onset decreased from 30% to 29% between 
2012 and 2013, but increased to 34% in 2014 (Table 2). 
Origin: Location where the patient acquired the CDI
For the majority of CDI cases, the infection was acquired 
in a healthcare setting (healthcare-associated) (n=1,131; 
63.5%). Community-associated cases accounted for 
21.5% (n = 383) and in 6% (n = 111) the origin could 
not be assigned as either healthcare or community-
associated, as the patient had been discharged from a 
healthcare facility between four and 12 weeks prior to 
the CDI onset date. For the remaining 9% (n = 155) of 
cases, the origin was unknown (Table 2).
Of the 1,131 healthcare-associated CDI cases, 76% 
(n=860) originated in the reporting hospital, 4.5% 
(n=52) originated in a hospital other than the reporting 
hospital, 16.5% (n=189) originated in a LTCF and 3% 
(n=33) originated in another unspecified healthcare 
facility or were of unknown origin.
Between 2012 and 2014, there was a decrease in 
the proportion of cases associated with a healthcare 
facility (68 to 64%), although the reporting hospital 
and other hospital categories remained stable. The 
proportion of cases associated with the community 
increased from 17% to 21%, but there was little change 
in cases classified as indeterminate. Cases classified as 
‘unknown’ increased from 10% to 14% between 2012 
and 2013 but decreased to 9% in 2014 (Table 2).     
Of the 1,131 cases of healthcare-associated CDI:
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Table 3. National Reporting of C. difficile ribotyping data: 2011 - 2014 
Year
Total number 
of CDI cases 
reported
Number (%) 
of cases with 
ribotype data
Number of hospitals 
providing ribotype 
data
2011 1511 211 (14%) 10
2012 1735 263 (15%) 14
2013 1801 258 (14%) 19
2014 1780 290 (16%) 20
•  87% (n=982) experienced onset of CDI symptoms at 
least 48 hours following admission to a healthcare 
facility (healthcare-onset, healthcare-associated)
•  13% (n=147) experienced symptom onset in the 
community, within four weeks of discharge from a 
healthcare facility (community-onset, healthcare-
associated)
•  0.1% (n = 2) had no information recorded on symptom 
onset
Of the 383 cases of community-associated CDI: 
•  91.5% (n=350) experienced CDI symptom onset while 
outside a healthcare facility and without a history of 
discharge from a healthcare facility within the previous 
12 weeks
•  8% (n=31) experienced symptom onset within the first 
48 hours of admission to a healthcare facility, without 
a history of admission to or residence in a healthcare 
facility within the previous 12 weeks 
•  0.5% (n = 2) had no information recorded on symptom 
onset
Information was also captured on the location where 
the patient’s faeces specimen was taken. The reporting 
hospital accounted for the majority (77%) of specimens 
(n=1,366), with 10% (n=183) taken in the GP surgery, 9% 
(n=160) in LTCF and 2.5% (n=44) in a hospital other than 
the reporting hospital. For the remaining 1.5% (n=27), 
no information was provided.
Discussion
The collation of national data on C. difficile through 
CIDR notifications and the enhanced CDI surveillance 
system has provided a valuable insight into the burden 
of CDI in Ireland. Both surveillance systems present 
a similar decreasing trend since 2009. The notifiable 
surveillance system, which reflects total burden of 
disease, shows that the CDI rate stabilised between 
2012 and 2014, while the enhanced surveillance system 
shows a decrease in the CDI rate during this time 
period, including a decrease in the number of new CDI 
cases acquired in an acute hospital. The reasons for 
this decrease are unknown, but may be attributed to 
improved hand hygiene compliance and other infection 
control practices, changes in antimicrobial prescribing or 
changes in laboratory testing practices. 
In 2014, recurrent CDI accounted for 8% of notifications 
through the enhanced surveillance scheme, a slight 
decrease from 8.5% in 2013. Recurrent CDI may result 
in severe infection, which places a further burden 
on limited hospital isolation resources and results in 
significant patient morbidity. 
CDI is not confined to acute healthcare settings and 
is increasingly common in LTCF and the community. 
In 2014, 11% of cases had onset in LTCF, with 34% 
having onset in the community. Of the 383 community-
associated cases reported in 2014, 91% experienced 
CDI symptom onset in the community, without a 
history of discharge from a healthcare facility within the 
previous 12 weeks. It is important to consider CDI in 
the differential diagnosis of all patients presenting with 
diarrhoea of potentially infectious origin and to send 
specimens in a timely fashion for laboratory diagnosis. 
 C. difficile PCR ribotyping
As part of the voluntary C. difficile enhanced surveillance 
scheme, participating hospitals are requested to provide 
C. difficile PCR ribotyping information, where available. 
Ireland does not yet have a national C. difficile reference 
laboratory or ribotyping service. Therefore, laboratories 
submit specimens abroad for ribotyping. In 2014, 
ribotyping data was provided for 290 C. difficile isolates 
(16% of all samples) from 20 hospitals (Table 3). The 
most common ribotypes reported in 2014 were: 078 and 
014 (both n=31; 11%), 015 (n=27, 9%) and 005 (n=18, 
6%) (Figure 4). 
Laboratory Testing of C.difficile in Ireland
Since 2010, information on C. difficile testing has been 
collected quarterly as part of the enhanced surveillance 
system. In the first quarter of 2010, the majority of 
hospitals participating in the enhanced surveillance 
project were using a one step Toxin EIA (60%). In the last 
quarter of 2014, this had reduced to 0%. All hospitals 
participating in the enhanced surveillance system 
are now using a method which complies with what is 
recommended in the 2014 update of the 2008 Irish C. 
difficile guidelines. This includes either a PCR test for 
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Figure 3. Quarterly national rate of healthcare-associated 
CDI (new and recurrent): 2009 – 2014
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Figure 4. Most frequently reported C. difficile ribotypes in 
Ireland: 2010 – 2014
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detection of toxin genes (43%, n=23) or a two-step 
testing method (57%, n=30) (Figure 5). 
Owing to considerable variations in current Irish 
laboratory C. difficile testing methodologies, inter-
hospital comparison of CDI rates is not recommended 
where testing methods differ, as the data in the 
national quarterly enhanced surveillance reports are 
not adjusted for differences in the sensitivities of the 
different diagnostic methodologies.
Conclusion
The continued excellent participation in the voluntary 
CDI enhanced surveillance scheme ensures that a 
significant amount of information is collected regarding 
the burden of CDI in Ireland. 
The updated National Clinical Guidelines on the 
Surveillance, Diagnosis and Management of CDI in 
Ireland were updated in 2013 and endorsed by the 
National Clinical Effectiveness Committee in 2014. The 
updated guidelines may be accessed on the HPSC 
website at:
http://www.hpsc.ie/A-Z/Gastroenteric/
Clostridiumdifficile/Guidelines/.
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Figure 5. Changes in C. difficile laboratory testing protocols: 
2011 - 2014
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Summary
Key Points
•  The median rate of alcohol hand rub consumption 
in acute hospital in Ireland increased by 5% to 27.7 
litres per 1,000 bed-days used in 2014, from 26.3 in 
2013
Hand hygiene is one of the most important actions to 
prevent HCAI. Alcohol hand rubs (AHR) are an effective 
and rapid method of hand hygiene, and recommended 
as the primary means of hand hygiene in national and 
international guidelines. Measurement, which includes 
alcohol hand gels and foams, of hospital-level 
consumption of AHR, expressed as volume used per 
1,000 bed-days, has been shown to correlate with 
overall hand hygiene activity in hospitals. It is a 
recommended process measure of hand hygiene 
activity by both the World Health Organization (WHO) 
and the US Centers for Disease Control & Prevention 
(CDC). 
HPSC has collated data on AHR consumption in acute 
public hospitals in Ireland since 2006. The data are 
collected quarterly and represent the total volume of 
AHR dispensed to wards, clinics and other hospital 
areas for hospitals that provide the data via their 
pharmacy department, and total volume purchased 
for hospitals that provide the data via their supplies 
department. Quantities used for pre-operative surgical 
hand hygiene were excluded. The rate of usage per 
hospital is calculated as the total volume of AHR 
consumed in litres per 1,000 bed-days used (Table 1). 
In 2014 the median rate of AHR consumption increased 
to 27.7 litres per 1,000 bed-days used, from a 26.3 in 
2013, an increase of 5%. The wide variation in levels 
of AHR consumption between hospitals (4.3 - 72.1 
litres per 1,000 bed-days used) though not as wide as 
seen in past years, may be explained by differences in 
methodologies for collecting and reporting the data, 
and difference in types and range of hand hygiene 
agents used. One limitation of this surveillance system 
is that the data refer to the use of AHR only, and do 
not take account of the other hand hygiene agents 
(e.g. medicated liquid soap) that may also be in use in 
hospitals. In addition, the data do not give an indication 
of the frequency with which hand decontamination is 
carried out at a given hospital, whether or not hand 
hygiene is carried out at the correct time or using the 
correct technique, nor distinguish between who has 
used the AHR (visitor, patient or healthcare worker). 
Nevertheless, given that AHR should be used for the 
vast majority of hand hygiene opportunities in hospital 
settings, AHR consumption remains a useful process 
measure for hand hygiene activity.
The data are prone to reporting artefacts, particularly 
for hospitals that report supplies (rather than pharmacy 
dispensing) data. For example, the hospital with the 
highest reported rate had undergone a change in 
suppliers and the products had been restocked in all 
areas of the hospital over a relatively short period of 
time. It is expected that there will be occasional outliers 
of this nature. Using the median consumption figure 
provides a stable indicator of the national AHR rate 
over time. However, the volume of AHR consumed 
remains a crude measure of hand hygiene activity at 
individual hospital level and must be viewed with other 
indicators such as direct observation of hand hygiene 
compliance.
Table 1. National data on AHR consumption in acute public 
hospitals in Ireland by year, 2006 – 2014.
 
Number of 
participating 
hospitals
National 
consumption 
rate*
Range for 
participating 
hospitals 
2006 52 10.0 0.5 - 29.0
2007 50 15.0 5.2 - 47.1
2008 50 18.1 5.9 - 67.0
2009 49 20.3 4.1 - 47.7
2010 45 18.8 4.2 - 36.4
2011 43 21.3 10.9 - 130.0
2012 44 23.8 9.6 - 160.0
2013 44 26.3 16.4 - 132.5
2014 43 27.7 4.3 - 72.1
*  The consumption rate is the total volume of AHR consumed in the 
defined time period in litres per 1,000 bed-days used. The national 
rate represents the median of the national sample for each time 
period.
9.2 Alcohol Hand Rub Surveillance 
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Summary
•  Two national hand hygiene compliance audits took 
place in 2014
•  For Period 7 (May/June), 51 hospitals participated: 
44 HSE and 7 private. In total, 10,669 opportunities 
for hand hygiene were observed; achieving an 
average compliance of 86.8%, range 62.4% to 
97.1%
•  For Period 8 (October/November), 51 hospitals 
participated: 44 HSE and 7 private. In total, 10,672 
opportunities for hand hygiene were observed; 
achieving an average compliance of 88.1%, range 
70.0% to 98.6%
•  The overall compliance for the combined periods 
for HSE hospitals was 86.4%, which is below 
the HSE target for 2014 of 90%, however, the 
underlying trend is increasing. Compliance for the 
participating private hospitals over both periods 
was 94.0%
Hand hygiene is one the most important actions to 
prevent HCAI. Measuring hand hygiene compliance 
by direct observation is described by the World Health 
Organization (WHO) as the gold standard. In Ireland, 
biannual hand hygiene compliance data from acute 
hospitals commenced in 2011. Healthcare workers 
(HCWs) were observed for their compliance against the 
‘5 moments of hand hygiene’ by trained auditors using 
the WHO methodology for hand hygiene audits. Each 
hospital was required to measure HCW compliance 
against 30 hand hygiene opportunities for each of the 
seven randomly selected wards in their facility resulting 
in a maximum of 210 opportunities per hospital per 
period. In 2013, the analysis and management of data 
were moved to the HPSC online service, MicroB.
Biannual audits were undertaken in May/June (Period 
7) and October/November 2013 (Period 8). In total, 
10,669 opportunities for hand hygiene were observed 
for Period 7; achieving an average compliance of 
86.8%, range 62.4% to 97.1%. For Period 8, 10,672 
opportunities for hand hygiene were observed; 
achieving an average compliance of 88.1%, range 
70.0% to 98.6%
Table 1:  Summary of hand hygiene compliance in acute hospitals in Ireland combined for the two national audit periods in 2014. 
Note that data from private hospitals were excluded for the Staff Categories and WHO 5 Moments sections.
 
Hand Hygiene 
Opportunities
Hand Hygiene 
Actions
Percent 
Compliance
Lower 95% 
Confidence Interval
Upper 95% Confidence 
Interval
Overall 21,341 18,655 87.4% 86.9% 87.9%
HSE Hospitals 18,430 15,918 86.4% 85.8% 86.9%
Private Hospitals 2,911 2,737 94.0% 93.1% 94.9%
HSE - South 6,294 5,390 85.6% 84.7% 86.6%
HSE - Dublin North-East 3,772 3,209 85.1% 83.8% 86.3%
HSE - Dublin Mid-Leinster 4,194 3,656 87.2% 86.1% 88.3%
HSE - West 4,170 3,663 87.8% 86.8% 88.9%
Nurse/Midwife 10,653 9,595 90.1% 89.5% 90.7%
Auxiliary 2,900 2,445 84.3% 82.9% 85.8%
Medical 3,478 2,648 76.1% 74.5% 77.8%
Allied health/Other 1,399 1,230 87.9% 86.1% 89.7%
Moment 1 4,917 4,269 86.8% 85.8% 87.8%
Moment 2 986 819 83.1% 80.5% 85.6%
Moment 3 1,381 1,262 91.4% 89.8% 92.9%
Moment 4 6,693 6,019 89.9% 89.2% 90.7%
Moment 5 5,548 4,543 81.9% 80.8% 83.0%
Staff category: “Auxiliary” includes healthcare assistants, porters, catering and household services; “Allied health/Other” includes 
physiotherapists, radiologists, dieticians, social workers and pharmacists
Moment 1: Before touching a patient; 
Moment 2: Before clean/aseptic procedure; 
Moment 3: After body fluid exposure risk; 
Moment 4: After touching a patient; 
Moment 5: After touching patient surroundings
9.3 Hand Hygiene Compliance 
-152-HPSC Annual Epidemiological Report 2014 Healthcare Associated Infections
Results for the two periods are combined in a summary 
in Table 1 and Figure 1. In 2014, the overall compliance 
for HSE and private hospitals combined was 87.4%, and 
was 86.4% for HSE hospitals, below the 2013 target 
of 90%. The underlying trend for compliance among 
HSE hospitals has increased (Figure 2) over the first six 
periods, however, over the last two periods, compliance 
has levelled. Participating private hospitals had 
reported an overall compliance of 94.0% in 2014. 
In 2014, of the four major HCW categories, medical 
staff had the lowest compliance at 76.1% and nurse/
midwife staff the highest at 90.1%. Based on the WHO 
‘5 moments for hand hygiene’, compliance for moment 
5 (after touching patient surroundings) was the lowest 
at 81.9% and the highest for moment 3 (after body 
fluid exposure risk) at 91.4%. The proportion of hand 
hygiene actions that were undertaken using soap and 
water was 30.2% as opposed to hand rub at 69.8%. 
Note that data from private hospitals were excluded for 
the Staff Categories and WHO 5 Moments sections in 
Table 1 and Figure 1.
While standardised hand hygiene auditor training and 
validation (with inter-rater reliability testing) should 
ensure that measurement of hand hygiene should be 
comparable, the results have not been validated by 
external auditors. Furthermore, all auditors measured 
compliance in the facility in which they work; therefore 
there may be an element of bias in the results. It is 
therefore possible that hand hygiene auditing may 
not have been performed in a comparable fashion in 
all hospitals. The results may also not be reflective of 
HCW compliance at all times. Compliance with hand 
hygiene is measured by auditors observing HCWs 
workers undertaking patient care who may change 
their behaviour if aware that they are being observed. 
However, it is also known that this effect (known as 
the Hawthorne effect) diminishes over time and HCWs 
under observation may not be aware of the presence 
of the auditor due to the many competing demands 
on their attention. Auditors are requested to give 
immediate feedback to ward staff following an audit, 
thereby increasing awareness and knowledge of hand 
hygiene. This risk of bias should be balanced by the 
benefits of increasing local staff’s knowledge and 
awareness of hand hygiene. 
Figure 2:  Summary of hand hygiene compliance in HSE acute 
hospitals in Ireland for the last eight national audit periods, 
2011 to 2014. The HSE target for each year is shown as red 
lines.
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Figure 1:  Summary of hand hygiene compliance in acute 
hospitals in Ireland combined for the two national audit periods 
in 2014. The 95% confidence intervals are shown in bars and 
the HSE target for 2014 (90%) is shown as a red line. 
Note that data from private hospitals were excluded for the Staff Categories and 
WHO 5 Moments.
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Ireland participates in ECDC’s European Surveillance of 
Antimicrobial Consumption (ESAC-Net) project which 
aims to collect systemic antimicrobial usage data from 
the outpatient (ambulatory, community or primary 
care) setting and from the hospital (inpatient) setting. 
Antimicrobial consumption is measured in Defined 
Daily Dose (DDD), which is the assumed average 
maintenance dose per day for a drug used for its main 
indication in adults. Rates are calculated in DDD per 
1000 inhabitants per day (DID) for outpatients and DDD 
per 100 bed-days used (DBD) for inpatients. Please 
see “Antimicrobial consumption” and “Denominator 
data” parts of the explanatory notes section for further 
details. 
Outpatient Antimicrobial Consumption
The overall outpatient antimicrobial consumption for 
Ireland in 2014 was 23.1 DID, a decrease of 3% from 
the previous year’s rate of 23.8 DID. In the latest interim 
ESAC-Net report (provisional 2014 data), the reported 
range of outpatient antimicrobial usage among 
European countries was 10.6 to 34.1 DID; the median 
for 30 European countries with reliable data was 19.8 
DID, with Ireland ranking as the ninth highest.
The underlying trend for outpatient antimicrobial 
consumption for Ireland (Figure 1) has been increasing 
steadily since 2000. After a decrease in 2008 and 2009, 
the rate increased again to the highest level so far in 
quarter 1 of 2013, before a small decrease in the first 
half of 2014. There is a marked seasonal fluctuation in 
usage, with the highest levels occurring during periods 
of increased influenza activity.
In Ireland in 2014, outpatient consumption of penicillins 
accounted for the largest class used (57% of total at 
13.2 DID), followed by macrolides (18%, 4.2 DID), 
tetracyclines (12%, 2.7 DID), cephalosporins (5%, 1.1 
DID), sulphonamides/trimethoprim (4%, 1.0 DID) and 
fluoroquinolones (4%, 0.8 DID). Penicillin in combination 
with a beta-lactamase inhibitor (such as co-amoxiclav) 
accounted for the largest proportion of all penicillins 
at 45% (6.0 DID). Broad-spectrum penicillin (such as 
amoxicillin) usage was also high at 33% of all penicillins 
(4.3 DID). See Table 1 for a detailed breakdown by 
pharmacological drug groups.
There was considerable variability in the overall 
outpatient antimicrobial usage at county level (16.8 to 
32.8 DID) as shown in Figure 2. 
Hospital Antimicrobial Consumption
Forty-three public acute hospitals provided valid 
antimicrobial usage data for 2014. The median rate of 
antimicrobial consumption was 82.9 DBD (range 36.4 – 
128.8 DBD). This was a 2% decrease from the previous 
year’s median rate of 84.4 DBD. The overall rate for 
2014 was 82.1 DBD. These levels are mid-to-high in 
Europe.
The largest group of antimicrobials, penicillins 
at 39.9 DBD accounted for 49% of all inpatient 
antimicrobial usage. The use of fluoroquinolones 
such as ciprofloxacin (representing 6% of all inpatient 
antimicrobial usage) was 5.3 DBD. Consumption of 
cephalosporins, monobactams and carbapenems 
(representing 10% of all inpatient antimicrobial usage) 
was 7.9 DBD. Consumption of glycopeptides such as 
intravenous vancomycin, imidazoles such as intravenous 
metronidazole and nitrofurans (representing 11% 
of all inpatient antimicrobial usage) was 8.9 DBD. 
Consumption of erythromycin and related agents 
(macrolides, representing 14% of all inpatient 
antimicrobial usage) was 11.7 DBD. Less frequently 
used agents in hospitals are tetracyclines, sulfonamides/
trimethoprim, aminoglycosides and other systemic 
9.4 Antimicrobial Consumption 
Key Points
•  The overall outpatient antimicrobial consumption in 
Ireland for 2014 was 23.1 DID, a 3% decrease from 
the 2013 rate of 23.8 DID. This rate is mid-to-high 
in comparison with other European countries
•  The median rate of hospital antimicrobial 
consumption in Ireland for 2014 was 82.9 DBD 
(range 36.4 – 128.8 DBD), a 2% decrease from 
2013. This rate is mid-range in comparison with 
other European countries. Forty-three public acute 
hospitals contributed data in 2014
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antimicrobials; collectively these drugs represent 
less than 10% of all inpatient antimicrobial usage. All 
consumptions levels remained proportionately the 
same as those seen 2013 (see Figure 3). The rate of 
carbapenem use has increased sharply from a rate of 
1.2 DBD in 2007 to 3.3 in 2013, however, the level has 
remained the same for 2014.
It should be noted that the data do not indicate 
whether or not the level of antimicrobial use is 
appropriate for a given patient populations. For 
example, higher levels of antimicrobial consumption 
among tertiary hospitals may be appropriate if such 
hospitals have specific patient populations that are 
more likely to require antimicrobial therapy (e.g. 
organ transplant, cystic fibrosis etc). Furthermore, 
DDD calculations are based on adult dosing and may 
therefore underestimate antimicrobial consumption in 
paediatric settings.
Though HPSC antimicrobial consumption data are 
comprehensive, gaps remain. Most notably, data from 
private hospitals is missing. All hospitals dispense 
to outpatients, day-patients and external long term 
facilities, and the data representing this volume is 
excluded from our analyses. Outpatient data represents 
95% of wholesaler to retail pharmacy transactions, 
therefore, there is a further gap in the data. Collectively, 
these gaps would represent about 10% of the total 
antimicrobial consumption for Ireland. Though HPSC 
-154-HPSC Annual Epidemiological Report 2014 Healthcare Associated Infections
10 
15 
20 
25 
30 
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
De
fin
ed
 D
ai
ly
 D
os
es
 p
er
 1
00
0 
In
ha
bi
ta
nt
s 
pe
r D
ay
 (D
ID
) 
Observed Use Underlying Trend 
Figure 1. Outpatient antibiotic consumption in Ireland by quarter, 2000-2014.
Table 1. Breakdown by pharmacological drug groups for outpatient antibiotic use in Ireland for 2012 and 2013. 
2013 Percent of 2013 2014 Percent of 2014 Percent Change  2013 to 2014
Penicillins 13.1 55.1% 13.2 56.9% 0.3%
Narrow spectrum penicillins 1.1 4.5% 1.0 4.5% -2.2%
Beta-lactamase resistant penicillins 1.2 5.0% 1.8 8.0% 54.6%
Broad spectrum penicillins 3.9 16.4% 4.3 18.4% 9.3%
Penicillin with beta-lactamase inhibitor 7.0 29.2% 6.0 26.0% -13.6%
Macrolides and related drugs 4.4 18.5% 4.2 18.1% -5.0%
Tetracylines 3.0 12.5% 2.7 11.8% -7.7%
Cephalosporins and other beta-lactam drugs 1.4 5.7% 1.1 4.8% -18.5%
First-generation cephalosporins 0.2 0.8% 0.2 1.1% 25.3%
Second-generation cephalosporins 1.1 4.5% 0.8 3.4% -26.0%
Third-generation cephalosporins 0.1 0.4% 0.1 0.3% -25.9%
Quinolones 0.9 3.7% 0.8 3.7% -3.1%
Sulfonamides and Trimethoprim 1.0 4.1% 1.0 4.4% 2.3%
Other antibiotics 0.1 0.4% 0.1 0.4% -14.8%
TOTAL 23.8 100.0% 23.1 100.0% -2.8%
provides antifungal consumption data to ESAC-Net, 
this report is primarily focussed on antibacterial drug 
consumption only. ESAC-Net collects data on antiviral 
and antiprotozoal agents which HPSC currently do not 
provide. 
More detailed analyses of antimicrobial usage data can 
be found on the www.hpsc.ie website, through “Topics 
A-Z”, under “Antibiotic Consumption Surveillance”. 
Details of the WHO ATC/DDD system of classifying and 
measuring drug consumption can be found at 
www.whocc.no/atc_ddd_index/. The figures presented 
in this report may vary from previously published levels 
owing to methodological changes.
Figure 2. Outpatient antibiotic consumption in Ireland by 
county, in DDD per 1000 inhabitants per day for 2014. 
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Figure 3. Overall hospital antibiotic consumption rate in DDD per 100 BDU by pharmacological subgroup (ATC level 3) by year.
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9.5 Antimicrobial Resistance
Key Points
•   There were 2,771 reports of invasive E. coli 
infection, an increase of 9.5% from 2,530 in 2013:  
 o   The proportions of invasive E. coli 
resistant to 3rd generation cephalosporins 
(3GCs) (12.9%), ciprofloxacin (26.2%) and 
aminoglycosides (14.5%)  and those that 
exhibited multi-drug resistance (15.0%) were 
at their highest levels since surveillance 
began
•   There were 1,118 reports of S. aureus bloodstream 
infection (BSI), an increase of 2.2% from 1,094 in 
2013:
 o   Of those, 218 (19.5%) were meticillin-
resistant S. aureus (MRSA), which is the 
lowest annual proportion reported to date
 o   For acute hospitals, the rate of MRSA BSI 
was 0.055 cases per 1,000 bed days used 
(BDU), a slight decrease from 0.056 in 2013. 
Conversely, the rate of meticillin-susceptible 
S. aureus (MSSA) BSI increased from 0.218 in 
2013 to 0.227 in 2014
•   There were 404 reports of E. faecium BSI, a slight 
decrease of 1.2% from 409 in 2013:
 o   Vancomycin-resistant E. faecium (VREfm) 
accounted for 46.0%, which is the highest 
annual proportion reported to date
•   There were 358 reports of invasive K. pneumoniae 
infection, an  increase of 9.8% from 326 in 2013:
 o   The proportions of invasive K. pneumoniae 
resistant to 3GCs (12.8%) and those that 
were ESBL-positive (11.0%) decreased from 
2013 (21.2% and 18.4%, respectively) when 
they were at their highest levels reported to 
date
 o   Two predominant clones have been 
identified among K. pneumoniae that are 
both ESBL-positive and non-susceptible to 
ciprofloxacin and gentamicin. Some also 
produce carbapenemases. Together, these 
are termed multi-drug resistant  
K. pneumoniae (MDRKP). An outbreak 
control team was established in October 
2013 to investigate this emerging threat. 
The proportion of invasive K. pneumoniae 
that were MDRKP decreased between 2013 
(12.3%, or 40 of 325 isolates) and 2014 
(8.1%, or 29 of 358 isolates) 
 o   Two invasive K. pneumoniae isolates were 
carbapenemase-producers, also known as 
carbapenem-resistant Enterobacteriaceae 
(CRE)
•   There were 331 reports of invasive S. pneumoniae 
infection, an increase of 6.4% from 311 in 2013:
 o   Of those, 56 (17.1%) were penicillin non-
susceptible S. pneumoniae (PNSP), a 
decrease from 20.7% in 2013
 o   The national rate of invasive infection was 
7.2 per 100,000 population, an increase 
compared to 6.8 in 2013
 o   Serotype data were available for 298 (or 
90%) of 331 invasive S. pneumoniae isolates. 
Results indicate good coverage (68%) for 
the 23-valent pneumococcal polysaccharide 
vaccine (PPV23) in its target population 
(adults ≥65 years)
 
•   There were 182 reports of invasive P. aeruginosa 
infection, a decrease of 12% from 207 in 2013 and 
resistance to all indicator antimicrobials, except for 
piperacillin-tazobactam, decreased
•   Enhanced surveillance data were provided on 2,202 
records (cases or isolates under the EARS-Net 
definition) from 21 laboratories, representing 40% 
of all reported cases in 2014
•   See http://www.hpsc.ie for further details of EARS-
Net, antimicrobial resistance and enhanced BSI 
surveillance in Ireland
•   European data are available at http://ecdc.europa.
eu/en/activities/surveillance/EARS-Net/Pages/
Database.aspx
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Introduction
The European Antimicrobial Resistance Surveillance 
Network (EARS-Net), previously the European 
Antimicrobial Resistance Surveillance System (EARSS), 
collects routinely-generated antimicrobial susceptibility 
testing data on seven important bacterial pathogens 
using the EARS-Net case definition. Participating 
laboratories in Ireland submit data on the “primary” 
or first isolate from blood or cerebrospinal fluid (CSF) 
per patient per quarter. EARS-Net does not distinguish 
clinically significant isolates from contaminants, nor does 
it distinguish between hospital-acquired, healthcare-
associated and community-acquired infections. EARS-
Net primarily serves as a surveillance system to measure 
national levels of antimicrobial resistance (AMR). In 
2014, all 39 microbiology laboratories participated in 
EARS-Net resulting in complete coverage of the Irish 
population.
Escherichia coli
There were 2,771 reports of invasive E. coli infection 
(2,765 from blood and six from CSF) from 2,705 
patients, an increase of 9.5% from 2,530 reports in 
2013.  Table 1 displays the annual trends since 2005 
in the proportion of E. coli isolates resistant to the 
five “indicator” antimicrobials/antimicrobial classes 
[ampicillin, third-generation cephalosporins (3GCs); 
cefotaxime, ceftriaxone, ceftazidime or cefpodoxime, 
fluoroquinolones (ciprofloxacin or ofloxacin), 
aminoglycosides (gentamicin, amikacin or tobramycin) 
and carbapenems (meropenem or ertapenem)]:  
•   Of 2,769 isolates, 357 (12.9%) were resistant to 3GCs 
and of those, 268 were extended-spectrum beta-
lactamase (ESBL)-positive and 87 ESBL-negative 
•   Of 2,769 isolates, 725 (26.2%) were resistant to 
ciprofloxacin 
•   Of 2,771 isolates, 310 (11.2%) were resistant 
to gentamicin [403 (14.5%) of 2,771 were 
aminoglycoside-resistant (i.e. resistant to gentamicin, 
tobramycin or amikacin)]
•   Two (0.1%) of 2,270 isolates were resistant to 
carbapenems, one of which was confirmed to be a 
carbapenemase-producer (an NDM)
In 2014, resistance to 3GCs, ciprofloxacin and 
aminoglycosides were at their highest levels since 
surveillance began (Figure 1). The trend in 3GC 
resistance was upwards between 2004 and 2014, which 
is highly significant (P<0.001), although there appeared 
to be a levelling off in 2014. 
In 2014, Ireland had moderately high levels (10 to <25%) 
of resistance to 3GCs (Figure 2) and aminoglycosides 
(ranking 13th and 11th, respectively, out of 30 countries 
reporting to EARS-Net) and a higher level (25 to <50%) 
of resistance to ciprofloxacin (ranking 13th). The median 
proportions for resistance among EARS-Net countries 
was 11.3% for 3GCs, 22.5% for ciprofloxacin and 12.3% 
for aminoglycosides.
ESBLs are enzymes that confer resistance to most 
penicillins and cephalosporins (including 3GCs). ESBL-
positive bacteria (including E. coli and K. pneumoniae) 
are also often resistant to other classes of antimicrobials 
and have emerged as important causes of healthcare-
associated infection (HCAI). ESBLs were detected in 
280 (10.2%) of 2,757 isolates tested. In 2014, ESBL 
production amongst invasive E. coli isolates was at 
its second highest level (after 2013) since surveillance 
began. The trend in ESBL production was upwards 
between 2004 and 2013, which was highly significant 
(P<0.001). In 2014, ESBL production appeared to level 
off. 
Of 2,766 isolates tested against all five “indicator” 
antimicrobials, 416 (15.0%) reported from 50 hospitals/
institutions were identified as multi-drug resistant (MDR) 
E. coli, defined as resistance to three or more of the 
indicator antimicrobials OR any isolate with resistance to 
carbapenems), a slight increase from 14.8% in 2013:
•   153 resistant to ampicillin, 3GCs, ciprofloxacin and 
aminoglycosides (of which 137 ESBL-positive and 15  
ESBL-negative)
•   119 resistant to ampicillin, 3GCs and ciprofloxacin (of 
which 108 ESBL-positive and 11 ESBL-negative)
•   134 resistant to ampicillin, ciprofloxacin and 
aminoglycosides (of which 4 ESBL-positive and 129 
ESBL-negative)
•   Eight resistant to ampicillin, 3GCs and 
aminoglycosides (of which 5 ESBL-positive and 3 
ESBL-negative)
•   One resistant to ampicillin, 3GCs and carbapenems 
(ESBL not reported)
•   One resistant to ampicillin and carbapenems (ESBL-
negative)
In 2014, MDR E. coli was at its highest level since 
surveillance began. Since 2009, the trend in MDR E. coli 
has been upwards, which is highly significant (P<0.001).
Females were slightly more likely (1.1-times) to have an 
invasive E. coli infection than males (highly significant, 
P<0.001).  The frequency of invasive E. coli infection 
increased with age, with the majority (n=2,134; 77%) 
occurring in adults aged over 60. The median age was 
74 years (95%CI, 73-74).
Staphylococcus aureus
There were 1,118 reports of S. aureus BSI from 1,072 
patients, an increase of 2.2% from 2013 (n=1,094). 
Of those, 218 (19.5%) were MRSA, which represents 
the lowest annual proportion since surveillance began 
in 1999 (Table 1 shows data from 2005). In 2010, 
the proportion was 24.4%, the first year that MRSA 
accounted for <25% of S. aureus BSI in Ireland, thus 
changing from red to orange on the EARS-Net map 
and 2014 was the eighth successive year in which a 
decrease was observed. The overall downward trend 
over this time period is highly significant (P<0.001) 
(Figure 3).  Overall, there was a 1.8% reduction in the 
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Table 1. Summary of EARS-Net data by pathogen and year, 2005-2014
Pathogen 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Number laboratories by year-end 41 42 44 42 43 40† 41† 41 41 39†
E. coli
Number of isolates 1445 1656 1785 1926 2064 2170 2210 2450 2530 2771
%Ampicillin-R* 67.6 70.7 68.3 70.4 68.7 68.4 71.9 69.6 70.9 69.9
%3GC-R* 4.1 4.2 6.7 7.4 7.5 8.3 9.5 10.8 12.8 12.9
%ESBL-producers* 2.4 2.5 4.1 5.0 5.8 6.1 7.5 8.8 10.5 10.2
%Ciprofloxacin-R* 17.3 21.5 22.1 23.3 22.3 23.6 23.8 25.2 25.3 26.2
%Gentamicin-R* 8.5 7.7 9.9 10.2 7.7 9.4 8.7 9.7 9.8 11.2
%Gentamicin/Amikacin/Tobramycin-R* 8.6 8.6 10.6 11.0 9.3 11.8 12.2 12.6 12.8 14.5
%Carbapenem1-R* 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1
%MDR* 7.7 9.0 11.3 12.1 10.4 11.7 13.0 13.4 14.8 15.0
Number laboratories by year-end 42 42 44 43 43 40† 41† 41 41 39†
S. aureus
Number of isolates 1424 1412 1393 1303 1309 1251 1095 1060 1094 1118
Number Meticillin-R (or MRSA) 592 592 536 439 355 305 263 242 222 218
%Meticillin-R (or MRSA) 41.6 41.9 38.5 33.7 27.1 24.4 24.0 22.8 20.3 19.5
Number laboratories by year-end 41 42 44 42 43 40† 41† 41 41 39†
E. faecium
Number of isolates 224 265 330 406 397 392 364 392 409 404
%Ampicillin-R* 92.3 93.9 93.1 95.1 92.9 95.6 95.9 92.9 93.2 95.3
%Vancomycin-R (VREfm) 31.7 37.1 33.4 35.7 38.3 39.3 37.4 45.4 43.1 46.0
%HLG-R* 51.4 44.3 35.2 28.1 39.1 39.6 36.8 39.3 41.4 44.1
%MDR* 25.6 25.6 22.7 16.2 26.7 24.9 21.1 20.3 19.6 22.2
Number laboratories by year-end 36 39 41 42 40† 41† 41 41 39†
K. pneumoniae
Number of isolates
No data
217 244 310 323 326 312 345 326 358
%Ampicillin-R* 97.7 99.2 99.7 99.7 99.1 100.0 98.5 99.1 100.0
%3GC-R* 10.2 9.9 11.4 11.2 10.5 8.0 11.9 21.2 12.8
%ESBL-producers* 8.6 3.7 7.7 8.2 5.0 5.6 8.8 18.4 11.0
%Ciprofloxacin-R* 15.3 18.1 12.8 13.0 10.5 13.2 11.9 20.9 17.3
%Gentamicin-R* 7.8 9.9 10.7 11.1 6.8 7.4 9.9 16.9 12.6
%Gentamicin/Amikacin/Tobramycin-R* 9.2 11.1 10.7 11.1 7.1 8.3 9.6 17.5 13.2
%Carbapenem1-R* 0.0 0.6 0.0 0.0 0.0 1.6 0.3 1.2 1.1
%MDRKP2* 1.7 2.9 3.9 4.3 2.2 4.6 5.3 12.3 8.1
%MDR* 11.2 11.9 10.6 11.9 8.0 8.4 9.9 19.7 13.7
Number laboratories by year-end 42 42 44 42 43 40† 41† 41 41 39†
S. pneumoniae
Number of isolates 401 407 438 447 356 314 327 321 311 331
%Penicillin-NS* 11.7 15.7 17.4 23.1 20.2 18.2 19.6 19.6 20.8 17.1
of which:   %HLR 3.0 2.9 5.7 6.0 5.6 4.8 6.1 4.7 2.3 2.4
 %Int 8.7 12.5 11.0 16.8 13.8 12.7 13.5 15.0 18.3 14.5
%Erythromycin-R* 12.1 16.1 16.4 16.7 17.3 15.7 18.9 16.9 17.9 13.8
%Penicillin-NS/Erythromycin-R 3.2 7.4 7.9 10.2 11.9 12.6 13.8 12.1 13.3 10.4
Number laboratories by year-end 41 42 44 42 43 40† 41† 41 41 39†
E. faecalis
Number of isolates 290 294 280 301 289 298 265 298 336 316
%Ampicillin-R* 3.5 4.5 2.2 0.7 2.1 0.7 0.8 4.0 2.7 1.9
%Vancomycin-R (VREfa) 2.5 3.7 2.9 3.7 0.7 0.3 4.9 3.0 2.1 2.8
%HLG-R* 44.4 42.4 36.9 30.5 36.7 29.7 29.1 32.9 33.6 33.0
Number laboratories by year-end 36 39 41 42 40† 41† 41 41 39†
P. aeruginosa
Number of isolates
No data
128 177 199 248 222 184 219 207 182
%Piperacillin/tazobactam-R* 9.4 12.6 9.7 8.9 10.0 2.8 17.4 15.2 16.5
%Ceftazidime-R* 10.6 11.8 8.7 11.8 9.2 8.2 15.2 10.7 8.9
%Imipenem/meropenem-R* 11.8 12.2 9.3 10.2 8.3 12.0 19.6 12.1 11.6
%Ciprofloxacin-R* 18.0 22.9 21.8 12.1 13.2 12.6 20.6 15.0 13.7
%Gentamicin-R* 10.2 13.3 9.0 7.7 8.7 6.5 11.9 11.6 4.9
%Gentamicin/Amikacin/Tobramycin-R* 10.2 13.3 9.0 7.7 8.7 6.5 11.9 11.6 5.5
%MDR* 9.5 12.4 11.1 6.4 6.5 4.0 13.0 9.4 6.7
Number laboratories by year-end 41 39†
Acinetobacter spp.
Number of isolates
No data No data No data No data No data No data No data No data
91 93
%Ciprofloxacin-R* 3 8
%Gentamicin-R* 0 3
%Gentamicin/Amikacin/Tobramycin-R* 1 3
%Carbapenem1-R* 4 4
%MDR* 0 2
R, Resistant; NS, Non-Susceptible [includes isolates with intermediate (Int) and high-level resistance (HLR)]
MRSA, Meticillin-Resistant S. aureus; VREfm, Vancomycin-Resistant E. faecium; VREfa, Vancomycin-Resistant E. faecalis
HLG, High-Level Gentamicin; 3GC, 3rd-Generation Cephalosporin (includes cefotaxime, ceftriaxone, ceftazidime 
and cefpodoxime); ESBL, Extended-Spectrum Beta-Lactamase; MDR, Multi-Drug Resistant
* Not all isolates tested
† The number of laboratories processing blood cultures has changed a number of times between 2006 and 2014; however, coverage of acute hospitals has remained at 100%
1 Carbapenems include imipenem, meropenem and ertapenem
2 MDRKP, MDR K. pneumoniae phenotype (ESBL-producer plus non-susceptibility to Ciprofloxacin and Gentamicin) OR carbapenemase-producer (e.g. KPC, OXA-48)
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number of reported MRSA BSI compared with 2013 
(218 versus 222). In contrast, the total number of MSSA 
BSI increased by 3.2% compared with 2013 (900 versus 
872). 
Despite the decrease in numbers and proportion of 
MRSA BSI in 2014, Ireland still had one of the higher 
proportions of MRSA in Europe (see http://ecdc.europa.
eu/en/activities/surveillance/EARS-Net/Pages/Database.
aspx for more detailed European data, including 
EARS-Net tables, charts and maps) (Figure 4). Ireland 
ranked 12th out of 30 countries reporting to EARS-Net 
(compared to 11th of 30 countries in 2013), with the 
median proportion of MRSA BSI at 13.1%. All countries 
with MRSA proportions higher than Ireland are located 
in Southern and Central/Eastern Europe.
The MRSA rate for all acute hospitals in 2014 was 0.055 
cases per 1,000 BDU, a slight decrease from 0.056 in 
2013, whilst the MSSA rate increased from 0.219 to 
0.227 [rates are calculated from denominator data (bed 
days used) obtained from the HSE Business Intelligence 
Unit (BIU) for all acute public hospitals; and directly from 
private hospitals where available, where both numerator 
(S. aureus numbers) and denominator data have been 
provided]. 
Males were approximately 1.8-times more likely to 
have invasive S. aureus, MRSA or MSSA infection than 
females (highly significant; P<0.001). The frequency of 
invasive S. aureus infection increased with age, with the 
majority of infections (n=678; 61%) occurring in adults 
aged over 60. The median age for MRSA infection was 
73 years (95%CI, 71-76) and for MSSA infection was 
64 years (95%CI, 62-65). This was considered to be a 
Figure 1. Trends for E. coli – total numbers of E. coli and percentage resistance to 3rd 
generation cephalosporins (3GCs), ciprofloxacin/ofloxacin (CIP/OFX), gentamicin (GEN) and 
gentamicin/amikacin/tobramycin (GEN/AMK/TOB) with 95% confidence intervals
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Table 2. Age and gender breakdown of patients by organism with major resistance profiles (data from laboratories participating 
in enhanced surveillance for 2014). The proportion of isolates detected <48 hours and >5 days post-admission is also shown
 Total for  2014 Percent female Mean age in 
years
Detected <48 
hours after 
admission
Detected >5 
days after 
admission
Staphylococcus 
aureus
Meticillin-resistant (MRSA) 92 42% 71.5 57% 32%
Meticillin-susceptible 378 35% 56.5 62% 25%
Streptococcus 
pneumoniae
Penicillin-non-susceptible 21 52% 53.9 90% 5%
Penicillin-susceptible 111 51% 61.2 95% 2%
Enterococci Vancomycin-resistant 77 40% 65.5 9% 81%
 Vancomycin-sensitive 221 46% 67.3 40% 48%
Escherichia coli
Fluoroquinolone-resistant 273 45% 76.2 73% 22%
Fluoroquinolone-susceptible 819 56% 68.5 74% 19%
Klebsiella pneumoniae 139 45% 66.7 51% 35%
Pseudomonas aeruginosa 71 44% 69.0 68% 23%
significant difference, as the confidence intervals did 
not overlap.
Enterococcus faecium
There were 404 reports of E. faecium BSI from 390 
patients, a decrease of 1.2% from 2013 (n=409). Table 1 
displays the annual trends since 2005 in the proportion 
of E. faecium isolates resistant to the three “indicator” 
antimicrobials (ampicillin, vancomycin and high-level 
gentamicin):  
•   Of 404 isolates, 186 (46.0%) were resistant to 
vancomycin, with an increase in the proportion of 
vancomycin-resistant E. faecium (VREfm) from 43.1% 
(2013) (Figure 5) 
•   Of 392 isolates, 173 (44.1%) were resistant to high-
level gentamicin (Figure 5) 
•   Of 392 isolates tested against the three “indicator” 
antimicrobials, 87 (22.2%) reported from 20 hospitals 
[with the majority (71; or 82%) coming from the 
nine tertiary hospitals] were resistant to all three 
and termed MDR E. faecium, which represents an 
increase from 19.6% in 2013 
Since 2008, Ireland has had the highest proportion 
of VREfm in Europe. In 2014, countries with the next 
highest proportions of VREfm were: Cyprus (40%), 
Greece (27.3%) and Romania (25%) (Figure 6), whilst 
the median proportion of VREfm in EARS-Net countries 
was just 4.5%.
Males were approximately 1.4-times more likely to have 
invasive E. faecium infection than females (approaching 
borderline significance; P=0.06). The frequency of 
invasive E. faecium infection increased with age, with 
the majority of infections (n=299; 74%) occurring in 
adults aged over 60. The median age was 69 years 
(95%CI, 67-71).
Klebsiella pneumoniae
There were 358 reports of invasive K. pneumoniae 
infection (354 from blood and four from CSF) from 356 
patients, an increase of 9.8% from 2013 (n=326).  Table 
1 displays annual trends since 2006 in the proportion of 
K. pneumoniae isolates resistant to the five “indicator” 
antimicrobials (as for E. coli above): 
•   Of 358 isolates, 46 (12.8%) were resistant to 3GCs, of 
which 37 were ESBL-positive and nine were ESBL-
negative 
•   Of 358 isolates, 62 (17.3%) were resistant to 
ciprofloxacin
•   Of 357 isolates, 45 (12.6%) were resistant to 
gentamicin [47 (13.2%) of 357 were aminoglycoside-
resistant (i.e. resistant to gentamicin, tobramycin or 
amikacin)]
•   Of 354 isolates, four (1.1%) were resistant 
to carbapenems, with two confirmed to be 
carbapenemase-producers (from different hospitals; 
one OXA-48 and one KPC-type CRE) and two 
confirmed not to be carbapenemase-producers. 
The two invasive carbapenemase-producing K. 
pneumoniae isolates in 2014 followed two isolates 
in 2013 (both OXA-48) and four isolates in 2011 (3 
OXA-48 and one KPC)
Figure 2. Distribution of 3rd-generation cephalosporin resistant E. coli in EARS-Net 
countries in 2014
Map downloaded from ECDC’s TESSy database on 21/10/2015:
http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx
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Resistance to 3GCs, ciprofloxacin and gentamicin/
aminoglycosides all decreased in 2014 compared 
with 2013 when they were at their highest levels since 
surveillance began (Figure 7).
No invasive K. pneumoniae isolates were reported as 
susceptible to ampicillin, which is as expected as K. 
pneumoniae are inherently resistant to ampicillin.
ESBLs were detected in 39 (11.0%) of 354 isolates 
tested. In 2014, ESBL production amongst invasive 
K. pneumoniae isolates was at its second highest level 
(after 2013) since surveillance began. 
Of 357 isolates, 49 (13.7%) reported by 22 hospitals that 
were tested against all five “indicator” antimicrobials 
were identified as MDR Klebsiella pneumoniae, a 
decrease from 19.7% in 2013:
•   Three resistant to ampicillin, 3GCs, ciprofloxacin, 
aminoglycosides and carbapenems (of which one 
ESBL-positive and two ESBL-negative)
•   30 resistant to ampicillin, 3GCs, ciprofloxacin and 
aminoglycosides (of which 28 ESBL-positive and two 
ESBL-negative)
•   One resistant to ampicillin, 3GCs, aminoglycosides 
and carbapenems (ESBL-positive)
•   Three resistant to ampicillin, 3GCs and ciprofloxacin 
(of which two ESBL-positive and one ESBL-negative)
•   Two resistant to ampicillin, 3GCs and aminoglycosides 
(both ESBL-positive)
•   10 resistant to ampicillin, ciprofloxacin and 
aminoglycosides (of which nine ESBL-negative)
In 2013, the Antimicrobial Resistance and Microbial 
Ecology (ARME) group at NUI Galway alerted HPSC to 
the presence of two predominant K. pneumoniae clones 
implicated in both patient infection and colonisation 
in a number of Irish hospitals. Both clones were 
simultaneously ESBL-positive and non-susceptible to 
ciprofloxacin and gentamicin. Some were also found to 
produce carbapenemases. Together, these are termed 
multi-drug resistant K. pneumoniae (MDRKP). The 
proportion of invasive K. pneumoniae that were MDRKP 
increased from 5.3% (18 of 342 isolates) in 2012 to 
12.3% (40 of 325 isolates) in 2013 as displayed in Figure 
8. An outbreak control team was established in October 
2013 to evaluate this emerging threat. In 2014, the 
proportion decreased to 8.1% (29 of 358 isolates).
Antimicrobial resistance in invasive K. pneumoniae 
isolates in Ireland have been among the lowest 
in Europe, but this appeared to be changing as 
of 2013 (Figure 7). However, resistance to 3GCs, 
fluoroquinolones and aminoglycosides all decreased 
in 2014 (perhaps in response to implementation of 
measures recommended by the MDRKP outbreak 
control team) with Ireland ranking 21st, 20th and 19th, 
respectively, among 29 countries reporting to EARS-
Net indicating that resistance levels in Ireland are 
still relatively low. The median proportions among 
EARS-Net countries were 30.7% for 3GCs, 33.3% for 
fluoroquinolones and 22.3% for aminoglycosides. 
With only two reports of carbapenemase-producing K. 
pneumoniae, Ireland ranked 23rd of 28 countries in 2014, 
with the median proportion among EARS-Net countries 
being 1.3% (Figure 9).
Males were approximately 1.5-times more likely to 
have an invasive K. pneumoniae infection than females 
(highly significant, P=0.001).  The frequency of invasive 
K. pneumoniae infection increased with age with the 
majority of infections (n=252; 70%) occurring in adults 
aged over 60. The median age was 69 years (95%CI, 
67-71).
Streptococcus pneumoniae
There were 331 reports of invasive S. pneumoniae 
infection (322 from blood and nine from CSF) from 310 
patients, an increase of 6.4% from 2013 (n=311). Table 
Figure 3. Trends for S. aureus – total numbers of S. aureus/MRSA and percentage
MRSA with 95% confidence intervals
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1 displays annual trends since 2005 in the proportions 
of S. pneumoniae isolates non-susceptible/resistant to 
penicillin and erythromycin.  
Penicillin non-susceptible S. pneumoniae (PNSP) 
accounted for 17.1% (n=56) of all isolates tested against 
penicillin (n=328) in 2014. Of the PNSP isolates, 48 
were intermediately-resistant (Int; MIC=0.1-1 mg/L for 
laboratories following the Clinical Laboratory Standards 
Institute (CLSI) guidelines (for non-meningitis syndrome 
via oral administration) and MIC=0.1-2mg/L for those 
following European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) non-meningitis 
guidelines) and eight were high-level resistant (HLR; 
MIC >1.0mg/L for CLSI and >2mg/L for EUCAST) to 
penicillin. Penicillin susceptibility was not determined for 
three isolates. Forty-four (13.8%) of 319 isolates were 
resistant to erythromycin.  
There was a decrease in the proportion of PNSP isolates 
from 20.8% in 2013 to 17.1% in 2014 as displayed in 
Figure 10. The proportion that displayed penicillin HLR 
remained stable at 2.5%.  In 2014, Ireland remained 
among European countries with the highest proportions 
of PNSP ranking 8th of 28 countries overall; and 4th of 
20 countries reporting ≥50 isolates. In 2014, the median 
proportion amongst EARS-Net countries was 8.9%. 
However, it is important to consider that comparison 
Figure 5. Trends for E. faecium – total numbers of E. faecium and percentage resistance to 
vancomycin (VREfm) and high-level gentamicin (HLG) with 95% confidence intervals
Figure 4. Distribution of MRSA in EARS-Net countries in 2014
Map obtained from ECDC on 21/10/2015:
http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx
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with other EARS-Net countries can be problematic due 
to the possibility of different interpretive criteria being 
applied to the data from different countries (and indeed 
from different laboratories within a country): 
•   CLSI provides three sets of breakpoints for 
interpreting penicillin susceptibility of S. pneumoniae 
isolates: meningitis, non-meningitis and oral
•   EUCAST provides two sets of breakpoints: meningitis 
and infections other than meningitis 
Many Irish microbiology laboratories have already 
switched, or are currently in the process of switching, 
from CLSI to EUCAST guidelines: 33 laboratories 
had switched by the end of 2014, an increase from 
27 by the end of 2013. In Ireland, EARS-Net data are 
reported using the EUCAST breakpoints for infections 
other than meningitis or the CLSI breakpoints for “oral 
administration” (which correspond to the original 
CLSI breakpoints), as these are broadly similar for 
epidemiological purposes and thus facilitate a more 
meaningful analysis of the data. This also permits a 
relatively consistent approach for comparing historical 
data. 
Moderately high levels of erythromycin resistance were 
seen, with Ireland ranking 16th of 28 countries overall 
and 14th of 21 countries reporting 50 or more isolates. 
This is similar to the situation observed in much of 
Southern and Central/Eastern Europe. In 2014, the 
median proportion amongst EARS-Net countries was 
14.3%.
Of 317 isolates tested against both penicillin and 
erythromycin in 2014, 33 (10.4%) were simultaneously 
PNSP (28 Int, 5 HLR) and erythromycin-resistant, which 
is the lowest proportion in the last six years.
In early 2007, a national pilot project was established 
as a collaborative initiative between RCSI/Beaumont 
Hospital, Children’s University Hospital, Temple 
St and HPSC, with the aim of providing baseline 
serotyping data on invasive S. pneumoniae isolates.  
This project pre-dates the introduction of the 7-valent 
pneumococcal conjugate vaccine (PCV7) into the 
childhood immunisation schedule in September 2008. 
PCV13 replaced PCV7 from September 2010. 
In 2014, serotype data were available for 298 
pneumococcal isolates reported by 32 of the 34 
laboratories reporting pneumococcal isolates to EARS-
Net, representing 90% of all pneumococcal isolates 
reported: 
•   Of 154 isolates from patients aged ≥65 years, 105 
(68%) belonged to serotypes included in the PPV23 
vaccine
•   Only 13 isolates were referred for typing from 
patients aged <2 years (the target population for 
the PCV13 vaccine) and all 13 were non-vaccine 
serotypes 
The most common serotypes identified were: 7F 
(n=31), 15A and 22F (n=25 each), 3 (n=24), 8 (n=22), 
19A (n=19), 10A (n=14) and 6C and 33F (n=12 each) 
representing 62% of all isolates typed. 
Of the 56 PNSP isolates, 51 (91%) were serotyped: 
•   Of 32 isolates from patients age ≥65 years, 16 (50%) 
belonged to serotypes included in the pneumococcal 
polysaccharide vaccine (PPV23) vaccine
•   Of two isolates from children <2 years, one belonged 
to a serotype included in the PCV13 vaccine
Ongoing surveillance of the predominant serotypes is 
required, as strains with non-vaccine serotypes have 
Figure 6. Distribution of vancomycin-resistant E. faecium (VREfm) in EARS-Net countries in 2014
Map downloaded from ECDC’s TESSy database on 21/10/2015:
http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx
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Figure 7. Trends for K. pneumoniae – total numbers of K. pneumoniae and percentage 
resistance to 3rd generation cephalosporins (3GCs), ciprofloxacin/ofloxacin (CIP/OFX), 
gentamicin (GEN) and gentamicin/amikacin/tobramycin (GEN/AMK/TOB) with 95% 
confidence intervals
Number of participating laboratories indicated above the bars
been reported to increase in prevalence following the 
introduction of conjugate vaccines in other countries, 
hence the need for a fully-resourced Irish pneumococcal 
reference laboratory. The separate chapter on invasive 
pneumococcal disease (IPD) in Ireland in 2014 contains 
additional information on pneumococcal serotyping.
In 2014, the rate of IPD in Ireland was estimated at 7.2 
cases per 100,000 population, an increase compared 
with 6.8 in 2013 (note that both rates were calculated 
using 2011 census data). The highest rates of IPD were 
observed in the older age groups [adults aged 65-
74 (23.9 per 100,000), 75-79 (36.3 per 100,000) and 
≥80 (47.5 per 100,000)] with a smaller peak in young 
children [aged <1 year (12.4 per 100,000) and 1 year 
(9.0 per 100,000)] as displayed in Figure 11. The IPD 
rates in all age groups were broadly similar to 2013.  
Males were approximately 1.1-times more likely to 
have an invasive S. pneumoniae infection than females, 
but this was not statistically significant (P=0.41). The 
frequency of invasive S. pneumoniae infection increased 
with age, with the majority (n=200; 60%) occurring in 
adults aged over 60. The median age was 66 years 
(95%CI, 62-68).
Enterococcus faecalis
There were 316 reports of E. faecalis BSI from 308 
patients, a decrease of 6.0% from 2013 (n=336).  Table 
1 displays annual trends since 2005 in the proportions 
of E. faecalis isolates resistant to the three “indicator” 
antimicrobials (as for E. faecium):  
•   Of 316 isolates, nine (2.8%) were resistant to 
vancomycin (VREfa), with Ireland ranking 5th amongst 
European countries for resistance. The median 
proportion in Europe was 0.2%, although the 
proportion of VREfa in Ireland has decreased from 
the highest reported proportion of 4.9% in 2011 
•   Of 300 isolates, 99 (33.0%) were resistant to high-
level gentamicin 
Six isolates were reported resistant to ampicillin, 
which is suggestive of misidentification of species or 
misclassification, as resistance to ampicillin is rare in 
E. faecalis.
Males were approximately 1.5-times more likely to 
have invasive E. faecalis infection than females (highly 
significant; P<0.001). The frequency of invasive 
E. faecalis infection increased with age, with the 
majority of infections (n=211; 67%) occurring in adults 
aged over 60.  The median age was 68 years (95%CI, 
67-71).
Pseudomonas aeruginosa
There were 182 reports of invasive P. aeruginosa 
infection (179 from blood and three from CSF) from 176 
patients, a decrease of 12.0% from 2013 (n=207).  Table 
1 displays annual trends since 2006 in the proportion 
of P. aeruginosa isolates resistant to the five “indicator” 
antimicrobials/antimicrobial classes [piperacillin-
tazobactam, ceftazidime, carbapenems (meropenem 
or imipenem), fluoroquinolones (ciprofloxacin or 
ofloxacin) and aminoglycosides (gentamicin, amikacin 
or tobramycin)]:  
•   Of 182 isolates, 30 (16.5%) were resistant to 
piperacillin-tazobactam 
•   Of 179 isolates, 16 (8.9%) were resistant to 
ceftazidime
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•   Of 181 isolates, 21 (11.6%) were resistant to 
imipenem or meropenem
•   Of 182 isolates, 25 (13.7%) were resistant to 
ciprofloxacin
•   Of 182 isolates, 9 (4.9%) were resistant to gentamicin 
[10 (5.5%) of 182 were aminoglycoside-resistant (i.e. 
resistant to gentamicin, tobramycin or amikacin)] 
In 2014, resistance to all but one of the indicator 
antimicrobials (piperacillin-tazobactam) decreased 
compared with 2013.
Twelve (6.7%) of 179 isolates reported from 10 
hospitals that were tested against all five “indicator” 
antimicrobials were identified as MDR Pseudomonas 
aeruginosa, defined as resistance to three or more of 
the indicator antimicrobials:
•   Three resistant to all five antimicrobial classes
•   Two resistant to four of five antimicrobial classes
•   Seven resistant to three of five antimicrobial classes
Antimicrobial resistance levels amongst P. aeruginosa 
isolates in Ireland are at moderately low levels in 
comparison with other European countries, with Ireland 
ranking between 16th and 24th of 29 countries for all five 
indicator antimicrobials.
Males were approximately 1.5-times more likely to have 
invasive P. aeruginosa infection than females (significant; 
P=0.01). The frequency of invasive P. aeruginosa 
infection increased with age, with the majority of 
infections (n=130; 71%) occurring in adults aged over 
60. The median age was 68 years (95%CI, 66-72).
Acinetobacter spp.
There were 93 reports of invasive infection caused 
by Acinetobacter spp. (90 from blood and one from 
CSF) from 91 patients, a slight increase from 2013 
(n=91).  Table 1 displays annual trends since 2013 in 
the proportion of Acinetobacter spp. isolates resistant 
to the three “indicator” antimicrobials/antimicrobial 
classes [carbapenems (meropenem or imipenem), 
fluoroquinolones (ciprofloxacin or ofloxacin) and 
gentamicin]:  
•   Of 83 isolates, three were resistant to imipenem or 
meropenem
•   Of 88 isolates, seven were resistant to ciprofloxacin
•   Of 91 isolates, three were resistant to gentamicin 
[no additional isolates were resistant to the other 
aminoglycosides (amikacin or tobramycin)] 
Two of 83 isolates reported from two hospitals were 
identified as MDR Acinetobacter spp., i.e. resistant to all 
three “indicator” antimicrobials.
Enhanced Surveillance
The voluntary EARS-Net enhanced surveillance 
programme was established in 2004. Laboratories that 
participate in EARS-Net are invited to provide additional 
demographic and clinical data on invasive pathogens 
causing BSI.
In 2014, enhanced surveillance data on 2,202 individual 
records (cases or isolates under the EARS-Net definition) 
were submitted from 21 participating laboratories, 
representing 40% of all reports to EARS-Net.  Table 
2 displays demographic and other basic data for the 
major resistance profiles of pathogens reported to 
EARS-Net enhanced surveillance. 
Figure 8. Trends for K. pneumoniae isolates with the MDRKP phenotype (simultaneously 
ESBL-producers and non-susceptible to both ciprofloxacin and gentamicin and/or a 
carbapenemase-producer) –– numbers and percentage with MDRKP phenotype with 95% 
confidence intervals
Number of participating laboratories indicated above the bars
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1. S. aureus BSI
•   51% of MRSA BSIs and 51% of MSSA BSIs were 
reported as healthcare-associated infection
•   18% of MRSA BSIs were reported as device-
associated with
 o   10% CVC/CVC-PICC-associated and  3% PVC-
associated BSIs specifically reported
•   26% of MSSA BSIs were reported as device-associated 
with
 o   11% CVC/CVC-PICC-associated, 7% PVC-
associated and 5% dialysis catheter-associated 
BSIs specifically reported
•   27% of patients with MRSA and 21% of patients with 
MSSA BSIs were noted as having recent exposure to 
antibiotics
2. Enterococcal BSI 
•   All of the vancomycin-resistant enterococcal BSIs 
(VRE) and 67% of the vancomycin-susceptible 
enterococcal (VSE) BSIs were reported as healthcare-
associated infection 
•   31% of VRE BSIs were reported as device-associated 
with
 o   24% specifically reported as CVC/CVC-PICC-
associated BSIs
•   17% of VSE BSIs were reported as device-associated 
with
 o   11% specifically reported as CVC/CVC-PICC-
associated BSIs
•   29% of patients with VRE BSIs and 19% of patients 
with VSE BSIs were noted as having recent exposure 
to antibiotics
Figure 9. Distribution of carbapenem-resistant K. pneumonie in EARS-Net countries in 2014
Map downloaded from ECDC’s TESSy database on 21/10/2015:
http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx
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Figure 10. Trends for S. pneumoniae – total numbers of S. pneumoniae/PNSP and 
percentage PNSP with 95% confidence intervals
HLR, High-level resistant; I, Intermediately resistant
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3. S. pneumoniae BSI 
•   The majority of both PNSP and PSSP BSIs were 
community-acquired
•   Respiratory tract infection remained the most 
common source of pneumococcal BSI
4. E. coli BSI 
•   The majority (52%) of fluoroquinolone-resistant E. 
coli (FQREC) BSIs were reported as healthcare-
associated infection, which contrasts with 36% for 
fluoroquinolone-susceptible E. coli 
 o    The most common source of E. coli 
bloodstream infection was urinary tract 
infection, with 11% FQREC BSI reported in 
association with the presence of a urinary 
catheter
 o   Recent antibiotic exposure was noted in 23% 
of cases of E. coli BSI
 
Conclusion
For the eighth consecutive year, the proportion of 
S. aureus BSI attributable to MRSA further declined 
to 19.5%, the lowest reported level since Ireland 
joined EARS-Net in 1999. Unfortunately, antimicrobial 
resistance in other important BSI causative pathogens 
increased further and remains a cause for concern. 
For the eighth consecutive year, Ireland remained 
the European country with the highest proportion of 
VREfm BSI (46.0%), with Cyprus, Greece and Romania 
now also reporting proportions over 25% and therefore 
appearing red on the map. 
Following the establishment of the national multidrug 
resistant K. pneumoniae (MDRKP) outbreak control 
team (OCT) in 2013 to look at the emerging problem 
of MDRKP, initial recommendations were made 
to try to control the spread of MDRKP strains in 
healthcare settings. Due to the wide-reaching nature 
of this outbreak and the growing threat posed by 
antimicrobial resistance, the OCT proposed that a 
national task force should be established with greater 
powers to influence and implement changes in policy 
and infrastructure needed. Between 2012 and 2013, 
EARS-Net data revealed a large increase in invasive K. 
pneumoniae that were MDRKP (from 5.3% to 12.3% 
of isolates), supporting the hypothesis of emergence 
and dissemination of MDRKP in Ireland. A reduction 
in MDRKP was seen in 2014 (to 8.1% of isolates) 
and this may be in part due to some of the control 
measures put in place during 2014. However, many 
of the recommendations have still not been fully 
implemented due to resource issues: screening for 
carriage of MDRKP (and other resistant organisms) is 
still not widely carried out and there is an overall lack of 
isolation facilities. 
In 2014, there were two reported cases of invasive 
carbapenemase-producing K. pneumoniae (CRE) 
infection in Ireland. Greece (63%) and Italy (36%) 
remained the European countries with the largest 
proportions of invasive CRE infections (amongst K. 
pneumoniae). For the first time, all 29 EARS-Net 
participant countries that provided data reported 
one or more cases of invasive CRE with 16 of these 
reporting five or more cases. This clearly illustrates 
the successful dissemination of these highly 
resistant microorganisms in Europe. Suboptimal 
infection prevention and control practices and lack 
of antimicrobial stewardship programmes in both 
acute and non-acute healthcare settings may have 
contributed to this dissemination. To address the threat 
of MDR-Enterobacteriaceae, such as MDRKP, ESBLs 
and CRE to Ireland, it is vital that control measures are 
strengthened in both acute and non-acute healthcare 
settings, with implementation of the recommendations 
contained in the “Guidelines for the prevention and 
control of multi-drug resistant organisms, other than 
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Figure 11. Numbers and age-specific incidence rates of patients with invasive 
S. pneumoniae infection in 2014 compared with 2013
ASIR, age-specific incidence rate
MRSA”, published in 2013  (available at http://www.
hpsc.ie/A-Z/MicrobiologyAntimicrobialResistance/
InfectionControlandHAI/Guidelines/) and the 
“Guidelines for antimicrobial stewardship in hospitals”, 
published in 2009 (available at http://www.hpsc.
ie/A-Z/MicrobiologyAntimicrobialResistance/
StrategyforthecontrolofAntimicrobialResistanceinIreland 
SARI/AntibioticStewardship/Publications/). 
The decline in the burden of MRSA BSI in recent years 
may be partly attributable to improvements in infection 
prevention and control interventions, such as increased 
emphasis on and improved healthcare worker awareness 
of the importance of compliance with standard and 
contact precautions, screening of patients for MRSA 
carriage and the availability of decolonisation regimens 
to eradicate MRSA carriage. The development of and 
strengthening of hospital antimicrobial stewardship 
programmes and restricted prescribing of certain broad 
spectrum antimicrobials, particularly in response to other 
healthcare associated infections, such as Clostridium 
difficile infection, may also have positively contributed 
to the decreasing proportion of MRSA BSI. 
Since 2008, pneumococcal conjugate vaccines have 
been a component of the childhood immunisation 
programme, an intervention which has already resulted 
in a reduction in the burden of paediatric invasive 
pneumococcal disease (IPD) in Ireland. However, 
pneumococcal antimicrobial resistance remains a 
major problem in Ireland. Clearly, IPD manifesting 
as BSI or meningitis reflects the most severe form 
of pneumococcal infection and data on other more 
common manifestations of infection (e.g., pneumonia, 
sinusitis and otitis media) are not captured by EARS-Net. 
While data from invasive infections is extremely valuable 
in comparing national levels of AMR, the true burden of 
infection caused by antimicrobial-resistant pneumococci 
may be underestimated.
The enhanced EARS-Net surveillance data are 
particularly useful in informing infection prevention 
and control programmes, both nationally and in those 
hospitals that participate in the surveillance scheme. 
Participation in enhanced surveillance can also help 
to identify risk factors and potentially preventable 
healthcare-associated infections that can be targeted as 
part of preventative programmes (e.g. invasive medical 
device-related infections).
Infections caused by antimicrobial-resistant bacteria 
result in excess patient mortality, morbidity and costs 
to the healthcare system. Rising levels of AMR threaten 
many aspects of healthcare that we currently take 
for granted. It is critical that comprehensive infection 
prevention and control and antimicrobial stewardship 
programmes continue to be developed and maintained 
at all levels and settings within the Irish health service. 
To this end, it is vital that recommendations and 
guidelines produced by the HSE RCPI Clinical Advisory 
Group on HCAI and AMR are implemented.
HPSC thanks all the microbiology laboratories for their 
continued participation and enthusiasm for the EARS-
Net project.
The data presented in this report were taken from the 
EARS-Net database on 1st October 2015.
Enhanced surveillance of Carbapenem Resistant 
Enterobacteriaceae (CRE) 
Summary:
•   In 2014, enhanced surveillance data was 
received on 43 cases of CRE colonisation/ 
infection. This represented an increase 
compared with 2013 and 2012, when 
enhanced surveillance data was received on 
24 and 32 CRE cases, respectively. In contrast, 
the National Carbapenemase Producing 
Enterobacteriaceae (CPE) Reference Laboratory 
Service (CPEaRLS) at Galway University Hospital 
confirmed carbapenemase production in 82 
Enterobacteriaceae isolates in 2014 
•   Five patients (12%) had a history of 
hospitalisation abroad (Ghana, India, Libya/
Tunisia, Vietnam: OXA-48-type CRE isolated; 
Iraq: NDM-type CRE isolated)
•   The clinical significance of the CRE isolate 
was reported for all patients, representing 
colonisation in the majority (n=32; 74%). CRE 
infection was reported for the remaining 11 
patients
Introduction
Carbapenem-resistant Enterobacteriaceae (CRE) are 
multi-drug resistant Gram-negative bacteria and includes 
carbapenemase enzyme producers and those bacteria 
that are resistant to carbapenems (e.g. imipenem, 
meropenem) as a result of a combination of resistance 
mechanisms (such as broad-spectrum β-lactamases and 
bacterial cell porin loss). These bacteria can be easily 
spread between patients in healthcare settings and 
have the ability to cause infections for which effective 
antimicrobial therapy may be lacking. Carbapenemase 
production has spread worldwide in the past 15 years 
and is now a prominent resistance mechanism reported 
in many countries.
 
Detection of confirmed carbapenemase-producing CRE, 
hereafter known as CRE, became notifiable in Ireland 
in March 2011 under the category of ”unusual cluster 
or changing pattern of illness”. Upon amendment 
to the Infectious Diseases Regulations in September 
2011, invasive CRE infection (blood, CSF or normally 
sterile site) became notifiable in its own category. The 
CRE enhanced surveillance scheme was established in 
June 2011 and reporting of CRE isolates from any site, 
whether colonisation or infection is encouraged.
 
Enhanced surveillance data
CRE cases reported to enhanced surveillance
In 2014, enhanced surveillance data was received from 9 
laboratories on 43 confirmed cases of carbapenemase-
producing CRE and one tertiary hospital reported a CRE 
outbreak. Figure 1 displays annual trends in CRE cases 
and types reported to enhanced surveillance since 2011. 
Of the 43 patients, 23 were female (53%). The median 
age was 71 years (range: 1 – 94 years). 
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Patient location 
At the time of CRE detection, 40 patients (93%) 
were hospitalised, two (4%) were in long-term care 
facilities and one (2%) was in the community. Of the 40 
hospitalised patients, 10 (25%) had been admitted from 
home, seven (16%) were transfers from another acute 
hospital, three had been admitted from long-term care/
nursing homes (7%) and the source of admission was 
not provided for the remaining 20 patients (45%). Of the 
seven patients who had been transferred from another 
acute hospital, two were repatriated from hospitals 
abroad (in Libya/Tunisia and Vietnam). 
Time to CRE colonisation/infection (days from patient’s 
admission to the time they became positive for CRE) 
could be calculated for 36 of 40 admitted patients. The 
median time to CRE colonisation/infection was 7.5 days 
(range: 0 – 42).
Presence of other multi-drug resistant organisms 
(MDROs)
At the time of CRE detection, 13 patients (30%) were 
already known to be colonised or infected with one or 
more other multi-drug resistant organisms (MDROs), 
including eight with MRSA, four with ESBL-producing 
Enterobacteriaceae, three with VRE and one with 
Pseudomonas (note: two patients were colonised with 
two and three other MDROs, respectively), and 11 of 
those were inpatients. 
Travel history
Seven patients (16%) reported foreign travel (Ghana, 
India, Iraq, Libya/Tunisia, Norway, Philippines and 
Vietnam) in the last 12 months and 21 (48%) reported 
none. The travel history was unknown for the remaining 
16 (36%). 
Risk factors
Two patients had no identifiable risk factors for CRE 
colonisation or infection and risk factor data was 
unknown or not provided for four patients. Of the 
remaining 37 patients, 26 (70%) had more than one risk 
factor. Reported risk factors included: hospitalisation 
in the past 12 months (35; 95%); history of surgery in 
the past six months (12; 32%); and history of admission 
to intensive care in the last 12 months (8; 21%). 
Reported underlying co-morbidities included: diabetes 
mellitus (6 patients); chronic lung disease (6 patients); 
immunocompromise (5 patients); renal disease (5 
patients); urological abnormality (4 patients); and liver 
disease (1 patient). 
Prior antimicrobial exposure
Antimicrobial exposure history prior to isolation of CRE 
was provided for 29 patients (67%), 27 of whom were 
hospitalised and eight of whom received more than one 
antimicrobial class: 
•   β-lactam – β-lactamase inhibitor combination 
agents - 25 (86%) 
•   Carbapenems - 4 (14%) 
•   Aminoglycosides - 4 (14%)
•   Fluoroquinolones - 3 (10%) 
•   Cephalosporins - 2 (7%)
•   Colistin - 1 (3%)
•   Co-trimoxazole - 1 (3%) 
Clinical significance and source of infection
The clinical significance of the CRE isolate was reported 
for all patients, representing colonisation in the majority 
(n=32). CRE infection was reported for the remaining 11 
patients, with three cases of respiratory tract infection, 
two cases each of bacteraemia, intra-abdominal 
infection and urinary tract infection, and one case each 
of skin/soft tissue infection and infection of prosthetic 
material. 
Specimen type
The majority of CRE (n=33; 77%) were isolated from 
screening swabs (rectal or stoma) or faeces. Three 
isolates were detected from blood (7%), five from 
urine (11%), and one each from peritoneal fluid and a 
peritoneal swab. 
Outcome
Outcome was reported for 36 of the 40 hospitalised 
patients (90%):
•   Five died (14%) 
For four of the five deaths, the patient was reported 
to have had CRE infection. The potential contribution 
of CRE infection to patient death was not collected. 
Date of death was provided for all five patients 
allowing the interval between CRE-positive specimen 
date and death to be calculated for all patients. 
These intervals were one, two, eight, 45 and 90 days, 
respectively
•   27 (75%) were discharged home 
•   Four (11%) remained inpatients at the time the 
surveillance form was returned, one of whom had 
already had CRE infection; however, it is not known 
if the remaining three CRE colonised patients 
subsequently went on to develop CRE infection later 
in the hospital admission 
Outcome was also reported for the three non-
hospitalised patients, all of whom survived. 
 
Enterobacteriaceae species 
Klebsiella pneumoniae accounted for the majority 
(n=27; 63%) of CRE isolates. In addition, there were 
eight cases of Escherichia coli CRE, 6 cases of K. 
oxytoca CRE and one case each of Citrobacter freundii 
CRE and Enterobacter cloacae CRE reported.  
Carbapenemase types reported
The carbapenemase enzyme types reported to 
enhanced surveillance were: 20 KPC (47%), 12 NDM 
(28%), nine OXA48 (21%), one IMP and one VIM. This 
contrasts with 82 CRE confirmed by the CPEaRLS in 
2014, subdivided as follows: 44 KPC (54%), 17 OXA48 
(21%), 17 NDM-1 (21%), 2 IMP and 2 VIM. Therefore, a 
significant proportion of confirmed CPE cases (48%) in 
2014 were not reported to the enhanced surveillance 
scheme.
-170-HPSC Annual Epidemiological Report 2014 Healthcare Associated Infections
0
5
10
15
20
25
30
35
40
45
2011 2012 2013 2014
TOTAL 37 33 24 43
KPC 16 15 11 20
NDM 1 6 2 12
OXA 20 8 11 9
VIM 4 1
IMP 1
N
um
be
r o
f c
as
es
Figure 1. Annual trends in CRE cases and types reported to 
HPSC since enhanced surveillance of CRE commenced in 2011 
Please note that the reduction in reported cases between 2012 
and 2013 reflects under-reporting rather than a true decline in CRE. 
Approximately twice as many isolates were confirmed by the CPEaRLS, 
Galway University Hospital in 2013 (n=48) and 2014 (n=82) than were 
reported to the voluntary CRE enhanced surveillance scheme
Susceptibility of isolates 
Susceptibility testing data was provided on all 43 
isolates:
•   Carbapenems 
 o   Meropenem: reported on all 43 isolates, 
with 39 resistant (91%); minimum inhibitory 
concentrations ranged from 0.064 to >256 
mg/L 
 o   Ertapenem: reported on all 43 isolates, with 
all isolates resistant; minimum inhibitory 
concentrations ranged from 2 to >256 mg/L
•   Aminoglycosides: reported on 40 isolates, 
with 29 (73%) resistant to one or more of the 
aminoglycosides listed below 
 o   Gentamicin: reported on 38 isolates, with 14 
resistant (37%)
 o   Tobramycin: reported on 38 isolates, with 13 
resistant (34%)
 o   Amikacin: reported on 37 isolates, with 19 
resistant (51%)
•   Fluoroquinolones: reported on 31 isolates, with 23 
resistant (74%) 
•   Tigecycline: reported on 34 isolates, with 10 resistant 
(29%) 
•   Colistin: reported on 33 isolates, with three resistant 
(9%)
Conclusion
In 2014, 43 cases of CRE colonisation/ infection were 
reported to the enhanced CRE surveillance system 
representing an increase of 80% from 24 cases in 2013; 
however, data from the CPEaRLS indicate that there 
were twice as many confirmed cases. 
In response to the emergence of CRE, Irish “Guidelines 
for the prevention and control of multi-drug resistant 
organisms, excluding MRSA, in the healthcare 
setting” were developed under the auspices of 
the Royal College of Physicians of Ireland (RCPI) 
Clinical Advisory Group on Healthcare-Associated 
Infections and Antimicrobial Resistance and were 
first published in early 2013 (available at http://www.
hpsc.ie/A-Z/MicrobiologyAntimicrobialResistance/
InfectionControlandHAI/Guidelines/). In response 
to the changing epidemiology of CRE and other 
types of multi-drug resistance in Enterobacteriaceae 
in Ireland, the guidelines on screening for carriage 
of resistant Enterobacteriaceae were further 
updated in July 2014. The latest versions of the 
guidelines are available at http://www.hpsc.
ie/A-Z/MicrobiologyAntimicrobialResistance/ 
Strategyforthecontrolof Antimicrobial 
ResistanceinIrelandSARI/Carbapenem 
ResistantEnterobacteriaceaeCRE/
ScreeningforCREinIreland/
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CIDR OPERATIONS
INFRASTRUCTURE AND SOFTWARE UPGRADES FOR 
CIDR
A new security model for the CIDR virtual infrastructure 
was developed, implemented and independently 
audited in 2014.The backup system was updated to 
incorporate the new virtual system software versions 
and the new hardware and was configured to operate 
in parallel with the existing data backup system. The 
Disaster Recovery system was fully incorporated into 
the nightly backup process to increase resilience.  
This provides an independent fully functional copy of 
the entire production system nightly, to the Disaster 
Recovery system.The RSA Authentication software was 
also updated during 2014.
 
INFORMATION SECURITY ACCREDITATION
Following two maintenance audits in March and 
September 2014, HPSC and CIDR retained ISO 27001 
accreditation. The HPSC Information Governance 
Framework, which includes CIDR, provides re-assurance 
to users and partners of the CIDR system, the Data 
Protection Commissioner and the data subjects relating 
to sensitive data stored and managed by the system.  
Maintenance of this accreditation standard is vital to 
information security.
CIDR USER TRAINING
25 new CIDR users were trained during 2014. There 
were 16 public health and 9 laboratory users trained.
CIDR APPLICATION SOFTWARE UPDATES
There were two major functional releases (v3.1 and 
v3.2) and two minor maintenance releases (v3.2.1 and 
10. Computerised Infectious Disease 
 Reporting (CIDR)
Figure 1. The volume of  statutory infectious disease notifications and corresponding number 
of diseases in CIDR per year, since 2005 when national implementation commenced (as of 14th 
September, 2015)
Summary
•  The highest ever annual number of notifications 
was recorded on CIDR in 2014
•  Virtual infrastructure security model and backup 
procedures developed and implemented
•  IS27001 Information Security accreditation was 
retained
•  The number of active CIDR users in 2014 was 269
•  25 new users were trained during 2014
•  CIDR versions 3.1, 3.2, 3.2.1 and 3.2.2 were 
released
•  CIDR Business Rules v3 were finalised and 
approved
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3.2.2) of the CIDR Application software during 2014. 
The outbreak management functionality was improved 
significantly in release v3.2.
GOVERNANCE AND COMMUNICATIONS
The National CIDR Steering Group continued to provide 
guidance and oversight of CIDR through 2014 and met 
by teleconference on two occasions during the year. The 
National CIDR User Group convened on four occasions 
throughout the year, also by teleconference, to discuss 
the ongoing use of CIDR and associated developments. 
CIDR BUSINESS RULES
The CIDR National Business Rules Review Group met on 
six occasions by teleconference to review and update 
the CIDR Business Rules. CIDR Business Rules v3 were 
finalised and approved during 2014.
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Figure 2. The number of users of the CIDR system in 
Departments of Public Health, in diagnostic and reference 
laboratories and in HPSC in 2014 (total=269)
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Notes:
Figures for the year 2014 presented in this appendix were extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on the 4th September, 2015. Please note that some figures may differ from figures 
published previously for other chapters in this report, due to on-going updating of notification data on CIDR.
Figures on EARS-Net pathogens and certain sexually transmitted infections (specifically, ano-genital warts and 
non-specific urethritis) are not presented here, since these diseases were not reported via the CIDR system during 
2014; separate databases are used to collate data on these diseases.
Table A1.1. List of notifiable infectious diseases and their respective causative pathogens (relevant to 2014) under Infectious 
Diseases (Amendment) (No. 3) Regulations 2011 (S.I. No. 452 of 2011)
Infectious Disease Causative Pathogen(s)
Acute anterior poliomyelitis Polio virus
Ano-genital warts Human papilloma virus
Anthrax Bacillus anthracis
Bacillus cereus food-borne infection/intoxication Bacillus cereus
Bacterial meningitis (not otherwise specified)  
Botulism Clostridium botulinum
Brucellosis Brucella spp.
Campylobacter infection Campylobacter spp.
Carbapenem-resistant Enterobacteriaceae infection (invasive) 
Carbapenem-resistant Enterobacteriaceae (blood, CSF or other normally 
sterile site)
Chancroid Haemophilus ducreyi
Chickenpox – hospitalised cases Varicella-zoster virus
Chikungunya disease Chikungunya virus
Chlamydia trachomatis infection (genital) Chlamydia trachomatis
Cholera Vibrio cholerae
Clostridium difficile infection Clostridium difficile
Clostridium perfringens (type A) food-borne disease Clostridium perfringens
Creutzfeldt Jakob disease  
variant Creutzfeldt Jakob disease  
Cryptosporidiosis Cryptosporidium parvum, hominis
Cytomegalovirus infection (congenital) Cytomegalovirus
Dengue fever Dengue virus
Diphtheria Corynebacterium diphtheriae or ulcerans (toxin producing)
Echinococcosis Echinococcus spp.
Enterococcal bacteraemia Enterococcus spp. (blood)
Escherichia coli infection (invasive) Escherichia coli (blood, CSF)
Giardiasis Giardia lamblia
Gonorrhoea Neisseria gonorrhoeae
Granuloma inguinale Klebsiella granulomatis
Haemophilus influenzae disease (invasive) Haemophilus influenzae (blood, CSF or other normally sterile site)
Hepatitis A (acute) infection Hepatitis A virus
Hepatitis B (acute and chronic) infection Hepatitis B virus
Hepatitis C infection Hepatitis C virus
Herpes simplex (genital) Herpes simplex virus
Human immunodeficiency virus infection Human immunodeficiency virus
Influenza Influenza A and B virus
Klebsiella pneumoniae infection (invasive) Klebsiella pneumoniae (blood or CSF)
Legionellosis Legionella spp.
Leprosy Mycobacterium leprae
Leptospirosis Leptospira spp.
Listeriosis Listeria monocytogenes
Lyme disease (neuroborreliosis) Borrelia burgdorferi
Lymphogranuloma venereum Chlamydia trachomatis
Malaria Plasmodium falciparum, vivax, knowlesi, ovale, malariae
Measles Measles virus
Meningococcal disease Neisseria meningitidis
Mumps Mumps virus
Non-specific urethritis  
Noroviral infection Norovirus
Paratyphoid Salmonella Paratyphi
Pertussis Bordetella pertussis
Plague Yersinia pestis
Pseudomonas aeruginosa infection (invasive) Pseudomonas aeruginosa (blood or CSF)
Q Fever Coxiella burnetii
Rabies Rabies virus
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Respiratory syncytial virus infection Respiratory syncytial virus
Rotavirus infection Rotavirus
Rubella Rubella virus
Salmonellosis Salmonella spp. other than S. Typhi and S. Paratyphi
Severe Acute Respiratory Syndrome (SARS) SARS-associated coronavirus
Shigellosis Shigella spp.
Smallpox Variola virus
Staphylococcal food poisoning Enterotoxigenic Staphylococcus aureus
Staphylococcus aureus bacteraemia Staphylococcus aureus (blood)
Streptococcus group A infection (invasive) Streptococcus pyogenes (blood, CSF or other normally sterile site)
Streptococcus group B infection (invasive) Streptococcus agalactiae (blood, CSF or other normally sterile site)
Streptococcus pneumoniae infection (invasive) Streptococcus pneumoniae (blood, CSF or other normally sterile site)
Syphilis Treponema pallidum
Tetanus Clostridium tetani
Toxoplasmosis Toxoplasma gondii
Trichinosis Trichinella spp.
Trichomoniasis Trichomonas vaginalis
Tuberculosis Mycobacterium tuberculosis complex
Tularemia Francisella tularensis
Typhoid Salmonella Typhi
Typhus Rickettsia prowazekii
Verotoxigenic Escherichia coli infection Verotoxin producing Escherichia coli
Viral encephalitis  
Viral haemorrhagic fevers  
Viral meningitis  
West Nile fever West Nile virus
Yellow fever Yellow fever virus
Yersiniosis Yersinia enterocolitica, Yersinia pseudotuberculosis
Table A1.1. List of notifiable infectious diseases and their respective causative pathogens (relevant to 2014) under Infectious 
Diseases (Amendment) (No. 3) Regulations 2011 (S.I. No. 452 of 2011)
(Continued)
Infectious Disease Causative Pathogen(s)
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Table A1.2 Number of notifiable infectious diseases, 2012-2014 and crude incidence rates of diseases, 2014
Infectious Disease 2012* 2013 2014 CIR2 2014
Acute anterior poliomyelitis 0 0 0 0.0
Anthrax 0 0 0 0.0
Bacillus cereus food-borne infection/intoxication 0 0 0 0.0
Bacterial meningitis (not otherwise specified) 29 21 23 0.5
Botulism 0 1 1 0.0
Brucellosis 2 1 3 0.1
Campylobacter infection 2388 2276 2616 57.0
Carbapenem-resistant Enterobacteriaceae infection (invasive) 0 0 5 0.1
Chancroid NA 0 0 0.0
Chickenpox - hospitalised cases 80 53 61 -
Chikungunya disease 0 0 1 0.0
Chlamydia trachomatis infection (genital)† NA 6257 6697 146.0
Cholera 0 0 0 0.0
Clostridium difficile infection‡ 1822 1813 1802 39.3
Clostridium perfringens (type A) food-borne disease 0 1 0 0.0
Creutzfeldt Jakob disease 5 5 2 0.0
Creutzfeldt Jakob disease (variant) 0 0 0 0.0
Cryptosporidiosis 556 514 394 8.6
Cytomegalovirus infection (congenital) 8 7 12 0.3
Dengue fever 7 15 21 0.5
Diphtheria 0 0 0 0.0
Echinococcosis 0 1 0 0.0
Giardiasis 54 44 71 1.6
Gonorrhoea NA 1286 1319 28.8
Granuloma inguinale NA 0 0 0.0
Haemophilus influenzae disease (invasive) 41 41 61 1.3
Hepatitis A (acute) 29 50 21 0.5
Hepatitis B (acute and chronic) 563 425 445 9.7
Hepatitis C 885 761 710 15.5
Herpes simplex (genital) NA 1127 1235 26.9
Human immunodeficiency virus infection 339 341 377 8.2
Influenza 743 1602 1757 38.3
Legionellosis§ 15 14 8 0.2
Leprosy 0 2 0 0.0
Leptospirosis 15 14 23 0.5
Listeriosis 11 8 15 0.3
Lyme disease 8 13 18 0.4
Lymphogranuloma venereum NA 5 35 0.8
Malaria 65 71 80 1.7
Measles|| 103 51 33 0.7
Meningococcal disease 66 81 82 1.8
Mumps 163 223 742 16.2
Noroviral infection† 1704 1486 808 17.6
Paratyphoid 5 2 5 0.1
Pertussis 458 173 73 1.6
Plague 0 0 0 0.0
Q fever 6 0 0 0.0
Rabies 0 0 0 0.0
Respiratory syncytial virus infection† 1972 1283 2479 54.0
Rotavirus infection† 2651 2512 2061 44.9
Rubella 9 0 3 0.1
Salmonellosis 313 324 260 5.7
Severe Acute Respiratory Syndrome (SARS) 0 0 0 0.0
Shigellosis 29 49 57 1.2
Smallpox 0 0 0 0.0
Staphylococcal food poisoning 0 0 0 0.0
Streptococcus group A infection (invasive) 122 168 164 3.6
Streptococcus group B infection (invasive)¶ 76 66 68 1.5
Streptococcus pneumoniae infection (invasive) 427 637 681 14.8
Syphilis** 494 551 281 6.1
Tetanus 1 1 1 0.0
Toxoplasmosis 36 32 20 0.4
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Trichinosis 0 0 0 0.0
Trichomoniasis NA 74 92 2.0
Tuberculosis 359 370 318 6.9
Tularemia 0 0 0 0.0
Typhoid 8 10 7 0.2
Typhus 0 0 0 0.0
Verotoxigenic Escherichia coli infection 554 701 707 15.4
Viral encephalitis 18 6 68 1.5
Viral haemorrhagic fevers 0 0 0 0.0
Viral meningitis 235 281 435 9.5
West Nile fever 0 1 0 0.0
Yellow fever 0 0 0 0.0
Yersiniosis 2 4 5 0.1
Total 17476 25855 27263  
Notes: 
1.  NA: Indicates that data not available in CIDR for the diseases and years indicated above
2. C IR, Crude incidence rate per 100,000 total population
* In 2012, new notifiable diseases were introduced on January 1st 2012 along with the revised versions of case definitions of certain diseases at 
that time
† Since 17/03/2013, figures for Chlamydia trachomatis, noroviral infection, respiratory syncytial virus infection and rotavirus infection may refer 
to notifications from HSE E rather than events. Such notifications from HSE E may also refer to area of laboratory testing rather than patient’s 
area of residence
‡ Since 01/01/2012 both new and recurrent cases of Clostridium difficile infection are notifiable, prior to this only new cases were notifiable; 
please interpret comparisons between current and historical data with caution 
§Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
||Table excludes two measles notifications in 2013 that are on CIDR, but were laboratory negative for measles and were not epidemiologically 
linked to a confirmed measles case
¶ Streptococcus group B infection (invasive) infections in infants <90 days old or stillborn infants
** The Irish case definition for syphilis changed on 1st January 2014, and from this date, syphilis notifications include early (infectious) syphilis 
only. Direct comparison of 2014 syphilis notification data with 2012 or 2013 syphilis notification data (which includes non infectious cases) is 
not valid.
Infectious Disease 2012* 2013 2014 CIR2 2014
Table A1.2 Number of notifiable infectious diseases, 2012-2014 and crude incidence rates of diseases, 2014
(Continued)
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 Table A1.3 Number of notifiable infectious diseases by HSE area, 2014
Infectious Disease
HSE 
E
HSE 
M
HSE 
MW
HSE 
NE
HSE 
NW
HSE 
SE
HSE 
S
HSE 
W
Total
Bacterial meningitis (not otherwise specified) 7 1 0 2 2 5 5 1 23
Botulism * * * * * * * * 1
Brucellosis * * * * * * * * 3
Campylobacter infection 753 215 229 194 121 391 405 308 2616
Carbapenem-resistant Enterobacteriaceae infection 
(invasive)
3 0 1 0 0 0 0 1 5
Chickenpox - hospitalised cases 33 1 3 4 5 6 8 1 61
Chikungunya disease * * * * * * * * 1
Chlamydia trachomatis infection (genital)† 3444 207 445 339 294 649 758 561 6697
Clostridium difficile infection‡ 715 76 182 106 72 195 231 225 1802
Creutzfeldt Jakob disease * * * * * * * * 2
Cryptosporidiosis 23 43 34 32 40 55 103 64 394
Cytomegalovirus infection (congenital) 8 0 2 0 0 0 0 2 12
Dengue fever 12 1 0 0 0 4 1 3 21
Giardiasis 31 8 3 1 0 5 15 8 71
Gonorrhoea 943 20 58 27 17 65 92 97 1319
Haemophilus influenzae disease (invasive) 16 5 8 7 1 12 8 4 61
Hepatitis A (acute) 10 2 2 1 1 0 3 2 21
Hepatitis B (acute and chronic) 253 31 21 37 11 25 43 24 445
Hepatitis C 493 19 38 41 8 37 53 21 710
Herpes simplex (genital) 725 24 81 68 20 121 107 89 1235
Human immunodeficiency virus infection 261 15 18 22 7 10 32 12 377
Influenza 733 60 185 143 72 211 184 169 1757
Legionellosis§ 6 0 0 0 1 0 0 1 8
Leptospirosis 4 3 3 3 4 3 2 1 23
Listeriosis 2 0 0 2 0 2 4 5 15
Lyme disease 1 0 5 0 0 2 8 2 18
Lymphogranuloma venereum 34 0 0 1 0 0 0 0 35
Malaria 34 1 1 10 2 5 17 10 80
Measles 9 1 2 1 0 1 4 15 33
Meningococcal disease 25 10 1 14 4 8 8 12 82
Mumps 142 21 47 13 41 141 258 79 742
Noroviral infection† 441 56 57 72 27 40 59 56 808
Paratyphoid 3 1 0 0 0 0 1 0 5
Pertussis 25 1 9 5 5 8 9 11 73
Respiratory syncytial virus infection† 1357 125 153 181 116 232 189 126 2479
Rotavirus infection† 411 208 115 174 171 344 309 329 2061
Rubella * * * * * * * * 3
Salmonellosis 90 23 19 24 19 27 32 26 260
Shigellosis 27 1 7 4 0 5 3 10 57
Streptococcus group A infection (invasive) 65 4 13 12 3 18 27 22 164
Streptococcus group B infection (invasive)|| 33 3 2 10 4 5 6 5 68
Streptococcus pneumoniae infection (invasive) 207 26 124 47 30 158 56 33 681
Syphilis 203 4 15 8 5 8 26 12 281
Tetanus * * * * * * * * 1
Toxoplasmosis 5 1 1 0 0 4 2 7 20
Trichomoniasis 46 4 11 9 9 5 7 1 92
Tuberculosis 135 16 16 22 17 29 66 17 318
Typhoid 4 0 0 0 1 2 0 0 7
Verotoxigenic Escherichia coli infection 96 66 107 55 17 116 120 130 707
Viral encephalitis 18 6 5 11 4 7 14 3 68
Viral meningitis 218 18 16 35 14 35 56 43 435
Yersiniosis 2 0 0 0 0 1 1 1 5
Notes: 
1.  This table does not include details of diseases for which a zero number of cases were notified; see Appendix A1.1 for details of thsese 
diseases in 2014
* Data not reported to HSE area level when total number in Ireland <5 cases
† Since 17/03/2013, figures for Chlamydia trachomatis, noroviral infection, respiratory syncytial virus infection and rotavirus infection may refer 
to notifications from HSE E rather than events. Such notifications from HSE E may also refer to area of laboratory testing rather than patient’s 
area of residence
‡ C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2014 epidemiological calendar year as shown here
§Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
||Streptococcus group B infection (invasive) infections in infants <90 days old or stillborn infants
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Table A1.4 Number of notifiable infectious diseases by HSE region, 2014
Infectious Disease
Dublin Mid 
Leinster
Dublin 
North East South West
HSE E LHO area 
unspecified Total
Bacterial meningitis (not otherwise specified) 5 5 10 3 0 23
Botulism * * * * * 1
Brucellosis * * * * * 3
Campylobacter infection 720 442 796 658 0 2616
Carbapenem-resistant Enterobacteriaceae infection 
(invasive)
3 0 0 2 0 5
Chickenpox - hospitalised cases 21 17 14 9 0 61
Chikungunya disease * * * * * 1
Chlamydia trachomatis infection (genital)† 470 523 1407 1300 2997 6697
Clostridium difficile infection‡ 532 365 426 479 0 1802
Creutzfeldt Jakob disease 0 0 0 2 * 2
Cryptosporidiosis 61 37 158 138 0 394
Cytomegalovirus infection (congenital) 5 3 0 4 0 12
Dengue fever 8 5 5 3 0 21
Giardiasis 28 12 20 11 0 71
Gonorrhoea 767 223 157 172 0 1319
Haemophilus influenzae disease (invasive) 17 11 20 13 0 61
Hepatitis A (acute) 10 3 3 5 0 21
Hepatitis B (acute and chronic) 165 156 68 56 0 445
Hepatitis C 338 215 90 67 0 710
Herpes simplex (genital) 547 270 228 190 0 1235
Human immunodeficiency virus infection 147 151 42 37 0 377
Influenza 467 469 395 426 0 1757
Legionellosis§ 3 3 0 2 0 8
Leptospirosis 5 5 5 8 0 23
Listeriosis 1 3 6 5 0 15
Lyme disease 1 0 10 7 0 18
Lymphogranuloma venereum 24 11 0 0 0 35
Malaria 19 26 22 13 0 80
Measles 6 5 5 17 0 33
Meningococcal disease 26 23 16 17 0 82
Mumps 115 61 399 167 0 742
Noroviral infection† 78 83 99 140 408 808
Paratyphoid 4 0 1 0 * 5
Pertussis 16 15 17 25 0 73
Respiratory syncytial virus infection† 144 189 421 395 1330 2479
Rotavirus infection† 225 177 653 615 391 2061
Rubella * * * * * 3
Salmonellosis 74 63 59 64 0 260
Shigellosis 17 15 8 17 0 57
Streptococcus group A infection (invasive) 53 28 45 38 0 164
Streptococcus group B infection (invasive)|| 26 20 11 11 0 68
Streptococcus pneumoniae infection (invasive) 104 176 214 187 0 681
Syphilis 152 63 34 32 0 281
Tetanus * * * * * 1
Toxoplasmosis 5 1 6 8 0 20
Trichomoniasis 26 33 12 21 0 92
Tuberculosis 88 85 95 50 0 318
Typhoid 1 3 2 1 0 7
Verotoxigenic Escherichia coli infection 146 71 236 254 0 707
Viral encephalitis 15 20 21 12 0 68
Viral meningitis 167 104 91 73 0 435
Yersiniosis 1 1 2 1 * 5
Notes: 
1.  This table does not include details of diseases for which a zero number of cases were notified; see Appendix A1.1 for details of thsese 
diseases in 2014
* Data not reported to HSE region level when total number in Ireland <5 cases
† Since 17/03/2013, figures for Chlamydia trachomatis, noroviral infection, respiratory syncytial virus infection and rotavirus infection may refer 
to notifications from HSE E rather than events. Such notifications from HSE E may also refer to area of laboratory testing rather than patient’s 
area of residence
‡ C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2014 epidemiological calendar year as shown here
§ Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
||Streptococcus group B infection (invasive) infections in infants <90 days old or stillborn infants 
-180-HPSC Annual Epidemiological Report 2014 Appendix 1 - Notifiable Infectious Diseases in Ireland
Table A1.5 Number of notifiable infectious diseases by age group (years), 2014
Infectious Disease 0-4 5-9 10-14 15-19 20-24 25-34 35-44 45-54 55-64 65+ Unknown Total
Bacterial meningitis (not otherwise specified) 12 0 0 2 0 5 0 1 1 1 1 23
Botulism 1 0 0 0 0 0 0 0 0 0 0 1
Brucellosis 1 0 0 0 0 1 0 0 1 0 0 3
Campylobacter infection 586 177 91 126 199 336 259 261 202 375 4 2616
Carbapenem-resistant Enterobacteriaceae 
infection (invasive) 0 0 0 0 0 0 0 0 2 3 0
5
Chickenpox - hospitalised cases 32 12 4 0 4 2 3 2 0 2 0 61
Chikungunya disease 0 0 0 0 0 1 0 0 0 0 0 1
Chlamydia trachomatis infection (genital)* || || || 741 2685 2544 516 132 42 9 15 6697
Clostridium difficile infection† 40 11 10 24 41 86 97 90 200 1202 1 1802
Creutzfeldt Jakob disease 0 0 0 0 0 0 0 0 1 1 0 2
Cryptosporidiosis 205 91 42 7 12 19 9 3 3 3 0 394
Cytomegalovirus infection (congenital) 12 0 0 0 0 0 0 0 0 0 0 12
Dengue fever 0 0 0 1 2 7 7 1 2 1 0 21
Giardiasis 13 3 0 1 11 20 10 2 7 4 0 71
Gonorrhoea || || || 138 428 509 157 67 17 1 0 1319
Haemophilus influenzae disease (invasive) 22 1 1 1 1 2 4 2 6 21 0 61
Hepatitis A (acute) 1 5 2 1 2 4 1 3 2 0 0 21
Hepatitis B (acute and chronic) 1 0 1 10 38 195 116 51 18 15 0 445
Hepatitis C 7 0 0 2 30 220 238 135 58 17 3 710
Herpes simplex (genital) || || || 153 323 425 204 88 28 7 2 1235
Human immunodeficiency virus infection 0 2 1 3 41 170 100 39 15 6 0 377
Influenza 158 55 41 39 63 245 219 146 176 615 0 1757
Legionellosis‡ 0 0 0 0 0 0 2 1 2 3 0 8
Leptospirosis 0 0 0 3 2 4 3 3 5 3 0 23
Listeriosis 4 0 0 0 0 4 0 0 3 4 0 15
Lyme disease 0 0 0 2 1 3 1 4 4 3 0 18
Lymphogranuloma venereum || || || 0 2 15 12 5 1 0 0 35
Malaria 4 1 5 3 5 16 26 17 1 2 0 80
Measles 9 1 2 8 7 4 2 0 0 0 0 33
Meningococcal disease 48 6 3 7 3 4 3 3 0 5 0 82
Mumps 27 27 42 283 192 76 37 25 21 9 3 742
Noroviral infection* 248 21 12 11 9 33 28 23 43 377 3 808
Paratyphoid 0 0 0 0 4 1 0 0 0 0 0 5
Pertussis 43 4 7 0 0 8 3 7 1 0 0 73
Respiratory syncytial virus infection* 2349 11 3 1 3 13 13 18 19 46 3 2479
Rotavirus infection* 1972 59 11 3 1 1 4 0 0 9 1 2061
Rubella 1 1 0 1 0 0 0 0 0 0 0 3
Salmonellosis 65 13 8 12 23 43 24 20 16 36 0 260
Shigellosis 7 2 4 1 4 19 7 9 2 2 0 57
Streptococcus group A infection (invasive) 19 18 6 6 5 12 17 10 15 56 0 164
Streptococcus group B infection (invasive)§ 68 0 0 0 0 0 0 0 0 0 0 68
Streptococcus pneumoniae infection (invasive) 46 18 3 5 5 20 41 57 109 377 0 681
Syphilis || || || 3 35 108 78 37 15 5 0 281
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Tetanus 0 0 0 1 0 0 0 0 0 0 0 1
Toxoplasmosis 0 0 0 2 2 10 3 1 1 1 0 20
Trichomoniasis || || || 7 19 27 19 14 2 2 2 92
Tuberculosis 0 3 4 10 21 72 58 42 38 70 0 318
Typhoid 0 2 0 0 2 2 1 0 0 0 0 7
Verotoxigenic Escherichia coli infection 327 53 33 19 24 57 42 30 31 91 0 707
Viral encephalitis 11 1 1 3 5 4 8 6 3 26 0 68
Viral meningitis 203 11 13 39 30 89 39 5 1 5 0 435
Yersiniosis 1 0 1 0 0 0 0 0 0 3 0 5
Total 6543 609 351 1679 4284 5436 2411 1360 1114 3418 38 27263
Notes: 
1. This table does not include details of diseases for which a zero number of cases were notified; see Appendix A1.1 for details of thsese diseases 
in 2014
*Since 17/03/2013, figures for Chlamydia trachomatis, noroviral infection, respiratory syncytial virus infection and rotavirus infection may refer to 
notifications from HSE E rather than events. Such notifications from HSE E may also refer to area of laboratory testing rather than patient’s area 
of residence†C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2014 epidemiological calendar year as 
shown here
‡Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
§Streptococcus group B infection (invasive) infections in infants <90 days old or stillborn infants
||Data for the age groups 0-4 years, 5-9 years and 10-14 years are not presented here, but data for the age group 0-14 years are available in the 
STI annual slide-set at www.hpsc.ie 
Table A1.5 Number of notifiable infectious diseases by age group (years), 2014
(Continued)
Infectious Disease 0-4 5-9 10-14 15-19 20-24 25-34 35-44 45-54 55-64 65+ Unknown Total
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Table A1.6 Number of notifiable infectious diseases by gender, 2014
Infectious Disease Male Female Unknown Not Specified Total
Bacterial meningitis (not otherwise specified) 8 13 2 0 23
Botulism 0 1 0 0 1
Brucellosis 1 2 0 0 3
Campylobacter infection 1428 1184 4 0 2616
Carbapenem-resistant Enterobacteriaceae infection (invasive) 3 2 0 0 5
Chickenpox - hospitalised cases 34 27 0 0 61
Chikungunya disease 0 1 0 0 1
Chlamydia trachomatis infection (genital)* 3043 3618 35 1 6697
Clostridium difficile infection† 710 1092 0 0 1802
Creutzfeldt Jakob disease 0 2 0 0 2
Cryptosporidiosis 191 203 0 0 394
Cytomegalovirus infection (congenital) 5 6 1 0 12
Dengue fever 13 8 0 0 21
Giardiasis 40 31 0 0 71
Gonorrhoea 1096 220 3 0 1319
Haemophilus influenzae disease (invasive) 38 22 0 1 61
Hepatitis A (acute) 10 11 0 0 21
Hepatitis B (acute and chronic) 267 168 10 0 445
Hepatitis C 497 211 2 0 710
Herpes simplex (genital) 304 925 6 0 1235
Human immunodeficiency virus infection 277 100 0 0 377
Influenza 717 1037 3 0 1757
Legionellosis‡ 4 4 0 0 8
Leptospirosis 20 3 0 0 23
Listeriosis 8 7 0 0 15
Lyme disease 8 10 0 0 18
Lymphogranuloma venereum 35 0 0 0 35
Malaria 54 25 1 0 80
Measles 22 11 0 0 33
Meningococcal disease 44 38 0 0 82
Mumps 406 336 0 0 742
Noroviral infection* 375 429 4 0 808
Paratyphoid 3 2 0 0 5
Pertussis 30 42 1 0 73
Respiratory syncytial virus infection* 1354 1122 3 0 2479
Rotavirus infection* 1103 957 1 0 2061
Rubella 1 2 0 0 3
Salmonellosis 148 112 0 0 260
Shigellosis 39 17 1 0 57
Streptococcus group A infection (invasive) 94 70 0 0 164
Streptococcus group B infection (invasive)§ 34 24 10 0 68
Streptococcus pneumoniae infection (invasive) 346 335 0 0 681
Syphilis 248 33 0 0 281
Tetanus 0 1 0 0 1
Toxoplasmosis 5 13 2 0 20
Trichomoniasis 2 90 0 0 92
Tuberculosis 174 144 0 0 318
Typhoid 4 3 0 0 7
Verotoxigenic Escherichia coli infection 314 393 0 0 707
Viral encephalitis 35 33 0 0 68
Viral meningitis 223 205 7 0 435
Yersiniosis 4 1 0 0 5
Total 13819 13346 96 2 27263
Notes: 
1. This table does not include details of diseases for which a zero number of cases were notified; see Appendix A1.1 for details of thsese 
diseases in 2014
*Since 17/03/2013, figures for Chlamydia trachomatis, noroviral infection, respiratory syncytial virus infection and rotavirus infection may refer to 
notifications from HSE E rather than events. Such notifications from HSE E may also refer to area of laboratory testing rather than patient’s area 
of residence
†C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2014 epidemiological calendar year as shown here
‡Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
§Streptococcus group B infection (invasive) infections in infants <90 days  old or stillborn infants
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Table A1.7 Number of notifiable infectious diseases by case classification, 2014
Infectious Disease Confirmed Probable Possible Total
Bacterial meningitis (not otherwise specified) 13 8 2 23
Botulism 1 0 0 1
Brucellosis 3 0 0 3
Campylobacter infection 2614 2 0 2616
Carbapenem-resistant Enterobacteriaceae infection (invasive) 5 0 0 5
Chickenpox - hospitalised cases 42 0 19 61
Chikungunya disease 1 0 0 1
Chlamydia trachomatis infection (genital)* 6697 0 0 6697
Clostridium difficile infection† 1802 0 0 1802
Creutzfeldt Jakob disease 2 0 0 2
Cryptosporidiosis 391 3 0 394
Cytomegalovirus infection (congenital) 12 0 0 12
Dengue fever 21 0 0 21
Giardiasis 71 0 0 71
Gonorrhoea 1319 0 0 1319
Haemophilus influenzae disease (invasive) 61 0 0 61
Hepatitis A (acute) 21 0 0 21
Hepatitis B (acute and chronic) 445 0 0 445
Hepatitis C 710 0 0 710
Herpes simplex (genital) 1167 68 0 1235
Human immunodeficiency virus infection 377 0 0 377
Influenza 1742 5 10 1757
Legionellosis‡ 8 0 0 8
Leptospirosis 22 1 0 23
Listeriosis 15 0 0 15
Lyme disease 18 0 0 18
Lymphogranuloma venereum 35 0 0 35
Malaria 80 0 0 80
Measles§ 20 5 8 33
Meningococcal disease 80 0 2 82
Mumps 299 222 221 742
Noroviral infection* 808 0 0 808
Paratyphoid 5 0 0 5
Pertussis 63 3 7 73
Respiratory syncytial virus infection* 2479 0 0 2479
Rotavirus infection* 2061 0 0 2061
Rubella 0 1 2 3
Salmonellosis 260 0 0 260
Shigellosis 54 3 0 57
Streptococcus group A infection (invasive) 160 4 0 164
Streptococcus group B infection (invasive)§ 68 0 0 68
Streptococcus pneumoniae infection (invasive) 350 0 331 681
Syphilis 278 3 0 281
Tetanus 0 1 0 1
Toxoplasmosis 20 0 0 20
Trichomoniasis 92 0 0 92
Tuberculosis 236 30 52 318
Typhoid 7 0 0 7
Verotoxigenic Escherichia coli infection 570 135 2 707
Viral encephalitis 68 0 0 68
Viral meningitis 428 7 0 435
Yersiniosis 5 0 0 5
Total 26106 501 656 27263
Notes: 
1.  This table does not include details of diseases for which a zero number of cases were notified; see Appendix A1.1 for details of these 
diseases in 2014
2.  The case definitions booklet, available at www.hpsc.ie has been updated since 2012; case classifications are assigned to notifications as per 
the Case Definitions for Notifiable Diseases during 2014
* Since 17/03/2013, figures for Chlamydia trachomatis, noroviral infection, respiratory syncytial virus infection and rotavirus infection may refer 
to notifications from HSE E rather than events. Such notifications from HSE E may also refer to area of laboratory testing rather than patient’s 
area of residence
†C . difficile figures in the C. difficile chapter are presented by quarter rather than using the 2014 epidemiological calendar year as shown here
‡ Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
§S treptococcus group B infection (invasive) infections in infants <90 days  old or stillborn infants
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Notifiable Infectious Diseases
Computerised Infectious Disease Reporting (CIDR) 
system
For the majority of the notifiable infectious diseases 
(see Appendix 1), data were collated using the 
Computerised Infectious Disease Reporting (CIDR) 
system. During 2014, notification data were inputted 
directly by areas using the system. Enhanced 
surveillance was undertaken for certain diseases 
and these data are collated on CIDR. Outbreak data 
were also collated on CIDR using the same process 
outlined above. Weekly Reports on infectious disease 
notifications (including a separate report for Clostridium 
difficile associated disease, HIV & STIs) and outbreaks 
were produced by HPSC and published on the HPSC 
website, www.hpsc.ie. Throughout the year data were 
cleaned and validated on an ongoing basis and final 
data checks and cleaning were undertaken following 
year end by HPSC and the Departments of Public 
Health. Data analysis was performed using CIDR 
Business Objects Reporting and MS Excel. Figures for 
the relevant chapters within this report were extracted 
from CIDR between February and November 2015. 
These figures may differ from those previously published 
due to ongoing updating of data on CIDR.
HIV
HIV was made a notifiable disease in Ireland in 
September 2011. Since 1st January 2012, CIDR has been 
used to record notifications of HIV, thereby allowing 
the replacement of HIV case based reporting. Since 1st 
January 2012, AIDS diagnoses are only reported if they 
occur at the time of HIV diagnoses. 
Sexually Transmitted Infections (STIs)
Data on ano-genital warts (AG) and non-specific 
urethritis (NSU) are not collated using the CIDR system. 
Instead, clinicians notified their respective Departments 
of Public Health of cases of ano-genital warts and 
non-specific urethritis. Data for 2014 were collated 
and analysed by Departments of Public Health and 
aggregated data were reported quarterly to HPSC. 
National data were collated on an MS Access database, 
analysis preformed and reports produced by HPSC.
Data on all other STIs are collated using the CIDR 
system, including: chancroid, Chlamydia trachomatis 
infection, gonorrhoea, granuloma inguinale, herpes 
simplex (genital), lymphogranuloma venereum, syphilis 
and trichomiasis.
Other Surveillance Systems
Influenza/Influenza-like illness Surveillance Systems
Since 2000, HPSC has worked in collaboration with 
the National Virus Reference Laboratory (NVRL), the 
Irish College of General Practitioners (ICGP) and the 
Departments of Public Health on the influenza sentinel 
surveillance project. Sixty-one general practices 
(located in all HSE-Areas and representing 5.8% of the 
population) were recruited to report electronically, on 
a weekly basis, the number of patients who consulted 
with influenza-like illness (ILI).  ILI is defined using 
the Irish case definition for ILI which is sudden onset 
of symptoms AND at least one of the following four 
systemic symptoms: fever, malaise, headache, myalgia; 
AND at least one of the following three respiratory 
symptoms: cough, sore throat, shortness of breath. 
Sentinel GPs were requested to send a combined nasal 
and throat swab on one ILI patient per week to the 
NVRL. The NVRL also tested respiratory non-sentinel 
specimens, referred mainly from hospitals. Other 
surveillance systems set up to monitor influenza/ILI 
activity include a network of sentinel hospitals reporting 
admissions data. The Departments of Public Health also 
notified HPSC weekly of all cases of influenza (including 
hospitalisation status), all influenza/ILI outbreaks and 
enhanced surveillance data on all hospitalised cases of 
confirmed influenza in 0-14 year olds. HPSC was notified 
of all registered deaths on a daily basis from the General 
Register Office.
Several surveillance projects that were initiated/
augmented during the 2009 influenza pandemic were 
continued during subsequent influenza seasons:
•  Surveillance of all calls to GP out-of-hours (OOHs) 
centres were monitored for self-reported influenza. 
These data were provided by HSE-NE.  
•  Intensive Care Society of Ireland (ICSI) enhanced 
surveillance of all critical care patients with confirmed 
influenza in all critical care units and enhanced 
surveillance of all severe acute respiratory infections 
(SARI) in two pilot ICU sites.  
•  Enhanced surveillance of all confirmed influenza 
deaths.
Explanatory Notes
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Other routine surveillance include the monitoring of 
the uptake of the seasonal influenza vaccine among 
residents in long term care facilities (LTCFs) and that 
of the health care workers in both LTCFs and hospitals 
since the 2011/2012 season. Uptake levels by different 
categories of staff over time, along with other details 
are presented in the influenza chapter of this report.
At HPSC, data were collated from the various sources, 
analysed and routine reports were produced. Influenza 
surveillance reports were posted on the HPSC website 
www.hpsc.ie. Aggregated clinical and virological data 
and annonymised data on confirmed influenza cases 
admitted to hospital were reported weekly to the 
European Centre for Disease Prevention and Control 
(ECDC).
Immunisation Uptake
•  Immunisation uptake among children at 12 and 24 
months of age
  Each HSE Area maintains a childhood immunisation 
database. In 2014, HSE Areas provided HPSC with 
immunisation uptake data for their area and for each 
of the Local Health Offices in their area on a quarterly 
basis. National data were collated and analysed at 
HPSC using a MS Excel database.  Quarterly reports 
were produced and are available on the HPSC 
website. For further details on methods used, please 
see the immunisation uptake chapter within this 
report.
•  HPV uptake
  Following a recommendation from the National 
Immunisation Advisory Committee, that human 
papillomavirus (HPV) vaccine should be given to 12 
year old girls, a routine HSE school HPV vaccination 
programme began in May 2010.  HPV vaccinations 
provided through the schools immunisation 
programme are now collated on a national database.  
Uptake of HPV vaccine, provided through the school 
immunisation programme in the academic year 
2013/2014 and recorded on the database, is reported 
in the HPV uptake chapter within this report. For 
further details please see the HPV uptake chapter.
•  Other school immunisations excluding HPV
  Since the 2011/2012 academic year, the uptake of the 
DTaP and MMR vaccines in 4-5 year old schoolchildren 
(at Junior Infant level) has been monitored across 
all Local Health Offices (LHOs) each year. Each LHO 
provides details of the cohort size and the number 
of vaccinated children and the returns collated to 
calculate uptake levels which are also presented in 
maps in the ‘other school immunisations’ chapter. 
Uptake of the Tdap vaccine, provided through the 
school immunisation programme in the academic year 
2013/2014 and recorded on a national database, is 
also reported in this chapter.
European Antimicrobial Resistance Surveillance 
Network (EARS-Net)
Data were collected by participating EARS-Net (formerly 
the European Antimicrobial Resistance Surveillance 
System, EARSS) laboratories in 2012 on the first invasive 
isolate per patient per quarter on Staphylococcus 
aureus and Enterococcus faecalis from blood only 
and on Streptococcus pneumoniae, Escherichia coli, 
Klebsiella pneumoniae and Pseudomonas aeruginosa 
from blood and cerebrospinal fluid (CSF). Data were 
reported quarterly to HPSC, via WHONET software, 
and collated in an MS Access database. Quarterly and 
annual reports were produced.
Note: Invasive infections due to K. pneumoniae and P. aeruginosa 
became notifiable as of 13th September 2011.
Antimicrobial consumption
Community (outpatient) consumption data were 
obtained from IMS Health and represent wholesaler 
to retail pharmacy sales figures for Ireland. Hospital 
(inpatient) consumption data were obtained directly 
from clinical pharmacies and validated with the support 
of the Irish Antimicrobial Pharmacists Association. 
Quarterly and annual consumption trends by named 
public acute hospitals are published on the HPSC 
website. All data were interpreted using the WHO 
Anatomical Therapeutic Chemicals index   
(www.whocc.no/atcddd/) in line with European 
Surveillance of Antimicrobial Consumption (ESAC-Net) 
methodology, which is now managed by the ECDC. See 
relevant section for notes on the denominator data.
Healthcare associated infections
•  Clostridium difficile: Data on C.difficile enhanced 
surveillance were collected by participating hospitals, 
reported quarterly to the HPSC and stored in an MS 
Access database. Quarterly and annual reports were 
produced. 
•  Data were also collected on the total volume of 
alcohol-based hand rub used per hospital per year/
quarter, excluding that used for pre-operative surgical 
“scrub”. See relevant section for notes on the 
denominator data. The rate of usage per hospital was 
calculated as the total volume of hand rub consumed 
(in litres) per 1000 bed days used, and quarterly and 
annual reports were produced for publication on the 
HPSC website.
Denominator Data
To calculate disease incidence rates, Census of 
Population data were used as the denominator 
(available from the Central Statistics Office,  
http://www.cso.ie).  Population figures were applied as 
follows: 
•  Census 2011 for analysis of 2009-2014 data 
•  Census 2006 for analysis of 2004-2008 data
•  Census 2002 for 2000-2003 data 
•  Census 1996 for 1999 data 
Monthly population changes were estimated between 
1993 and 2014 using a curve interpolation method for 
the calculation of outpatient antibiotic consumption 
rate. 
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Bed-days used and other activity data for public acute 
hospitals were provided by the Performance Monitoring 
Unit of the HSE and used to calculate rates of MRSA, 
hospital antibiotic consumption and rates used in other 
hospital-based surveillance systems. Similar activity data 
were obtained directly from private acute hospitals.
HSE Areas
Although organisational changes have taken place 
in the Health Services, the term HSE Areas are used 
in this report when analysing and presenting data by 
geographical area (equating to the eight former health 
board regions/areas). This is because operationally 
the surveillance, prevention and control of infectious 
diseases are still managed by eight Departments of 
Public Health, one in each HSE Area.
Regional Directors of Operations (RDO’s)
The range of health and personal social services 
provided by the HSE and its funded agencies are 
managed within four regions known as RDOs. Details of 
the four RDOs and their relationship with the eight HSE 
areas are shown below.
1.  Dublin Mid Leinster (HSE-Midland plus CCA1-5 and 
CCA9-10 of HSE-East)
2.  Dublin North East (HSE-North East plus CCA6-8 of 
HSE-East)
3.  South (HSE-South and HSE-South East)
4.  West (HSE-Midwest, HSE-North West and HSE-
West)
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Glossary of Terms 
AHR Alcohol hand rubs
CDI Clostridium difficile infection
CIDR Computerised Infectious Disease Reporting
CIR Crude incidence rate
DoH Department of Health
EARS-Net European Antimicrobial Resistance Surveillance Network
ECDC European Centre for Disease Prevention and Control
EISN European Influenza Surveillance Network
ICGP Irish College of General Practitioners
ILI Influenza-like illness
IMMRL Irish Meningococcal and Meningitis Reference Laboratory
IPD Invasive pneumococcal disease
HCAI Healthcare associated infections
HCWs Healthcare Workers
HPSC Health Protection Surveillance Centre
HSE Health Services Executive
HSE E HSE Eastern Region
HSE M HSE Midland Area
HSE MW HSE Mid-Western Area
HSE NE HSE North Eastern Area
HSE NW HSE North Western Area
HSE SE HSE South Eastern Area
HSE S HSE Southern Area
HSE W HSE Western Area
LTCFs Long term care facilities
MRSA Meticillin Resistance Staphylococcus aureus
MSM Men who have sex with men
NSSLRL National Salmonella, Shigella and Listeria Reference Laboratory
NIO National Immunisation Office
NVRL National Virus Reference Laboratory
PWID People who inject drugs
SIS School Immunisation System
STIs Sexually Transmitted Infections
TB Tuberculosis
WHO World Health Organization
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